
<html lang="en"     class="pb-page"  data-request-id="42dcfb97-ee85-4ca5-8a90-f885d74fd955"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.9b00946;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models" /></meta><meta name="dc.Creator" content="Sida  Shen" /></meta><meta name="dc.Creator" content="Melissa  Hadley" /></meta><meta name="dc.Creator" content="Kseniya  Ustinova" /></meta><meta name="dc.Creator" content="Jiri  Pavlicek" /></meta><meta name="dc.Creator" content="Tessa  Knox" /></meta><meta name="dc.Creator" content="Satish  Noonepalle" /></meta><meta name="dc.Creator" content="Mauricio T.  Tavares" /></meta><meta name="dc.Creator" content="Chad A.  Zimprich" /></meta><meta name="dc.Creator" content="Guiping  Zhang" /></meta><meta name="dc.Creator" content="Matthew B.  Robers" /></meta><meta name="dc.Creator" content="Cyril  Bařinka" /></meta><meta name="dc.Creator" content="Alan P.  Kozikowski" /></meta><meta name="dc.Creator" content="Alejandro  Villagra" /></meta><meta name="dc.Description" content="Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HD..." /></meta><meta name="Description" content="Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HD..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 15, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00946" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00946" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00946" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00946" /></link>
        
    
    

<title>Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00946" /></meta><meta property="og:title" content="Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0013.jpeg" /></meta><meta property="og:description" content="Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HDAC6-selective inhibitor containing the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker. A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination observed for HDAC6 complexes with phenylhydroxamate-based inhibitors. While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model. These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00946"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00946">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00946&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00946&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00946&amp;href=/doi/10.1021/acs.jmedchem.9b00946" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8557-8577</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00911" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00963" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sida Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sida Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sida++Shen">Sida Shen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0295-2545" title="Orcid link">http://orcid.org/0000-0002-0295-2545</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa Hadley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa Hadley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa++Hadley">Melissa Hadley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kseniya Ustinova</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kseniya Ustinova</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</div><div class="loa-info-affiliations-info">Department of Biochemistry, Faculty of Natural Science, Charles University, Albertov 6, 128 43 Prague 2, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kseniya++Ustinova">Kseniya Ustinova</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiri Pavlicek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiri Pavlicek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiri++Pavlicek">Jiri Pavlicek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tessa Knox</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tessa Knox</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tessa++Knox">Tessa Knox</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Satish Noonepalle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Satish Noonepalle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Satish++Noonepalle">Satish Noonepalle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mauricio T. Tavares</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mauricio T. Tavares</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mauricio+T.++Tavares">Mauricio T. Tavares</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4400-7787" title="Orcid link">http://orcid.org/0000-0002-4400-7787</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chad A. Zimprich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chad A. Zimprich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Promega Corporation, Madison, Wisconsin 53711, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chad+A.++Zimprich">Chad A. Zimprich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guiping Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guiping Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bontac Bio-Engineering (Shenzhen) Co., Ltd, Shenzhen, Guangdong 518102, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guiping++Zhang">Guiping Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9818-4773" title="Orcid link">http://orcid.org/0000-0001-9818-4773</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew B. Robers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew B. Robers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Promega Corporation, Madison, Wisconsin 53711, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+B.++Robers">Matthew B. Robers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cyril Bařinka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cyril Bařinka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cyril++Ba%C5%99inka">Cyril Bařinka</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2751-3060" title="Orcid link">http://orcid.org/0000-0003-2751-3060</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan P. Kozikowski</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan P. Kozikowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">StarWise Therapeutics LLC, University Research Park, Inc., Madison, Wisconsin 53719, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#89e8e2e6f3e0e2e6fefae2e0c9fafde8fbfee0faecfdfbf1a7eae6e4"><span class="__cf_email__" data-cfemail="b9d8d2d6c3d0d2d6cecad2d0f9cacdd8cbced0cadccdcbc197dad6d4">[email protected]</span></a>. Phone: +1-773-793-5866 (A.P.K.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan+P.++Kozikowski">Alan P. Kozikowski</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Alejandro Villagra</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alejandro Villagra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#fa9b8c9396969b9d889bba9f979b9396d49d8d8fd49f9e8f"><span class="__cf_email__" data-cfemail="b9d8cfd0d5d5d8decbd8f9dcd4d8d0d597dececc97dcddcc">[email protected]</span></a>. Phone: +1-202-994-9547 (A.V.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alejandro++Villagra">Alejandro Villagra</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00946&amp;href=/doi/10.1021%2Facs.jmedchem.9b00946" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8557–8577</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 15, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 June 2019</li><li><span class="item_label"><b>Published</b> online</span>15 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 September 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00946" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00946</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8557%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSida%2BShen%252C%2BMelissa%2BHadley%252C%2BKseniya%2BUstinova%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D18%26contentID%3Dacs.jmedchem.9b00946%26title%3DDiscovery%2Bof%2Ba%2BNew%2BIsoxazole-3-hydroxamate-Based%2BHistone%2BDeacetylase%2B6%2BInhibitor%2BSS-208%2Bwith%2BAntitumor%2BActivity%2Bin%2BSyngeneic%2BMelanoma%2BMouse%2BModels%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8577%26publicationDate%3DSeptember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00946"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3773</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">26</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00946" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sida&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;Hadley&quot;},{&quot;first_name&quot;:&quot;Kseniya&quot;,&quot;last_name&quot;:&quot;Ustinova&quot;},{&quot;first_name&quot;:&quot;Jiri&quot;,&quot;last_name&quot;:&quot;Pavlicek&quot;},{&quot;first_name&quot;:&quot;Tessa&quot;,&quot;last_name&quot;:&quot;Knox&quot;},{&quot;first_name&quot;:&quot;Satish&quot;,&quot;last_name&quot;:&quot;Noonepalle&quot;},{&quot;first_name&quot;:&quot;Mauricio&quot;,&quot;last_name&quot;:&quot;T. Tavares&quot;},{&quot;first_name&quot;:&quot;Chad&quot;,&quot;last_name&quot;:&quot;A. Zimprich&quot;},{&quot;first_name&quot;:&quot;Guiping&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;B. Robers&quot;},{&quot;first_name&quot;:&quot;Cyril&quot;,&quot;last_name&quot;:&quot;Bařinka&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;P. Kozikowski&quot;},{&quot;first_name&quot;:&quot;Alejandro&quot;,&quot;last_name&quot;:&quot;Villagra&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;8557-8577&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00946&quot;},&quot;abstract&quot;:&quot;Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HDAC6-selective inhibitor containing the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker. A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination observed for HDAC6 complexes with phenylhydroxamate-based inhibitors. While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model. These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00946&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00946" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00946&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00946" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00946&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00946" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00946&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00946&amp;href=/doi/10.1021/acs.jmedchem.9b00946" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00946" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00946" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00946%26sid%3Dliteratum%253Aachs%26pmid%3D31414801%26genre%3Darticle%26aulast%3DShen%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ba%2BNew%2BIsoxazole-3-hydroxamate-Based%2BHistone%2BDeacetylase%2B6%2BInhibitor%2BSS-208%2Bwith%2BAntitumor%2BActivity%2Bin%2BSyngeneic%2BMelanoma%2BMouse%2BModels%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D18%26spage%3D8557%26epage%3D8577%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/jmcmar.2019.62.issue-18/20190926/jmcmar.2019.62.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors. Here, we report the design, synthesis, and structural and biological characterization of SS-208, a novel HDAC6-selective inhibitor containing the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker. A crystal structure of the <i>Danio rerio</i> HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination observed for HDAC6 complexes with phenylhydroxamate-based inhibitors. While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model. These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46437" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46437" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Malignant melanoma represents the most aggressive and the deadliest form of cutaneous cancer with increasing incidence, high metastasis, rapid disease progression, poor prognosis, and high mortality.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Patients with metastatic melanoma have poor prognosis with a 5 year survival rate of less than 10%.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> A few targeted agent therapies have recently become available for metastatic melanoma. For instance, BRAF inhibitors (i.e., dabrafenib) and MEK1/2 inhibitors (trametinib) have been approved as monotherapy or combined approach for the treatment of melanoma with mutation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, the clinical benefit of these therapies is limited due to the rapid development of resistance associated with the activation of alternative pro-oncogenic pathways.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Within the last five years, immunotherapy has revolutionized the treatment of patients with advanced-stage melanoma. Antibodies that block the negative co-stimulatory receptors CTLA-4 (ipilimumab),<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> and programmed cell death-1 (PD-1) (nivolumab and pembrolizumab)<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> have been approved based on significantly longer overall survival in clinical trials compared to other therapies. The objective response rates of these immune checkpoint blockades are around 20–30%,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> while primary, adaptive, and acquired resistance to immunotherapy is common and may be related to the lack of recognition by T-cells.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Novel aiming to overcome these limitations, especially the resistance mechanisms originated in other components of the tumor microenvironment (TME) are still highly needed to improve current available therapeutics.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a></div><div class="NLM_p">Histone deacetylases (HDACs) are a family of proteins involved in the epigenetic regulation of target genes through deacetylating lysine ε-amino groups on histone tails to promote a status of DNA condensation and transcriptional silencing.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Furthermore, HDACs have been found to modify other nonhistone proteins, and these modifications can influence a variety of cellular functions without modifying the acetylation of the chromatin acetylation status.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> HDACs have been proven to be promising therapeutic targets for the treatment of cancer based on the successful launch of five HDAC inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and chidamide) which are relatively nonselective.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> In general, broad-spectrum HDAC inhibitors (pan-HDACis) are involved in chromosome remodeling, cell cycle arrest, apoptosis, and cytotoxicity in transformed cancer cells.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> In addition to these effects, there is growing evidence to demonstrate that the treatment with HDACis increases differentiation antigen expression, enhances major histocompatibility complex (MHC) class I and II surface expression, and elevates immunogenicity in terms of increased expression of CD25, CD40, or CD80.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> It has been reported that pan-HDACis can upregulate the expression of PD-L1 and PD-L2 in human and murine melanoma cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Therefore, pan-HDACis show the ability to possess antitumor activity through inhibiting proliferation and improving immune responses.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, phase I/II clinical trials of pan-HDACis (vorinostat, panobinostat, and quisinostat) with melanoma patients only exhibited limited efficacy and tolerability as single agents, while hematological toxicity, fatigue, nausea, and laboratory abnormalities occurred as frequent adverse events.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Important concerns regarding the toxicity of pan-HDACis are rising because their broad inhibition may result in unwanted off-target effects that eventually impair their clinical profile. Thus, there is an emerging interest in the development and investigation of selective HDACis to better understand the molecular mechanisms mediating the antitumor effects.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> So far, there are few subtype-selective or isoform-selective inhibitors that are noncytotoxic and better tolerated, and that effectively impair tumor growth in preclinical models.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35">(30−35)</a></div><div class="NLM_p">Eighteen known mammalian HDACs have been identified, which can be classified into four subgroups according to their homology to yeast enzymes: class I (HDAC1, 2, 3, and 8), class IIa (HDAC4, 5, 7, and 9), class IIb (HDAC6 and HDAC10), class III or sirtuins (SIRT 1–7), and class IV (HDAC11).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Class I, II, and IV HDACs require Zn<sup>2+</sup> (zinc ion) as a cofactor to exert their hydrolytic activity and are also referred to as the conventional HDACs. On the other hand, SIRT 1–7 are dependent on nicotinamide adenine dinucleotide for their activity.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In comparison with other HDAC family members, HDAC6 is relatively unique. It contains two tandem deacetylase catalytic domains (CD1 and CD2) and is primarily localized to the cytosol, and its preferred substrates include a variety of nonhistone proteins, such as α-tubulin, cortactin, HSP-90, and HSF-1.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Moreover, only CD2 exhibits catalytic activity with broad specificity.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Intriguingly, according to a patent survey based on the recent efforts on the synthesis and applications of HDACis from 2013 to 2017, most patents focused on the discovery of new HDAC6 inhibitors (HDAC6is).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Up to date, two partially selective HDAC6is, ricolinostat (ACY-1215)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and citarinostat (ACY-241),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> have been advanced into clinical trials for different types of cancer, such as multiple myeloma, lymphoma, breast cancer, and melanoma, through monotherapy or a combination approach. Moreover, selective HDAC6is have been considered as potential therapeutic agents for the treatment of various neurological disorders.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44−46)</a></div><div class="NLM_p">HDAC6 promotes the proliferation and metastasis of melanoma cells, and knockdown of HDAC6 decreases proliferation and induces the G1-cell cycle arrest of melanoma cells.<a onclick="showRef(event, 'ref28 ref47'); return false;" href="javascript:void(0);" class="ref ref28 ref47">(28,47)</a> Moreover, it was found that HDAC6 increases the protein level of tyrosine-protein phosphatase nonreceptor type 1 (PTPN1), which is responsible for promoting proliferation, colony formation, and migration while decreasing the apoptosis of melanoma cells through activating extracellular signal-regulated kinase 1/2 (ERK1/2).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> A preclinical study of ricolinostat showed that this partially selective HDAC6i-impaired proliferation and induced apoptosis of BRAF-mutant melanoma A375 cells.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Notably, the combination treatment of BRAF inhibitor vemurafenib and ricolinostat displayed a synergetic effect in BRAF-mutant melanoma cells partially through the induction of endoplasmic reticulum stress and inactivation of ERK.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In addition to the effects on survival, we have found that HDAC6 is a modulator of the expression of specific tumor-associated antigens, MHC class I, and costimulatory molecules in melanoma.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In previous works, we reported that either selective pharmacological inhibition or genetic abrogation of HDAC6 plays a critical role in the immune checkpoint blockade by downregulating the expression of PD-L1, which exhibits an opposite effect relative to class I and pan-HDACis.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Also, we recently found that the combination of a selective HDAC6i, nexturastat A (NextA), and PD-1 immune blockade resulted in significant improvement in antitumor immune responses leading to the further reduction of tumor growth compared to monotherapy.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Taken together, all the preclinical and clinical stage studies indicate that HDAC6 inhibition shows potential to become a promising approach for melanoma therapy. However, neither ricolinostat nor citarinostat can be considered to be highly selective HDAC6is because of their 10-fold enzymic selectivity against the class I isoform, HDAC1 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Therefore, there is a need for the advancement of drug candidates with higher selectivity and good pharmacologic attributes.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of recent published HDAC6 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A typical HDACi structure contains a zinc-binding group (ZBG) that coordinates the active-site Zn<sup>2+</sup> at the deep bottom of the substrate pocket, a linker to occupy the hydrophobic channel, and a capping group (cap) to interact with residues at the rim of the catalytic cavity. Recent results suggest that the connecting unit (CU) region that links the cap with the linker and ZBG may strongly impact the ligand’s selectivity toward HDAC6.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The phenylhydroxamate moiety has been recognized as a useful ZBG as well as a hydrophobic linker in the discovery of selective HDAC6is (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref31 ref34 ref55 ref56 ref57 ref58 ref59 ref60 ref61 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref31 ref34 ref55 ref56 ref57 ref58 ref59 ref60 ref61 ref62 ref63 ref64">(31,34,55−64)</a> The majority of recent advancements has concentrated on the development of hydroxamate analogues bearing a phenyl or pyrimidyl ring.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> Meanwhile, minimal effort has gone into developing linkers containing five-membered heteroaromatics such as thiazole and oxazole.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> Isoxazole is a five-membered heterocycle which contains two heteroatoms, one oxygen, and one nitrogen atom, in adjacent positions. Two double bonds contribute to the unsaturated character of the molecule. The structural features of isoxazole make it suitable for multiple noncovalent interactions, including hydrogen bonding (N and O as acceptors) and π–π stacking.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> We note that the isoxazole moiety is a central part of multiple compounds aimed at a wide spectrum of biological targets, and the inclusion of isoxazole in a structure may contribute to its increased efficacy, decreased toxicity, and improved pharmacokinetic profile.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Herein, we report the discovery of SS-208, a novel isoxazole-3-hydroxamate-based, selective HDAC6i, its structural characterization in a complex with the catalytic domain 2 of <i>Danio rerio</i> HDAC6 (drHDAC6), and the in vivo efficacy results in a syngeneic mouse model of melanoma.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">In our prior work, we identified an isoxazole-3-hydroxamate-based hit <b>1a</b>, which demonstrates potent HDAC6 inhibitory activity and modest potency against HDAC1, a member of class I HDACs,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> unlike its corresponding alkylhydroxamate (<b>1b</b>) and phenylhydroxamate (<b>1c</b>) analogues. Moreover, the compound <b>1d</b> incorporating the reverse direction of the amide CU dramatically loses selectivity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73">(71−73)</a> However, the nonideal physicochemical properties of <b>1a</b> [topological polar surface area (TPSA) = 168.82, MW = 457.44, calculated by SwissADME<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> and short half-lives (<i>t</i><sub>1/2</sub>) in microsomal stability studies (mouse: 16 min; human: 85 min, determined by Pharmaron, Inc., Irvine, CA) constitute an obstacle for its advance into in vivo studies. Notably, <b>1a</b> was incubated with two strains of <i>Salmonella typhimurium</i> (TA97A and TA1537) by Pharmaron in the presence and absence of mammalian microsomal enzymes (S9 mix) to evaluate the mutagenicity potential of the hydroxamate moiety.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The results in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf" class="ext-link">Table S1</a> indicate that <b>1a</b> is Ames-negative under the testing conditions, which encouraged us to pursue further structural tuning in order to discover more druggable isoxazole-3-hydroxamate-based HDAC6is.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of isoxazole-3-hydroxamate HDAC inhibitors <b>1a–d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To improve the physicochemical properties of this series of compounds, we started our optimization by replacing the Boc-protected phenylisoxazole cap with simple monocyclic and bicyclic aromatic rings (<b>7a–d</b>), while keeping the same ethylamide and isoxazole-3-hydroxamate moieties to maintain close structural similarity to <b>1a</b>. The synthetic routes to analogues <b>7a–d</b> as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> started from 3-butyn-1-ol (<b>2a</b>) and led to the preparation of the same 1-amino-3-butyne intermediate <b>4</b> through a Mitsunobu reaction using phthalimide/Ph<sub>3</sub>P/diethyl azodicarboxylate (DEAD). Subsequent deprotection and acylation with the appropriate acyl chlorides provided the alkyne intermediates <b>5a–d</b>. The acetylenic moieties in <b>5a–d</b> were transformed into the isoxazole esters <b>6a–d</b> by 1,3-dipolar cycloaddition with a nitrile oxide generated in situ from ethyl 2-chloro-2(hydroximino)acetate and a base under microwave conditions.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> These esters upon treatment with aqueous NH<sub>2</sub>OH/NaOH solution efficiently afforded the desired hydroxamic acids <b>7a–d</b> bearing aromatic caps.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to Compounds <b>7a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Phthalimide, Ph<sub>3</sub>P, DEAD, tetrahydrofuran (THF), 0 °C to rt, yield: 93%; (b) hydrazine monohydrate, MeOH, rt; (c) ArCOCl, TEA, dichloromethane (DCM), 0 °C, yields: 52–90% over two steps; (d) ethyl 2-chloro-2-(hydroxyimino)acetate, NaHCO<sub>3</sub>, EtOAc, 100 °C (MW), yields: 49–78%; (e) NH<sub>2</sub>OH (aq, 50%), NaOH, THF/MeOH (1:1), 0 °C to rt, yields: 10–43%.</p></p></figure><div class="NLM_p">Given the wide rim of the HDAC6 substrate pocket, aryl caps bearing a sterically bulky moiety are usually preferred to enhance inhibitor affinity and specificity via interactions with the residues forming the surface.<a onclick="showRef(event, 'ref55 ref64 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref55 ref64 ref77 ref78">(55,64,77,78)</a> Therefore, we further investigated the replacement of the cap and amide CU in <b>1a</b> with bicyclic and tricyclic caps. To prepare the indole-capped analogue <b>11a</b> illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, 1,3-dipolar cycloaddition of 5-hexyn-1-ol (<b>2b</b>) and ethyl 2-chloro-2(hydroximino)acetate was conducted to establish the key isoxazole ester <b>8a</b> from the beginning. Subsequently, <b>8a</b> underwent bromination with CBr<sub>4</sub>/Ph<sub>3</sub>P, N-alkylation under Cs<sub>2</sub>CO<sub>3</sub>/<i>N</i>,<i>N</i>-dimethylformamide (DMF) conditions, and transformation into the desired hydroxamate analogue <b>11a</b> in the presence of aqueous NH<sub>2</sub>OH/NaOH solution. The synthetic routes to <b>11b–c</b> started from 4-chloroaniline (<b>12</b>), which was first converted to the <i>N</i>-phenyl amides <b>13a–b</b> by treating with 3-chloropropanoyl chloride and 3,3-dimethylacryloyl chloride, respectively. Subsequently, intramolecular Friedel–Crafts cyclization under AlCl<sub>3</sub> conditions followed by the reduction of the intermediate lactam with LiAlH<sub>4</sub> afforded tetrahydroquinolines <b>14a–b</b>.<a onclick="showRef(event, 'ref63 ref79'); return false;" href="javascript:void(0);" class="ref ref63 ref79">(63,79)</a> Reductive amination of <b>14a–b</b> and the aldehyde intermediate <b>9b</b> which was prepared from <b>8a</b> by pyridinium chlorochromate (PCC) oxidation, provided the corresponding esters <b>10b–c</b>. In the end, the desired hydroxamate analogues <b>11b–c</b> were obtained using the same standard procedure as above. The synthetic route to the dibenz[<i>b</i>,<i>f</i>]azepine-capped analogue <b>11d</b> began with the dichlorination of <b>15</b> using <i>N</i>-chlorosuccinimide (NCS)/silica gel<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> followed by N-alkylation with 1,4-dibromobutane under NaH/DMF conditions and alkynation with sodium acetylide to provide the key dibenz[<i>b</i>,<i>f</i>]azepine-substituted alkyne <b>18</b>. Then, the building block <b>18</b> underwent 1,3-dipolar cycloaddition, and the desired isoxazole-3-hydroxamate <b>11d</b> was then obtained in the usual manner.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes to Compounds <b>11a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Ethyl 2-chloro-2-(hydroxyimino)acetate, NaHCO<sub>3</sub>, EtOAc, 100 °C (MW), yields: 67–87%; (b) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, rt, yield: 89%; (c) 5,6-dichloro-1<i>H</i>-indole, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 80%; (d) NH<sub>2</sub>OH (aq, 50%), NaOH, THF/MeOH (1:1), 0 °C to rt, yields: 34–94%; (e) PCC, DCM, rt, yield: 88%; (f) 3-chloropropanoyl chloride, acetone, reflux, yield: 54%; (g) (i) AlCl<sub>3</sub>, 140 °C (neat), (ii) LiAlH<sub>4</sub>, THF, 0 °C to reflux, yield: 70% over two steps; (h) <b>9b</b>, NaBH(OAc)<sub>3</sub>, AcOH/EtOH, rt, yields: 42–58%; (i) 3,3-dimethylacryloyl chloride, CHCl<sub>3</sub>, reflux, yield: 48%; (j) (i) AlCl<sub>3</sub>, toluene, 80 °C, (ii) LiAlH<sub>4</sub>, THF, 0 °C to reflux, yield: 55% over two steps; (k) NCS, silica gel, CHCl<sub>3</sub>, rt, yield: 74%; (l) 1,4-dibromobutane, NaH, DMF, rt, yield: 43%; (m) sodium acetylide, xylene/DMF, 40 °C, yield: 25%.</p></p></figure><div class="NLM_p">As a 3,4-dichlorophenyl cap on <b>7b</b> retained the HDAC6 potency and selectivity over HDAC1 (data are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), we further synthesized compounds <b>20a–c</b> in order to evaluate the effects of the amide CU and isoxazole-based ZBG. To prepare the analogue <b>20a</b> which contains an ether linker in place of the amide group, the synthetic route shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> was followed. 1,3-Dipolar cycloaddition between 4-pentyn-1-ol (<b>2c</b>) and ethyl 2-chloro-2-(hydroximino)acetate generated the isoxazole ring (compound <b>8b</b>). This intermediate underwent bromination with CBr<sub>4</sub>/Ph<sub>3</sub>P followed by O-alkylation with 3,4-dichlorophenol under Cs<sub>2</sub>CO<sub>3</sub>/DMF conditions. The synthesis was completed as above to afford the desired hydroxamate <b>20a</b>. To synthesize analogue <b>20b</b> which only contains an alkyl chain rather than an amide group, the α,β-unsaturated carboxylic acid in the starting material <b>21</b> was first transformed into a bromoalkyl intermediate <b>22</b> through LiAlH<sub>4</sub> reduction and bromination with CBr<sub>4</sub>/Ph<sub>3</sub>P. Compound <b>22</b> was further converted to the nitrile <b>23</b> with NaCN. Subsequent hydrolysis under basic condition and borane reduction provided the butanol <b>24</b>. The alkyne <b>25</b> was obtained through bromination and alkynation under similar conditions as described above and underwent 1,3-dipolar cycloaddition and conversion to the hydroxamic acid <b>20b</b>. The synthetic route to the benzyl hydroxamate analogue <b>20c</b> started from the Cu(OAc)<sub>2</sub>-catalyzed one-pot conversion of 3,4-dichlorobenzaldehyde (<b>26</b>) into 3,4-dichlorobenzamide (<b>27</b>) through a Beckmann-type rearrangement.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Subsequent reductive N-alkylation of the amide intermediate <b>27</b> using trifluoroacetic acid (TFA)/Et<sub>3</sub>SiH with methyl 4-formylbenzoate led to the generation of the corresponding ester <b>19c</b>,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> which upon standard treatment afforded the desired hydroxamate <b>20c</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes to Compounds <b>20a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) ethyl 2-chloro-2-(hydroxyimino)acetate, NaHCO<sub>3</sub>, EtOAc, 100 °C (MW), yields: 58–96%; (b) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, rt, yield: 83%; (c) 3,4-dichlorophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, yield: 80%; (d) NH<sub>2</sub>OH (aq, 50%), NaOH, THF/MeOH (1:1), 0 °C to rt, yields: 30–40%; for <b>20c</b>, yield: 22% over three steps; (e) (i) LiAlH<sub>4</sub>, THF, 0 °C to reflux, (ii) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, 0 °C to rt, yield: 11% over two steps; (f) NaCN, dimethyl sulfoxide (DMSO), 100 °C, yield: 72%; (g) (i) aq NaOH, EtOH, reflux, (ii) BH<sub>3</sub>-THF, THF, 0 °C to rt, yield: 88% over two steps; (h) (i) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, rt, (ii) sodium acetylide, DMF, 40 °C, yield: 39% over two steps; (i) NH<sub>2</sub>OH·HCl, K<sub>2</sub>CO<sub>3</sub>, Cu(OAc)<sub>2</sub>, H<sub>2</sub>O, reflux; (j) TFA, Et<sub>3</sub>SiH, methyl 4-formylbenzoate, toluene, reflux.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. HDAC1 and HDAC6 Enzymatic Evaluation of Analogues <b>7a–d</b>, <b>11a–d</b>, and <b>20a–c</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0011.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of two experiments obtained from curve-fitting of a 10-point enzymatic assay starting from 30 μM with 3-fold serial dilution against HDAC1 and HDAC6 (Reaction Biology Corp, Malvern, PA).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SI: HDAC6 selectivity over HDAC1.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">LE: ligand efficiency = 1.4 × pIC<sub>50</sub>/number of heavy atoms.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">LipE: lipophilic ligand efficiency = pIC<sub>50</sub> – clog <i>P</i><sub>o/w</sub>.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">IC<sub>50</sub> values were extracted from the article by Gaisina, I. N. et al., <i>ChemMedChem</i><b>2016,</b><i>11,</i> 81–92.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">IC<sub>50</sub> values were extracted from the article by Kozikowski, A. P. et al., <i>ACS Chem. Neurosci.</i><b>2019,</b><i>10,</i> 1679–1695.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">TSA: trichostatin A.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> HDAC Isoform Inhibition</h3><div class="NLM_p">To evaluate isoform potency and selectivity of all new analogues (<b>7a–d</b>, <b>11a–d</b>, and <b>20a–c</b>), we first prescreened their inhibitory activity against human HDAC6 and HDAC1 in vitro (performed by Reaction Biology Corp, Malvern, PA). As illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the replacement of the phenylisoxazole cap of the parent compound <b>1a</b> with phenyl rings as in compounds <b>7a–b</b> led to a 12.5-fold to 32-fold decrease in inhibitory potency for HDAC6, while micromolar inhibition values against HDAC1 remained constant. Compounds <b>7c–d</b>, in which the cap moiety was replaced with a naphthyl or biphenyl group, retained low nanomolar inhibitory potency for HDAC6 with a concomitant decrease of the HDAC1/HDAC6 selectivity index. Notably, this replacement significantly decreased the number of heavy atoms and TPSA values compared to the hit <b>1a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf" class="ext-link">Table S2</a>) and improved the ligand efficiency (LE) values beyond 0.4 while keeping the lipophilic ligand efficiency (LipE) values above 5.0 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> The incorporation of sterically bulky caps into the molecule to form the bicyclic- or tricyclic-capped analogues <b>11a–d</b> resulted in a significant decrease in potency, and none of them delivered meaningful LE values (LE and LipE). The replacement of the amide moiety in <b>7b</b> with an ether (<b>20a</b>) or alkyl chain (<b>20b</b>) was also disadvantageous, as it resulted in a 3-fold to 26-fold decrease in HDAC6 potency, suggesting that the amide moiety is necessary for retaining high potency in this class. Compared to <b>7b</b>, its corresponding phenylhydroxamate analogue <b>20c</b> demonstrated about 3-fold improvement in HDAC6 potency (IC<sub>50</sub> = 28 nM) and similar LE values. However, the isozyme selectivity significantly fell to around 7-fold, and the observed trend replicates finding for the <b>1a</b> and <b>1c</b> pair (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Based on the evaluation results of LE and maintained modest potency against HDAC1, we chose compound <b>7b</b>, named SS-208, for further investigation.</div><div class="NLM_p">To fully evaluate the advantage of isoxazole-3-hydroxamates relative to the typical phenylhydroxamate-based HDAC6 inhibitors, we assessed SS-208, <b>20c</b>, and NextA against Class I HDACs 1 and 8, Class IIa HDACs 4, 5, 7, and 9, Class IIb HDAC6, and Class IV HDAC11 in-house. The HDAC profiling against Class IIa and Class IV isoforms shows that SS-208 only exhibited micromolar potency against all these isoforms. In the side-by-side comparison with the selective HDAC6i, NextA, SS-208 exhibited similarly low nanomolar HDAC6 inhibitory activity with better selectivity over all the other tested HDAC isoforms (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. HDAC Profiles of the 3,4-Dichlorophenyl Capped Compounds SS-208 and <b>20c</b>, As Well As NextA<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0012.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are the mean of two experiments ± SEM obtained from curve-fitting of a 10-point enzymatic assay starting from 100 μM with 3-fold serial dilution against the HDAC isoform.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">SI: HDAC6 selectivity index over other HDAC isoforms.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Crystallization Studies</h3><div class="NLM_p">The recently published co-crystal structures of phenylhydroxamate-based HDAC6is in complex with drHDAC6 displayed a unusual monodentate phenylhydroxamate-Zn<sup>2+</sup> coordination geometry, while a bidentate coordination is generally observed for inhibitors that possess either flexible aliphatic linkers or aromatic linkers lacking a cap.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> The recent findings demonstrated that the caps attached to phenylhydroxamate affect the coordination between the hydroxamates and the catalytic Zn<sup>2+</sup> to be bidentate or monodentate, which is also crucial to stabilize the monodentate coordination mode that is slightly less stable (0.5 kcal/mol) than the bidentate coordination mode.<a onclick="showRef(event, 'ref85 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref87">(85,87)</a> Moreover, the key residues H463, P464, F583, and L712 create an L1-loop pocket to provide a rigid binding site for hydrophobic caps. Recent research further supports that the interaction between the ligand and L1-loop pocket is critical for maintaining high selectivity against class I HDACs.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p">To investigate the molecular basis of interactions between SS-208 and HDAC6, we solved the crystal structure of the drHDAC6-CD2/SS-208 complex to an ultra-high resolution limit of 1.15 Å. The binding of SS-208 to HDAC6 did not cause any major structural rearrangement of the enzyme as documented by the root-mean-square deviation of 0.15 Å for 300 Cα atoms between the drHDAC6/SS-208 complex and the unliganded enzyme (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM">5EEM</a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The hydroxamate functional group of SS-208 coordinates the active-site zinc ion in a canonical bidentate fashion, forming a typical five-membered chelate complex with an interatomic distance of 2.1 Å between the Zn<sup>2+</sup> and each of the hydroxamate C═O and N–O groups (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Moreover, the hydroxamate C═O group accepts a hydrogen bond from the hydroxyl group of Y745 (2.7 Å), and the N–O– group forms hydrogen bonds with the side chains of H573 (2.6 Å) and H574 (2.5 and 2.9 Å). The isoxazole ring and the distal ethylene part of the linker are positioned within van der Waals distances from the side chains of F583, F643, and L712. The C═O group of the amide moiety establishes an interaction with S531 in a distance of 3.3 Å, and the N–H group engages in a water-mediated interaction with H614 as observed in the binding with other HDAC6is in the literature.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Finally, the capping dichlorophenyl ring packs against the hydrophobic patch at the entrance of the internal tunnel, the L1-loop pocket, formed by the side chains of H463, P464, F583, and L712 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of the drHDAC6-CD2/SS-208 complex. (A) Detailed view of the substrate tunnel of HDAC6 in the complex with SS-208. <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> maps (green mesh) for SS-208 are contoured at 4.0 σ and the inhibitor and selected HDAC6 residues are shown in stick representation with atoms colored grey (carbon), red (oxygen), blue (nitrogen), and green (chlorine). The active-site zinc ion and water molecules are shown as orange and red spheres, respectively. H-bonds and salt bridges are shown as dashed lines. (B) Interactions between the capping dichlorophenyl moiety and the “L1-loop pocket” formed by side chains of H463, P464, F583, and L712 (colored blue). The surface of HDAC6 is shown in a semitransparent surface representation. (C) Superposition of SS-208 and DDK-115 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DVL">6DVL</a>) in the substrate tunnel of HDAC6. Carbon atoms are colored green and pink for SS-208 and DDK-115, respectively. The active-site zinc ion is coordinated in a bidentate fashion by SS-208, while the monodentate coordination is observed for DDK-115, resulting in a 0.5 Å shift of the SS-208 ring closer toward the zinc ion.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is interesting to note that the bidentate zinc ion coordination reported here differs from the preferred monodentate coordination observed in drHDAC6 complexes where a phenylhydroxamate group is capped by a hydrophobic moiety of an inhibitor.<a onclick="showRef(event, 'ref40 ref85 ref87'); return false;" href="javascript:void(0);" class="ref ref40 ref85 ref87">(40,85,87)</a> In our complex, the center of the isoxazole ring is shifted by 0.5 Å toward the active-site Zn<sup>2+</sup>, and this shift stems from the bidentate coordination of the Zn<sup>2+</sup> by the hydroxamate moiety (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). This shift is likely facilitated by the presence of a “long” four-atom linker between the isoxazole ring and the capping dichlorophenyl moiety, allowing thus for the more energetically favorable bidentate hydroxamate coordination while simultaneously preserving hydrophobic interactions between the cap and the L1-loop pocket.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> HDAC Target Engagement Measurement in HEK293 Cells</h3><div class="NLM_p">We further assessed the potency and selectivity of SS-208 in live cells using a NanoBERT-target engagement assay to investigate its binding characteristics with HDAC1 and HDAC6 within intact cells.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> These results performed in HEK293 are summarized in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, and suggest that SS-208 retains modest activity against HDAC1 in cells (IC<sub>50</sub> = 6.67 μM), while the measured potency of SS-208 against the α-tubulin preferring deacetylase domain of HDAC6, the catalytic domain 2 (IC<sub>50</sub> = 0.5 μM), indicates that SS-208 retains about 13-fold selectivity over HDAC1 in cells (418-fold enzymatic selectivity over HDAC1 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) which is comparable with our recent observation of another highly selective HDAC6i, SW-100, tested under the same conditions.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> SW-100 showed an IC<sub>50</sub> value of 2.3 nM against HDAC6 and 2273-fold selectivity over HDAC1 in the enzymatic assay, while it exhibited an IC<sub>50</sub> of 0.10 μM against HDAC6-CD2 and 46-fold selectivity over HDAC1 in the cellular target engagement assay.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Vorinostat (SAHA), tested as a positive control, demonstrated to be potent and nonselective toward HDAC6-CD2 (IC<sub>50</sub> = 0.24 μM) as well as HDAC1 (IC<sub>50</sub> = 0.12 μM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SS-208 selectively inhibits HDAC6-CD2 in cells. The HDAC1 and HDAC6 (catalytic domain 2) NanoBRET target engagement assay for compound SS-208 in HEK293. IC<sub>50</sub> values are the mean of four technical replicates ± SD obtained from curve-fitting of a 12-point engagement assay starting from a concentration of 20 μM with 3-fold serial dilution. SAHA was used as a positive control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Initial ADMET Properties</h3><div class="NLM_p">To evaluate the potential mutagenicity of this hydroxamate-based compound, SS-208 was incubated with two strains of <i>S. typhimurium</i> (TA98 and TA1537) in the presence and absence of mammalian microsomal enzymes (S9 mix). SS-208 did not induce ≥2-fold increases (for tester strain TA98) or ≥3-fold increases (for tester strain TA1537) in the mean number of revertant colonies at any dose levels when compared to the concurrent negative/solvent control, both in the presence and absence of the S9 mix, thus supporting the lack of mutagenicity of SS-208 under the conditions of the Ames assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf" class="ext-link">Table S3</a>). No significant inhibition was observed in the hERG assay up to 30 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf" class="ext-link">Figure S1</a>). The liver microsomal stability is shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> (half-lives of 37 and 135 min in mouse and human microsomes, respectively). This constitutes an improvement relative to the original compound <b>1a</b>. Moreover, half-lives of 22 and 135 min in mouse and human hepatocytes were determined, respectively.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Initial ADMET Profiling of Compound SS-208<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Ames test (with and without S9)</th><th class="colsep0 rowsep0" align="center">TA98, TA1537</th><th class="colsep0 rowsep0" align="center">negative</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG test (IC<sub>50</sub>, μM)</td><td class="colsep0 rowsep0" align="left">HEK293 cells</td><td class="colsep0 rowsep0" align="left">>30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">liver microsomal stability (<i>t</i><sub>1/2</sub> min, with NADPH)</td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">135</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">hepatocytes stability (<i>t</i><sub>1/2</sub> min)</td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">108</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All the ADMET assays were conducted by Pharmaron, Inc., Irvine, CA.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Inhibitory Potency of SS-208 is Comparable to NextA and Tubastatin A in Cancer Cells</h3><div class="NLM_p">As mentioned before, several selective HDAC6is are currently available for preclinical research. Among them, NextA and tubastatin A (TubA) were reported by our group.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> Although these two compounds have shown outstanding in vivo antitumor effects in numerous syngeneic tumor models,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> they were found to be Ames-positive (data are not shown). We thus wanted to compare the Ames-negative HDAC6i SS-208 with these two previously reported HDAC6is. We performed an initial screening of the in vitro activity of SS-208 by evaluating the acetylation status of α-tubulin (Ac-α-Tubulin), the best characterized physiological substrate of HDAC6. As expected, SS-208 increased Ac-α-Tubulin levels in SM1 murine melanoma (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) and WM164 human melanoma (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Additionally, SS-208 had a negligible effect on the levels of acetylated histone H3 (Ac-H3) in SM1 murine melanoma cells, and these findings are comparable to the results of experiments where NextA was used (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SS-208 activity is similar to other selective HDAC6is in cancer cells in vitro. (A) SS-208 treatment of SM1 murine melanoma cells resulted in increased Ac-α-Tubulin similar to other HDAC6is NextA and TubA. (B) Activity of HDAC6 inhibition with SS-208 was dose-dependent as indicated by the Western-blot analysis of Ac-α-Tubulin in WM164 human melanoma cells. (C) SM1 melanoma cells were treated with SS-208, NextA, or LBH589 for 24 h. The levels of Ac-H3 were evaluated by the Western-blot analysis. (D) SS-208, NextA, and TubA exhibited a similar inhibition of deacetylase activity when tested in a panel of cell lines of various tissue origins. (E) Similarly, HDAC6is did not induce cell death across the range of concentrations tested. (F) Multiplexed assay indicated that pan-HDACi, LBH589 exhibited apoptosis and cytotoxicity at concentrations as low as 100 nM, while the HDAC6is tested did not affect cell viability up to 10 μM. HDAC6is also did not induce apoptosis and cytotoxicity compared to LBH589.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We previously observed that the selective HDAC6is NextA and TubA had similar in vitro HDAC inhibitory potency across different human and murine cancer cell lines.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> A similar outcome was observed with SS-208, which was also comparable to the above-mentioned selective HDAC6is when tested in human PC3, human 5637, human T24, and mouse SM1 cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). We also observed that SS-208-induced minimal cell death in the concentration range evaluated above, and these results were also comparable to NextA and TubA (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E). Importantly, we have reported that the in vivo antitumor effect of selective HDAC6is is mainly mediated by their role as modulators of antitumor immune responses and that their direct cytotoxicity toward cancer cells is minimal at concentrations lower than 5 μM.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Supporting these previously reported findings, we observed that SS-208 has marginal effects on viability, cytotoxicity, and apoptosis in murine SM1 melanoma cells evaluated by the multiplexed Apotox assay (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>F). The absence of cytotoxic effects in cells treated with these selective HDAC6is is in sharp contrast to the effects observed with other pan-HDACis such as panobinostat (LBH589 in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>F), among others, therefore removing one of the most critical side effects of nonselective HDACis or other cytotoxic anticancer drugs.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> SS-208 Reduces the Expression of PD-L1 in Melanoma Cells</h3><div class="NLM_p">Our group has previously reported that the genetic and pharmacological targeting of HDAC6 affected the expression of the immunosuppressive molecule PD-L1 (CD274). The abrogation of HDAC6 activity results in the inactivation of the STAT3 pathways upon treatment with HDAC6is or knockdown of HDAC6.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> To further evaluate if SS-208 affects the processes mentioned above, we evaluated the activation of the STAT3 pathway by assessing the phosphorylation of STAT3 after treatment with SS-208 (5 μM). The Western blot results illustrated in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A demonstrated that SS-208 efficiently reduced IL-6-mediated Y705 phosphorylation of STAT3 and the subsequent downregulation of the PD-L1 expression. HDAC6 inhibition was evidenced by the increased levels of Ac-α-Tubulin. Further verification by qRT-PCR indicated that IL-6 significantly increased the CD274 gene expression by at least 2-fold compared to the untreated conditions, and SS-208 effectively negated the IL-6-induced CD274 gene expression suggesting that this HDAC6i regulates the PD-L1 expression at the mRNA level rather than through post-translational modifications at the protein level (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Immunomodulatory role of SS-208 by decreasing the expression of PD-L1 in melanoma cells. (A) SM1 murine melanoma cells were pre-treated with 5 μM of SS-208 followed by IL-6 treatment overnight and effectively reduced the expression of immunosuppressive molecule PD-L1 at the protein level. (B) SS-208 decreased IL-6 mediated STAT3 activation measured as Y705 phosphorylation and subsequently PD-L1 gene expression measured by qRT-PCR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> SS-208 Impairs Melanoma Tumor Growth in Immunocompetent Mice</h3><div class="NLM_p">The in vivo antitumor effect of selective HDAC6is has been extensively investigated.<a onclick="showRef(event, 'ref35 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref35 ref50 ref51">(35,50,51)</a> Importantly, this activity needs the presence of an intact host immune system.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Therefore, we wanted to evaluate whether SS-208 could also impair tumor growth in a syngeneic murine model with a functional immune system. To evaluate this possibility, we injected immunogenic murine SM1 melanoma cells subcutaneously in the flank of C57BL/6 mice and subsequently treated them with SS-208 (25 mg/kg, ip administration) or vehicle after one-week post tumor engraftment. As observed previously for other HDAC6is, the tumor growth was significantly reduced after treatment with SS-208 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,B), suggesting that this Ames-negative selective HDAC6i also exerts its antitumor effect by modulating the host immune system. To test this hypothesis, we evaluated the composition of different cellular components of the TME. Although we did not observe a significant infiltration of cytotoxic T cells (CD8+), their presence in the TME was slightly superior to the vehicle control (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C). Among other screened tumor-infiltrating lymphocytes, the infiltration of CD4+ T cells did not change (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). However, the infiltration of natural killer T cells (NKT) was significantly upregulated in the SS-208 treatment arm (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo antitumor activity of SS-208 is mediated through the modulation of TME. (A) SS-208 treatment (25 mg/kg, ip) significantly decreased the tumor growth compared to the control group in the SM1 murine melanoma syngeneic model. (B) Tumor growth curves of individual animals in control and SS-208 treatment groups. Animals receiving SS-208 treatment consistently showed a lower tumor volume during the course of the study compared to control groups. The decrease in tumor volume in the SS-208 treatment group was associated with the infiltration of intratumoral CD8+ T-cells (C), CD4+ T-cells (D), and a significant increase in NKT-cells (E). SS-208 treatment was associated with a significant increase in antitumor M1 macrophages (F), M2 macrophages (G), and the ratio of M1/M2 (H) which is an indication of effective antitumor immunity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The antitumoral M1 macrophage phenotype has been reported to have associated with a better prognosis in several malignancies, and there is an active search for agents improving their infiltration in tumors<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> On the other hand, tumor infiltration of pro-tumoral M2 macrophages is directly associated with a bad prognosis in cancer.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> In previous studies from our group, we observed a significant increase in the ratio of M1 and M2 macrophages in tumors treated with selective HDAC6is but not with other nonselective inhibitors.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> As expected, this outcome was also observed in the melanomas of the mice treated with SS-208 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>F–H), confirming that this compound possesses similar immunological properties as previously investigated NextA.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31482" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31482" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have designed and synthesized a series of HDAC6 inhibitors bearing isoxazole-3-hydroxamate instead of phenylhydroxamate as ZBG. By evaluating their inhibitory activities at HDAC isoforms, we found that: (a) the amide moiety is an important constituent of the CU to retain a high HDAC6 potency; (b) bulky caps, like napththyl and biphenyl groups, result in better HDAC6 activity but lower selectivity versus HDAC1; (c) the replacement of the corresponding phenylhydroxamate leads to a significant potency improvement against HDAC6 but the loss of hundred-fold HDAC1 selectivity. We have thus identified a novel potent and selective HDAC6i, namely, SS-208. The X-ray structure analysis of the crystallized complex of SS-208 with catalytic domain 2 from <i>D. rerio</i> HDAC6 demonstrates that: (a) the hydroxamate moiety coordinates in a distinct bidentate manner with the active-site zinc ion, forming a typical five-membered chelate complex, in contrast to the preferred monodentate coordination observed in most HDAC6 complexes with phenylhydroxamate-based inhibitors; (b) direct and indirect engagements are observed between the key amide moiety and amino acid residues in the active site that may be responsible for the ligand’s nanomolar HDAC6 potency; (c) the interactions between the 3,4-dichlorophenyl cap and the L1-loop pocket is critical for high selectivity against HDAC1. Both in vitro and in vivo ADMET profiling and pharmacological observation suggest that: (a) SS-208 shows Ames-negative results under testing conditions and no significant inhibition in the hERG assay, and is more metabolically stable relative to the original compound <b>1a</b>; (b) in murine and human melanoma cells, SS-208 induces minimal cell death and exhibits marginal effects on viability, cytotoxicity, and apoptosis, while significantly increasing the levels of Ac-α-Tubulin; (c) furthermore, SS-208 efficiently reduces the IL-6-mediated Y705 phosphorylation of STAT3 and downregulates the expression of PD-L1 at the mRNA levels in melanoma cells; (d) finally, SS-208 impairs tumor growth in a murine SM1 syngeneic melanoma mouse model which is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the TME.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> General Information</h4><div class="NLM_p"><sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on 400/101 and 500/126 MHz Bruker spectrometers, except where noted otherwise, using the solvent residual peak as the internal reference (chemical shifts: CDCl<sub>3</sub>, δ 7.26/77.0; DMSO-<i>d</i><sub>6</sub>, 2.50/39.52; acetone-<i>d</i><sub>6</sub>, 2.05/29.84 and 206.26). The following abbreviations for multiplicities were used: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dd = double doublet, dt = double triplet, ddd = double–double doublet, and br s = broad singlet. TLC plates (Merck silica gel 60 F<sub>254</sub>, 250 μm thickness) were used to monitor the reaction progress, and spots were visualized under UV (254 nm). High-resolution mass spectrometry (HRMS) was carried out on a Shimadzu IT-TOF instrument under the following conditions: column, ACE 3AQ (50 Χ 2.1 mm, id); mobile phase, 5–100% acetonitrile/water containing 0.1% formic acid at a flow rate of 0.5 mL/min for 4 min. Flash chromatography was performed on a CombiFlash Rf system (Teledyne ISCO) with silica gel cartridges. Preparative HPLC was used in the purification of all final compounds using a Shimadzu preparative LC under the following conditions: column, ACE 5AQ (150 × 21.2 mm, id); mobile phase: 5–100% acetonitrile/water containing 0.05% TFA at a flow rate of 17 mL/min for 30 min; UV detection at 254 and 280 nm. Analytical HPLC was used to determine the purity of all the final products using an Agilent 1260 series instrument under the following conditions: column, ACE 3 (150 × 4.6 mm, id); mobile phase, 5–100% acetonitrile/water containing 0.05% TFA at a flow rate of 1.0 mL/min for 25 min; UV detection at 254 nm. The purity of all the tested compounds for in vitro biological studies was >95%. The purity of SS-208 for crystallographic and in vivo studies was >98%.</div><div class="NLM_p">2-(But-3-yn-1-yl)isoindoline-1,3-dione (<b>3</b>). To a stirred solution of 3-butyn-1-ol (<b>2a</b>, 140 mg, 2.0 mmol), phthalimide (382 mg, 2.6 mmol), and Ph<sub>3</sub>P (682 mg, 2.6 mmol) was added DEAD (525 mg, 2.6 mmol) at 0 °C under an argon atmosphere. The resulting mixture was slowly warmed to room temperature and stirred at the same temperature for 2.5 h. Then, the reaction was quenched with H<sub>2</sub>O and extracted with EtOAc (20 mL × 3). The combined organic extracts were washed with brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–50% EtOAc/hexane) to afford <b>3</b> as a white powder (370 mg, 93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86 (dd, <i>J</i> = 5.5, 3.0 Hz, 2H), 7.73 (dd, <i>J</i> = 5.5, 3.0 Hz, 2H), 3.89 (t, <i>J</i> = 7.1 Hz, 2H), 2.62 (td, <i>J</i> = 7.1, 2.7 Hz, 2H), 1.96 (t, <i>J</i> = 2.7 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.0, 134.1, 132.0, 123.4, 80.3, 70.3, 36.6, 18.4.</div><div class="NLM_p"><i>N</i>-(But-3-yn-1-yl)benzamide (<b>5a</b>). General procedure A: (i) to a stirred solution of <b>3</b> (180 mg, 0.9 mmol) in MeOH (5 mL) was added hydrazine monohydrate (0.06 mL, 1.13 mmol. The resulting mixture was stirred at room temperature for 16 h. The precipitate was filtered off, and the filtrate was diluted with water (5 mL) and acidified to pH = 2 with 2 N HCl. The solution was concentrated under vacuum to afford <b>4</b> as a white powder. The crude product was used directly in the next step. (ii) To a stirred solution of <b>4</b> in DCM (5 mL) were added TEA (0.37 mL, 2.7 mmol) and benzoyl chloride (252 mg, 1.8 mmol) at 0 °C. Then, the resulting mixture was stirred at the same temperature for 30 min. The reaction was quenched with water (5 mL), and the mixture was extracted with DCM (10 mL × 3). The combined organic extracts were washed with brine (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–50% EtOAc/hexane) to afford <b>5a</b> as a white powder (140 mg, 90%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.94–7.92 (m, 3H), 7.58–7.53 (m, 1H), 7.52–7.45 (m, 2H), 3.57 (td, <i>J</i> = 7.1, 6.0 Hz, 2H), 2.55 (td, <i>J</i> = 7.1, 2.7 Hz, 2H), 2.43 (t, <i>J</i> = 2.7 Hz, 1H).</div><div class="NLM_p"><i>N</i>-(But-3-yn-1-yl)-3,4-dichlorobenzamide (<b>5b</b>)was synthesized from <b>3</b> (260 mg, 1.3 mmol) and 3,4-dichlorobenzoyl chloride (543 mg, 2.6 mmol) following general procedure A and was obtained as a colorless solid (220 mg, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.88 (d, <i>J</i> = 2.0 Hz, 1H), 7.60 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.52 (d, <i>J</i> = 8.3 Hz, 1H), 6.41 (s, 1H), 3.61 (q, <i>J</i> = 6.2 Hz, 2H), 2.53 (td, <i>J</i> = 6.3, 2.6 Hz, 2H), 2.07 (t, <i>J</i> = 2.6 Hz, 1H).</div><div class="NLM_p">Ethyl 5-(2-Benzamidoethyl)isoxazole-3-carboxylate (<b>6a</b>). General procedure B: to a solution of <b>5a</b> (140 mg, 0.8 mmol) in EtOAc (2 mL) were added NaHCO<sub>3</sub> (201 mg, 2.4 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (367 mg, 2.4 mmol) in a microwave reaction tube. The mixture was heated at 100 °C for 1 h in a microwave reactor. After completion of the reaction, the solid was filtered off and the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography (0–50% EtOAc/hexane) to afford <b>6a</b> as colorless oil (140 mg, 61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74 (dt, <i>J</i> = 7.1, 1.3 Hz, 2H), 7.55–7.46 (m, 1H), 7.46–7.36 (m, 2H), 6.51 (s, 2H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 3.82 (q, <i>J</i> = 6.4 Hz, 2H), 3.19 (t, <i>J</i> = 6.5 Hz, 2H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.7, 167.8, 159.9, 156.6, 134.1, 131.8, 128.7, 126.9, 102.7, 62.2, 37.9, 27.2, 14.1.</div><div class="NLM_p">Ethyl 5-(2-(3,4-Dichlorobenzamido)ethyl)isoxazole-3-carboxylate (<b>6b</b>) was synthesized from <b>5b</b> (220 mg, 0.9 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (408 mg, 2.7 mmol) following general procedure B and was obtained as a white solid (250 mg, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.85 (t, <i>J</i> = 5.5 Hz, 1H), 8.03 (d, <i>J</i> = 1.4 Hz, 1H), 7.82–7.71 (m, 2H), 6.76 (s, 1H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 3.60 (q, <i>J</i> = 6.5 Hz, 2H), 3.11 (t, <i>J</i> = 6.7 Hz, 2H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.5, 164.2, 159.6, 156.1, 134.6, 134.2, 131.3, 130.8, 129.2, 127.5, 102.5, 61.8, 37.4, 26.3, 14.0.</div><div class="NLM_p">Ethyl 5-(2-(2-Naphthamido)ethyl)isoxazole-3-carboxylate (<b>6c</b>). (i) <b>5c</b> was synthesized from <b>3</b> (215 mg, 1.08 mmol) and 2-naphthoyl chloride (246 mg, 1.3 mmol) following general procedure A and was obtained as a white powder (170 mg, 70%); (ii) <b>6c</b> was synthesized from <b>5c</b> (170 mg, 0.76 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (344 mg, 2.28 mmol) following general procedure B and was obtained as a white solid (150 mg, 58%).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.25 (s, 1H), 7.86–7.77 (m, 4H), 7.57–7.45 (m, 2H), 6.90 (t, <i>J</i> = 5.7 Hz, 1H), 6.50 (s, 1H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 3.85 (q, <i>J</i> = 6.5 Hz, 2H), 3.20 (t, <i>J</i> = 6.6 Hz, 2H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p">Ethyl 5-(2-(Biphenyl-3-ylcarboxamido)ethyl)isoxazole-3-carboxylate (<b>6d</b>). (i) <b>5d</b> was synthesized from <b>3</b> (215 mg, 1.08 mmol) and biphenyl-3-carbonyl chloride (280 mg, 1.3 mmol) following general procedure A and was obtained as a white powder (140 mg, 52%). (ii) <b>6d</b> was synthesized from <b>5d</b> (170 mg, 0.56 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (255 mg, 1.69 mmol) following general procedure B and was obtained as colorless oil (100 mg, 49%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.98 (s, 1H), 7.76–7.65 (m, 2H), 7.58–7.51 (m, 2H), 7.45–7.38 (m, 3H), 7.36–7.30 (m, 1H), 7.06 (t, <i>J</i> = 5.4 Hz, 1H), 6.47 (s, 1H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 3.78 (q, <i>J</i> = 6.5 Hz, 2H), 3.14 (t, <i>J</i> = 6.6 Hz, 2H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p">5-(2-Benzamidoethyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (<b>7a</b>). General procedure C: in a round-bottom flask, NaOH (160 mg, 4.0 mmol) was dissolved in 50% aqueous NH<sub>2</sub>OH (1.6 mL, approx. 50 equiv) at 0 °C. A solution of <b>6a</b> (140 mg, 0.5 mmol) in 1:1 THF/MeOH (6 mL) was added dropwise and stirring was continued for 30 min while the mixture was allowed to warm to room temperature. The solution was neutralized with 2 N HCl and extracted with EtOAc (15 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–10% MeOH/DCM) or preparative HPLC and lyophilized to afford <b>7a</b> as a white powder (60 mg, 43%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.68 (t, <i>J</i> = 5.5 Hz, 1H), 7.81 (d, <i>J</i> = 7.1 Hz, 2H), 7.53 (t, <i>J</i> = 7.3 Hz, 1H), 7.46 (t, <i>J</i> = 7.3 Hz, 2H), 6.63 (s, 1H), 3.60 (q, <i>J</i> = 6.6 Hz, 2H), 3.09 (t, <i>J</i> = 6.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.4, 166.4, 157.4, 156.2, 134.3, 131.3, 128.3 (2C), 127.1 (2C), 101.1, 37.2, 26.3. ESI HRMS: calcd for C<sub>13</sub>H<sub>14</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 276.0979; found, 276.0984.</div><div class="NLM_p">5-(2-(3,4-Dichlorobenzamido)ethyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (7b, SS-208) was synthesized from <b>6b</b> (250 mg, 0.7 mmol) following general procedure C and was obtained as a white powder (70 mg, 29%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.46 (s, 1H), 9.33 (s, 1H), 8.87 (t, <i>J</i> = 5.3 Hz, 1H), 8.04 (d, <i>J</i> = 1.6 Hz, 1H), 7.83–7.72 (m, 2H), 6.63 (s, 1H), 3.59 (q, <i>J</i> = 6.4 Hz, 2H), 3.09 (t, <i>J</i> = 6.8 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.3, 164.1, 157.4, 156.2, 134.5, 134.1, 131.3, 130.8, 129.1, 127.5, 101.2, 37.4, 26.1. ESI HRMS: calcd for C<sub>13</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 344.0205; found, 344.0198. Purity: 98.8% (254 nm).</div><div class="NLM_p">5-(2-(2-Naphthamido)ethyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (<b>7c</b>) was synthesized from <b>6c</b> (150 mg, 0.44 mmol) following general procedure C and was obtained as a white powder (15 mg, 10%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.45 (br s, 1H), 9.33 (br s, 1H), 8.85 (t, <i>J</i> = 5.2 Hz, 1H), 8.41 (s, 1H), 8.03–7.88 (m, 3H), 7.90 (d, <i>J</i> = 8.6 Hz, 1H), 7.63–7.57 (m, 2H), 6.66 (s, 1H), 3.66 (q, <i>J</i> = 6.5 Hz, 2H), 3.14 (t, <i>J</i> = 6.7 Hz, 2H). ESI HRMS: calcd for C<sub>17</sub>H<sub>16</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 326.1135; found, 326.1137.</div><div class="NLM_p">5-(2-([1,1′-Biphenyl]-3-ylcarboxamido)ethyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (<b>7d</b>) was synthesized from <b>6d</b> (100 mg, 0.27 mmol) following general procedure C and was obtained as an off-white powder (30 mg, 32%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.47 (br s, 1H), 9.33 (br s, 1H), 8.81 (t, <i>J</i> = 5.6 Hz, 1H), 8.08 (s, 1H), 7.82 (t, <i>J</i> = 7.4 Hz, 2H), 7.72 (d, <i>J</i> = 7.4 Hz, 2H), 7.56 (t, <i>J</i> = 7.7 Hz, 1H), 7.50 (t, <i>J</i> = 7.6 Hz, 2H), 7.41 (t, <i>J</i> = 7.1 Hz, 1H), 6.64 (s, 1H), 3.63 (q, <i>J</i> = 6.5 Hz, 2H), 3.12 (t, <i>J</i> = 6.8 Hz, 3H). ESI HRMS: calcd for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub>O<sub>4</sub> [M – H]<sup>+</sup><i>m</i>/<i>z</i>, 350.1146; found, 350.1136.</div><div class="NLM_p">Ethyl 5-(4-Hydroxybutyl)isoxazole-3-carboxylate (<b>8a</b>) was synthesized from 5-hexyn-1-ol (<b>2b</b>, 200 mg, 2.0 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (906 mg, 6.0 mmol) following general procedure B and was obtained as colorless oil (370 mg, 87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.41 (s, 1H), 4.42 (qd, <i>J</i> = 7.1, 1.3 Hz, 2H), 3.68 (td, <i>J</i> = 6.3, 1.3 Hz, 2H), 2.84 (t, <i>J</i> = 7.5 Hz, 2H), 1.90–1.76 (m, 2H), 1.67–1.60 (m, 2H), 1.40 (td, <i>J</i> = 7.1, 1.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.4, 160.3, 156.5, 101.7, 62.3, 62.2, 31.9, 26.6, 23.9, 14.3.</div><div class="NLM_p">Ethyl 5-(3-Hydroxypropyl)isoxazole-3-carboxylate (<b>8b</b>) was synthesized from 4-pentyn-1-ol (<b>2c</b>, 300 mg, 3.57 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (1.6 g, 10.7 mmol) following general procedure B and was obtained as colorless oil (680 mg, 96%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.42 (s, 1H), 4.40 (q, <i>J</i> = 7.1 Hz, 2H), 3.70 (t, <i>J</i> = 6.1 Hz, 2H), 2.92 (t, <i>J</i> = 7.6 Hz, 2H), 1.97–1.88 (m, 2H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.2, 160.3, 156.5, 101.8, 62.2, 61.3, 30.2, 23.3, 14.2.</div><div class="NLM_p">Ethyl 5-(4-Bromobutyl)isoxazole-3-carboxylate (<b>9a</b>). To a stirred solution of <b>8a</b> (100 mg, 0.47 mmol) in DCM (5 mL) were added CBr<sub>4</sub> (232 mg, 0.47 mmol) and Ph<sub>3</sub>P (184 mg, 0.47 mmol) at 0 °C. Then, the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL) and extracted with DCM (15 mL × 3). The combined organic extracts were washed with brine (30 mL), dried over Na<sub>2</sub>CO<sub>3</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–40% EtOAc/hexane) to afford <b>9a</b> as colorless oil (90 mg, 89%).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.41 (s, 1H), 4.40 (q, <i>J</i> = 7.1 Hz, 2H), 3.40 (t, <i>J</i> = 6.2 Hz, 2H), 2.83 (t, <i>J</i> = 6.9 Hz, 2H), 1.89–1.87 (m, 4H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.7, 160.2, 156.5, 101.8, 62.1, 32.8, 31.8, 26.0, 25.9, 14.2.</div><div class="NLM_p">Ethyl 5-(4-Oxobutyl)isoxazole-3-carboxylate (<b>9b</b>). To a stirred solution of <b>8a</b> (150 mg, 0.70 mmol) in DCM (5 mL) was added PCC (300 mg, 1.4 mmol) at room temperature. The resulting mixture was stirred at the same temperature for 2 h. Then, the solid was filtered off and the filtrate was concentrated under vacuum. The crude product was purified by flash chromatography (0–60% EtOAc/hexane) and <b>9b</b> was obtained as colorless oil (130 mg, 88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.75 (t, <i>J</i> = 1.1 Hz, 1H), 6.40 (s, 1H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 2.83 (t, <i>J</i> = 7.3 Hz, 2H), 2.53 (td, <i>J</i> = 7.1, 1.0 Hz, 2H), 2.11–1.94 (m, 2H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 200.9, 174.3, 160.1, 156.5, 101.9, 62.1, 42.6, 25.8, 19.8, 14.1.</div><div class="NLM_p">Ethyl 5-(3-Bromopropyl)isoxazole-3-carboxylate (<b>9c</b>) was synthesized from <b>8b</b> (680 mg, 3.42 mmol), CBr<sub>4</sub> (1.70 g, 5.13 mmol), and Ph<sub>3</sub>P (1.35 g, 5.13 mmol) using a procedure similar to that described for the synthesis of <b>9a</b> and was obtained as colorless oil (850 mg, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.46 (s, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 3.43 (t, <i>J</i> = 6.3 Hz, 2H), 3.01 (t, <i>J</i> = 7.3 Hz, 2H), 2.33–2.18 (m, 2H), 1.40 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 173.6, 160.1, 156.6, 102.3, 62.3, 31.9, 30.2, 25.3, 14.3.</div><div class="NLM_p">Ethyl 5-(4-(5,6-Dichloro-1<i>H</i>-indol-1-yl)butyl)isoxazole-3-carboxylate (<b>10a</b>). To a stirred solution of <b>9a</b> (90 mg, 0.33 mmol) in DMF (3 mL) were added 5,6-dichloro-1<i>H</i>-indole (56 mg, 0.30 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (217 mg, 0.66 mmol) at room temperature. The resulting mixture was heated at 80 °C overnight. The reaction was quenched with sat. NH<sub>4</sub>Cl aqueous solution (5 mL) and extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–30% EtOAc/hexane) to afford <b>10a</b> as colorless oil (90 mg, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.68 (s, 1H), 7.39 (s, 1H), 7.08 (d, <i>J</i> = 3.2 Hz, 1H), 6.42 (dd, <i>J</i> = 3.1, 0.7 Hz, 1H), 6.35 (s, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 4.09 (t, <i>J</i> = 6.9 Hz, 2H), 2.80 (t, <i>J</i> = 7.4 Hz, 2H), 1.92–1.85 (m, 2H), 1.77–1.65 (m, 2H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.5, 160.2, 156.6, 134.9, 129.7, 128.3, 125.7, 123.6, 122.1, 110.9, 101.9, 101.3, 62.3, 46.3, 29.5, 26.4, 25.0, 14.3.</div><div class="NLM_p">Ethyl 5-(4-(6-Chloro-3,4-dihydroquinolin-1(2<i>H</i>)-yl)butyl)isoxazole-3-carboxylate (<b>10b</b>). To a stirred solution of <b>9b</b> (130 mg, 0.62 mmol) and <b>14a</b> (104 mg, 0.62 mmol) in EtOH/AcOH (5 mL/0.5 mL) was added NaBH(OAc)<sub>3</sub> (263 mg, 1.24 mmol) at room temperature. Then, the resulting mixture was stirred at the same temperature overnight. The reaction was quenched with saturated aqueous NaHCO<sub>3</sub> solution (5 mL), and the mixture was extracted with DCM (10 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–20% EtOAc/hexane) to afford <b>11b</b> as colorless oil (130 mg, 58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.95 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.88 (d, <i>J</i> = 2.6 Hz, 1H), 6.42 (d, <i>J</i> = 8.0 Hz, 1H), 6.41 (s, 1H), 4.43 (q, <i>J</i> = 7.1 Hz, 2H), 3.29–3.12 (m, 4H), 2.84 (t, <i>J</i> = 7.3 Hz, 2H), 2.69 (t, <i>J</i> = 6.3 Hz, 2H), 1.94–1.88 (m, 2H), 1.80–1.72 (m, 2H), 1.67–1.60 (m, 2H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.1, 160.2, 156.5, 143.8, 128.8, 126.8, 124.1, 120.1, 111.5, 101.7, 62.2, 51.1, 49.5, 28.1, 26.7, 25.7, 25.2, 22.1, 14.2.</div><div class="NLM_p">Ethyl 5-(4-(6-Chloro-4,4-dimethyl-3,4-dihydroquinolin-1(2<i>H</i>)-yl)butyl)isoxazole-3-carboxylate (<b>10c</b>) was synthesized from <b>9b</b> (130 mg, 0.62 mmol) and <b>14b</b> (121 mg, 0.62 mmol) using a procedure similar to that described for the synthesis of <b>10b</b> and was obtained as colorless oil (100 mg, 42%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.10 (d, <i>J</i> = 2.6 Hz, 1H), 6.96 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.42 (d, <i>J</i> = 9.5 Hz, 1H), 6.41 (s, 1H), 4.43 (q, <i>J</i> = 7.1 Hz, 2H), 3.32–3.19 (m, 4H), 2.85 (t, <i>J</i> = 7.4 Hz, 2H), 1.80–1.64 (m, 6H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H), 1.25 (s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.1, 160.3, 156.5, 142.5, 132.9, 126.6, 126.1, 120.3, 111.7, 101.8, 62.2, 51.3, 45.9, 36.8, 32.3, 30.6 (2C), 26.8, 25.6, 25.3, 14.3.</div><div class="NLM_p">Ethyl 5-(4-(2,8-Dichloro-10,11-dihydro-5<i>H</i>-dibenz[<i>b</i>,<i>f</i>]azepin-5-yl)butyl)isoxazole-3-carboxylate (<b>10d</b>) was synthesized from <b>18</b> (100 mg, 0.30 mmol) and ethyl 2-chloro-2-(hydroxyimino)acetate (135 mg, 0.90 mmol) following general procedure B and was obtained as light-yellow oil (100 mg, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.09–7.08 (m, 4H), 6.96–6.93 (m, 2H), 6.31 (s, 1H), 4.43 (q, <i>J</i> = 7.1 Hz, 2H), 3.67 (t, <i>J</i> = 6.6 Hz, 2H), 3.10 (s, 4H), 2.74 (t, <i>J</i> = 7.4 Hz, 2H), 1.76–1.59 (m, 4H), 1.41 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p">5-(4-(5,6-Dichloro-1<i>H</i>-indol-1-yl)butyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (<b>11a</b>) was synthesized from <b>10a</b> (90 mg, 0.24 mmol) following general procedure C and was obtained as an off-white powder (35 mg, 39%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.43 (s, 1H), 9.32 (d, <i>J</i> = 1.6 Hz, 1H), 7.89 (s, 1H), 7.79 (s, 1H), 7.51 (d, <i>J</i> = 3.1 Hz, 1H), 6.51 (s, 1H), 6.46 (d, <i>J</i> = 3.1 Hz, 1H), 4.22 (t, <i>J</i> = 7.0 Hz, 2H), 2.82 (t, <i>J</i> = 7.5 Hz, 2H), 1.65–1.75 (m, 2H), 1.65–1.54 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 174.3, 157.4, 156.3, 134.7, 131.3, 127.9, 123.5, 121.5, 121.4, 111.7, 100.6, 100.5, 45.2, 29.14, 25.27, 24.12. ESI HRMS: calcd for C<sub>16</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub>Cl<sub>2</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 368.0563; found, 368.0555.</div><div class="NLM_p">5-(4-(6-Chloro-3,4-dihydroquinolin-1(2<i>H</i>)-yl)butyl)-<i>N</i>-hydroxyisoxazole-3-carboxa-mide (<b>11b</b>) was synthesized from <b>10b</b> (130 mg, 0.36 mmol) following general procedure C and was obtained as an off-white powder (100 mg, 79%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.43 (s, 1H), 6.93 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.88 (d, <i>J</i> = 2.7 Hz, 1H), 6.55 (s, 1H), 6.53 (d, <i>J</i> = 8.8 Hz, 1H), 3.29–3.16 (m, 4H), 2.84 (t, <i>J</i> = 7.4 Hz, 2H), 2.65 (t, <i>J</i> = 6.3 Hz, 2H), 1.86–1.77 (m, 2H), 1.69–1.64 (m, 2H), 1.57–1.50 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 174.5, 157.4, 156.3, 143.8, 128.1, 126.3, 123.8, 118.1, 111.6, 100.5, 50.0, 48.5, 27.4, 25.7, 24.7, 24.4, 21.3. ESI HRMS: calcd for C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>Cl [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 350.1266; found, 350.1256.</div><div class="NLM_p">5-(4-(6-Chloro-4,4-dimethyl-3,4-dihydroquinolin-1(2<i>H</i>)-yl)butyl)-<i>N</i>-hydroxyisoxazo-le-3-carboxamide (<b>11c</b>) was synthesized from <b>10c</b> (100 mg, 0.28 mmol) following general procedure C and was obtained as an off-white powder (100 mg, 94%).<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.43 (s, 1H), 7.07 (d, <i>J</i> = 2.7 Hz, 1H), 6.94 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.55 (s, 1H), 6.54 (d, <i>J</i> = 9.0 Hz, 1H), 3.28–3.21 (m, 4H), 2.84 (t, <i>J</i> = 7.3 Hz, 2H), 1.71–1.46 (m, 6H), 1.19 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 174.5, 163.0, 157.4, 142.5, 132.5, 126.2, 125.3, 118.4, 111.9, 100.5, 50.2, 44.7, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1, 38.9, 36.0, 31.8, 30.2 (2C), 25.6, 24.6, 24.5. ESI HRMS: calcd for C<sub>19</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub>Cl [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 378.1579; found, 378.1576.</div><div class="NLM_p">5-(4-(2,8-Dichloro-10,11-dihydro-5<i>H</i>-dibenz[<i>b</i>,<i>f</i>]azepin-5-yl)butyl)-<i>N</i>-hydroxyisoxa-zole-3-carboxamide (<b>11d</b>) was synthesized from <b>10d</b> (100 mg, 0.20 mmol) following general procedure C and was obtained as a white powder (30 mg, 34%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.09–7.07 (m, 4H), 6.95–6.92 (m, 2H), 6.37 (s, 1H), 3.66 (t, <i>J</i> = 6.5 Hz, 2H), 3.09 (s, 4H), 2.72 (t, <i>J</i> = 7.4 Hz, 2H), 1.76–1.68 (m, 2H), 1.63–1.57 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.2, 156.0, 154.0, 146.3 (2C), 135.7 (2C), 129.7 (2C), 127.9 (2C), 126.4 (2C), 121.2 (2C), 100.7, 50.0, 31.7 (2C), 26.8, 26.7, 24.8. ESI HRMS: calcd for C<sub>22</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 446.1033; found, 446.1030.</div><div class="NLM_p">3-Chloro-<i>N</i>-(4-chlorophenyl)propanamide (<b>13a</b>). To a round-bottom flask charged with 4-chloroaniline (<b>12</b>, 5.0 g, 39.4 mmol) in acetone (50 mL) was added 3-chloropropanoyl chloride (1.9 mL, 19.7 mmol) at room temperature. The resulting mixture was allowed to stir for 1 h under reflux conditions. The mixture was cooled to room temperature, quenched with 2 N HCl (30 mL), and extracted with EtOAc (25 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. <b>13a</b> was obtained as an off-white powder (4.6 g, 54%) and used directly in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.56 (br s, 1H), 7.46 (d, <i>J</i> = 8.7 Hz, 2H), 7.28 (d, <i>J</i> = 8.8 Hz, 2H), 3.87 (t, <i>J</i> = 6.3 Hz, 2H), 2.81 (t, <i>J</i> = 6.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 167.9, 136.0, 129.8, 129.1 (2C), 121.4 (2C), 40.4, 39.8.</div><div class="NLM_p"><i>N</i>-(4-Chlorophenyl)-3-methylbut-2-enamide (<b>13b</b>). To a round-bottom flask charged with 4-chloroaniline (<b>12</b>, 1.27 g, 10.0 mmol) in CHCl<sub>3</sub> (20 mL) was added 3,3-dimethylacryloyl chloride (1.18 g, 10.0 mmol). The resulting mixture was heated to reflux for 2 h. The mixture was cooled to room temperature and quenched with 2 N HCl (20 mL), and then extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–80% EtOAc/hexane) to afford <b>13b</b> as a white powder (1.00 g, 48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.54 (br s, 1H), 7.47 (d, <i>J</i> = 8.1 Hz, 2H), 7.22 (d, <i>J</i> = 8.8 Hz, 2H), 5.70 (s, 1H), 2.19 (s, 3H), 1.86 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 165.2, 154.0, 136.8, 128.8 (4C), 121.0, 118.4, 27.3, 20.0.</div><div class="NLM_p">6-Chloro-1,2,3,4-tetrahydroquinoline (<b>14a</b>). (i) In a three-necked flask charged with <b>13a</b> (4.6 g, 21.1 mmol) under an argon atmosphere was added AlCl<sub>3</sub> (5.47 g, 42.2 mmol) at 140 °C. The resulting mixture was stirred at the same temperature for 12 h. Then, the reaction was cautiously quenched with 1 N HCl (20 mL) at 0 °C, and the mixture was extracted with EtOAc (30 mL × 3). The combined organic extracts were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–80% EtOAc/hexane) to afford the lactam intermediate as a white powder (3.1 g, 17.1 mmol). (ii) To a stirred solution of LiAlH<sub>4</sub> (1.95 g, 51.4 mmol) in THF (30 mL) were added dropwise a solution of the lactam intermediate (3.1 g, 17.1 mmol) in THF (20 mL) at 0 °C. The resulting mixture was stirred at the same temperature for 20 min and then heated at reflux for an additional 1 h. The reaction was subsequently quenched with water (2.0 mL), 5 N NaOH (2.0 mL), and water (10 mL). The resulting precipitate was filtered off and washed with EtOAc (20 mL × 3). The filtrate was washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. <b>14a</b> was obtained as colorless oil (2.43 g, 70% over two steps) and used directly in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.93–6.86 (m, 2H), 6.38 (d, <i>J</i> = 8.0 Hz, 1H), 3.77 (br s, 1H), 3.33–3.15 (m, 2H), 2.72 (t, <i>J</i> = 6.4 Hz, 2H), 1.94–1.88 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 143.2, 128.8, 126.3, 122.7, 120.9, 114.9, 41.7, 26.7, 21.6.</div><div class="NLM_p">6-Chloro-4,4-dimethyl-1,2,3,4-tetrahydroquinoline (<b>14b</b>). (i) To a round-bottom flask charged with <b>13b</b> (1.0 g, 4.78 mmol) in Toluene (15 mL) was added AlCl<sub>3</sub> (2.50 g, 19.1 mmol) at room temperature. The resulting mixture was heated at 80 °C for 2 h. Then, the reaction was cautiously quenched with 1 N HCl (10 mL) at 0 °C, and the mixture was extracted with EtOAc (15 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–80% EtOAc/hexane) to afford the lactam intermediate as a brown powder (640 mg, 64%); (ii) to a stirred solution of LiAlH<sub>4</sub> (250 mg, 6.60 mmol) in THF (10 mL) was dropwise added the lactam intermediate (460 mg, 2.20 mmol) in THF (20 mL) at 0 °C. The resulting mixture was stirred at the same temperature for 20 min and then heated to reflux conditions for an additional 1 h. The reaction was subsequently quenched with water (0.5 mL), 5 N NaOH (0.5 mL), and water (2.5 mL). The resulting precipitate was filtered off and washed with EtOAc (20 mL × 3). The filtrate was washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–20% EtOAc/hexane) to afford compound <b>14b</b> as colorless oil (370 mg, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.05 (d, <i>J</i> = 2.5 Hz, 1H), 6.83 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.44 (d, <i>J</i> = 8.6 Hz, 1H), 5.91 (br s, 1H), 3.21–3.12 (m, 2H), 1.61–1.53 (m, 2H), 1.20 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 143.1, 130.5, 125.9, 125.3, 118.3, 114.8, 37.0, 36.0, 31.5, 30.3 (2C).</div><div class="NLM_p">2,8-Dichloro-10,11-dihydro-5<i>H</i>-dibenz[<i>b</i>,<i>f</i>]azepine (<b>16</b>). To a stirred solution of 10,11-dihydro-5<i>H</i>-dibenz[<i>b</i>,<i>f</i>]azepine (<b>15</b>, 500 mg, 2.56 mmol) in CHCl<sub>3</sub> (75 mL) was added at room temperature predried silica gel (10 g, 2 g per mmol of NCS). The mixture was stirred gently, and the reaction vessel covered with foil to exclude light. NCS (685 mg, 5.12 mmol) was then added portion-wise over 1 h at room temperature. The mixture was stirred at the same temperature overnight. After completion of the reaction, excess silica gel was removed by vacuum filtration. The filtrate was washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by flash chromatography using (0–10% EtOAc/hexane) to afford <b>16</b> as a white solid (500 mg, 74%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.04–7.02 (m, 4H), 6.65 (d, <i>J</i> = 6.2 Hz, 2H), 5.93 (s, 1H), 3.02 (s, 4H).</div><div class="NLM_p">2,8-Dichloro-5-(hex-5-yn-1-yl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>b</i>,<i>f</i>]azepine (<b>18</b>). (i) To a stirred solution of <b>16</b> (300 mg, 1.15 mmol) in DMF (5 mL) was slowly added NaH (60%, 140 mg, 3.45 mmol). The mixture was stirred at room temperature for 15 min, followed by a dropwise addition of 1,4-dibromobutane (364 mg, 1.7 mmol). The mixture was stirred at room temperature for 1 h. After completion of the reaction, 1 N HCl aqueous solution was added to adjust the pH to 6–7. Then, the solution was extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by flash chromatography (0–5% EtOAc/hexane) to afford <b>17</b> as colorless oil (200 mg, 43%). (ii) To a stirred solution of <b>17</b> (200 mg, 0.5 mmol) in xylene/DMF (2/2 mL) was added a sodium acetylide suspension (0.2 mL, 18 wt % slurry in xylene) under an argon atmosphere at room temperature. Then, the mixture was stirred at 40 °C overnight. After completion, the reaction solution was quenched with water (10 mL), and the mixture was extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by flash chromatography (0–5% EtOAc/hexane) to afford <b>18</b> (100 mg, 25%) as colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.09–7.07 (m, 4H), 6.97 (d, <i>J</i> = 9.0 Hz, 2H), 3.67 (t, <i>J</i> = 6.8 Hz, 2H), 3.10 (s, 4H), 2.14 (td, <i>J</i> = 7.0, 2.6 Hz, 2H), 1.89 (t, <i>J</i> = 2.6 Hz, 1H), 1.67–1.64 (m, 2H), 1.55–1.51 (m, 2H).</div><div class="NLM_p">Ethyl 5-(3-((3,4-Dichlorophenyl)amino)propyl)isoxazole-3-carboxylate (<b>19a</b>) was synthesized from <b>9c</b> (464 mg, 2.85 mmol) and 3,4-dichlorophenol (850 mg, 3.41 mmol) using a procedure similar to that described for the synthesis of <b>10a</b> and was obtained as colorless oil (490 mg, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.28 (d, <i>J</i> = 8.9 Hz, 1H), 6.94 (d, <i>J</i> = 2.8 Hz, 1H), 6.71 (dd, <i>J</i> = 8.9, 2.9 Hz, 1H), 6.43 (s, 1H), 4.41 (q, <i>J</i> = 7.1 Hz, 2H), 3.96 (t, <i>J</i> = 5.9 Hz, 2H), 3.00 (t, <i>J</i> = 7.5 Hz, 2H), 2.26–2.08 (m, 2H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.3, 160.1, 157.7, 156.5, 132.9, 130.8, 124.2, 116.4, 114.5, 102.0, 66.9, 62.2, 27.0, 23.4, 14.2.</div><div class="NLM_p">Ethyl 5-(4-(3,4-Dichlorophenyl)butyl)isoxazole-3-carboxylate (<b>19b</b>) was synthesized from <b>25</b> (18 mg, 0.1 mmol) following general procedure B and was obtained as colorless oil (20 mg, 58%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.34 (d, <i>J</i> = 8.2 Hz, 1H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 6.99 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 6.40 (s, 1H), 4.55–4.46 (m, 2H), 2.83 (t, <i>J</i> = 7.3 Hz, 2H), 2.61 (t, <i>J</i> = 7.4 Hz, 2H), 1.78–1.64 (m, 4H).</div><div class="NLM_p">5-(3-((3,4-Dichlorophenyl)amino)propyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (<b>20a</b>) was synthesized from <b>19a</b> (160 mg, 0.47 mmol) following general procedure C and was obtained as a white powder (65 mg, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.45 (s, 1H), 9.33 (s, 1H), 7.51 (d, <i>J</i> = 8.9 Hz, 1H), 7.23 (d, <i>J</i> = 2.9 Hz, 1H), 6.96 (dd, <i>J</i> = 8.9, 2.9 Hz, 1H), 6.60 (s, 1H), 4.06 (t, <i>J</i> = 6.1 Hz, 2H), 2.96 (t, <i>J</i> = 7.5 Hz, 2H), 2.15–2.03 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.8, 157.9, 157.5, 156.3, 131.6, 131.0, 122.4, 116.4, 115.5, 100.7, 67.2, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1, 38.9, 26.4, 22.6. ESI HRMS: calcd for C<sub>13</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 331.0247; found, 331.0244.</div><div class="NLM_p">5-(4-(3,4-Dichlorophenyl)butyl)-<i>N</i>-hydroxyisoxazole-3-carboxamide (<b>20b</b>) was synthesized from <b>19b</b> (50 mg, 0.15 mmol) following general procedure C and was obtained as an off-white powder (15 mg, 30%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.34 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (s, 1H), 6.98 (d, <i>J</i> = 7.7 Hz, 1H), 6.45 (s, 1H), 2.82 (t, <i>J</i> = 7.2 Hz, 2H), 2.60 (t, <i>J</i> = 7.2 Hz, 2H), 1.78–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 175.2, 169.0, 156.2, 141.9, 132.3, 130.3, 130.3, 129.9, 127.8, 100.8, 34.6, 30.3, 26.8, 26.5. ESI HRMS: calcd for C<sub>14</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 329.0454; found, 329.0456.</div><div class="NLM_p">3,4-Dichloro-<i>N</i>-(4-(hydroxycarbamoyl)benzyl)benzamide (<b>20c</b>). (i) To a stirred suspension of 3,4-dichlorobenzaldehyde (<b>26</b>, 1.04 g, 6.0 mmol) in water (20 mL) NH<sub>2</sub>OH·HCl (0.42 g, 6.0 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.83 g, 6.0 mmol) were added, followed by the addition of Cu(OAc)<sub>2</sub> (20 mg, 0.12 mmol). The reaction mixture was heated to reflux for 6 h. After completion of the reaction, the solution was extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was washed with Et<sub>2</sub>O to afford amide intermediate <b>27</b> as a white powder (0.80 g, 70%). (ii) To a suspension of 3,4-dichlorobenzamide (<b>27</b>, 0.80 g, 4.25 mmol) and methyl 4-formylbenzoate (232 mg, 1.41 mmol) in toluene (10 mL) was added TFA (325 μL, 4.25 mmol) and triethylsilane (677 μL, 4.25 mmol) at room temperature. The resulting mixture was heated to reflux overnight. After completion of the reaction, the solution was extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product <b>19c</b> containing excess dichlorobenzamide (∼800 mg) was advanced in the next step without further purification. (iii) Compound <b>20c</b> was synthesized from the crude compound <b>19c</b> (∼800 mg) following general procedure C and was obtained as an off-white powder (150 mg, 31% over two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.17 (s, 1H), 9.27 (t, <i>J</i> = 6.0 Hz, 1H), 8.99 (s, 1H), 8.13 (d, <i>J</i> = 2.1 Hz, 1H), 7.87 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.78 (d, <i>J</i> = 8.4 Hz, 1H), 7.71 (d, <i>J</i> = 8.0 Hz, 2H), 7.38 (d, <i>J</i> = 8.0 Hz, 2H), 4.51 (d, <i>J</i> = 5.9 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 164.0, 164.0, 142.4, 134.5, 134.1, 131.4, 131.3, 130.8, 129.2, 127.6, 127.2 (2C), 126.9 (2C), 42.6. ESI HRMS: calcd for C<sub>15</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup><i>m</i>/<i>z</i>, 339.0298; found, 339.0306.</div><div class="NLM_p">4-(3-Bromopropyl)-1,2-dichlorobenzene (<b>22</b>). (i) A suspension of LiAlH<sub>4</sub> (262 mg, 6.9 mmol) in THF (23 mmol, 0.3 M solution) was prepared in an ice bath and under an argon atmosphere. To this suspension was added dropwise a THF solution (8 mL) of 3,4-dichlorocinnamic acid (<b>21</b>, 500 mg, 2.3 mmol). After the addition of the substrate solution, the resulting mixture was left to warm to room temperature while stirring. Then, it was heated to reflux for 5 h. The reaction was quenched with water (0.3 mL), 5 N NaOH (0.3 mL), and water (1.5 mL), the precipitate was filtered off, and the filtrate was extracted with EtOAc (10 mL × 3). The organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–50% EtOAc/hexane) to afford the intermediate alcohol as colorless oil (80 mg, 17%). (ii) To a stirred solution of the intermediate (80 mg, 0.40 mmol) in DCM (5 mL) were added CBr<sub>4</sub> (194 mg, 0.6 mmol) and Ph<sub>3</sub>P (160 mg, 0.6 mmol) at 0 °C. Then, the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL), extracted with DCM (10 mL × 3). The combined organic extracts were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–20% EtOAc/hexane) to afford <b>22</b> as colorless oil (70 mg, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36 (d, <i>J</i> = 8.2 Hz, 1H), 7.29 (d, <i>J</i> = 2.0 Hz, 1H), 7.04 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 3.38 (t, <i>J</i> = 6.4 Hz, 2H), 2.79–2.70 (m, 2H), 2.19–2.08 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 140.8, 132.4, 130.5, 130.4, 130.2, 128.0, 33.7, 33.1, 32.5.</div><div class="NLM_p">4-(3,4-Dichlorophenyl)butanenitrile (<b>23</b>). To a solution of <b>22</b> (70 mg, 0.26 mmol) in DMSO (3 mL) were added NaCN (115 mg, 2.36 mmol) at room temperature. Then, the resulting mixture was heated at 100 °C for 1 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (10 mL × 3). The combined organic extracts were washed with aqueous FeSO<sub>4</sub> solution (10 mL) and brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. Compound <b>23</b> was obtained as yellow oil (40 mg, 72%) and used directly into the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37 (dd, <i>J</i> = 8.2, 0.8 Hz, 1H), 7.28 (d, <i>J</i> = 1.2 Hz, 1H), 7.03 (dd, <i>J</i> = 8.2, 1.5 Hz, 1H), 2.75 (t, <i>J</i> = 7.5 Hz, 2H), 2.34 (t, <i>J</i> = 7.0 Hz, 2H), 1.96 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 140.0, 132.6, 130.6, 130.4 (2C, overlapping), 127.9, 119.1, 33.5, 26.6, 16.4.</div><div class="NLM_p">4-(3,4-Dichlorophenyl)butan-1-ol (<b>24</b>). (i) To a stirred solution of <b>23</b> (40 mg, 0.19 mmol) in EtOH (1 mL) was added 50% w/v aq NaOH (1 mL) at room temperature. The resulting mixture was heated at 80 °C for 3 h. Then, the mixture was diluted with water (5 mL) and extracted with EtOAc (10 mL × 3). The aqueous layer was separated and acidified with 2 N HCl to pH = 3–4, then extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude carboxylic acid product was obtained as a pink solid (40 mg, 90%) and used directly in the next step without further purification. (ii) To a stirred solution of the carboxylic acid (40 mg, 0.17 mmol) in THF (3 mL) was added BF<sub>3</sub>·THF (1 M in THF, 0.34 mL) at 0 °C after 5 min. The resulting mixture was allowed to warm to room temperature overnight. The reaction was quenched with 1 N NaOH, and the mixture was extracted with EtOAc (10 mL × 3). The combined organic layers were washed with water (30 mL) and brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. <b>24</b> was obtained as colorless oil (40 mg, 98%) and used directly in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.33 (d, <i>J</i> = 8.2 Hz, 1H), 7.27 (d, <i>J</i> = 1.8 Hz, 1H), 7.01 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 3.66 (t, <i>J</i> = 6.3 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 1.74–1.64 (m, 2H), 1.62–1.55 (m, 2H), 1.53 (br s, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 142.6, 132.2, 130.3, 130.2, 129.7, 127.9, 62.6, 34.8, 32.1, 27.3.</div><div class="NLM_p last">1,2-Dichloro-4-(hex-5-yn-1-yl)benzene (<b>25</b>). (i) To a stirred solution of <b>24</b> (40 mg, 0.18 mmol) in DCM (3 mL) were added CBr<sub>4</sub> (90 mg, 0.27 mmol) and Ph<sub>3</sub>P (70 mg, 0.27 mmol) at 0 °C. Then, the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL) and extracted with DCM (10 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The crude product was purified by flash chromatography (0–20% EtOAc/hexane) to afford the intermediate bromide as colorless oil (20 mg, 40%). (ii) To a stirred solution of the bromide (20 mg, 0.07 mmol) in DMF (2 mL) was added a sodium acetylide suspension (18 wt % slurry in xylene, 0.03 mL) under an argon atmosphere. The resulting mixture was stirred at 40 °C overnight. The reaction was quenched with water (5 mL), extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. <b>25</b> was obtained as colorless oil (18 mg, 98%) and used directly in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.33 (d, <i>J</i> = 8.2 Hz, 1H), 7.28–7.25 (m, 1H), 7.01 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 2.59 (t, <i>J</i> = 7.7 Hz, 2H), 2.22 (td, <i>J</i> = 7.0, 2.6 Hz, 2H), 1.95 (t, <i>J</i> = 2.6 Hz, 1H), 1.74–1.70 (m, 2H), 1.58–1.51 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 142.4, 132.2, 130.3, 130.2, 129.7, 127.9, 84.0, 68.6, 34.5, 30.0, 27.8, 18.2.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> HDAC 1 and 6 Enzymatic Assay Procedure</h3><div class="NLM_p last">HDAC inhibition assays in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were performed by the Reaction Biology Corporation (Malvern, PA) using human full-length recombinant HDAC1 and 6, isolated from a baculovirus expression system in Sf9 cells. An acetylated, fluorogenic peptide derived from residues 379–382 of p53 (RHKKAc, 50 μM) was used as the substrate in the assays. The reaction buffer contained: 50 mM Tris·HCl pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mg/mL BSA, and a final concentration of 1% DMSO. The enzyme was added into wells of the reaction plate, and stock solutions of compounds were distributed into the enzyme mixture by acoustic technology (Echo550 instrument; nanoliter range). The plates were spun down and pre-incubated for 5–10 min. The substrate was then delivered to all reaction wells to initiate the reaction, which was incubated for 2 h at 30 °C. After incubation, developer and trichostatin A (TSA) were added to quench the reaction and generate fluorescence. Kinetic measurements were then taken for 1.5 h at 15 min intervals to ensure that the development was complete. Endpoint readings were taken for analysis after the development reached a plateau. Dose response curves were generated, and the IC<sub>50</sub> value for each compound was extrapolated from the generated plots (10-point IC<sub>50</sub> curves were generated using a 3-fold serial dilution pattern starting at 30 μM).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Expression and Purification of HDACs1, 4–9, and 11</h3><div class="NLM_p last">Large scale expression of human HDACs was carried out in HEK293/T17 cells essentially as described previously.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> Briefly, transiently transfected cells were harvested three days post transfection and the cell pellets resuspended in a lysis buffer (50 mM Tris, 150 mM NaCl, 10 mM KCl, 2 mM MgCl<sub>2</sub>, 10% glycerol, 0.2% NP-40, 2 units/mL benzonase, pH 8) supplemented with a cocktail of protease inhibitors (Roche, Basel, Switzerland). The cells were lysed by sonication (30 W; 3 × 20 s) on ice and the cell lysate cleared by centrifugation at 40 000<i>g</i> for 30 min at 4 °C. Recombinant fusion HDAC proteins were purified via Strep-Tactin affinity chromatography (IBA, Göttingen, Germany) with the elution buffer comprising 50 mM HEPES, 100 mM NaCl, 50 mM KCl, 10% glycerol, and 3 mM desthiobiotin, pH 7.5. Purified proteins were concentrated to 1 mg/mL, aliquoted, flash-frozen in liquid nitrogen and stored at −80 °C until further use.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Determination of Inhibitory Activity Against HDACs1, 4–9, and 11</h3><div class="NLM_p last">IC<sub>50</sub> values in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> were determined using a fluorescence-based assay with 10 μM Ac-GAK(Ac)-AMC (HDAC 1, 6) or 10 μM Boc-Lys(TFA)-AMC (HDAC 4, 5, 7, 8, 9, 11) as a substrate.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Briefly, individual HDACs were pre-incubated with dilution series of tested inhibitors (0–100 μM) in a 384-well plate in the total volume of 40 μL for 10 min at 37 °C in reaction buffer comprising 50 mM HEPES, 140 mM NaCl, 10 mM KCl, 1 mM TCEP, 0.1% BSA, pH 7.4. The deacetylation reaction was started by the addition of 10 μL of a 10 μM substrate into the HDAC/inhibitor mixture. Following the 30 min incubation at 37 °C, the reaction was terminated by the addition of 25 μL of the trypsin solution (4 mg/mL). Fluorescence development by trypsin was carried out at 37 °C for 15 and 60 min for the Ac-GAK(Ac)-AMC and Boc-Lys(TFA)-AMC substrate, respectively. Released aminomethylcoumarin was quantified using a CLARIOstar fluorimeter with the excitation and emission wavelengths set to 365 and 440 nm, respectively. A nonlinear regression analysis was employed to calculate IC<sub>50</sub> values using GraphPad Prism software (10-point IC<sub>50</sub> curves were generated using a 3-fold serial dilution pattern starting at 100 μM). Reactions without the enzyme or the inhibitor were used to define 0 and 100% of the HDAC activity, respectively.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> drHDAC6 Expression and Purification</h3><div class="NLM_p last">The second catalytic domain of HDAC6 from <i>D. rerio</i> (drHDAC6; amino acids 440–798) was expressed and purified essentially as described previously.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Briefly, the synthetic gene encoding HDAC6 was recombined into a Gateway expression plasmid in frame with the TEV-cleavable His-MBP N-terminal tag. The fusion protein was expressed in <i>Escherichia coli</i> BL21-Codon plus (DE3)-RIPL at 16 °C overnight. The purification protocol comprised the HisTrap HP affinity step (GE Healthcare, Chicago, IL, USA), removal of the tag by the TEV protease, affinity purification on an amylose resin (New England Biolabs, Ipswitch, MA, USA), ion-exchange chromatography on HiTrap Q sepharose (GE Healthcare), and size-exclusion chromatography on a HiLoad Superdex 75 pg column (GE Healthcare; mobile phase: 50 mM HEPES, 100 mM KCl, 5% glycerol, 1 mM TCEP, pH 7.5) as the final step. The purity of the final protein preparation was >98% as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and purified drHDAC6-CD2 was concentrated to 10 mg/mL, aliquoted, flash-frozen in liquid nitrogen and stored at −80 °C until further use.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Crystallization and Data Collection</h3><div class="NLM_p last">The drHDAC6 stock solution was mixed with 1/20 volume of the SS-208 solution (80 mM in DMSO), and the crystallization droplets were prepared by combining 1 μL of the complex solution with 1 μL of a reservoir solution containing 19% PEG 3350 (Sigma-Aldrich), 0.2 M KSCN (Hampton research), 0.1 M Bis-Tris (Sigma-Aldrich) at pH 6.5. To bolster the nucleation step, the droplets were streak-seeded using the seed stock prepared from crystals of the HDAC6/SAHA complex using a Crystal Crusher (Hampton Research). The crystals were grown by the hanging drop vapor diffusion method at 283 K. Diffraction quality crystals were vitrified in liquid nitrogen from the mother liquor supplemented with 20% (v/v) glycerol. The diffraction data were collected from a single crystal at 90 K using synchrotron radiation at a Bessy II beamline MX 14.2 (Berlin, Germany) equipped with a Pilatus 2M detector at an X-ray wavelength of 0.92 Å. Data processing was performed with the XDSAPP software package.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Structure Determination and Refinement</h3><div class="NLM_p last">The difference Fourier method was used to determine the structure of the drHDAC6-CD2/SS-208 complex using the drHDAC6/TSA complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEK">5EEK</a>) without the inhibitor and water molecules as a starting model.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Iterative refinement and model building cycles were performed using Refmac 5.8. and Coot, respectively.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> Ligand topologies and coordinates were generated with AceDRG<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> and the inhibitor was fitted into the |<i>F</i><sub>o</sub>| – |<i>F</i><sub>c</sub>| electron density maps in the final stages of the refinement. Approximately 2500 randomly selected reflections were kept aside for cross-validation (Rfree) during the refinement process. The final model was validated using the MolProbity server.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The data collection and structure refinement statistics are summarized in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf" class="ext-link">Table S4</a>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cell Transfection, Treatments, and BRET Measurements</h3><div class="NLM_p last">NanoBRET target engagement was performed against HDAC6 (CD2) and HDAC1 according to the manufacturer’s protocol (Promega) in HEK293 cells (ATCC). HEK293 cells were transfected with plasmid constructs encoding HDAC6 (CD2)-NanoLuc and HDAC1-NanoLuc as described previously.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> HDAC6 (CD2)-NanoLuc encoded a GSSGAIA linker between HDAC (CD2) and NanoLuc, and HDAC1–NanoLuc encoded a SWTWEGNKWTWK linker between HDAC1 and NanoLuc. NanoBRET HDAC tracer (Promega) was added to a final concentration of 250 and 1000 nM for HDAC6 (CD2) and HDAC1, respectively, immediately prior to testing compound addition. Tracer concentrations were selected for each HDAC such that tracer occupancy did not impart a shift in the observed compound IC<sub>50</sub> value. The serially diluted test compounds were then added to the cells and allowed to equilibrate for 2 h prior to BRET measurements. To measure BRET, a NanoBRET NanoGlo Substrate-(Promega) and Extracellular NanoLuc inhibitor was added per the manufacturer’s protocol, and filtered luminescence was measured on a GloMax Discover luminometer equipped with a 450 nm BP filter (donor) and 610 nm LP filter (acceptor), using a 0.5 s integration time. Milli-BRET units (mBU) are the BRET values × 1000. Competitive displacement data were then graphed with GraphPad Prism software using a 3-parameter curve fit with the following equation (equation).<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_m001.gif" alt="" id="_i29" /></img></span></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Mice</h3><div class="NLM_p">Experiments involving mice were performed in accordance with approved protocols by the Institutional Care and Use Committee (IACUC) at The George Washington University (Protocol A354). The C57BL/6 mice were obtained from the Charles River Laboratories (Wilmington, Massachusetts, USA). All the in vivo studies performed used tumor cells passaged in vivo (mouse to mouse) a minimum of five times before the tumor challenge experiment. Once the in vivo passaged cells were obtained, the mice were injected subcutaneously with 1.0 × 10<sup>6</sup> melanoma cells suspended in 100 μL 1× phosphate buffered saline (PBS) (Corning, 21-040-CV). Treatment started once tumors were palpable or as indicated in particular experiments. The mice were treated intraperitoneally with SS-208 (25 mg/kg) or vehicle control depending on the randomly assigned treatment group (10 female mice per group, 4–6 weeks old). The control mice were injected with 100 μL 1× PBS as the vehicle control. The mice were treated five days a week until tumors in the control group reached maximum size according to our IACUC protocol. Tumor volume was calculated using caliper measurements by the formula <i>L</i> × <i>W</i>2/2.</div><div class="NLM_p last">All animal studies were done with consideration for toxicity in relation to each individual agent and using a dose that was previously verified through in vivo testing. However, we routinely monitored for early signs of toxicity. A particular focus was given to mortality, body weight, and food consumption. At the end-point postmortem evaluation, using gross visual examination of organs, was done for each condition.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Cell Culture</h3><div class="NLM_p last">In vivo tumors: SM1 cells were originally obtained from the laboratory of Dr. A. Ribas at the University of California Los Angeles.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> SM1 tumor cells were passaged in vivo directly from mouse to mouse for at least five passages. Tumors were grown and selected for optimal and consistent growth rate. When preparing cells for subcutaneous injection, mice with a tumor burden measuring approximately 7 mm × 7 mm were euthanized. Tumors were extracted and processed under sterile conditions. A cell count was used to adjust the cell concentration to 1.0 × 10<sup>6</sup> per 100 μL of PBS, indicative of the volume per mouse injection. These cells were immediately injected into the experimental mice, as described above. The cells in excess from the tumor processing were frozen in 90% fetal bovine serum (Serum Source, FB02-500HI) with 10% DMSO (Sigma-Aldrich, D2650) and stored in liquid nitrogen for future experiments.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> HDACis for Cellular Studies</h3><div class="NLM_p last">SS-208 was kept as a stock solution of 10 mg/mL and diluted with a buffer provided by the manufacturer to the concentration used for each particular experiment. NextA was provided by StarWise Therapeutics LLC. TubA (S8049) was purchased from Selleckchem. The pan-HDACi LBH589 (50-148-338) was purchased from Biotang Inc.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Cellular Viability and Apoptosis Assays</h3><div class="NLM_p last">Using a ApoTox-Glo Triplex Assay (Promega, G6321) viability and apoptosis were measured. The SM1 cells were treated with individual HDACis along with the recommended assay controls. Pan-HDACi, LBH589 was also used as a control on all plates. Following the manufacturer’s protocol, viability/cytotoxicity reagents were added, and fluorescence was measured at specific wavelengths—that is, 400Ex/505Em (viability) and 485Ex/520Em (cytotoxicity). Next, the Caspase 3/7 reagent was added, and luminescence was measured at Lm578 (apoptosis). The measurements were collected using a SpectraMax 3i multi-mode microplate reader.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Cellular HDAC Inhibition</h3><div class="NLM_p last">Using HDAC-Glo I/II Assay (Promega, G6420) Cells were plated at a density of 10 000 cells per/well overnight in a white, flat clear bottom 96 well plate. After 24 h, the plate was then treated with the compounds of interest (NextA, TubA, and SS-208) at the desired concentrations and incubated at 37 °C and 5% CO<sub>2</sub> for 1 h. After incubation with the compounds, the developer is added to the substrate, mixed, and added directly to the plate, following the manufactured protocol. Immediately after plating, the plate was read for an hour and 15 min with a reading done every 2 min, using the SpectraMax 3i multi-mode plate reader.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Flow Cytometry</h3><div class="NLM_p">Tumor cells were immediately processed into single cell suspensions for analysis by flow cytometry. The first panel for flow cytometry was to analyze the expression of immune cell surface markers. These cells were stained with phycoerythrin (PE)-conjugated antibodies in a 96-well format. The antibodies were purchased from BD Biosciences (San Jose, California, USA), Biolegend (San Diego, California, USA), and eBioscience (San Diego, California, USA). Tumor cells were stained with antimouse CD274 (PD-L1) (BD Biosciences, 558091), antimouse CD 273 (PD-L2) (Biolegend, 107205), antimouse CD276 (B7-H3) (Biolegend, 124507), antimouse B7-H4 (Biolegend, 139405), antimouse Galactin-9 (Biolegend, 137903), antimouse CD252 (OX40-L), antimouse CD275 (ICOS-L) (eBioscience, 12-5985-81), antimouse MHC I (H-2Kb) (eBioscience, 12-5958-80), or antimouse MHC II (I-A/I-E) (eBioscience, 12-5321-81). After staining for 30 min at room temperature, the cells were washed at least three times with 1× PBS and resuspended in FACS buffer.</div><div class="NLM_p">The second panel for flow cytometry was designed to measure the activity and infiltration of Natural Killer (NK) and T-cells. The following antibodies were used: PerCP/Cy5.5 antimouse CD3 (T-cells) (Biolegend, 100218), Alexa Fluor 488 antimouse CD4 (CD4+ T cells) (Biolegend, 100423), PE/Cy7 antimouse CD8a (CD8+ T cells) (Biolegend, 100766), APC/Fire 750 antimouse CD49b (NK cells) (Biolegend, 108922), Brilliant Violet 421 antimouse CD25 (T-cell activation) (Biolegend, 102034), and Brilliant Violet 785 antimouse CD45.2 (T-cell activation) (Biolegend, 109839). Finally, the third flow cytometry panel measured the activity and infiltration of myeloid cells using the following markers: Brilliant Violet 421 antimouse/human C11b (Macrophage) (Biolegend, 101236), APC antimouse CD80 (M1) (Biolegend, 104714), PE/Cy7 antimouse CD206 MMR (M2) (Biolegend, 141720), Brilliant Violet 630 antimouse CD11c (mDC) (Biolegend, 117339), APC/Fire 750 antimouse CD45.2 (MDSC) (Biolegend, 109852), PE antimouse CD123 [IL-3 receptor (IL-3Rα)] (Biolegend, 106005), Brilliant Violet 603 antimouse Ly-6G/Ly-6C (MDSC) (Biolegend, 108440), FITC antimouse H 2 (M2) (Biolegend, 125508), and Brilliant Violet 785 antimouse F4/80 (Macrophage) (Biolegend, 123141). After staining for 30 min at room temperature, the cells were washed with 1× PBS, similar to the first panel. The samples were fixed with Life Technologies IC Fixation Buffer (FB001) from ThermoFisher Scientific (Waltham, Massachusetts, USA) according to the manufacturer’s protocol and resuspended in FACS buffer.</div><div class="NLM_p last">To determine viability, all flow cytometry panels used LIVE/DEAD Fixable Aqua Dead Cell Stain (L34957) from ThermoFisher Scientific. The samples were run in a BD Celesta cell analyzer, recording at least 30 000 events. The results were analyzed using FlowJo software 10.4.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Quantitative Real-Time PCR</h3><div class="NLM_p last">SM1 murine melanoma cells were plated in a 6-well plate. The cells were serum starved overnight followed by pretreatment with 5 μM SS-208 for 1 h. Subsequently, treatment with recombinant murine IL-6 (Biolegend, San Diego, CA 92121) at 30 ng/mL was performed for overnight. Following the manufacturer’s instructions, total RNA was extracted from the cells using the Trizol (Life Technologies, Carlsbad, CA, 92008). The samples were processed immediately or stored at −80 °C. Quantification of RNA was done using a ND-1000 NanoDrop spectrophotometer (NanoDrop Technologies, Inc., Wilmington, Delaware). The 260/280 ratios were routinely over 1.9. sample cDNA was produced using a iScript cDNA synthesis kit (Bio-Rad, 1708891). Target mRNA was quantified using an iQ SYBR green Supermix (Bio-Rad, 1708882). Primers targeting PD-L1 and GAPDH for qRT-PCR were purchased from Invitrogen (Waltham, Massachusetts, USA) and the sequences are listed in the previous publication.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Cycling conditions were used as per manufacturer’s instructions. Single product amplification was confirmed by the melting curve analysis, and primer efficiency was near 100% in all the experiments performed. Quantification is expressed in arbitrary units, and target mRNA levels were normalized to GAPDH expression using the method described by Pfaffl<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> using Microsoft Excel Software (Microsoft, Redmond, WA).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Immunoblotting</h3><div class="NLM_p last">Cells were lysed in RIPA buffer (Pierce, 89900) with a 1× protease and phosphatase inhibitor (Pierce, A32961). Lysates were sonicated in a Bioruptor (Diagenode, Denville, NJ, USA) in a 4 °C water bath for 8 min (8 cycles of 30 s on, 30 s off). The protein concentration was determined using a Pierce BCA protein assay kit (Thermo Fisher Scientific, 23225) according to the manufacturer’s protocol. The samples were mixed with a NuPAGE LDS 4× loading gel (NP0007) and NuPAGE 10× reducing agent (NP0009), then placed on a heating block at 100 °C. Next, the samples were loaded onto 4–20% (BioRad, 4561093) or 10% gels (BioRad, 4561033) and transferred to LF PVDF (BioRad, 170-4274). The membranes were blocked with LI-COR Biosciences (Lincoln, Nebraska, USA) Odyssey blocking buffer (927-40100). The bands were detected using an Azure Biosystems (Dublin, California, USA) imaging system c600. The antibodies used for immunoblotting included: PD-L1 (ProSci, 4059), PD-L2 (ProSci, 4063), total STAT3 (Cell Signal, 12640), phosphor-STAT3 (Y705) (Cell Signal, 9138), α-Tubulin (Cell Signaling, 3873), Ac-α-Tubulin (Cell Signaling, 3971), histone H3 (Cell Signaling 3638), Ac-histone H3 (Cell Signaling 9649S), and HDAC6 (Assay Biotech C0226). The bands were analyzed using ImageJ (NIH).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Statistical Analysis and Reproducibility</h3><div class="NLM_p last">The experiments were done in triplicate unless otherwise noted. The analysis was done using unpaired <i>t</i>-tests with significance at <i>p</i> < 0.05 and the Kaplan–Meier survival curves using GraphPad Prism 7. All analyses of cell viability, apoptosis, and cytotoxicity were completed using Microsoft Excel Software (Microsoft, Redmond, WA).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00946" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48736" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48736" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00946" class="ext-link">10.1021/acs.jmedchem.9b00946</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional data on the Ames test and the hERG assay, crystallization data collection, and refinement statistics, and physicochemical properties, <sup>1</sup>H NMR spectra, and <sup>13</sup>C NMR spectra for compounds <b>7a–d</b>, <b>11a–d</b>, and <b>20a–c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings including screening data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf">jm9b00946_si_001.pdf (3.15 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_002.csv">jm9b00946_si_002.csv (2.66 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and corresponding structure factors for the drHDAC6-CD2/SS-208 complex have been deposited at the Protein Data Bank as the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0K">6R0K</a> entry.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00946" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan P. Kozikowski</span> - <span class="hlFld-Affiliation affiliation">StarWise
Therapeutics LLC, University Research Park, Inc., Madison, Wisconsin 53719, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#54353f3b2e3d3f3b23273f3d1427203526233d273120262c7a373b39"><span class="__cf_email__" data-cfemail="64050f0b1e0d0f0b13170f0d2417100516130d170110161c4a070b09">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alejandro Villagra</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cbaabda2a7a7aaacb9aa8baea6aaa2a7e5acbcbee5aeafbe"><span class="__cf_email__" data-cfemail="7514031c191914120714351018141c195b1202005b101100">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sida Shen</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</span>; 
    <span>Present Address:
                        Departments of Chemistry, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois 60208, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0295-2545" title="Orcid link">http://orcid.org/0000-0002-0295-2545</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa Hadley</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kseniya Ustinova</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Structural Biology, Institute of Biotechnology
of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, Faculty of Natural Science, Charles University, Albertov 6, 128 43 Prague 2, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiri Pavlicek</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Structural Biology, Institute of Biotechnology
of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tessa Knox</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satish Noonepalle</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20052, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mauricio T. Tavares</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</span>; 
    <span>Present Address:
                        Department of Chemistry, Scripps Research, Jupiter, Florida 33458, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4400-7787" title="Orcid link">http://orcid.org/0000-0002-4400-7787</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chad A. Zimprich</span> - <span class="hlFld-Affiliation affiliation">Promega
Corporation, Madison, Wisconsin 53711, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiping Zhang</span> - <span class="hlFld-Affiliation affiliation">Bontac Bio-Engineering
(Shenzhen) Co., Ltd, Shenzhen, Guangdong 518102, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9818-4773" title="Orcid link">http://orcid.org/0000-0001-9818-4773</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew B. Robers</span> - <span class="hlFld-Affiliation affiliation">Promega
Corporation, Madison, Wisconsin 53711, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cyril Bařinka</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Structural Biology, Institute of Biotechnology
of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2751-3060" title="Orcid link">http://orcid.org/0000-0003-2751-3060</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.S. and M.H. contributed equally to this paper. A.V. and A.P.K. conceived the original idea, initiated the project, and oversaw all the chemical, biological, and in vivo experimental designs and data analysis. S.S. designed and synthesized compounds, oversaw all the experimental design, analyzed data, and wrote the manuscript with assistance from the other authors. M.H., S.N., and T.K. designed and performed all biological and in vivo experimental designs, analyzed data, and contributed to the manuscript writing. J.P. crystallized the drHDAC6/SS-208 complex; K.U. solved, refined, and analyzed the drHDAC6/SS-208 X-ray structure; C.B. determined IC50 values of HDAC isoforms, analyzed data, and contributed to manuscript writing. M.T.T. and G.Z. assisted the scale-up work of SS-208 and assisted in the preparation of the manuscript. C.A.Z. designed and performed the cellular HDAC target engagement assay; M.B.R. oversaw the experimental design and data analyses of the target engagement study and assisted in the preparation of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funded by NIH R21 CA184612-01 and Melanoma Research Foundation CDA Grant Award (A.V.); NIH R01NS079183, R43HD093464, and R41AG058283 (A.P.K.). Additionally, this work was in part supported by the CAS (RVO: 86652036), the Czech Science Foundation (15-19640S), the MEYS CR (CIISB for Biocev: LM2015043), the Grant Agency of Charles University (project number: 1558218), and project BIOCEV (CZ.1.05/1.1.00/02.0109) from the ERDF (C.B.). We would like to acknowledge the important technical contributions and advice of Kimberlyn Acklin, MS, SCYM (ASCP), at The George Washington University Flow Cytometry Core Facility and Bethany Rentz, RVT, at The George Washington University Office of Animal Research. We thank Petra Baranova and Barbora Havlinova for excellent technical assistance and Lucia Motlova for helping with crystallization experiments. We also thank Dr. Werner Tueckmantel for proofreading the article and providing comments. We acknowledge the Helmholtz-Zentrum Berlin for the allocation of synchrotron radiation beamtime at the MX14.2 beamline and the support by the project CALIPSOplus (grant agreement 730872) from the EU Framework Programme for Research and Innovation HORIZON 2020.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion, and toxicity</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human Ether-à-go-go related gene</p></td></tr><tr><td class="NLM_term">DEAD</td><td class="NLM_def"><p class="first last">diethyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">PCC</td><td class="NLM_def"><p class="first last">pyridinium chlorochromate</p></td></tr><tr><td class="NLM_term">NCS</td><td class="NLM_def"><p class="first last"><i>N</i>-chlorosuccinimide</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">1,2-dichloroethane</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">PD-L1/2</td><td class="NLM_def"><p class="first last">programmed death-ligand 1/2</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death-1</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr><tr><td class="NLM_term">MHC</td><td class="NLM_def"><p class="first last">major histocompatibility complex</p></td></tr><tr><td class="NLM_term">CD25/40/80</td><td class="NLM_def"><p class="first last">cluster of differentiation 25/40/80</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70612" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70612" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 101 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfinos, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oratz, R.</span></span> <span> </span><span class="NLM_article-title">A comparison of survival rates for treatment of melanoma metastatic to the brain</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1081/cnv-200026387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1081%2Fcnv-200026387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15565805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD2crpt1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=492-497&author=A.+Stoneauthor=J.+Cooperauthor=K.+L.+Koenigauthor=J.+G.+Golfinosauthor=R.+Oratz&title=A+comparison+of+survival+rates+for+treatment+of+melanoma+metastatic+to+the+brain&doi=10.1081%2Fcnv-200026387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of survival rates for treatment of melanoma metastatic to the brain</span></div><div class="casAuthors">Stone Anne; Cooper Jay; Koenig Karen L; Golfinos John G; Oratz Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">492-7</span>
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    </div><div class="casAbstract">INTRODUCTION:  A retrospective review of 91 patients with brain metastases from malignant melanoma treated at New York University Medical Center between 1989-1999.  Overall survival was the outcome evaluated.  METHODS:  Charts of 91 patients having malignant melanoma with brain metastases were reviewed.  Cases were stratified according to therapy: surgical excision, surgical excision plus whole brain radiation therapy, gamma knife stereotactic radiosurgery, gamma knife stereotactic radiosurgery plus whole brain radiation therapy, and whole brain radiation therapy alone.  Patients treated with gamma knife stereotactic radiosurgery plus radiation therapy were combined with patients treated with surgical excision plus radiation therapy and compared to those treated with radiation therapy alone.  Prognostic characteristics of the two groups were compared and survival curves were generated using the Kaplan-Meier method.  The Cox proportional hazards model was used to control for prognostic factors that differed between the groups.  RESULTS:  Patients treated with gamma knife stereotactic radiosurgery or surgical excision plus radiation therapy were younger, less likely to present with symptoms, and presented with fewer metastases to the brain than patients treated with radiation therapy alone.  A survival benefit of 7.3 months (p = 0.05) was found to be associated with gamma knife radiosurgery or surgical excision plus radiation therapy over radiation therapy alone after controlling for differences in age, number of brain lesions, and presence of symptoms.  DISCUSSION:  This retrospective study of 91 patients treated for melanoma metastases to the brain attempts to examine the effectiveness of different treatments in prolonging survival.  Our results suggest that surgical excision or stereotactic radiosurgery with gamma knife in addition to radiation therapy may be more effective than radiation alone at prolonging survival for patients with a limited number of brain lesions.  CONCLUSION:  Survival of patients with melanoma metastases to the brain may be prolonged by treatment with gamma knife stereotactic radiosurgery or surgical excision plus whole brain radiation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxg-QgcqARse_Q9URG6Dx8fW6udTcc2ebSxBnsAxDaarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpt1Cgsg%253D%253D&md5=139a7351d4c7ca2ce4308c23d424e7d4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1081%2Fcnv-200026387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252Fcnv-200026387%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DK.%2BL.%26aulast%3DGolfinos%26aufirst%3DJ.%2BG.%26aulast%3DOratz%26aufirst%3DR.%26atitle%3DA%2520comparison%2520of%2520survival%2520rates%2520for%2520treatment%2520of%2520melanoma%2520metastatic%2520to%2520the%2520brain%26jtitle%3DCancer%2520Invest.%26date%3D2004%26volume%3D22%26spage%3D492%26epage%3D497%26doi%3D10.1081%2Fcnv-200026387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, E. P.</span></span> <span> </span><span class="NLM_article-title">Management of cutaneous melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">2770</span>– <span class="NLM_lpage">2771</span>, <span class="refDoi"> DOI: 10.1056/nejm200412233512620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejm200412233512620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15619744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD2cnktFemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=2770-2771&author=E.+P.+Miranda&title=Management+of+cutaneous+melanoma&doi=10.1056%2Fnejm200412233512620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Management of cutaneous melanoma</span></div><div class="casAuthors">Miranda Edward P</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2770-1; author reply 2770-1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCLjbo6IonL_6xYuD7tu2XfW6udTcc2ebSxBnsAxDaarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cnktFemsA%253D%253D&md5=d9bf7b30515be1642c0916cbfb167394</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2Fnejm200412233512620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejm200412233512620%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DE.%2BP.%26atitle%3DManagement%2520of%2520cutaneous%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D2770%26epage%3D2771%26doi%3D10.1056%2Fnejm200412233512620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Targeted agents and immunotherapies: optimizing outcomes in melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnrclinonc.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28374786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFSisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=463-482&author=J.+J.+Lukeauthor=K.+T.+Flahertyauthor=A.+Ribasauthor=G.+V.+Long&title=Targeted+agents+and+immunotherapies%3A+optimizing+outcomes+in+melanoma&doi=10.1038%2Fnrclinonc.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted agents and immunotherapies: optimizing outcomes in melanoma</span></div><div class="casAuthors">Luke, Jason J.; Flaherty, Keith T.; Ribas, Antoni; Long, Georgina V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">463-482</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Treatment options for patients with metastatic melanoma, and esp. BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents.  During this period, the treatment paradigm for BRAF-mutant disease has evolved rapidly: the std.-of-care BRAF-targeted approach has shifted from single-agent BRAF inhibition to combination therapy with a BRAF and a MEK inhibitor.  Concurrently, immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic T-lymphocyte-assocd. antigen-4 (CTLA-4) and, now, the programmed cell-death protein 1 (PD-1) immune checkpoints.  These changes in the treatment landscape have dramatically improved patient outcomes, with the median overall survival of patients with advanced-stage melanoma increasing from approx. 9 mo before 2011 to at least 2 years - and probably longer for those with BRAF-V600-mutant disease.  Herein, we review the clin. trial data that established the std.-of-care treatment approaches for advanced-stage melanoma.  Mechanisms of resistance and biomarkers of response to BRAF-targeted treatments and immunotherapies are discussed, and the contrasting clin. benefits and limitations of these therapies are explored.  We summarize the state of the field and outline a rational approach to frontline-treatment selection for each individual patient with BRAF-mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CKP8dyLWfbVg90H21EOLACvtfcHk0lhTE6U9rwD_BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFSisr8%253D&md5=a1811bd4b82d81e7210c2f7f29086c84</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DTargeted%2520agents%2520and%2520immunotherapies%253A%2520optimizing%2520outcomes%2520in%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D463%26epage%3D482%26doi%3D10.1038%2Fnrclinonc.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livingstone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaubel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management</span>. <i>Chin. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2304-3865.2014.03.03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.3978%2Fj.issn.2304-3865.2014.03.03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25841455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjht1Sqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=29&author=E.+Livingstoneauthor=L.+Zimmerauthor=J.+Vaubelauthor=D.+Schadendorf&title=BRAF%2C+MEK+and+KIT+inhibitors+for+melanoma%3A+adverse+events+and+their+management&doi=10.3978%2Fj.issn.2304-3865.2014.03.03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management</span></div><div class="casAuthors">Livingstone Elisabeth; Zimmer Lisa; Vaubel Julia; Schadendorf Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Chinese clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The introduction of tyrosine kinase inhibitors for the treatment of malignant melanoma has led to unprecedented response rates with superior overall survival rates in patients with targetable kinase mutations.  Even though targeted, the effects of these new therapies are not limited to the cancer cells and induce a wide array of different adverse events (AEs).  Most toxicities are mild to moderate in severity and often only affect the skin, but quality of life of patients is still affected.  To prevent dose reduction and/or interruption, a sound knowledge of potential AEs and their management is required.  BRAF inhibitors should not be used in patients with known RAS-mutant tumour in the medical history.  We review common AEs of BRAF, MEK and KIT inhibitors used for the treatment of malignant melanoma and their management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjs4F7oPLiz0kUaC_kzhvyfW6udTcc2ebSxBnsAxDaarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjht1Sqtg%253D%253D&md5=148b30da11eedc55a9e251835ce2afc3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2304-3865.2014.03.03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2304-3865.2014.03.03%26sid%3Dliteratum%253Aachs%26aulast%3DLivingstone%26aufirst%3DE.%26aulast%3DZimmer%26aufirst%3DL.%26aulast%3DVaubel%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DBRAF%252C%2520MEK%2520and%2520KIT%2520inhibitors%2520for%2520melanoma%253A%2520adverse%2520events%2520and%2520their%2520management%26jtitle%3DChin.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D3%26spage%3D29%26doi%3D10.3978%2Fj.issn.2304-3865.2014.03.03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahinian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griesser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1126/science.270.5238.985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1126%2Fscience.270.5238.985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=7481803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADyaK2MXptlOlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=985-988&author=P.+Waterhouseauthor=J.+M.+Penningerauthor=E.+Timmsauthor=A.+Wakehamauthor=A.+Shahinianauthor=K.+P.+Leeauthor=C.+B.+Thompsonauthor=H.+Griesserauthor=T.+W.+Mak&title=Lymphoproliferative+disorders+with+early+lethality+in+mice+deficient+in+Ctla-4&doi=10.1126%2Fscience.270.5238.985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4</span></div><div class="casAuthors">Waterhouse, Paul; Penninger, Josef M.; Timms, Emma; Wakeham, Andrew; Shahinian, Arda; Lee, Kelvin P.; Thompson, Craig B.; Griesser, Henrik; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5238</span>),
    <span class="NLM_cas:pages">985-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The role of the cell-surface mol. CTLA-4 in the regulation of T cell activation has been controversial.  Here, lymph nodes and spleens of CTLA-4-deficient mice accumulated T cell blasts with up-regulated activation markers.  These blast cells also infiltrated liver, heart, lung, and pancreas tissue, and amts. of serum Ig were elevated.  The mice invariably became moribund by 3 to 4 wk of age.  Although CTLA-4-deficient T cells proliferated spontaneously and strongly when stimulated through the T cell receptor, they were sensitive to cell death induced by crosslinking of the Fas receptor and by gamma irradn.  Thus, CTLA-4 acts as a neg. regulator of T cell activation and is vital for the control of lymphocyte homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrORE4YgijCTrVg90H21EOLACvtfcHk0lh1kFTuFGfquA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlOlurk%253D&md5=f2837d566cedd0c1cd071e423f16cf0e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5238.985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5238.985%26sid%3Dliteratum%253Aachs%26aulast%3DWaterhouse%26aufirst%3DP.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DTimms%26aufirst%3DE.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DShahinian%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BP.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26aulast%3DGriesser%26aufirst%3DH.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DLymphoproliferative%2520disorders%2520with%2520early%2520lethality%2520in%2520mice%2520deficient%2520in%2520Ctla-4%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D985%26epage%3D988%26doi%3D10.1126%2Fscience.270.5238.985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polkowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekk-Cierniakowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czepielewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozłowska-Wojciechowska, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1007/s00228-018-2590-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1007%2Fs00228-018-2590-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=30386910" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2018&pages=329-334&author=M.+Polkowskaauthor=P.+Ekk-Cierniakowskiauthor=E.+Czepielewskaauthor=M.+Koz%C5%82owska-Wojciechowska&title=Efficacy+and+safety+of+BRAF+inhibitors+and+anti-CTLA4+antibody+in+melanoma+patients-real-world+data&doi=10.1007%2Fs00228-018-2590-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs00228-018-2590-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-018-2590-6%26sid%3Dliteratum%253Aachs%26aulast%3DPolkowska%26aufirst%3DM.%26aulast%3DEkk-Cierniakowski%26aufirst%3DP.%26aulast%3DCzepielewska%26aufirst%3DE.%26aulast%3DKoz%25C5%2582owska-Wojciechowska%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520BRAF%2520inhibitors%2520and%2520anti-CTLA4%2520antibody%2520in%2520melanoma%2520patients-real-world%2520data%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D75%26spage%3D329%26epage%3D334%26doi%3D10.1007%2Fs00228-018-2590-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus Ipilimumab in Advanced Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2521</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1503093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejmoa1503093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25891173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2521-2532&author=C.+Robertauthor=J.+Schachterauthor=G.+V.+Longauthor=A.+Aranceauthor=J.+J.+Grobauthor=L.+Mortierauthor=A.+Daudauthor=M.+S.+Carlinoauthor=C.+McNeilauthor=M.+Lotemauthor=J.+Larkinauthor=P.+Loriganauthor=B.+Neynsauthor=C.+U.+Blankauthor=O.+Hamidauthor=C.+Mateusauthor=R.+Shapira-Frommerauthor=M.+Koshauthor=H.+Zhouauthor=N.+Ibrahimauthor=S.+Ebbinghausauthor=A.+Ribas&title=Pembrolizumab+versus+Ipilimumab+in+Advanced+Melanoma&doi=10.1056%2Fnejmoa1503093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus ipilimumab in advanced melanoma</span></div><div class="casAuthors">Robert, Caroline; Schachter, Jacob; Long, Georgina V.; Arance, Ana; Grob, Jean Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S.; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian U.; Hamid, Omid; Mateus, Christine; Shapira-Frommer, Ronnie; Kosh, Michele; Zhou, Honghong; Ibrahim, Nageatte; Ebbinghaus, Scot; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2521-2532</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The immune checkpoint inhibitor ipilimumab is the std.-of-care treatment for patients with advanced melanoma.  Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.  Methods In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kg of body wt.) every 2 wk or every 3 wk or four doses of ipilimumab (at 3 mg per kg) every 3 wk.  Primary end points were progression-free and overall survival. results The estd. 6-mo progression-free-survival rates were 47.3% for pembrolizumab every 2 wk, 46.4% for pembrolizumab every 3 wk, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens vs. ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, resp.).  Estd. 12-mo survival rates were 74.1%, 68.4%, and 58.2%, resp. (hazard ratio for death for pembrolizumab every 2 wk, 0.63; 95% CI, 0.47 to 0.83; P = 0.0005; hazard ratio for pembrolizumab every 3 wk, 0.69; 95% CI, 0.52 to 0.90; P = 0.0036).  The response rate was improved with pembrolizumab administered every 2 wk (33.7%) and every 3 wk (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons).  Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, resp., after a median follow-up of 7.9 mo.  Efficacy was similar in the two pembrolizumab groups.  Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%).  Conclusions The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKg2FC7SX5rVg90H21EOLACvtfcHk0lh1kFTuFGfquA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF&md5=b37f62f7aefe7d8948ff06babb9b711e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1503093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1503093%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DMcNeil%26aufirst%3DC.%26aulast%3DLotem%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DNeyns%26aufirst%3DB.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DKosh%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DEbbinghaus%26aufirst%3DS.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPembrolizumab%2520versus%2520Ipilimumab%2520in%2520Advanced%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2521%26epage%3D2532%26doi%3D10.1056%2Fnejmoa1503093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Vecchio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Rodas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queirolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pril, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabater, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span> <span> </span><span class="NLM_article-title">Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1824</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1709030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejmoa1709030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28891423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWku7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1824-1835&author=J.+Weberauthor=M.+Mandalaauthor=M.+Del+Vecchioauthor=H.+J.+Gogasauthor=A.+M.+Aranceauthor=C.+L.+Coweyauthor=S.+Dalleauthor=M.+Schenkerauthor=V.+Chiarion-Sileniauthor=I.+Marquez-Rodasauthor=J.-J.+Grobauthor=M.+O.+Butlerauthor=M.+R.+Middletonauthor=M.+Maioauthor=V.+Atkinsonauthor=P.+Queiroloauthor=R.+Gonzalezauthor=R.+R.+Kudchadkarauthor=M.+Smylieauthor=N.+Meyerauthor=L.+Mortierauthor=M.+B.+Atkinsauthor=G.+V.+Longauthor=S.+Bhatiaauthor=C.+Lebb%C3%A9author=P.+Rutkowskiauthor=K.+Yokotaauthor=N.+Yamazakiauthor=T.+M.+Kimauthor=V.+de+Prilauthor=J.+Sabaterauthor=A.+Qureshiauthor=J.+Larkinauthor=P.+A.+Ascierto&title=Adjuvant+Nivolumab+versus+Ipilimumab+in+Resected+Stage+III+or+IV+Melanoma&doi=10.1056%2Fnejmoa1709030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma</span></div><div class="casAuthors">Weber, J.; Mandala, M.; Del Vecchio, M.; Gogas, H. J.; Arance, A. M.; Cowey, C. L.; Dalle, S.; Schenker, M.; Chiarion-Sileni, V.; Marquez-Rodas, I.; Grob, J.-J.; Butler, M. O.; Middleton, M. R.; Maio, M.; Atkinson, V.; Queirolo, P.; Gonzalez, R.; Kudchadkar, R. R.; Smylie, M.; Meyer, N.; Mortier, L.; Atkins, M. B.; Long, G. V.; Bhatia, S.; Lebbe, C.; Rutkowski, P.; Yokota, K.; Yamazaki, N.; Kim, T. M.; de Pril, V.; Sabater, J.; Qureshi, A.; Larkin, J.; Ascierto, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1824-1835</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma.  In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial.  We wanted to det. the efficacy of nivolumab vs. ipilimumab for adjuvant therapy in patients with resected advanced melanoma. methods In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an i.v. infusion of either nivolumab at a dose of 3 mg per kg of body wt. every 2 wk (453 patients) or ipilimumab at a dose of 10 mg per kg every 3 wk for four doses and then every 12 wk (453 patients).  The patients were treated for a period of up to 1 yr or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent.  The primary end point was recurrence-free survival in the intention-to-treat population. results At a min. follow-up of 18 mo, the 12-mo rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001).  Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, resp.  Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. conclusions Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN1wxJv5dbtrVg90H21EOLACvtfcHk0ljZPLyfsjGfig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWku7jJ&md5=bd303be4878e58315a006ee879920840</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1709030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1709030%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDel%2BVecchio%26aufirst%3DM.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26aulast%3DArance%26aufirst%3DA.%2BM.%26aulast%3DCowey%26aufirst%3DC.%2BL.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DSchenker%26aufirst%3DM.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMarquez-Rodas%26aufirst%3DI.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DButler%26aufirst%3DM.%2BO.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DQueirolo%26aufirst%3DP.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DLebb%25C3%25A9%26aufirst%3DC.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DYokota%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3Dde%2BPril%26aufirst%3DV.%26aulast%3DSabater%26aufirst%3DJ.%26aulast%3DQureshi%26aufirst%3DA.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26atitle%3DAdjuvant%2520Nivolumab%2520versus%2520Ipilimumab%2520in%2520Resected%2520Stage%2520III%2520or%2520IV%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1824%26epage%3D1835%26doi%3D10.1056%2Fnejmoa1709030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrucci, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechter, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Rodas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidoboni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1709684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejmoa1709684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28889792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1345-1356&author=J.+D.+Wolchokauthor=V.+Chiarion-Sileniauthor=R.+Gonzalezauthor=P.+Rutkowskiauthor=J.-J.+Grobauthor=C.+L.+Coweyauthor=C.+D.+Laoauthor=J.+Wagstaffauthor=D.+Schadendorfauthor=P.+F.+Ferrucciauthor=M.+Smylieauthor=R.+Dummerauthor=A.+Hillauthor=D.+Hoggauthor=J.+Haanenauthor=M.+S.+Carlinoauthor=O.+Bechterauthor=M.+Maioauthor=I.+Marquez-Rodasauthor=M.+Guidoboniauthor=G.+McArthurauthor=C.+Lebb%C3%A9author=P.+A.+Asciertoauthor=G.+V.+Longauthor=J.+Cebonauthor=J.+Sosmanauthor=M.+A.+Postowauthor=M.+K.+Callahanauthor=D.+Walkerauthor=L.+Rollinauthor=R.+Bhoreauthor=F.+S.+Hodiauthor=J.+Larkin&title=Overall+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma&doi=10.1056%2Fnejmoa1709684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span></div><div class="casAuthors">Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.-J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; Dummer, R.; Hill, A.; Hogg, D.; Haanen, J.; Carlino, M. S.; Bechter, O.; Maio, M.; Marquez-Rodas, I.; Guidoboni, M.; McArthur, G.; Lebbe, C.; Ascierto, P. A.; Long, G. V.; Cebon, J.; Sosman, J.; Postow, M. A.; Callahan, M. K.; Walker, D.; Rollin, L.; Bhore, R.; Hodi, F. S.; Larkin, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.  We now report 3-yr overall survival outcomes in this trial. methods We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kg of body wt. plus ipilimumab at a dose of 3 mg per kg every 3 wk for four doses, followed by nivolumab at a dose of 3 mg per kg every 2 wk; nivolumab at a dose of 3 mg per kg every 2 wk plus placebo; or ipilimumab at a dose of 3 mg per kg every 3 wk for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent.  Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.  The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group vs. the ipilimumab group. results At a min. follow-up of 36 mo, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 mo in the nivolumab group, as compared with 19.9 mo in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]).  The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group.  The safety profile was unchanged from the initial report.  Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. conclusions Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY91ga-k7LxbVg90H21EOLACvtfcHk0liU86g2v8YqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I&md5=bf5e5c47178631cd4485cf79dca12dd8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1709684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1709684%26sid%3Dliteratum%253Aachs%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DCowey%26aufirst%3DC.%2BL.%26aulast%3DLao%26aufirst%3DC.%2BD.%26aulast%3DWagstaff%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DFerrucci%26aufirst%3DP.%2BF.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DA.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DBechter%26aufirst%3DO.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMarquez-Rodas%26aufirst%3DI.%26aulast%3DGuidoboni%26aufirst%3DM.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DLebb%25C3%25A9%26aufirst%3DC.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DRollin%26aufirst%3DL.%26aulast%3DBhore%26aufirst%3DR.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DOverall%2520survival%2520with%2520combined%2520nivolumab%2520and%2520ipilimumab%2520in%2520advanced%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2Fnejmoa1709684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan
Coyne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulley, J. L.</span></span> <span> </span><span class="NLM_article-title">Nivolumab: promising survival signal coupled with limited toxicity raises expectations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.54.5996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1200%2Fjco.2013.54.5996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=24590655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpvFOktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=986-988&author=G.+O%E2%80%99Sullivan%0ACoyneauthor=R.+A.+Madanauthor=J.+L.+Gulley&title=Nivolumab%3A+promising+survival+signal+coupled+with+limited+toxicity+raises+expectations&doi=10.1200%2Fjco.2013.54.5996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab: promising survival signal coupled with limited toxicity raises expectations</span></div><div class="casAuthors">O'Sullivan Coyne Geraldine; Madan Ravi A; Gulley James L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">986-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQw-fcUUfl7lhBrI9DTGjC0fW6udTcc2ea5PJ_WBrHTsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpvFOktA%253D%253D&md5=17c646c9a4176eb344ecc549a2a6687f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2Fjco.2013.54.5996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2013.54.5996%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%2BCoyne%26aufirst%3DG.%26aulast%3DMadan%26aufirst%3DR.%2BA.%26aulast%3DGulley%26aufirst%3DJ.%2BL.%26atitle%3DNivolumab%253A%2520promising%2520survival%2520signal%2520coupled%2520with%2520limited%2520toxicity%2520raises%2520expectations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D986%26epage%3D988%26doi%3D10.1200%2Fjco.2013.54.5996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13073-016-0365-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs13073-016-0365-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27782862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=111&author=J.+S.+O%E2%80%99Donnellauthor=M.+J.+Smythauthor=M.+W.+Teng&title=Acquired+resistance+to+anti-PD1+therapy%3A+checkmate+to+checkpoint+blockade%3F&doi=10.1186%2Fs13073-016-0365-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?</span></div><div class="casAuthors">O'Donnell, Jake S.; Smyth, Mark J.; Teng, Michele W. L.</div><div class="citationInfo"><span class="NLM_cas:title">Genome Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/3</span>CODEN:
                <span class="NLM_cas:coden">GMEECG</span>;
        ISSN:<span class="NLM_cas:issn">1756-994X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large no. of patients present with or develop resistance to them.  Unfortunately, very little is known regarding the mechanisms of resistance to such therapies.  A recent study sought to identify mutations assocd. with resistance to anti-PD1 therapy.  Results from this study demonstrated that mutations which affected the sensitivity of tumor cells to T-cell-derived interferons, and mutations limiting tumor-cell antigen presentation, could cause acquired resistance.  These findings have significant implications for understanding the mechanisms by which anti-PD1 therapies exert their efficacy, comprehending why and how some patients acquire resistance over time, and ultimately guiding the development of combination therapies designed to overcome, or potentially prevent, the development of acquired immunotherapeutic resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsMmJtpOsIe7Vg90H21EOLACvtfcHk0liU86g2v8YqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOkt7Y%253D&md5=c099718cdb766f6143f0e0fb0061ce11</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs13073-016-0365-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13073-016-0365-1%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BS.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26atitle%3DAcquired%2520resistance%2520to%2520anti-PD1%2520therapy%253A%2520checkmate%2520to%2520checkpoint%2520blockade%253F%26jtitle%3DGenome%2520Med.%26date%3D2016%26volume%3D8%26spage%3D111%26doi%3D10.1186%2Fs13073-016-0365-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gide, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilmott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolyer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-17-2267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F1078-0432.ccr-17-2267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29127120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1ymu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1260-1270&author=T.+N.+Gideauthor=J.+S.+Wilmottauthor=R.+A.+Scolyerauthor=G.+V.+Long&title=Primary+and+acquired+resistance+to+immune+checkpoint+inhibitors+in+metastatic+melanoma&doi=10.1158%2F1078-0432.ccr-17-2267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma</span></div><div class="casAuthors">Gide, Tuba N.; Wilmott, James S.; Scolyer, Richard A.; Long, Georgina V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1260-1270</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-stage metastatic melanoma, as well as patients with many other solid cancers, yielding long-lasting responses and improved survival.  However, a subset of patients who initially respond to immunotherapy, later relapse and develop therapy resistance (termed "acquired resistance"), whereas others do not respond at all (termed "primary resistance").  Primary and acquired resistance are key clin. barriers to further improving outcomes of patients with metastatic melanoma, and the known mechanisms underlying each involves various components of the cancer immune cycle, and interactions between multiple signaling mols. and pathways.  Due to this complexity, current knowledge on resistance mechanisms is still incomplete.  Overcoming therapy resistance requires a thorough understanding of the mechanisms underlying immune evasion by tumors.  In this review, we explore the mechanisms of primary and acquired resistance to immunotherapy in melanoma and detail potential therapeutic strategies to prevent and overcome them.  Clin Cancer Res; 24(6); 1260-70. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0AuajvHeorVg90H21EOLACvtfcHk0lgZkBW8gWROTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1ymu7k%253D&md5=52f94231395bc6d0beff0c5b9200ad54</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-17-2267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-17-2267%26sid%3Dliteratum%253Aachs%26aulast%3DGide%26aufirst%3DT.%2BN.%26aulast%3DWilmott%26aufirst%3DJ.%2BS.%26aulast%3DScolyer%26aufirst%3DR.%2BA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DPrimary%2520and%2520acquired%2520resistance%2520to%2520immune%2520checkpoint%2520inhibitors%2520in%2520metastatic%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D1260%26epage%3D1270%26doi%3D10.1158%2F1078-0432.ccr-17-2267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies</span>. <i>Am. Soc. Clin. Oncol. Educ. Book</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1200/edbk_237987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1200%2Fedbk_237987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=31099649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BB3M7mvVCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=165-174&author=M.+Dattaauthor=L.+M.+Coussensauthor=H.+Nishikawaauthor=F.+S.+Hodiauthor=R.+K.+Jain&title=Reprogramming+the+tumor+microenvironment+to+improve+immunotherapy%3A+emerging+strategies+and+combination+therapies&doi=10.1200%2Fedbk_237987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies</span></div><div class="casAuthors">Datta Meenal; Jain Rakesh K; Coussens Lisa M; Nishikawa Hiroyoshi; Hodi F Stephen</div><div class="citationInfo"><span class="NLM_cas:title">American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-174</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Emerging immunotherapeutic approaches have revolutionized the treatment of multiple malignancies.  Immune checkpoint blockers (ICBs) have enabled never-before-seen success rates in durable tumor control and enhanced survival benefit in patients with advanced cancers.  However, this effect is not universal, resulting in responder and nonresponder populations not only between, but also within solid tumor types.  Although ICBs are thought to be most effective against tumors with more genetic mutations and higher antigen loads, this is not always the case for all cancers or for all patients within a cancer subtype.  Furthermore, debilitating and sometimes deadly immune-related adverse events (irAEs) have resulted from aberrant activation of T-cell responses following immunotherapy.  Thus, we must identify new ways to overcome resistance to ICB-based immunotherapies and limit irAEs.  In fact, preclinical and clinical data have identified abnormalities in the tumor microenvironment (TME) that can thwart the efficacy of immunotherapies such as ICBs.  Here, we will discuss how reprogramming various facets of the TME (blood vessels, myeloid cells, and regulatory T cells [Tregs]) may overcome TME-instigated resistance mechanisms to immunotherapy.  We will discuss clinical applications of this strategic approach, including the recent successful phase III trial combining bevacizumab with atezolizumab and chemotherapy for metastatic nonsquamous non-small cell lung cancer that led to rapid approval by the U.S.  Food and Drug Administration of this regimen for first-line treatment.  Given the accelerated testing and approval of ICBs combined with various targeted therapies in larger numbers of patients with cancer, we will discuss how these concepts and approaches can be incorporated into clinical practice to improve immunotherapy outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZnD5FVjfpNRKDYG3bNImrfW6udTcc2ebZI0xMfX49L7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7mvVCmtw%253D%253D&md5=ca372b1e6f25a8416345564772f0abe3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2Fedbk_237987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fedbk_237987%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DM.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26aulast%3DNishikawa%26aufirst%3DH.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DReprogramming%2520the%2520tumor%2520microenvironment%2520to%2520improve%2520immunotherapy%253A%2520emerging%2520strategies%2520and%2520combination%2520therapies%26jtitle%3DAm.%2520Soc.%2520Clin.%2520Oncol.%2520Educ.%2520Book%26date%3D2019%26volume%3D39%26spage%3D165%26epage%3D174%26doi%3D10.1200%2Fedbk_237987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">Re-education of macrophages as a therapeutic strategy in cancer</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.2217/imt-2018-0156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.2217%2Fimt-2018-0156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=31088236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGnu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=677-689&author=J.+Kowalauthor=M.+Korneteauthor=J.+A.+Joyce&title=Re-education+of+macrophages+as+a+therapeutic+strategy+in+cancer&doi=10.2217%2Fimt-2018-0156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Re-education of macrophages as a therapeutic strategy in cancer</span></div><div class="casAuthors">Kowal, Joanna; Kornete, Mara; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">677-689</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-7448</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Tumor-assocd. macrophages (TAMs) can be educated within the tumor microenvironment to promote cancer development and progression.  While TAM-targeted agents have largely focused on macrophage depletion as an anticancer strategy, it is becoming increasingly evident that TAM re-education may represent a more effective approach.  In this perspective, we discuss different means to achieve TAM re-education, and review the beneficial effects of these strategies, particularly when combined with immune checkpoint inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8b0qb76nqB7Vg90H21EOLACvtfcHk0lgZkBW8gWROTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGnu77E&md5=6048835e73f46a8adada57e09d9131e9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2217%2Fimt-2018-0156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2018-0156%26sid%3Dliteratum%253Aachs%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DKornete%26aufirst%3DM.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DRe-education%2520of%2520macrophages%2520as%2520a%2520therapeutic%2520strategy%2520in%2520cancer%26jtitle%3DImmunotherapy%26date%3D2019%26volume%3D11%26spage%3D677%26epage%3D689%26doi%3D10.2217%2Fimt-2018-0156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voorwerk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slagter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlings, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vijver, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Maaker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nederlof, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluin, R. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiersma, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, N. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketelaars, S. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Werkhoven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tinteren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandjes, I. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onderwater, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilgenhof, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Visser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonke, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, M.</span></span> <span> </span><span class="NLM_article-title">Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1038/s41591-019-0432-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fs41591-019-0432-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=31086347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=920-928&author=L.+Voorwerkauthor=M.+Slagterauthor=H.+M.+Horlingsauthor=K.+Sikorskaauthor=K.+K.+van+de+Vijverauthor=M.+de+Maakerauthor=I.+Nederlofauthor=R.+J.+C.+Kluinauthor=S.+Warrenauthor=S.+Ongauthor=T.+G.+Wiersmaauthor=N.+S.+Russellauthor=F.+Lalezariauthor=P.+C.+Schoutenauthor=N.+A.+M.+Bakkerauthor=S.+L.+C.+Ketelaarsauthor=D.+Petersauthor=C.+A.+H.+Langeauthor=E.+van+Werkhovenauthor=H.+van+Tinterenauthor=I.+A.+M.+Mandjesauthor=I.+Kemperauthor=S.+Onderwaterauthor=M.+Chalabiauthor=S.+Wilgenhofauthor=J.+B.+A.+G.+Haanenauthor=R.+Salgadoauthor=K.+E.+de+Visserauthor=G.+S.+Sonkeauthor=L.+F.+A.+Wesselsauthor=S.+C.+Linnauthor=T.+N.+Schumacherauthor=C.+U.+Blankauthor=M.+Kok&title=Immune+induction+strategies+in+metastatic+triple-negative+breast+cancer+to+enhance+the+sensitivity+to+PD-1+blockade%3A+the+TONIC+trial&doi=10.1038%2Fs41591-019-0432-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial</span></div><div class="casAuthors">Voorwerk, Leonie; Slagter, Maarten; Horlings, Hugo M.; Sikorska, Karolina; van de Vijver, Koen K.; de Maaker, Michiel; Nederlof, Iris; Kluin, Roelof J. C.; Warren, Sarah; Ong, SuFey; Wiersma, Terry G.; Russell, Nicola S.; Lalezari, Ferry; Schouten, Philip C.; Bakker, Noor A. M.; Ketelaars, Steven L. C.; Peters, Dennis; Lange, Charlotte A. H.; van Werkhoven, Erik; van Tinteren, Harm; Mandjes, Ingrid A. M.; Kemper, Inge; Onderwater, Suzanne; Chalabi, Myriam; Wilgenhof, Sofie; Haanen, John B. A. G.; Salgado, Roberto; de Visser, Karin E.; Sonke, Gabe S.; Wessels, Lodewyk F. A.; Linn, Sabine C.; Schumacher, Ton N.; Blank, Christian U.; Kok, Marleen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">920-928</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-neg. breast cancer (TNBC) is low1-5, highlighting a need for strategies that render the tumor microenvironment more sensitive to PD-1 blockade.  Preclin. research has suggested immunomodulatory properties for chemotherapy and irradn.6-13.  In the first stage of this adaptive, non-comparative phase 2 trial, 67 patients with metastatic TNBC were randomized to nivolumab (1) without induction or with 2-wk low-dose induction, or with (2) irradn. (3 x 8 Gy), (3) cyclophosphamide, (4) cisplatin or (5) doxorubicin, all followed by nivolumab.  In the overall cohort, the objective response rate (ORR; iRECIST14) was 20%.  The majority of responses were obsd. in the cisplatin (ORR 23%) and doxorubicin (ORR 35%) cohorts.  After doxorubicin and cisplatin induction, we detected an upregulation of immune-related genes involved in PD-1-PD-L1 (programmed death ligand 1) and T cell cytotoxicity pathways.  This was further supported by enrichment among upregulated genes related to inflammation, JAK-STAT and TNF-α signaling after doxorubicin.  Together, the clin. and translational data of this study indicate that short-term doxorubicin and cisplatin may induce a more favorable tumor microenvironment and increase the likelihood of response to PD-1 blockade in TNBC.  These data warrant confirmation in TNBC and exploration of induction treatments prior to PD-1 blockade in other cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAB3hgaMeCUbVg90H21EOLACvtfcHk0ljX69NEwZqlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbrN&md5=43aa338a68b8efb399c983aab185e3f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41591-019-0432-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-019-0432-4%26sid%3Dliteratum%253Aachs%26aulast%3DVoorwerk%26aufirst%3DL.%26aulast%3DSlagter%26aufirst%3DM.%26aulast%3DHorlings%26aufirst%3DH.%2BM.%26aulast%3DSikorska%26aufirst%3DK.%26aulast%3Dvan%2Bde%2BVijver%26aufirst%3DK.%2BK.%26aulast%3Dde%2BMaaker%26aufirst%3DM.%26aulast%3DNederlof%26aufirst%3DI.%26aulast%3DKluin%26aufirst%3DR.%2BJ.%2BC.%26aulast%3DWarren%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DS.%26aulast%3DWiersma%26aufirst%3DT.%2BG.%26aulast%3DRussell%26aufirst%3DN.%2BS.%26aulast%3DLalezari%26aufirst%3DF.%26aulast%3DSchouten%26aufirst%3DP.%2BC.%26aulast%3DBakker%26aufirst%3DN.%2BA.%2BM.%26aulast%3DKetelaars%26aufirst%3DS.%2BL.%2BC.%26aulast%3DPeters%26aufirst%3DD.%26aulast%3DLange%26aufirst%3DC.%2BA.%2BH.%26aulast%3Dvan%2BWerkhoven%26aufirst%3DE.%26aulast%3Dvan%2BTinteren%26aufirst%3DH.%26aulast%3DMandjes%26aufirst%3DI.%2BA.%2BM.%26aulast%3DKemper%26aufirst%3DI.%26aulast%3DOnderwater%26aufirst%3DS.%26aulast%3DChalabi%26aufirst%3DM.%26aulast%3DWilgenhof%26aufirst%3DS.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%2BA.%2BG.%26aulast%3DSalgado%26aufirst%3DR.%26aulast%3Dde%2BVisser%26aufirst%3DK.%2BE.%26aulast%3DSonke%26aufirst%3DG.%2BS.%26aulast%3DWessels%26aufirst%3DL.%2BF.%2BA.%26aulast%3DLinn%26aufirst%3DS.%2BC.%26aulast%3DSchumacher%26aufirst%3DT.%2BN.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DKok%26aufirst%3DM.%26atitle%3DImmune%2520induction%2520strategies%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%2520to%2520enhance%2520the%2520sensitivity%2520to%2520PD-1%2520blockade%253A%2520the%2520TONIC%2520trial%26jtitle%3DNat.%2520Med.%26date%3D2019%26volume%3D25%26spage%3D920%26epage%3D928%26doi%3D10.1038%2Fs41591-019-0432-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyamfi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. S.</span></span> <span> </span><span class="NLM_article-title">The role of tumor-associated macrophage in breast cancer biology</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.14670/HH-11-916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.14670%2FHH-11-916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28681373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=133-145&author=J.+Choiauthor=J.+Gyamfiauthor=H.+Jangauthor=J.+S.+Koo&title=The+role+of+tumor-associated+macrophage+in+breast+cancer+biology&doi=10.14670%2FHH-11-916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The role of tumor-associated macrophage in breast cancer biology</span></div><div class="casAuthors">Choi, Junjeong; Gyamfi, Jones; Jang, Haerin; Koo, Ja Seung</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1,2,3</span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">University of Murcia</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most commonly diagnosed malignant tumor in women worldwide and contributes significantly as the primary cause of female cancer related mortality.  Hence, research is focused on discovering new and effective treatment targets.  The breast tumor microenvironment (TME) comprising of recruited host stromal cells and tumor cells, has recently emerged as an important player in tumor progression, with the potential for future treatment.  The TME comprises immune system elements (such as macrophages and lymphocytes), cells composing blood vessel, fibroblast, myofibroblast, mesenchymal stem cells, adipocytes and extracellular matrix (ECM).  Among these cells, tumor-assocd. macrophages (TAM) are the prominent components of TME in breast cancers.  Macrophages exhibit a high plasticity in response to various external signals and participate in innate and adoptive immune responses to control numerous factors of TME.  Depending on the microenvironmental signal present, macrophages are polarized into two distinct phenotypes, the classically activated (M1) or the alternative activated (M2) macrophages.  Tumor-assocd. macrophages (TAMs) closely resemble the M2-polarized.  Clinicopathol. studies have suggested that TAM accumulation in tumors correlates with a poor clin. outcome.  In human breast carcinomas, high TAM d. correlates with poor prognosis.  Over the years, studies into the role of TAMs in breast cancer progression have identified TAMs to be capable of inducing angiogenesis, remodelling the tumor extracellular matrix to aid invasion, modeling breast cancer cells to evade host immune system and recruiting immunosuppressive leukocytes to the tumor microenvironment.  Along with these functions, the potential role for TAMs in activation of breast cancer stem cells (CSC) has also emerged.  Thus, TAMs in breast cancer can enhance cancer cell invasion by degrading the ECM, stimulate tumor vascularization and angiogenesis and suppress the antitumor functions of cytotoxic T cells resulting in poor prognosis for patients.  These observations make TAMs an attractive target for therapeutic intervention by targeting various aspects of their function.  This review discusses the mechanisms responsible for TAM recruitment and highlights the roles of TAMs in regulating tumor angiogenesis, invasion, metastasis, immunosuppression, and chemotherapeutic resistance.  Finally, the potential for TAM-targeted therapy as a promising novel strategy is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKh8NLowpfLVg90H21EOLACvtfcHk0ljX69NEwZqlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGmsLs%253D&md5=f935c2ca750285a65c3fd1d1a1e3cee1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.14670%2FHH-11-916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-11-916%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DGyamfi%26aufirst%3DJ.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520role%2520of%2520tumor-associated%2520macrophage%2520in%2520breast%2520cancer%2520biology%26jtitle%3DHistol.%2520Histopathol.%26date%3D2018%26volume%3D33%26spage%3D133%26epage%3D145%26doi%3D10.14670%2FHH-11-916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=21416059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=166-179&author=H.+J.+Kimauthor=S.+C.+Bae&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action+and+clinical+trials+as+anti-cancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span></div><div class="casAuthors">Kim, Hyun-Jung; Bae, Suk-Chul</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-179</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells.  Recently, their use has been clin. validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA.  Also, clin. trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing.  However, the mol. mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood.  In this review, we summarize our understanding of the mol. and biol. events that underpin the anti-cancer effects of HDAC inhibitors and the outcomes of recent clin. trials involving these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6o4vH0OXL7bVg90H21EOLACvtfcHk0linRWUtV_Qm2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D&md5=2f4388dec15ec9b517836f4f3b225641</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DBae%26aufirst%3DS.%2BC.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%2520and%2520clinical%2520trials%2520as%2520anti-cancer%2520drugs%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2011%26volume%3D3%26spage%3D166%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 in cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+deacetylase+6+in+cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0linRWUtV_Qm2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%25206%2520in%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganai, S. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors modulating non-epigenetic players: the novel mechanism for small molecule based therapeutic intervention</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160527143257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.2174%2F1389450117666160527143257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27231104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFGisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=593-601&author=S.+A.+Ganai&title=Histone+deacetylase+inhibitors+modulating+non-epigenetic+players%3A+the+novel+mechanism+for+small+molecule+based+therapeutic+intervention&doi=10.2174%2F1389450117666160527143257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Modulating Nonepigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention</span></div><div class="casAuthors">Ganai, Shabir Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-601</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in regulating the expression and activity of myriad of proteins involved in tumor onset and progression.  HDAC activity results in a nonpermissive chromatin conformation by erasing acetyl moiety from histone substrates culminating in transcriptional repression of those genes having significant role in tumorigenesis.  Apart from histones, HDACs deacetylate a variety of nonhistone proteins including transcription factors involved in controlling cell growth, differentiation and apoptosis.  Histone deacetylase inhibitors (HDACi) are smallmols. restraining HDACs and hence modulating their biol. activity.  Emerging evidences suggest that acetylation of nonhistone proteins plays a crit. role in various cellular processes including mRNA stability, protein localization and degrdn.  Abnormal turnover or expression of nonhistone proteins like nuclear factor kappaB (NF&#954;B), heat shock protein 90 (HSP90) and frataxin fuels various diseases including cancer.  The present article explores the therapeutic role of HDACi with special emphasis on modulation of clin. relevant nonhistone mol. targets.  Extensive details regarding the nonhistone proteins and their deregulation in disease states have also been provided.  Moreover, the underlying mol. mechanism triggered by HDACi to overcome disease states by modulating the predefined targets has also been illuminated.  The article strongly suggests the promising use of HDACi in therapeutic intervention against complications arising due to nonhistone protein deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRxadLdK3QT7Vg90H21EOLACvtfcHk0linRWUtV_Qm2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFGisLc%253D&md5=b54f842bb35184b014eac0bf42fc843c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160527143257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160527143257%26sid%3Dliteratum%253Aachs%26aulast%3DGanai%26aufirst%3DS.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520modulating%2520non-epigenetic%2520players%253A%2520the%2520novel%2520mechanism%2520for%2520small%2520molecule%2520based%2520therapeutic%2520intervention%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2018%26volume%3D19%26spage%3D593%26epage%3D601%26doi%3D10.2174%2F1389450117666160527143257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Acetylation and deacetylation of non-histone proteins</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2005.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.gene.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=16289629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2005&pages=15-23&author=M.+A.+Glozakauthor=N.+Senguptaauthor=X.+Zhangauthor=E.+Seto&title=Acetylation+and+deacetylation+of+non-histone+proteins&doi=10.1016%2Fj.gene.2005.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation and deacetylation of non-histone proteins</span></div><div class="casAuthors">Glozak, Michele A.; Sengupta, Nilanjan; Zhang, Xiaohong; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs.  Of these, transcription factors comprise the largest class of new targets.  The substrates for HATs extend to cytoskeletal proteins, mol. chaperones and nuclear import factors.  Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function.  This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghezJOUSImbVg90H21EOLACvtfcHk0linRWUtV_Qm2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN&md5=c6befd12e4556a9154628d9fe9ebe53a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSengupta%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DAcetylation%2520and%2520deacetylation%2520of%2520non-histone%2520proteins%26jtitle%3DGene%26date%3D2005%26volume%3D363%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.gene.2005.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDACs and HDAC inhibitors in cancer development and therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a026831</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a026831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1101%2Fcshperspect.a026831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27599530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=a026831&author=Y.+Liauthor=E.+Seto&title=HDACs+and+HDAC+inhibitors+in+cancer+development+and+therapy&doi=10.1101%2Fcshperspect.a026831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HDACs and HDAC inhibitors in cancer development and therapy</span></div><div class="casAuthors">Li, Yixuan; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">a026831/1-a026831/35</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer.  Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.  Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs).  By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.  In addn.,HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biol. processes including cancer initiation and progression.  This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRL0Y7L3_s7Vg90H21EOLACvtfcHk0lhQgZaVW6V-Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D&md5=1c647aa38027de1c4c92f74340d9041a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDACs%2520and%2520HDAC%2520inhibitors%2520in%2520cancer%2520development%2520and%2520therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26spage%3Da026831%26doi%3D10.1101%2Fcshperspect.a026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as anticancer drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">E1414</span> <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+deacetylase+inhibitors+as+anticancer+drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0lhQgZaVW6V-Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landreville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agapova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matatall, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneass, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onken, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcock, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbour, J. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-0946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F1078-0432.ccr-11-0946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22038994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=408-416&author=S.+Landrevilleauthor=O.+A.+Agapovaauthor=K.+A.+Matatallauthor=Z.+T.+Kneassauthor=M.+D.+Onkenauthor=R.+S.+Leeauthor=A.+M.+Bowcockauthor=J.+W.+Harbour&title=Histone+deacetylase+inhibitors+induce+growth+arrest+and+differentiation+in+uveal+melanoma&doi=10.1158%2F1078-0432.ccr-11-0946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma</span></div><div class="casAuthors">Landreville, Solange; Agapova, Olga A.; Matatall, Katie A.; Kneass, Zachary T.; Onken, Michael D.; Lee, Ryan S.; Bowcock, Anne M.; Harbour, J. William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">408-416</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the mol. events that lead to metastasis.  We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely assocd. with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis.  The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM.  Exptl. Design: In silico screens were done to identify therapeutic compds. predicted to differentiate UM cells using Gene Set Enrichment Anal. and Connectivity Map databases.  Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects on UM cells using morphol. evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model.  RESULTS: Histone deacetylase (HDAC) inhibitors induced morphol. differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells.  VPA inhibited the growth of UM tumors in vivo.  CONCLUSIONS: These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4_gyFoEhAN7Vg90H21EOLACvtfcHk0lhQgZaVW6V-Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqsr4%253D&md5=a020fc9b897bc9eb8907fcb5d94330b8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-0946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-0946%26sid%3Dliteratum%253Aachs%26aulast%3DLandreville%26aufirst%3DS.%26aulast%3DAgapova%26aufirst%3DO.%2BA.%26aulast%3DMatatall%26aufirst%3DK.%2BA.%26aulast%3DKneass%26aufirst%3DZ.%2BT.%26aulast%3DOnken%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DR.%2BS.%26aulast%3DBowcock%26aufirst%3DA.%2BM.%26aulast%3DHarbour%26aufirst%3DJ.%2BW.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520induce%2520growth%2520arrest%2520and%2520differentiation%2520in%2520uveal%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D408%26epage%3D416%26doi%3D10.1158%2F1078-0432.ccr-11-0946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, G. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as cancer therapeutics</span>. <i>Ann. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">287</span>, <span class="refDoi"> DOI: 10.21037/atm.2016.07.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.21037%2Fatm.2016.07.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27568481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFKqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=287&author=G.+A.+Clawson&title=Histone+deacetylase+inhibitors+as+cancer+therapeutics&doi=10.21037%2Fatm.2016.07.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as cancer therapeutics</span></div><div class="casAuthors">Clawson, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">287/1-287/5</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Cancer cells contain significant alterations in their epigenomic landscape, which several enzyme families reversibly contribute to.  One class of epigenetic modifying enzymes is that of histone deacetylases (HDAC), which are receiving considerable scrutiny clin. as a therapeutic target in many cancers.  The underlying rationale is that inhibiting HDACs will reverse dysregulated target gene expression by modulating functional histone (or other) acetylation marks.  This perspective will discuss a recent paper by Markozashvili and co-workers which appeared in Gene, which indicates that the mechanisms by which HDAC inhibitors (HDACis) alter the epigenetic landscape include widespread alternative effects beyond simply controlling regional epigenetic marks.  HDACs are involved in many processes/diseases, and it is not surprising that HDACis have considerable off-target effects, and thus a major effort is being directed toward identification of inhibitors which are selective for HDAC isoforms often uniquely implicated in various cancers.  This Perspective will also discuss some representative work with inhibitors targeting individual HDAC classes or isoforms.  At present, it is not really clear that isoform-specific HDACis will avoid non-selective effects on other unrecognized activities of HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraa-xek0cV4LVg90H21EOLACvtfcHk0lgSlE_obdU6dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFKqsro%253D&md5=59c7b371e6d1a22ff874ba700500375f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.21037%2Fatm.2016.07.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2016.07.22%26sid%3Dliteratum%253Aachs%26aulast%3DClawson%26aufirst%3DG.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520cancer%2520therapeutics%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D287%26doi%3D10.21037%2Fatm.2016.07.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orillion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pili, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as immunomodulators in cancer therapeutics</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.2217/epi.15.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.2217%2Fepi.15.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26950532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=415-428&author=L.+Shenauthor=A.+Orillionauthor=R.+Pili&title=Histone+deacetylase+inhibitors+as+immunomodulators+in+cancer+therapeutics&doi=10.2217%2Fepi.15.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as immunomodulators in cancer therapeutics</span></div><div class="casAuthors">Shen, Li; Orillion, Ashley; Pili, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-428</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">HDAC inhibitors (HDACIs) are anticancer agents being developed in preclin. and clin. settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins.  Most HDACIs in clin. development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented.  Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies.  Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system.  In addn., we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different exptl. settings and the target immune cell populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWrKeBY7Wqw7Vg90H21EOLACvtfcHk0lgSlE_obdU6dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOju7k%253D&md5=22641a485661b749cc6710441760b619</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2217%2Fepi.15.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.15.118%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DOrillion%26aufirst%3DA.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520immunomodulators%2520in%2520cancer%2520therapeutics%26jtitle%3DEpigenomics%26date%3D2016%26volume%3D8%26spage%3D415%26epage%3D428%26doi%3D10.2217%2Fepi.15.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppt, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berking, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside</span>. <i>Exog. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1111/exd.13089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1111%2Fexd.13089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=831-838&author=E.+Hornigauthor=M.+V.+Hepptauthor=S.+A.+Grafauthor=T.+Ruzickaauthor=C.+Berking&title=Inhibition+of+histone+deacetylases+in+melanoma-a+perspective+from+bench+to+bedside&doi=10.1111%2Fexd.13089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fexd.13089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13089%26sid%3Dliteratum%253Aachs%26aulast%3DHornig%26aufirst%3DE.%26aulast%3DHeppt%26aufirst%3DM.%2BV.%26aulast%3DGraf%26aufirst%3DS.%2BA.%26aulast%3DRuzicka%26aufirst%3DT.%26aulast%3DBerking%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520histone%2520deacetylases%2520in%2520melanoma-a%2520perspective%2520from%2520bench%2520to%2520bedside%26jtitle%3DExog.%2520Dermatol.%26date%3D2016%26volume%3D25%26spage%3D831%26epage%3D838%26doi%3D10.1111%2Fexd.13089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodre, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.cir-15-0077-t</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F2326-6066.cir-15-0077-t" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26297712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=1375-1385&author=D.+M.+Woodsauthor=A.+L.+Sodreauthor=A.+Villagraauthor=A.+Sarnaikauthor=E.+M.+Sotomayorauthor=J.+Weber&title=HDAC+inhibition+upregulates+PD-1+ligands+in+melanoma+and+augments+immunotherapy+with+PD-1+blockade&doi=10.1158%2F2326-6066.cir-15-0077-t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade</span></div><div class="casAuthors">Woods, David M.; Sodre, Andressa L.; Villagra, Alejandro; Sarnaik, Amod; Sotomayor, Eduardo M.; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1375-1385</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression of PD-1 ligands by tumors and interaction with PD-1-expressing T cells in the tumor microenvironment can result in tolerance.  Therapies targeting this coinhibitory axis have proven clin. successful in the treatment of metastatic melanoma, non-small cell lung cancer, and other malignancies.  Therapeutic agents targeting the epigenetic regulatory family of histone deacetylases (HDAC) have shown clin. success in the treatment of some hematol. malignancies.  Beyond direct tumor cell cytotoxicity, HDAC inhibitors have also been shown to alter the immunogenicity and enhance antitumor immune responses.  Here, we show that class I HDAC inhibitors upregulated the expression of PD-L1 and, to a lesser degree, PD-L2 in melanomas.  Evaluation of human and murine cell lines and patient tumors treated with a variety of HDAC inhibitors in vitro displayed upregulation of these ligands.  This upregulation was robust and durable, with enhanced expression lasting past 96 h.  These results were validated in vivo in a B16F10 syngeneic murine model.  Mechanistically, HDAC inhibitor treatment resulted in rapid upregulation of histone acetylation of the PD-L1 gene leading to enhanced and durable gene expression.  The efficacy of combining HDAC inhibition with PD-1 blockade for treatment of melanoma was also explored in a murine B16F10 model.  Mice receiving combination therapy had a slower tumor progression and increased survival compared with control and single-agent treatments.  These results highlight the ability of epigenetic modifiers to augment immunotherapies, providing a rationale for combining HDAC inhibitors with PD-1 blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEnfkgZl-yp7Vg90H21EOLACvtfcHk0lgSlE_obdU6dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lu7zO&md5=c543bcb49c533bfadbdf9ab73c6c8a2e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.cir-15-0077-t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.cir-15-0077-t%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DD.%2BM.%26aulast%3DSodre%26aufirst%3DA.%2BL.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DHDAC%2520inhibition%2520upregulates%2520PD-1%2520ligands%2520in%2520melanoma%2520and%2520augments%2520immunotherapy%2520with%2520PD-1%2520blockade%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D1375%26epage%3D1385%26doi%3D10.1158%2F2326-6066.cir-15-0077-t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienlaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villaroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marante, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1447</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2015.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.molonc.2015.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25957812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1447-1457&author=K.+V.+Woanauthor=M.+Lienlafauthor=P.+Perez-Villaroelauthor=C.+Leeauthor=F.+Chengauthor=T.+Knoxauthor=D.+M.+Woodsauthor=K.+Barriosauthor=J.+Powersauthor=E.+Sahakianauthor=H.+W.+Wangauthor=J.+Canalesauthor=D.+Maranteauthor=K.+S.+M.+Smalleyauthor=J.+Bergmanauthor=E.+Setoauthor=A.+Kozikowskiauthor=J.+Pinilla-Ibarzauthor=A.+Sarnaikauthor=E.+Celisauthor=J.+Weberauthor=E.+M.+Sotomayorauthor=A.+Villagra&title=Targeting+histone+deacetylase+6+mediates+a+dual+anti-melanoma+effect%3A+enhanced+antitumor+immunity+and+impaired+cell+proliferation&doi=10.1016%2Fj.molonc.2015.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation</span></div><div class="casAuthors">Woan, K. V.; Lienlaf, M.; Perez-Villaroel, P.; Lee, C.; Cheng, F.; Knox, T.; Woods, D. M.; Barrios, K.; Powers, J.; Sahakian, E.; Wang, H. W.; Canales, J.; Marante, D.; Smalley, K. S. M.; Bergman, J.; Seto, E.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Celis, E.; Weber, J.; Sotomayor, E. M.; Villagra, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1457</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The median survival for metastatic melanoma is in the realm of 8-16 mo and there are few therapies that offer significant improvement in overall survival.  One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells.  Our group and others have previously demonstrated that pan-HDAC inhibitors induce apoptosis, cell cycle arrest and changes in the immunogenicity of melanoma cells.  Here we interrogated specific HDACs which may be responsible for this effect.  We found that both genetic abrogation and pharmacol. inhibition of HDAC6 decreases in vitro proliferation and induces G1 arrest of melanoma cell lines without inducing apoptosis.  Moreover, targeting this mol. led to an important upregulation in the expression of tumor assocd. antigens and MHC class I, suggesting a potential improvement in the immunogenicity of these cells.  Of note, this anti-melanoma activity was operative regardless of mutational status of the cells.  These effects translated into a pronounced delay of in vivo melanoma tumor growth which was, at least in part, dependent on intact immunity as evidenced by the restoration of tumor growth after CD4+ and CD8+ depletion.  Given our findings, we provide the initial rationale for the further development of selective HDAC6 inhibitors as potential therapeutic anti-melanoma agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDIQ5LKbZF8bVg90H21EOLACvtfcHk0lirXewmft12xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D&md5=7534df9db01f52a71f97f0e112db37cc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DWoan%26aufirst%3DK.%2BV.%26aulast%3DLienlaf%26aufirst%3DM.%26aulast%3DPerez-Villaroel%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DWoods%26aufirst%3DD.%2BM.%26aulast%3DBarrios%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%2BW.%26aulast%3DCanales%26aufirst%3DJ.%26aulast%3DMarante%26aufirst%3DD.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DTargeting%2520histone%2520deacetylase%25206%2520mediates%2520a%2520dual%2520anti-melanoma%2520effect%253A%2520enhanced%2520antitumor%2520immunity%2520and%2520impaired%2520cell%2520proliferation%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D1447%26epage%3D1457%26doi%3D10.1016%2Fj.molonc.2015.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">Inside HDACs with more selective HDAC inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2016.05.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27318122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=451-483&author=J.+Rocheauthor=P.+Bertrand&title=Inside+HDACs+with+more+selective+HDAC+inhibitors&doi=10.1016%2Fj.ejmech.2016.05.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inside HDACs with more selective HDAC inhibitors</span></div><div class="casAuthors">Roche, Joelle; Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451-483</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compds. approved by the Food and Drug Administration.  During the last five years, several groups have made continuous efforts to improve this class of compds., designing more selective compds. or compds. with multiple capacities.  After a survey of the HDAC biol. and structures, this review summarizes the results of the chemists working in this field, and highlights when possible the behavior of the mols. inside their targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHO5YBuaN7c7Vg90H21EOLACvtfcHk0lirXewmft12xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI&md5=3bbd062c1fb8a402c039e20bacd4af14</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.047%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DJ.%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DInside%2520HDACs%2520with%2520more%2520selective%2520HDAC%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D451%26epage%3D483%26doi%3D10.1016%2Fj.ejmech.2016.05.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponichtera, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourzia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span> <span> </span><span class="NLM_article-title">Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1038/nature21409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnature21409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28273064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=428-432&author=J.+L.+Guerrieroauthor=A.+Sotayoauthor=H.+E.+Ponichteraauthor=J.+A.+Castrillonauthor=A.+L.+Pourziaauthor=S.+Schadauthor=S.+F.+Johnsonauthor=R.+D.+Carrascoauthor=S.+Lazoauthor=R.+T.+Bronsonauthor=S.+P.+Davisauthor=M.+Loberaauthor=M.+A.+Nolanauthor=A.+Letai&title=Class+IIa+HDAC+inhibition+reduces+breast+tumours+and+metastases+through+anti-tumour+macrophages&doi=10.1038%2Fnature21409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Class IIa HDAC inhibition reduces breast tumors and metastases through anti-tumor macrophages</span></div><div class="casAuthors">Guerriero, Jennifer L.; Sotayo, Alaba; Ponichtera, Holly E.; Castrillon, Jessica A.; Pourzia, Alexandra L.; Schad, Sara; Johnson, Shawn F.; Carrasco, Ruben D.; Lazo, Suzan; Bronson, Roderick T.; Davis, Scott P.; Lobera, Mercedes; Nolan, Michael A.; Letai, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7645</span>),
    <span class="NLM_cas:pages">428-432</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the main focus of immuno-oncol. has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumor redn. and elimination.  Tumor-assocd. macrophages often have net pro-tumor effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumors.  Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumor-assocd. macrophages have had some success.  We hypothesized that pharmacol. modulation of macrophage phenotype could produce an anti-tumor effect.  We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.  Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumor microenvironment and reduces tumor burden and pulmonary metastases by modulating macrophage phenotypes.  TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors.  Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumor redn.  These data introduce class IIa HDAC inhibition as a means to harness the anti-tumor potential of macrophages to enhance cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEzcFKak-anrVg90H21EOLACvtfcHk0lirXewmft12xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D&md5=0356d851bbeb834038527f5190d0e4b8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnature21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21409%26sid%3Dliteratum%253Aachs%26aulast%3DGuerriero%26aufirst%3DJ.%2BL.%26aulast%3DSotayo%26aufirst%3DA.%26aulast%3DPonichtera%26aufirst%3DH.%2BE.%26aulast%3DCastrillon%26aufirst%3DJ.%2BA.%26aulast%3DPourzia%26aufirst%3DA.%2BL.%26aulast%3DSchad%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DS.%2BF.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DLazo%26aufirst%3DS.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DDavis%26aufirst%3DS.%2BP.%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26aulast%3DLetai%26aufirst%3DA.%26atitle%3DClass%2520IIa%2520HDAC%2520inhibition%2520reduces%2520breast%2520tumours%2520and%2520metastases%2520through%2520anti-tumour%2520macrophages%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D428%26epage%3D432%26doi%3D10.1038%2Fnature21409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Creation of a histone deacetylase 6 inhibitor and its biological effects</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">12005</span>– <span class="NLM_lpage">12010</span>, <span class="refDoi"> DOI: 10.1073/pnas.1515882112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1073%2Fpnas.1515882112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26371309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=12005-12010&author=J.-H.+Leeauthor=Y.+Yaoauthor=A.+Mahendranauthor=L.+Ngoauthor=G.+Venta-Perezauthor=M.+L.+Choyauthor=R.+Breslowauthor=P.+A.+Marks&title=Creation+of+a+histone+deacetylase+6+inhibitor+and+its+biological+effects&doi=10.1073%2Fpnas.1515882112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a histone deacetylase 6 inhibitor and its biological effects</span></div><div class="casAuthors">Lee, Ju-Hee; Yao, Yuanshan; Mahendran, Adaickapillai; Ngo, Lang; Venta-Perez, Gisela; Choy, Megan L.; Breslow, Ronald; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12005-12010</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor, HPB (N-hydroxy-4-[(N-(((2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide)]).  This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells.  The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonHNFE0-PzyLVg90H21EOLACvtfcHk0lhd7vKp6kWcjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK&md5=d6dc50c8c83e0b03c5ecebc3da3a96c7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1515882112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1515882112%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DCreation%2520of%2520a%2520histone%2520deacetylase%25206%2520inhibitor%2520and%2520its%2520biological%2520effects%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D12005%26epage%3D12010%26doi%3D10.1073%2Fpnas.1515882112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detroja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsin, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Targeting breast cancer stem cells by novel HDAC3-selective inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.08.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28923385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=42-51&author=H.-Y.+Hsiehauthor=H.-C.+Chuangauthor=F.-H.+Shenauthor=K.+Detrojaauthor=L.-W.+Hsinauthor=C.-S.+Chen&title=Targeting+breast+cancer+stem+cells+by+novel+HDAC3-selective+inhibitors&doi=10.1016%2Fj.ejmech.2017.08.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting breast cancer stem cells by novel HDAC3-selective inhibitors</span></div><div class="casAuthors">Hsieh, Hao-Yu; Chuang, Hsiao-Ching; Shen, Fang-Hsiu; Detroja, Kinjal; Hsin, Ling-Wei; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-51</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Although histone deacetylase (HDAC) inhibitors have been known to suppress the cancer stem cell (CSC) population in multiple types of cancer cells, it remains unclear which HDAC isoforms and corresponding mechanisms contribute to this anti-CSC activity.  Pursuant to our previous finding that HDAC8 regulates CSCs in triple-neg. breast cancer (TNBC) cells by targeting Notch1 stability, we investigated related pathways and found HDAC3 to be mechanistically linked to CSC homeostasis by increasing β-catenin expression through the Akt/GSK3β pathway.  Accordingly, we used a pan-HDAC inhibitor, AR-42 (1), as a scaffold to develop HDAC3-selective inhibitors, obtaining the proof-of-concept with 18 and 28.  These two derivs. exhibited high potency and isoform selectivity in HDAC3 inhibition.  Equally important, they showed in vitro and/or in vivo efficacy in suppressing the CSC subpopulation of TNBC cells via the down regulation of β-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooFIxRkkBCsrVg90H21EOLACvtfcHk0lhd7vKp6kWcjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsbnL&md5=a0ad5d8e018d7471975602be2ba238eb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.069%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DH.-Y.%26aulast%3DChuang%26aufirst%3DH.-C.%26aulast%3DShen%26aufirst%3DF.-H.%26aulast%3DDetroja%26aufirst%3DK.%26aulast%3DHsin%26aufirst%3DL.-W.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DTargeting%2520breast%2520cancer%2520stem%2520cells%2520by%2520novel%2520HDAC3-selective%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D42%26epage%3D51%26doi%3D10.1016%2Fj.ejmech.2017.08.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">80109</span>– <span class="NLM_lpage">80123</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.18632%2Foncotarget.19019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29113288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=80109-80123&author=T.+Hideshimaauthor=R.+Mazitschekauthor=J.+Qiauthor=N.+Mimuraauthor=J.-C.+Tsengauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=K.+C.+Anderson&title=HDAC6+inhibitor+WT161+downregulates+growth+factor+receptors+in+breast+cancer&doi=10.18632%2Foncotarget.19019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span></div><div class="casAuthors">Hideshima Teru; Qi Jun; Mimura Naoya; Bradner James E; Anderson Kenneth C; Mazitschek Ralph; Mimura Naoya; Tseng Jen-Chieh; Kung Andrew L; Tseng Jen-Chieh; Kung Andrew L; Kung Andrew L; Bradner James E</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">80109-80123</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models.  However, its activity in other type of cancers has not yet been shown.  In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines.  WT161 triggers apoptotic cell death in MCF7, T47D, BT474, and MDA-MB231 cells, associated with decreased expression of EGFR, HER2, and ERα and downstream signaling.  However, HDAC6 knockdown shows that cytotoxicity and destabilization of these receptors triggered by WT161 are not dependent on HDAC6 inhibition.  Moreover WT161 analog MAZ1793, which lacks HDAC inhibitory effect, similarly triggers cell line growth inhibition and downregulation of these receptors.  We also confirm that WT161 significantly inhibits in vivo MCF7 cell growth, associated with downregulation of ERα, in a murine xenograft model.  Finally, WT161 synergistically enhances bortezomib-induced cytotoxicity, even in bortezomib-resistant breast cancer cells.  Our results therefore provide the rationale to develop a novel class of therapeutic agents targeting growth pathways central to the pathogenesis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWi2bvABUN7K2q3xNe7a7QfW6udTcc2eYRpzIEfDZ3-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D&md5=50fcf37b8db1e8acb520e650f6702bf5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19019%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DHDAC6%2520inhibitor%2520WT161%2520downregulates%2520growth%2520factor%2520receptors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D80109%26epage%3D80123%26doi%3D10.18632%2Foncotarget.19019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">(N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=905-917&author=H.-Y.+Leeauthor=K.+Nepaliauthor=F.-I.+Huangauthor=C.-Y.+Changauthor=M.-J.+Laiauthor=Y.-H.+Liauthor=H.-L.+Huangauthor=C.-R.+Yangauthor=J.-P.+Liou&title=%28N-Hydroxycarbonylbenylamino%29quinolines+as+selective+histone+deacetylase+6+inhibitors+suppress+growth+of+multiple+myeloma+in+vitro+and+in+vivo&doi=10.1021%2Facs.jmedchem.7b01404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">(N-Hydroxycarbonylbenzylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span></div><div class="casAuthors">Lee, Hsueh-Yun; Nepali, Kunal; Huang, Fang-I.; Chang, Chih-Yi; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7-31) have been examd. as novel histone deacetylase 6 (HDAC6) inhibitors.  One compd. (13, N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide) exhibits remarkable inhibitory activity of HDAC6 with an IC50 value of 0.29 nM, which is 4000-43,000 times more selective over other HDAC isoforms.  Compd. 13 was shown to have antiproliferative activity against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells with no effect on normal bone marrow cells.  Compd. 13, as a single drug, suppresses the growth of tumors by a %TGI factor of 60.4% in human multiple myeloma RPMI 8226 xenograft models and, in combination with bortezomib, shows significant in vivo antitumor activity (%TGI = 86.2%).  Compd. 13 also demonstrates good human hepatocytic stability and high permeability, without any effect on mutagenicity and cytotoxicity.  Thus, compd. 13 is a potent HDAC6 inhibitor that could be developed for the treatment of multiple myeloma in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRGAacR3ID_LVg90H21EOLACvtfcHk0liZ6Xyh1iRgZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D&md5=4e76a60f13c7414ba7cf871aa0193b14</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01404%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DF.-I.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26aulast%3DHuang%26aufirst%3DH.-L.%26aulast%3DYang%26aufirst%3DC.-R.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3D%2528N-Hydroxycarbonylbenylamino%2529quinolines%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%2520suppress%2520growth%2520of%2520multiple%2520myeloma%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D905%26epage%3D917%26doi%3D10.1021%2Facs.jmedchem.7b01404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of selective histone deacetylase 6 inhibitors in melanoma models</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1031-1036&author=M.+T.+Tavaresauthor=S.+Shenauthor=T.+Knoxauthor=M.+Hadleyauthor=Z.+Kutilauthor=C.+Ba%C5%99inkaauthor=A.+Villagraauthor=A.+P.+Kozikowski&title=Synthesis+and+pharmacological+evaluation+of+selective+histone+deacetylase+6+inhibitors+in+melanoma+models&doi=10.1021%2Facsmedchemlett.7b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models</span></div><div class="casAuthors">Tavares, Mauricio T.; Shen, Sida; Knox, Tessa; Hadley, Melissa; Kutil, Zsofia; Barinka, Cyril; Villagra, Alejandro; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1031-1036</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Only a handful of therapies offer significant improvement in the overall survival in cases of melanoma, a cancer whose incidence has continued to rise in the past 30 years.  In our effort to identify potent and isoform-selective histone deacetylase (HDAC) inhibitors as a therapeutic approach to melanoma, a series of new HDAC6 inhibitors based on the nexturastat A scaffold were prepd.  The new analogs bearing added hydrophilic substituents, so as to establish addnl. hydrogen bonding on the rim of the HDAC6 catalytic pocket, exhibit improved potency against HDAC6 and retain selectivity over HDAC1.  Compd. I exhibits antiproliferative effects on several types of melanoma and lymphoma cells.  Further studies indicates that I selectively increases acetylated tubulin levels in vitro and elicits an immune response through down-regulating cytokine IL-10.  A preliminary in vivo efficacy study indicates that I possesses improved capability to inhibit melanoma tumor growth and that this effect is based on the regulation of inflammatory and immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cF7frE1ffLVg90H21EOLACvtfcHk0liZ6Xyh1iRgZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL&md5=305123b6d7ecc3e4273d5fa02565367f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00223%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%2520in%2520melanoma%2520models%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1031%26epage%3D1036%26doi%3D10.1021%2Facsmedchemlett.7b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruijter, A. J. M. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennip, A. H. v.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuilenburg, A. B. P. v.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=12429021" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+M.+d.+Ruijterauthor=A.+H.+v.+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+P.+v.+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3DRuijter%26aufirst%3DA.%2BJ.%2BM.%2Bd.%26aulast%3DGennip%26aufirst%3DA.%2BH.%2Bv.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3DKuilenburg%26aufirst%3DA.%2BB.%2BP.%2Bv.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1038/nrg2485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnrg2485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=19065135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=32-42&author=M.+Haberlandauthor=R.+L.+Montgomeryauthor=E.+N.+Olson&title=The+many+roles+of+histone+deacetylases+in+development+and+physiology%3A+implications+for+disease+and+therapy&doi=10.1038%2Fnrg2485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span></div><div class="casAuthors">Haberland, Michael; Montgomery, Rusty L.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The expression of many histone deacetylase (HDAC) isoforms in eukaryotic cells raises questions regarding their specificity and the programs of gene expression that they control.  HDAC knockout mice are a powerful tool for addressing these questions and have revealed that individual HDACs have specific functions in development and disease.  Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biol. processes, largely through their repressive influence on transcription.  The expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.  Recent analyses of HDAC knockout mice have revealed highly specific functions of individual HDACs in development and disease.  Mutant mice lacking individual HDACs are a powerful tool for defining the functions of HDACs in vivo and the mol. targets of HDAC inhibitors in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWcIo3mrsM7Vg90H21EOLACvtfcHk0liZ6Xyh1iRgZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI&md5=0678d8655e86994cd4f0174c1e9d0eb1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrg2485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2485%26sid%3Dliteratum%253Aachs%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DThe%2520many%2520roles%2520of%2520histone%2520deacetylases%2520in%2520development%2520and%2520physiology%253A%2520implications%2520for%2520disease%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2009%26volume%3D10%26spage%3D32%26epage%3D42%26doi%3D10.1038%2Fnrg2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khochbin, S.</span></span> <span> </span><span class="NLM_article-title">HDAC6 a new cellular stress surveillance factor</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.4161/cc.7.1.5186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.4161%2Fcc.7.1.5186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=18196966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVKntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=7-10&author=P.+Matthiasauthor=M.+Yoshidaauthor=S.+Khochbin&title=HDAC6+a+new+cellular+stress+surveillance+factor&doi=10.4161%2Fcc.7.1.5186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 a new cellular stress surveillance factor</span></div><div class="casAuthors">Matthias, Patrick; Yoshida, Minoru; Khochbin, Saadi</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-10</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Less than a decade has passed since histone deacetylase harboring (HDAC6) was first identified and regarded as an unusual histone deacetylase harboring 2 catalytic domains.  Early demonstration of its cytoplasmic localization, its ubiquitin-binding, and its tubulin-deacetylase activities took HDAC6 far away from everything known to involve other histone-deacetylases.  Recent discoveries confirmed the very unique functions of HDAC6 among deacetylases and pointed to this protein as a master regulator of cell response to cytotoxic assaults.  HDAC6 appears both as a sensor of stressful stimuli and as an effector, which, thanks to its wide range of activities, mediates and coordinates appropriate cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Tzz-Xi44N7Vg90H21EOLACvtfcHk0ljCVc5IUIxyCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVKntLY%253D&md5=6b0784dad7b4fac9a31e803548bc7a84</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4161%2Fcc.7.1.5186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.7.1.5186%26sid%3Dliteratum%253Aachs%26aulast%3DMatthias%26aufirst%3DP.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKhochbin%26aufirst%3DS.%26atitle%3DHDAC6%2520a%2520new%2520cellular%2520stress%2520surveillance%2520factor%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D7%26epage%3D10%26doi%3D10.4161%2Fcc.7.1.5186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span> <span> </span><span class="NLM_article-title">Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1549</span>, <span class="refDoi"> DOI: 10.1111/cas.13062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1111%2Fcas.13062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27554046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1543-1549&author=Y.+Imaiauthor=Y.+Maruauthor=J.+Tanaka&title=Action+mechanisms+of+histone+deacetylase+inhibitors+in+the+treatment+of+hematological+malignancies&doi=10.1111%2Fcas.13062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies</span></div><div class="casAuthors">Imai, Yoichi; Maru, Yoshiro; Tanaka, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1543-1549</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Histone deacetylases (HDACs) critically regulate gene expression by detg. the acetylation status of histones.  In addn., studies have increasingly focused on the activities of HDACs, esp. involving non-histone proteins, and their various biol. effects.  Aberrant HDAC expression obsd. in several kinds of human tumors makes HDACs potential targets for cancer treatment.  Several preclin. studies have suggested that HDAC inhibitors exhibit some efficacy in the treatment of acute myelogenous leukemia (AML) with AML1-ETO, which mediates transcriptional repression through its interaction with a complex including HDAC1.  Recurrent mutations in epigenetic regulators are found in T-cell lymphomas (TCLs), and HDAC inhibitors and hypomethylating agents were shown to act cooperatively in the treatment of TCLs.  Preclin. modeling has suggested that persistent activation of the signal transducer and activator of transcription (STAT) signaling pathway could serve as a useful biomarker of resistance to HDAC inhibitor in patients with cutaneous TCL.  Panobinostat, a pan-HDAC inhibitor, in combination with bortezomib and dexamethasone, has achieved longer progression-free survival in patients with relapsed/refractory multiple myeloma (MM) than the placebo in combination with bortezomib and dexamethasone.  Panobinostat inhibited MM cell growth by degrading protein phosphatase 3 catalytic subunit α (PPP3CA), a catalytic subunit of calcineurin.  This degrdn. was suggested to be mediated by the blockade of the chaperone function of heat shock protein 90 (HSP90) due to HDAC6 inhibition.  Aberrant PPP3CA expression in advanced MM indicated a possible correlation between high PPP3CA expression and the pathogenesis of MM.  Furthermore, PPP3CA was suggested as a common target of panobinostat and bortezomib.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8mVwuDgQ9LVg90H21EOLACvtfcHk0ljCVc5IUIxyCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O&md5=d97540b4f33bb4ce6c044717785f9954</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fcas.13062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13062%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DMaru%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DJ.%26atitle%3DAction%2520mechanisms%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1543%26epage%3D1549%26doi%3D10.1111%2Fcas.13062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keusch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span> <span> </span><span class="NLM_article-title">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnchembio.2140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27454931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=748-754&author=Y.+Miyakeauthor=J.+J.+Keuschauthor=L.+Wangauthor=M.+Saitoauthor=D.+Hessauthor=X.+Wangauthor=B.+J.+Melanconauthor=P.+Helquistauthor=H.+Gutauthor=P.+Matthias&title=Structural+insights+into+HDAC6+tubulin+deacetylation+and+its+selective+inhibition&doi=10.1038%2Fnchembio.2140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span></div><div class="casAuthors">Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong; Saito, Makoto; Hess, Daniel; Wang, Xiaoning; Melancon, Bruce J.; Helquist, Paul; Gut, Heinz; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor, nexturastat A.  The tandem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry.  The authors identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective inhibitors.  HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA had moderate selectivity for HDAC6.  The authors identified a uniquely positioned α-helix and a flexible Trp residue in the loop joining α-helixes H20 to H21 as crit. for deacetylation of the physiol. substrate, tubulin.  Using single-mol. measurements and biochem. assays, the authors demonstrated that HDAC6 catalytic domain 2 deacetylated α-tubulin Lys-40 in the lumen of microtubules, but that its preferred substrate was unpolymd. tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpERJRurS1cC7Vg90H21EOLACvtfcHk0ljCVc5IUIxyCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM&md5=4abe529ab89615df33f54350a1a8c69a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2140%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DKeusch%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DMatthias%26aufirst%3DP.%26atitle%3DStructural%2520insights%2520into%2520HDAC6%2520tubulin%2520deacetylation%2520and%2520its%2520selective%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fnchembio.2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faria
Freitas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuendet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors: a 2013-2017 patent survey</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1459568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1080%2F13543776.2018.1459568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVSns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=365-381&author=M.+Faria%0AFreitasauthor=M.+Cuendetauthor=P.+Bertrand&title=HDAC+inhibitors%3A+a+2013-2017+patent+survey&doi=10.1080%2F13543776.2018.1459568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors: a 2013-2017 patent survey</span></div><div class="casAuthors">Faria Freitas, Micaela; Cuendet, Muriel; Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-381</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A Review.  Zinc-dependent histone deacetylases (HDAC) inhibitors represent an important class of biol. active compds. with four of them approved by the FDA.  A wide range of mols. has been reported for applications in several human diseases.: This review covers recent efforts in the synthesis and applications of HDAC inhibitors from 2013-2017.: HDAC inhibitors represent an important class of biol. active compds. for single or combination therapies.  The current synthetic methodologies are oriented towards selective HDAC isoforms to achieve better therapeutic effects.  Among the recent patents available, most of them focus on HDAC6 selective inhibitors.  Beside this search for isoform selectivity, the quest for zinc binding groups with better pharmacokinetic properties and high potency against HDACs only motivates medicinal chemists, as well as the design of inhibitors targeting HDACs and at the same time another biol. target.  If the major applications are for anticancer activity, one can note the emerging applications in neurol. or metabolic disorders or for the stimulation of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgdOR23sC-crVg90H21EOLACvtfcHk0lh66pIUENe2rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVSns7w%253D&md5=0bed63ff4bcd3599758686197372f35b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1459568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1459568%26sid%3Dliteratum%253Aachs%26aulast%3DFaria%2BFreitas%26aufirst%3DM.%26aulast%3DCuendet%26aufirst%3DM.%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DHDAC%2520inhibitors%253A%2520a%25202013-2017%2520patent%2520survey%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D365%26epage%3D381%26doi%3D10.1080%2F13543776.2018.1459568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span> </span><span class="NLM_article-title">Clinical trials for ACY-1215</span>. <a href="https://clinicaltrials.gov/ct2/results?term=ACY-1215&amp;Search=Search" class="extLink">https://clinicaltrials.gov/ct2/results?term=ACY-1215&Search=Search</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+trials+for+ACY-1215.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DACY-1215%26Search%3DSearch+%28accessed+Mar+15%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DClinical%2520trials%2520for%2520ACY-1215%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span> </span><span class="NLM_article-title">Clinical
trials for ACY-241</span>. <a href="https://clinicaltrials.gov/ct2/results?term=ACY-241&amp;Search=Search" class="extLink">https://clinicaltrials.gov/ct2/results?term=ACY-241&Search=Search</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+ACY-241.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DACY-241%26Search%3DSearch+%28accessed+Mar+15%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DClinical%250Atrials%2520for%2520ACY-241%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Loss of deacetylation activity of Hdac6 affects emotional behavior in mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e30924</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0030924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1371%2Fjournal.pone.0030924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22328923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFyrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=M.+Fukadaauthor=A.+Hanaiauthor=A.+Nakayamaauthor=T.+Suzukiauthor=N.+Miyataauthor=R.+M.+Rodriguizauthor=W.+C.+Wetselauthor=T.-P.+Yaoauthor=Y.+Kawaguchi&title=Loss+of+deacetylation+activity+of+Hdac6+affects+emotional+behavior+in+mice&doi=10.1371%2Fjournal.pone.0030924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of deacetylation activity of Hdac6 affects emotional behavior in mice</span></div><div class="casAuthors">Fukada, Masahide; Hanai, Atsuko; Nakayama, Atsuo; Suzuki, Takayoshi; Miyata, Naoki; Rodriguiz, Ramona M.; Wetsel, William C.; Yao, Tso-Pang; Kawaguchi, Yoshiharu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e30924</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Acetylation is mediated by acetyltransferases and deacetylases, and occurs not only on histones but also on diverse proteins.  Although histone acetylation in chromatin structure and transcription has been well studied, the biol. roles of non-histone acetylation remain elusive.  Histone deacetylase 6 (Hdac6), a member of the histone deacetylase (HDAC) family, is a unique deacetylase that localizes to cytoplasm and functions in many cellular events by deacetylating non-histone proteins including α-tubulin, Hsp90, and cortactin.  Since robust expression of Hdac6 is obsd. in brain, it would be expected that Hdac6-mediated reversible acetylation plays essential roles in CNS.  Here we demonstrate the crucial roles of Hdac6 deacetylase activity in the expression of emotional behavior in mice.  We found that Hdac6-deficient mice exhibit hyperactivity, less anxiety, and antidepressant-like behavior in behavioral tests.  Moreover, administration of Hdac6-specific inhibitor replicated antidepressant-like behavior in mice.  In good agreement with behavioral phenotypes of Hdac6-deficient mice, Hdac6 dominantly localizes to the dorsal and median raphe nuclei, which are involved in emotional behaviors.  These findings suggest that HDAC6-mediated reversible acetylation might contribute to maintain proper neuronal activity in serotonergic neurons, and also provide a new therapeutic target for depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YHadk45NKLVg90H21EOLACvtfcHk0lh66pIUENe2rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFyrt7k%253D&md5=5e7626d464e872485369149e9e18d270</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0030924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0030924%26sid%3Dliteratum%253Aachs%26aulast%3DFukada%26aufirst%3DM.%26aulast%3DHanai%26aufirst%3DA.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMiyata%26aufirst%3DN.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DYao%26aufirst%3DT.-P.%26aulast%3DKawaguchi%26aufirst%3DY.%26atitle%3DLoss%2520of%2520deacetylation%2520activity%2520of%2520Hdac6%2520affects%2520emotional%2520behavior%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0030924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jochems, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blendy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berton, O.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnpp.2013.207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=23954848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=389-400&author=J.+Jochemsauthor=J.+Bouldenauthor=B.+G.+Leeauthor=J.+A.+Blendyauthor=M.+Jarpeauthor=R.+Mazitschekauthor=J.+H.+Van+Duzerauthor=S.+Jonesauthor=O.+Berton&title=Antidepressant-like+properties+of+novel+HDAC6-selective+inhibitors+with+improved+brain+bioavailability&doi=10.1038%2Fnpp.2013.207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability</span></div><div class="casAuthors">Jochems, Jeanine; Boulden, Janette; Lee, Bridgin G.; Blendy, Julie A.; Jarpe, Matthew; Mazitschek, Ralph; Van Duzer, John H.; Jones, Simon; Berton, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-400</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HDAC inhibitors have been reported to produce antidepressant and pro-cognitive effects in animal models, however, poor brain bioavailability or lack of isoform selectivity of current probes has limited our understanding of their mode of action.  We report the characterization of novel pyrimidine hydroxyl amide small mol. inhibitors of HDAC6, brain bioavailable upon systemic administration.  We show that two compds. in this family, ACY-738 and ACY-775, inhibit HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs.  In contrast to tubastatin A, a ref. HDAC6 inhibitor with similar potency and peripheral activity, but more limited brain bioavailability, ACY-738 and ACY-775 induce dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors in novel, but not familiar environments.  Interestingly, despite a lack of detectable effect on histone acetylation, we show that ACY-738 and ACY-775 share the antidepressant-like properties of other HDAC inhibitors, such as SAHA and MS-275, in the tail suspension test and social defeat paradigm.  These effects of ACY-738 and ACY-775 are directly attributable to the inhibition of HDAC6 expressed centrally, as they are fully abrogated in mice with a neural-specific loss of function of HDAC6.  Furthermore, administered in combination, a behaviorally inactive dose of ACY-738 markedly potentiates the anti-immobility activity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.  Our results validate new isoform-selective probes for in vivo pharmacol. studies of HDAC6 in the CNS and reinforce the viability of this HDAC isoform as a potential target for antidepressant development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yEjJGIv3jbVg90H21EOLACvtfcHk0lh66pIUENe2rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN&md5=9e0f4d3856c84e629602b589161eb4ab</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.207%26sid%3Dliteratum%253Aachs%26aulast%3DJochems%26aufirst%3DJ.%26aulast%3DBoulden%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BG.%26aulast%3DBlendy%26aufirst%3DJ.%2BA.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DVan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DBerton%26aufirst%3DO.%26atitle%3DAntidepressant-like%2520properties%2520of%2520novel%2520HDAC6-selective%2520inhibitors%2520with%2520improved%2520brain%2520bioavailability%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D389%26epage%3D400%26doi%3D10.1038%2Fnpp.2013.207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">d’Ydewalle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiheb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irobi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghe, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robberecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1038/nm.2396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnm.2396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=21785432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlamu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=968-974&author=C.+d%E2%80%99Ydewalleauthor=J.+Krishnanauthor=D.+M.+Chihebauthor=P.+Van+Dammeauthor=J.+Irobiauthor=A.+P.+Kozikowskiauthor=P.+V.+Bergheauthor=V.+Timmermanauthor=W.+Robberechtauthor=L.+Van+Den+Bosch&title=HDAC6+inhibitors+reverse+axonal+loss+in+a+mouse+model+of+mutant+HSPB1-induced+Charcot-Marie-Tooth+disease&doi=10.1038%2Fnm.2396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease</span></div><div class="casAuthors">d'Ydewalle, Constantin; Krishnan, Jyothsna; Chiheb, Driss M.; Van Damme, Philip; Irobi, Joy; Kozikowski, Alan P.; Vanden Berghe, Pieter; Timmerman, Vincent; Robberecht, Wim; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">968-974</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Charcot-Marie-Tooth disease (CMT) is the most common inherited disorder of the peripheral nervous system.  Mutations in the 27-kDa small heat-shock protein gene (HSPB1) cause axonal CMT or distal hereditary motor neuropathy (distal HMN).  We developed and characterized transgenic mice expressing two different HSPB1 mutations (S135F and P182L) in neurons only.  These mice showed all features of CMT or distal HMN dependent on the mutation.  Expression of mutant HSPB1 decreased acetylated α-tubulin abundance and induced severe axonal transport deficits.  An increase of α-tubulin acetylation induced by pharmacol. inhibition of histone deacetylase 6 (HDAC6) cor. the axonal transport defects caused by HSPB1 mutations and rescued the CMT phenotype of symptomatic mutant HSPB1 mice.  Our findings demonstrate the pathogenic role of α-tubulin deacetylation in mutant HSPB1-induced neuropathies and offer perspectives for using HDAC6 inhibitors as a therapeutic strategy for hereditary axonopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcNnO5Y6PAjLVg90H21EOLACvtfcHk0liEGkIW8mVaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlamu7o%253D&md5=3571d817e9a3d61d8df5f1dd6fc8358c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnm.2396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2396%26sid%3Dliteratum%253Aachs%26aulast%3Dd%25E2%2580%2599Ydewalle%26aufirst%3DC.%26aulast%3DKrishnan%26aufirst%3DJ.%26aulast%3DChiheb%26aufirst%3DD.%2BM.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DIrobi%26aufirst%3DJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DBerghe%26aufirst%3DP.%2BV.%26aulast%3DTimmerman%26aufirst%3DV.%26aulast%3DRobberecht%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DHDAC6%2520inhibitors%2520reverse%2520axonal%2520loss%2520in%2520a%2520mouse%2520model%2520of%2520mutant%2520HSPB1-induced%2520Charcot-Marie-Tooth%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D968%26epage%3D974%26doi%3D10.1038%2Fnm.2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span> <span> </span><span class="NLM_article-title">Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/s12967-015-0753-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs12967-015-0753-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26747087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=7&author=J.+Liuauthor=J.+Guauthor=Z.+Fengauthor=Y.+Yangauthor=N.+Zhuauthor=W.+Luauthor=F.+Qi&title=Both+HDAC5+and+HDAC6+are+required+for+the+proliferation+and+metastasis+of+melanoma+cells&doi=10.1186%2Fs12967-015-0753-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells</span></div><div class="casAuthors">Liu, Jiaqi; Gu, Jianying; Feng, Zihao; Yang, Yanhong; Zhu, Ningwen; Lu, Weiyue; Qi, Fazhi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7/1-7/13</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Histone deacetylase (HDAC) inhibitors are widely used in clin. investigation as novel drug targets.  For example, panobinostat and vorinostat have been used to treat patients with melanoma.  However, HDAC inhibitors are small-mol. compds. without a specific target, and their mechanism of action is unclear.  Therefore, it is necessary to investigate which HDACs are required for the proliferation and metastasis of melanoma cells.  Methods: We used overexpression and knocking down lentivirus to clarify the influence of HDAC5 and HDAC6 in melanoma development.  Also, we introduced stable HDAC5 or HDAC6 knockdown cells into null mice and found that the knockdown cells were unable to form solid tumors.  Finally, we tested HDAC5 and HDAC6 expression and sublocation in clin. melanoma tissues and tumor adjacent tissues.  Results: In this study, and found that HDAC5 and HDAC6 were highly expressed in melanoma cells but exhibited low expression levels in normal skin cells.  Furthermore, we knocked down HDAC5 or HDAC6 in A375 cells and demonstrated that both HDAC5 and HDAC6 contributed to the proliferation and metastasis of melanoma cells.  Conclusions: This study demonstrated both HDAC5 and HDAC6 were required for melanoma cell proliferation and metastasis through different signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQCR7qOohx8bVg90H21EOLACvtfcHk0liEGkIW8mVaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlWhsQ%253D%253D&md5=4c881a7dcd7a4a4e3ba9cc578b3a9daf</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs12967-015-0753-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-015-0753-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DF.%26atitle%3DBoth%2520HDAC5%2520and%2520HDAC6%2520are%2520required%2520for%2520the%2520proliferation%2520and%2520metastasis%2520of%2520melanoma%2520cells%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2016%26volume%3D14%26spage%3D7%26doi%3D10.1186%2Fs12967-015-0753-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span> <span> </span><span class="NLM_article-title">HDAC6 interacts with PTPN1 to enhance melanoma cells progression</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>495</i></span>,  <span class="NLM_fpage">2630</span>– <span class="NLM_lpage">2636</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.12.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bbrc.2017.12.145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29278704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=495&publication_year=2018&pages=2630-2636&author=J.+Liuauthor=W.+Luanauthor=Y.+Zhangauthor=J.+Guauthor=Y.+Shiauthor=Y.+Yangauthor=Z.+Fengauthor=F.+Qi&title=HDAC6+interacts+with+PTPN1+to+enhance+melanoma+cells+progression&doi=10.1016%2Fj.bbrc.2017.12.145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 interacts with PTPN1 to enhance melanoma cells progression</span></div><div class="casAuthors">Liu, Jiaqi; Luan, Wenjie; Zhang, Yong; Gu, Jianying; Shi, Yuedong; Yang, Yanwen; Feng, Zihao; Qi, Fazhi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">495</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2630-2636</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) plays an important role in oncogenic transformation and cancer metastasis.  Our previous study has demonstrated that HDAC6 was highly expressed in melanoma cells, and contributed to the proliferation and metastasis of melanoma cells.  However, the underlying mechanism of HDAC6 in melanoma metastasis and progression remains largely unclear.  In this study, we reported that HDAC6 directly interacted with Tyrosine-protein phosphatase non-receptor type 1 (PTPN1) by performing co-immunopptn. (Co-IP) combined with liq. chromatog. tandem mass spectrometry (LC-MS/MS).  HDAC6 increased the protein level of PTPN1 independent of histone modifying activity.  In addn., PTPN1 promoted proliferation, colony formation and migration while decreased apoptosis of melanoma cells through activating extracellular signal-regulated kinase 1/2 (ERK1/2).  Furthermore, we found that matrix metallopeptidase 9 (MMP9) was increased by HDAC6/PTPN1/ERK1/2 axis, which might serve as a mechanism for melanoma invasion and metastasis.  In conclusion, HDAC6 might enhance aggressive melanoma cells progression via interacting with PTPN1, which was independent of its histone modifying activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC7-FDLlSLm7Vg90H21EOLACvtfcHk0liEGkIW8mVaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGmtg%253D%253D&md5=fbc504a7e5bcccea92a737f0e1decdc0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.12.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.12.145%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DF.%26atitle%3DHDAC6%2520interacts%2520with%2520PTPN1%2520to%2520enhance%2520melanoma%2520cells%2520progression%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D495%26spage%3D2630%26epage%3D2636%26doi%3D10.1016%2Fj.bbrc.2017.12.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.3892/or.2016.5340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.3892%2For.2016.5340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28035401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1270-1276&author=U.+Pengauthor=Z.+Wangauthor=S.+Peiauthor=Y.+Ouauthor=P.+Huauthor=W.+Liuauthor=J.+Song&title=ACY-1215+accelerates+vemurafenib+induced+cell+death+of+BRAF-mutant+melanoma+cells+via+induction+of+ER+stress+and+inhibition+of+ERK+activation&doi=10.3892%2For.2016.5340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation</span></div><div class="casAuthors">Peng, Ueihuei; Wang, Zhihao; Pei, Sa; Ou, Yunchao; Hu, Pengchao; Liu, Wanhong; Song, Jiquan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1270-1276</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">BRAFV600E mutation is found in ∼50% of melanoma patients and BRAFV600E kinase activity inhibitor, vemurafenib, has achieved a remarkable clin. response rate.  However, most patients treated with vemurafenib eventually develop resistance.  Overcoming primary and secondary resistance to selective BRAF inhibitors remains one of the most critically compelling challenges for these patients.  HDAC6 has been shown to confer resistance to chemotherapy in several types of cancer.  Few studies focused on the role of HDAC6 in vemurafenib resistance.  Here we showed that overexpression of HDAC6 confers resistance to vemurafenib in BRAF-mutant A375 cells.  ACY-1215, a selective HDAC6 inhibitor, inhibits the proliferation and induces the apoptosis of A375 cells.  Moreover, ACY-1215 sensitizes A375 cells to vemurafenib induced cell proliferation inhibition and apoptosis induction, which occur partly through induction of endoplasmic reticulum (ER) stress and inactivation of extracellular signal-regulated kinase (ERK).  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of melanoma and overcoming resistance to vemurafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoILeMJkH572bVg90H21EOLACvtfcHk0liEGkIW8mVaCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyis7o%253D&md5=e023bf4ac17f556be9fd3dd6673bc626</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3892%2For.2016.5340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5340%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DU.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DACY-1215%2520accelerates%2520vemurafenib%2520induced%2520cell%2520death%2520of%2520BRAF-mutant%2520melanoma%2520cells%2520via%2520induction%2520of%2520ER%2520stress%2520and%2520inhibition%2520of%2520ERK%2520activation%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D1270%26epage%3D1276%26doi%3D10.3892%2For.2016.5340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lienlaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villarroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montecino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Essential role of HDAC6 in the regulation of PD-L1 in melanoma</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2015.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.molonc.2015.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26775640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=735-750&author=M.+Lienlafauthor=P.+Perez-Villarroelauthor=T.+Knoxauthor=M.+Pabonauthor=E.+Sahakianauthor=J.+Powersauthor=K.+V.+Woanauthor=C.+Leeauthor=F.+Chengauthor=S.+Dengauthor=K.+S.+M.+Smalleyauthor=M.+Montecinoauthor=A.+Kozikowskiauthor=J.+Pinilla-Ibarzauthor=A.+Sarnaikauthor=E.+Setoauthor=J.+Weberauthor=E.+M.+Sotomayorauthor=A.+Villagra&title=Essential+role+of+HDAC6+in+the+regulation+of+PD-L1+in+melanoma&doi=10.1016%2Fj.molonc.2015.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of HDAC6 in the regulation of PD-L1 in melanoma</span></div><div class="casAuthors">Lienlaf, M.; Perez-Villarroel, P.; Knox, T.; Pabon, M.; Sahakian, E.; Powers, J.; Woan, K. V.; Lee, C.; Cheng, F.; Deng, S.; Smalley, K. S. M.; Montecino, M.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Seto, E.; Weber, J.; Sotomayor, E. M.; Villagra, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">735-750</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment.  In this context, our present work demonstrates that the pharmacol. or genetic abrogation of HDAC6 in primary melanoma samples and cell lines, down-regulates the expression of PD-L1, an important co-stimulatory mol. expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T-cells.  Our data suggests that this novel mechanism of PD-L1 regulation is mainly mediated by the influence of HDAC6 over the recruitment and activation of STAT3.  Addnl., we obsd. that selective HDAC6 inhibitors impairs tumor growth and reduce the in vivo expression of several inhibitory check-point mols. and other regulatory pathways involved in immunosurveillance.  Most importantly, these results provide a key pre-clin. rationale and justification to further study isotype selective HDAC6 inhibitors as potential immuno-modulatory agents in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnUp3ctcdjRLVg90H21EOLACvtfcHk0ljuIGyOUwEyBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFWkuw%253D%253D&md5=6ead389dab6bd5f4fc621c452cd4e303</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DLienlaf%26aufirst%3DM.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DPabon%26aufirst%3DM.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DWoan%26aufirst%3DK.%2BV.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DMontecino%26aufirst%3DM.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DEssential%2520role%2520of%2520HDAC6%2520in%2520the%2520regulation%2520of%2520PD-L1%2520in%2520melanoma%26jtitle%3DMol.%2520Oncol.%26date%3D2016%26volume%3D10%26spage%3D735%26epage%3D750%26doi%3D10.1016%2Fj.molonc.2015.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia-Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6136</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-42237-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fs41598-019-42237-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=30992475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=6136&author=T.+Knoxauthor=E.+Sahakianauthor=D.+Banikauthor=M.+Hadleyauthor=E.+Palmerauthor=S.+Noonepalleauthor=J.+Kimauthor=J.+Powersauthor=M.+Gracia-Hernandezauthor=V.+Oliveiraauthor=F.+Chengauthor=J.+Chenauthor=C.+Barinkaauthor=J.+Pinilla-Ibarzauthor=N.+H.+Leeauthor=A.+Kozikowskiauthor=A.+Villagra&title=Selective+HDAC6+inhibitors+improve+anti-PD-1+immune+checkpoint+blockade+therapy+by+decreasing+the+anti-inflammatory+phenotype+of+macrophages+and+down-regulation+of+immunosuppressive+proteins+in+tumor+cells&doi=10.1038%2Fs41598-019-42237-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span></div><div class="casAuthors">Knox Tessa; Banik Debarati; Hadley Melissa; Palmer Erica; Noonepalle Satish; Kim Jennifer; Gracia-Hernandez Maria; Cheng Fengdong; Chen Jie; Lee Norman H; Villagra Alejandro; Sahakian Eva; Powers John; Pinilla-Ibarz Javier; Oliveira Vasco; Barinka Cyril; Kozikowski Alan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment.  Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific immune cells.  In particular, the selective inhibition of HDAC6 has been reported to decrease tumor growth in several malignancies.  However, there is still no clarity about the cellular components mediating this effect.  In this study, we evaluated the HDAC6i Nexturastat A as a priming agent to facilitate the transition of the tumor microenvironment from "cold" to "hot", and potentially augment immune check-point blockade therapies.  This combination modality demonstrated to significantly reduce tumor growth in syngeneic melanoma tumor models.  Additionally, we observed a complete neutralization of the up-regulation of PD-L1 and other immunosuppressive pathways induced by the treatment with anti-PD-1 blockade.  This combination also showed profound changes in the tumor microenvironment such as enhanced infiltration of immune cells, increased central and effector T cell memory, and a significant reduction of pro-tumorigenic M2 macrophages.  The evaluation of individual components of the tumor microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells.  Overall, our results indicate that selective HDAC6i could be used as immunological priming agents to sensitize immunologically "cold" tumors and subsequently improve ongoing immune check-point blockade therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl6RaBRQ4Kdw8IxFYvehhofW6udTcc2eawyF_2AGSGVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D&md5=137a9261e021e60b002d9312608eba76</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-42237-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-42237-3%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DBanik%26aufirst%3DD.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DE.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DGracia-Hernandez%26aufirst%3DM.%26aulast%3DOliveira%26aufirst%3DV.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DN.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DSelective%2520HDAC6%2520inhibitors%2520improve%2520anti-PD-1%2520immune%2520checkpoint%2520blockade%2520therapy%2520by%2520decreasing%2520the%2520anti-inflammatory%2520phenotype%2520of%2520macrophages%2520and%2520down-regulation%2520of%2520immunosuppressive%2520proteins%2520in%2520tumor%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D6136%26doi%3D10.1038%2Fs41598-019-42237-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2694</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.18632%2Foncotarget.13738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27926524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2694-2707&author=P.+Huangauthor=I.+Almeciga-Pintoauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Selective+HDAC+inhibition+by+ACY-241+enhances+the+activity+of+paclitaxel+in+solid+tumor+models&doi=10.18632%2Foncotarget.13738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span></div><div class="casAuthors">Huang Pengyu; Almeciga-Pinto Ingrid; Jarpe Matthew; van Duzer John H; Yang Min; Jones Simon S; Quayle Steven N; Mazitschek Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2694-2707</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242).  Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness.  We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth.  In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone.  Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells.  At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and γ-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification.  The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFIBfKb6ELK8t0fW6udTcc2ebffbYzfqJXvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D&md5=b8a516375b03fc65536598ab9c0e4a21</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13738%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DSelective%2520HDAC%2520inhibition%2520by%2520ACY-241%2520enhances%2520the%2520activity%2520of%2520paclitaxel%2520in%2520solid%2520tumor%2520models%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2694%26epage%3D2707%26doi%3D10.18632%2Foncotarget.13738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+activity%2C+pharmacodynamic%2C+and+pharmacokinetic+properties+of+a+selective+HDAC6+inhibitor%2C+ACY-1215%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0liDC2DSuWYuEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520activity%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520selective%2520HDAC6%2520inhibitor%252C%2520ACY-1215%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span> <span> </span><span class="NLM_article-title">How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin A enantiomers based on molecular dynamics</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2467</span>– <span class="NLM_lpage">2480</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00729</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00729" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1eksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2467-2480&author=Y.+Zhangauthor=J.+B.+Yingauthor=J.+J.+Hongauthor=F.+C.+Liauthor=T.+T.+Fuauthor=F.+Y.+Yangauthor=G.+X.+Zhengauthor=X.+J.+Yaoauthor=Y.+Louauthor=Y.+Qiuauthor=W.+W.+Xueauthor=F.+Zhu&title=How+does+chirality+determine+the+selective+inhibition+of+histone+deacetylase+6%3F+A+lesson+from+trichostatin+A+enantiomers+based+on+molecular+dynamics&doi=10.1021%2Facschemneuro.8b00729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics</span></div><div class="casAuthors">Zhang, Yang; Ying, Jun Biao; Hong, Jia Jun; Li, Feng Cheng; Fu, Ting Ting; Yang, Feng Yuan; Zheng, Guo Xun; Yao, Xiao Jun; Lou, Yan; Qiu, Yunqing; Xue, Wei Wei; Zhu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2467-2480</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) plays a key role in a variety of neurol. disorders, which makes it attractive drug target for the treatment of Alzheimer's disease, Parkinson's disease, and memory/learning impairment.  The selectivity of HDAC6 inhibitors (sHDAC6Is) are widely considered to be susceptible to the sizes of their Cap group and the physicochem. properties of their linker or zinc-binding group, which makes the discovery of new sHDAC6Is extremely difficult.  With the discovery of the distinct selectivity between Trichostatin A (TSA) enantiomers, the chirality residing in the connective units between TSA's Cap and linker shows a great impact on its selectivity.  However, the mechanism underlining (S)-TSA's selectivity is still elusive, and the way chirality switches the selective (S)-TSA to nonselective (R)-TSA is unknown.  In this study, multiple computational approaches were collectively applied to explore, validate, and differentiate the binding modes of two TSA enantiomers in HDACs (esp. the HDAC6) at at. level.  First, two nonconservative residues (G200/M205 and Y197/F202 in HDAC1/6) in loop3 and four conservative residues deep inside the hydrophobic binding pocket were discovered as the decisive residues of (S)-TSA's selectivity toward HDAC6.  Then, a novel mechanism underlying the selectivity of (S)-TSA toward HDAC6 was proposed, which was composed of the trigger by two nonconservative residues F202 and M205 in HDAC6 and a subsequently improved fit of (S)-TSA deep inside HDAC6's hydrophobic binding pocket.  TSA enantiomers were used as a mol. probe to explore the mechanism underlying sHDAC6Is' selectivity in this study.  Because of their decisive roles in (S)-TSA's selectivity to HDAC6, both F202 and M205 in HDAC6 should be esp. considered in the discovery of novel sHDAC6Is.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovlpI1_r-zqbVg90H21EOLACvtfcHk0liDC2DSuWYuEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1eksLY%253D&md5=cc905b1cad5fd1ad2b9fc677c3425dbc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00729%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYing%26aufirst%3DJ.%2BB.%26aulast%3DHong%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DF.%2BC.%26aulast%3DFu%26aufirst%3DT.%2BT.%26aulast%3DYang%26aufirst%3DF.%2BY.%26aulast%3DZheng%26aufirst%3DG.%2BX.%26aulast%3DYao%26aufirst%3DX.%2BJ.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DW.%2BW.%26aulast%3DZhu%26aufirst%3DF.%26atitle%3DHow%2520does%2520chirality%2520determine%2520the%2520selective%2520inhibition%2520of%2520histone%2520deacetylase%25206%253F%2520A%2520lesson%2520from%2520trichostatin%2520A%2520enantiomers%2520based%2520on%2520molecular%2520dynamics%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D2467%26epage%3D2480%26doi%3D10.1021%2Facschemneuro.8b00729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lgb2tmsi0WVbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villarroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9891</span>– <span class="NLM_lpage">9899</span>, <span class="refDoi"> DOI: 10.1021/jm301098e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301098e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9891-9899&author=J.+A.+Bergmanauthor=K.+Woanauthor=P.+Perez-Villarroelauthor=A.+Villagraauthor=E.+M.+Sotomayorauthor=A.+P.+Kozikowski&title=Selective+histone+deacetylase+6+inhibitors+bearing+substituted+urea+linkers+inhibit+melanoma+cell+growth&doi=10.1021%2Fjm301098e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth</span></div><div class="casAuthors">Bergman, Joel A.; Woan, Karrune; Perez-Villarroel, Patricio; Villagra, Alejandro; Sotomayor, Eduardo M.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9891-9899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies.  In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor.  Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compds. bearing a branched linker group results in increased potency and selectivity for HDAC6.  Compd. 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ∼600-fold relative to the inhibition of HDAC1.  These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth.  To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkTtPLqvwsrVg90H21EOLACvtfcHk0lgb2tmsi0WVbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ&md5=d6be4c0efb3922fc35d814ba00ae9ed1</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301098e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301098e%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DWoan%26aufirst%3DK.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%2520histone%2520deacetylase%25206%2520inhibitors%2520bearing%2520substituted%2520urea%2520linkers%2520inhibit%2520melanoma%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9891%26epage%3D9899%26doi%3D10.1021%2Fjm301098e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebl, M.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chindavong, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1006-1014&author=M.%0AG.+Streblauthor=A.+J.+Campbellauthor=W.-N.+Zhaoauthor=F.+A.+Schroederauthor=M.+M.+Rileyauthor=P.+S.+Chindavongauthor=T.+M.+Morinauthor=S.+J.+Haggartyauthor=F.+F.+Wagnerauthor=T.+Ritterauthor=J.+M.+Hooker&title=HDAC6+Brain+Mapping+with+%5B18F%5DBavarostat+Enabled+by+a+Ru-Mediated+Deoxyfluorination&doi=10.1021%2Facscentsci.7b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination</span></div><div class="casAuthors">Strebl, Martin G.; Campbell, Arthur J.; Zhao, Wen-Ning; Schroeder, Frederick A.; Riley, Misha M.; Chindavong, Peter S.; Morin, Thomas M.; Haggarty, Stephen J.; Wagner, Florence F.; Ritter, Tobias; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1006-1014</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) function and dysregulation have been implicated in the etiol. of certain cancers and more recently in central nervous system (CNS) disorders including Rett syndrome, Alzheimer's and Parkinson's diseases, and major depressive disorder.  HDAC6-selective inhibitors have therapeutic potential, but in the CNS drug space the development of highly brain penetrant HDAC inhibitors has been a persistent challenge.  Moreover, no tool exists to directly characterize HDAC6 and its related biol. in the living human brain.  Here, we report a highly brain penetrant HDAC6 inhibitor, Bavarostat, that exhibits excellent HDAC6 selectivity (>80-fold over all other Zn-contg. HDAC paralogues), modulates tubulin acetylation selectively over histone acetylation, and has excellent brain penetrance.  We further demonstrate that Bavarostat can be radiolabeled with 18F by deoxyfluorination through in situ formation of a ruthenium π-complex of the corresponding phenol precursor: the only method currently suitable for synthesis of [18F]Bavarostat.  Finally, by using [18F]Bavarostat in a series of rodent and nonhuman primate imaging expts., we demonstrate its utility for mapping HDAC6 in the living brain, which sets the stage for first-in-human neurochem. imaging of this important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXyZxgRQnAbVg90H21EOLACvtfcHk0lgb2tmsi0WVbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK&md5=269c6b99919bd156272afc8ad3502146</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00274%26sid%3Dliteratum%253Aachs%26aulast%3DStrebl%26aufirst%3DM.%2BG.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DRiley%26aufirst%3DM.%2BM.%26aulast%3DChindavong%26aufirst%3DP.%2BS.%26aulast%3DMorin%26aufirst%3DT.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DRitter%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DHDAC6%2520Brain%2520Mapping%2520with%2520%255B18F%255DBavarostat%2520Enabled%2520by%2520a%2520Ru-Mediated%2520Deoxyfluorination%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D1006%26epage%3D1014%26doi%3D10.1021%2Facscentsci.7b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Steen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaeghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougarne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bosscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">9868</span>– <span class="NLM_lpage">9871</span>, <span class="refDoi"> DOI: 10.1039/c5cc03295d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1039%2Fc5cc03295d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25994553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1eksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=9868-9871&author=R.+De%0AVreeseauthor=N.+Van+Steenauthor=T.+Verhaegheauthor=T.+Desmetauthor=N.+Bougarneauthor=K.+De+Bosscherauthor=V.+Benoyauthor=W.+Haeckauthor=L.+Van+Den+Boschauthor=M.+D%E2%80%99Hooghe&title=Synthesis+of+benzothiophene-based+hydroxamic+acids+as+potent+and+selective+HDAC6+inhibitors&doi=10.1039%2Fc5cc03295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">De Vreese, Rob; Van Steen, Nicholas; Verhaeghe, Tom; Desmet, Tom; Bougarne, Nadia; De Bosscher, Karolien; Benoy, Veronick; Haeck, Wanda; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9868-9871</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A small library of 3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophenes, e.g., I, was prepd. and assessed as a novel class of HDAC6 inhibitors, leading to the identification of three representatives as potent and selective HDAC6 inhibitors.  Further tests with regard to inflammatory responses indicated that HDAC6 inhibition can be uncoupled from transcriptional inhibition at the level of activated NF-κB, AP-1, and GR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pF0JIopbXLVg90H21EOLACvtfcHk0lg-CUTXQpPy7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1eksb0%253D&md5=ec0347e42b49e724615f45f5c4a12038</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1039%2Fc5cc03295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc5cc03295d%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DVan%2BSteen%26aufirst%3DN.%26aulast%3DVerhaeghe%26aufirst%3DT.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DBougarne%26aufirst%3DN.%26aulast%3DDe%2BBosscher%26aufirst%3DK.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DHaeck%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520benzothiophene-based%2520hydroxamic%2520acids%2520as%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D9868%26epage%3D9871%26doi%3D10.1039%2Fc5cc03295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frojuello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Bicyclic-capped histone deacetylase 6 inhibitors with improved activity in a model of axonal Charcot-Marie-Tooth disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyktLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=240-258&author=S.+Shenauthor=V.+Benoyauthor=J.+A.+Bergmanauthor=J.+H.+Kalinauthor=M.+Frojuelloauthor=G.+Vistoliauthor=W.+Haeckauthor=L.+Van+Den+Boschauthor=A.+P.+Kozikowski&title=Bicyclic-capped+histone+deacetylase+6+inhibitors+with+improved+activity+in+a+model+of+axonal+Charcot-Marie-Tooth+disease&doi=10.1021%2Facschemneuro.5b00286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease</span></div><div class="casAuthors">Shen, Sida; Benoy, Veronick; Bergman, Joel A.; Kalin, Jay H.; Frojuello, Mariana; Vistoli, Giulio; Haeck, Wanda; Van Den Bosch, Ludo; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-258</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Charcot-Marie-Tooth (CMT) disease is a disorder of the peripheral nervous system where progressive degeneration of motor and sensory nerves leads to motor problems and sensory loss and for which no pharmacol. treatment is available.  Recently, it has been shown in a model for the axonal form of CMT that histone deacetylase 6 (HDAC6) can serve as a target for the development of a pharmacol. therapy.  Therefore, the authors aimed at developing new selective and activity-specific HDAC6 inhibitors with improved biochem. properties.  By utilizing a bicyclic cap as the structural scaffold from which to build upon, the authors developed several analogs that showed improved potency compared to tubastatin A while maintaining excellent selectivity compared to HDAC1.  Further screening in N2a cells examg. both the acetylation of α-tubulin and histones narrowed down the library of compds. to three potent and selective HDAC6 inhibitors.  In mutant HSPB1-expressing DRG neurons, serving as an in vitro model for CMT2, these inhibitors were able to restore the mitochondrial axonal transport deficits.  Combining structure-based development of HDAC6 inhibitors, screening in N2a cells and in a neuronal model for CMT2F, and preliminary ADMET and pharmacokinetic profiles, resulted in the selection of compd. I that possesses improved biochem., functional, and druglike properties compared to tubastatin A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEQ8GZug94Z7Vg90H21EOLACvtfcHk0lg-CUTXQpPy7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyktLvF&md5=79b7f824103b5a0f799f1d69fafed7de</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00286%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DFrojuello%26aufirst%3DM.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DHaeck%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DBicyclic-capped%2520histone%2520deacetylase%25206%2520inhibitors%2520with%2520improved%2520activity%2520in%2520a%2520model%2520of%2520axonal%2520Charcot-Marie-Tooth%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D240%26epage%3D258%26doi%3D10.1021%2Facschemneuro.5b00286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer’s disease phenotypes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7087</span>– <span class="NLM_lpage">7102</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00151</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00151" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKmsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7087-7102&author=H.-Y.+Leeauthor=S.-J.+Fanauthor=F.-I.+Huangauthor=H.-Y.+Chaoauthor=K.-C.+Hsuauthor=T.+E.+Linauthor=T.-K.+Yehauthor=M.-J.+Laiauthor=Y.-H.+Liauthor=H.-L.+Huangauthor=C.-R.+Yangauthor=J.-P.+Liou&title=5-Aroylindoles+act+as+selective+histone+deacetylase+6+inhibitors+ameliorating+Alzheimer%E2%80%99s+disease+phenotypes&doi=10.1021%2Facs.jmedchem.8b00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes</span></div><div class="casAuthors">Lee, Hsueh-Yun; Fan, Sheng-Jun; Huang, Fang-I.; Chao, Hsin-Yi; Hsu, Kai-Cheng; Lin, Tony Eight; Yeh, Teng-Kuang; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7087-7102</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids.  N-Hydroxy-4-((5-(4-methoxybenzoyl)-1H-indol-1-yl)methyl)benzamide (6) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC50 value of 3.92 nM.  It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins.  Compd. 6 also shows neuroprotective activity by triggering ubiquitination.  In animal models, compd. 6 is able to ameliorate the impaired learning and memory, and it crosses the blood-brain barrier after oral administration.  Compd. 6 can be developed as a potential treatment for Alzheimer's disease in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrJdt1D5uVurVg90H21EOLACvtfcHk0lg-CUTXQpPy7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKmsL3L&md5=6065438bfabec38e1f8fa4b5ea47e3ce</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00151%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DFan%26aufirst%3DS.-J.%26aulast%3DHuang%26aufirst%3DF.-I.%26aulast%3DChao%26aufirst%3DH.-Y.%26aulast%3DHsu%26aufirst%3DK.-C.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26aulast%3DHuang%26aufirst%3DH.-L.%26aulast%3DYang%26aufirst%3DC.-R.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3D5-Aroylindoles%2520act%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%2520ameliorating%2520Alzheimer%25E2%2580%2599s%2520disease%2520phenotypes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7087%26epage%3D7102%26doi%3D10.1021%2Facs.jmedchem.8b00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of potent and selective HDAC6 inhibitors bearing a cyclohexane- or cycloheptane-annulated 1,5-benzothiazepine scaffold</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1002/chem.201604167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fchem.201604167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27717044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=128-136&author=R.+De%0AVreeseauthor=L.+Galleauthor=Y.+Depetterauthor=J.+Franceusauthor=T.+Desmetauthor=K.+Van+Heckeauthor=V.+Benoyauthor=L.+Van+Den%0ABoschauthor=M.+D%E2%80%99hooghe&title=Synthesis+of+potent+and+selective+HDAC6+inhibitors+bearing+a+cyclohexane-+or+cycloheptane-annulated+1%2C5-benzothiazepine+scaffold&doi=10.1002%2Fchem.201604167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold</span></div><div class="casAuthors">De Vreese, Rob; Galle, Lisa; Depetter, Yves; Franceus, Jorick; Desmet, Tom; Van Hecke, Kristof; Benoy, Veronick; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-136</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and isolation of (dihydrobenzo[b][1,4]thiazepinyl)methyl-N-hydroxybenzamides I [R = H, Cl, CF3; X = S, SO, SO2; n = 1, 2], a new class of HDAC6 inhibitors, is reported.  Evaluations of their HDAC-inhibiting activity resulted in the identification of I (X = SO2; n = 1; R = H, CF3) as highly potent and selective HDAC6 inhibitors with activity in the low nanomolar range, which also showed excellent selectivity on the enzymic and cellular levels.  Furthermore, four promising inhibitors were subjected to an Ames fluctuation assay, which revealed no mutagenic effects assocd. with these structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQAN_gYUuzi7Vg90H21EOLACvtfcHk0ljdA0fxli1zwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF&md5=589c80b2c951fd8e59b931875b9087f0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604167%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DGalle%26aufirst%3DL.%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DFranceus%26aufirst%3DJ.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%2520bearing%2520a%2520cyclohexane-%2520or%2520cycloheptane-annulated%25201%252C5-benzothiazepine%2520scaffold%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D128%26epage%3D136%26doi%3D10.1002%2Fchem.201604167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaeghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2537</span>– <span class="NLM_lpage">2549</span>, <span class="refDoi"> DOI: 10.1039/c5ob02625c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1039%2Fc5ob02625c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26822143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=2537-2549&author=R.+De%0AVreeseauthor=Y.+Depetterauthor=T.+Verhaegheauthor=T.+Desmetauthor=V.+Benoyauthor=W.+Haeckauthor=L.+Van+Den%0ABoschauthor=M.+D%E2%80%99hooghe&title=Synthesis+and+SAR+assessment+of+novel+Tubathian+analogs+in+the+pursuit+of+potent+and+selective+HDAC6+inhibitors&doi=10.1039%2Fc5ob02625c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">De Vreese, Rob; Depetter, Yves; Verhaeghe, Tom; Desmet, Tom; Benoy, Veronick; Haeck, Wanda; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2537-2549</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of novel isoform-selective HDAC inhibitors is considered to be an important, emerging field in medicinal chem.  In this paper, the prepn. and assessment of thirteen selective HDAC6 inhibitors is disclosed, elaborating on a previously developed thiaheterocyclic Tubathian series.  All compds. were evaluated in vitro for their ability to inhibit HDAC6, and a selection of five potent compds. was further screened toward all HDAC isoforms (HDAC1-11).  The capability of these Tubathian analogs to inhibit α-tubulin deacetylation was assessed as well, and ADME/Tox data were collected.  This thorough SAR evaluation revealed that the oxidized, para-substituted hydroxamic acids can be recognized as valuable lead structures in the pursuit of novel potent and selective HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOc-PcpWwhT7Vg90H21EOLACvtfcHk0ljdA0fxli1zwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslegtA%253D%253D&md5=d0a6f067b9c15cac567954b6fbf4ceab</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1039%2Fc5ob02625c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc5ob02625c%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DVerhaeghe%26aufirst%3DT.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DHaeck%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520SAR%2520assessment%2520of%2520novel%2520Tubathian%2520analogs%2520in%2520the%2520pursuit%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D2537%26epage%3D2549%26doi%3D10.1039%2Fc5ob02625c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarics, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Brain penetrable histone deacetylase 6 inhibitor SW-100 ameliorates memory and learning impairments in a mouse model of Fragile X Syndrome</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1679</span>– <span class="NLM_lpage">1695</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1679-1695&author=A.+P.+Kozikowskiauthor=S.+Shenauthor=M.+Pardoauthor=M.+T.+Tavaresauthor=D.+Szaricsauthor=V.+Benoyauthor=C.+A.+Zimprichauthor=Z.+Kutilauthor=G.+Zhangauthor=C.+Ba%C5%99inkaauthor=M.+B.+Robersauthor=L.+Van+Den+Boschauthor=J.+H.+Eubanksauthor=R.+S.+Jope&title=Brain+penetrable+histone+deacetylase+6+inhibitor+SW-100+ameliorates+memory+and+learning+impairments+in+a+mouse+model+of+Fragile+X+Syndrome&doi=10.1021%2Facschemneuro.8b00600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00600%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DSzarics%26aufirst%3DD.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DBrain%2520penetrable%2520histone%2520deacetylase%25206%2520inhibitor%2520SW-100%2520ameliorates%2520memory%2520and%2520learning%2520impairments%2520in%2520a%2520mouse%2520model%2520of%2520Fragile%2520X%2520Syndrome%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D10%26spage%3D1679%26epage%3D1695%26doi%3D10.1021%2Facschemneuro.8b00600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vögerl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01090</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01090" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1138-1166&author=K.+V%C3%B6gerlauthor=N.+Ongauthor=J.+Sengerauthor=D.+Herpauthor=K.+Schmidtkunzauthor=M.+Marekauthor=M.+M%C3%BCllerauthor=K.+Bartelauthor=T.+B.+Shaikauthor=N.+J.+Porterauthor=D.+Robaaauthor=D.+W.+Christiansonauthor=C.+Romierauthor=W.+Sipplauthor=M.+Jungauthor=F.+Bracher&title=Synthesis+and+biological+investigation+of+phenothiazine-based+benzhydroxamic+acids+as+selective+histone+deacetylase+6+inhibitors&doi=10.1021%2Facs.jmedchem.8b01090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Vogerl Katharina; Ong Nghia; Muller Martin; Bartel Karin; Bracher Franz; Senger Johanna; Herp Daniel; Schmidtkunz Karin; Jung Manfred; Marek Martin; Shaik Tajith B; Romier Christophe; Porter Nicholas J; Christianson David W; Robaa Dina; Sippl Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1138-1166</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phenothiazine system was identified as a favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors.  Here, we report the preparation and systematic variation of phenothiazines and their analogues containing a benzhydroxamic acid moiety as the zinc-binding group.  We evaluated their ability to selectively inhibit HDAC6 by a recombinant HDAC enzyme assay, by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines.  Structure-activity relationship studies revealed that incorporation of a nitrogen atom into the phenothiazine framework results in increased potency and selectivity for HDAC6 (more than 500-fold selectivity relative to the inhibition of HDAC1, HDAC4, and HDAC8), as rationalized by molecular modeling and docking studies.  The binding mode was confirmed by co-crystallization of the potent azaphenothiazine inhibitor with catalytic domain 2 from Danio rerio HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkSJzGKNxKWK69lAbTj9rGfW6udTcc2ea-SlMIk4xXxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D&md5=9d72da7b8f4bb63cd05ccc5f907d2dca</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01090%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25B6gerl%26aufirst%3DK.%26aulast%3DOng%26aufirst%3DN.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DBartel%26aufirst%3DK.%26aulast%3DShaik%26aufirst%3DT.%2BB.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%2520phenothiazine-based%2520benzhydroxamic%2520acids%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1138%26epage%3D1166%26doi%3D10.1021%2Facs.jmedchem.8b01090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, R.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1406</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29133060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1406-1418&author=X.-X.+Wangauthor=R.-Z.+Wanauthor=Z.-P.+Liu&title=Recent+advances+in+the+discovery+of+potent+and+selective+HDAC6+inhibitors&doi=10.1016%2Fj.ejmech.2017.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">Wang, Xiu-Xiu; Wan, Ren-Zhong; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1406-1418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among HDAC enzymes in having two active catalytic domains, and has unique physiol. function.  In addn. to the modification of histone, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degrdn., cell shape and migration.  Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, cancer, and immunol.  Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors.  Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur contg. ZBG based derivs. and other ZBG-derived compds., and their enzymic inhibitory activity, selectivity and other biol. activities are introduced and summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdsNBEWGhpCrVg90H21EOLACvtfcHk0ljVjaiCT2zaPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM&md5=f24fea971dbed247e1bb2568f85d1703</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-X.%26aulast%3DWan%26aufirst%3DR.-Z.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1406%26epage%3D1418%26doi%3D10.1016%2Fj.ejmech.2017.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28453994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslOhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=174-195&author=R.+De%0AVreeseauthor=M.+D%E2%80%99Hooghe&title=Synthesis+and+applications+of+benzohydroxamic+acid-based+histone+deacetylase+inhibitors&doi=10.1016%2Fj.ejmech.2017.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors</span></div><div class="casAuthors">De Vreese, Rob; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">174-195</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This paper provides an overview of the synthesis and biol. activity of the most representative benzohydroxamic acid-based histone deacetylase inhibitors published to date.  Benzohydroxamic acids comprise an important class of HDAC inhibitors, and recently several of these structures have been evaluated in clin. trials for the treatment of a variety of cancers.  In this overview, benzohydroxamic acids were divided in four different classes based on their reported selectivity towards zinc-dependent HDACs: a first and major class consists of HDAC6 selective inhibitors, a second class deals with pan-HDAC inhibitors, a third class comprises HDAC8 selective inhibitors and a fourth, minor class includes dual HDAC6/8 selective inhibitors.  Through this approach, structure-activity relationships were identified for each class, which could help future researchers in the design and development of novel benzohydroxamic acid-based HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyKAa1s9hoSbVg90H21EOLACvtfcHk0lj5CVi60agP-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslOhur0%253D&md5=769c343bdbb3fe610eff001afa79e0bb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520applications%2520of%2520benzohydroxamic%2520acid-based%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D135%26spage%3D174%26epage%3D195%26doi%3D10.1016%2Fj.ejmech.2017.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlimme, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carafa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolfa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellamare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span> <span> </span><span class="NLM_article-title">Carbamate prodrug concept for hydroxamate HDAC inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fcmdc.201100007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=21416613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1193-1198&author=S.+Schlimmeauthor=A.-T.+Hauserauthor=V.+Carafaauthor=R.+Heinkeauthor=S.+Kannanauthor=D.+A.+Stolfaauthor=S.+Cellamareauthor=A.+Carottiauthor=L.+Altucciauthor=M.+Jungauthor=W.+Sippl&title=Carbamate+prodrug+concept+for+hydroxamate+HDAC+inhibitors&doi=10.1002%2Fcmdc.201100007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors</span></div><div class="casAuthors">Schlimme, Sonja; Hauser, Alexander-Thomas; Carafa, Vincenzo; Heinke, Ralf; Kannan, Srinivasaraghavan; Stolfa, Diana A.; Cellamare, Saverio; Carotti, Angelo; Altucci, Lucia; Jung, Manfred; Sippl, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1193-1198</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Virtual screening against a HDAC6 homol. model has led to the indentification of a new HDAC6-selective inhibitor I and a carbamate deriv. that acts as a prodrug in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5mxc5jtnXe7Vg90H21EOLACvtfcHk0lj5CVi60agP-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCnsbs%253D&md5=21fdb2c7de1ca402e9cf370cd3607eeb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100007%26sid%3Dliteratum%253Aachs%26aulast%3DSchlimme%26aufirst%3DS.%26aulast%3DHauser%26aufirst%3DA.-T.%26aulast%3DCarafa%26aufirst%3DV.%26aulast%3DHeinke%26aufirst%3DR.%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DStolfa%26aufirst%3DD.%2BA.%26aulast%3DCellamare%26aufirst%3DS.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSippl%26aufirst%3DW.%26atitle%3DCarbamate%2520prodrug%2520concept%2520for%2520hydroxamate%2520HDAC%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D1193%26epage%3D1198%26doi%3D10.1002%2Fcmdc.201100007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melesina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01493</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01493" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1545-1555&author=J.+Sengerauthor=J.+Melesinaauthor=M.+Marekauthor=C.+Romierauthor=I.+Oehmeauthor=O.+Wittauthor=W.+Sipplauthor=M.+Jung&title=Synthesis+and+biological+investigation+of+oxazole+hydroxamates+as+highly+selective+histone+deacetylase+6+%28HDAC6%29+inhibitors&doi=10.1021%2Facs.jmedchem.5b01493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors</span></div><div class="casAuthors">Senger, Johanna; Melesina, Jelena; Marek, Martin; Romier, Christophe; Oehme, Ina; Witt, Olaf; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1545-1555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins.  Herein, the prepn. of thiazole-, oxazole-, and oxadiazole-contg. biarylhydroxamic acids by a short synthetic procedure is reported.  They were identified as selective HDAC6 inhibitors by investigating the inhibition of recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation).  The most active compds. exhibited nanomolar potency and high selectivity for HDAC6.  For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8.  This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent.  Compds. I (R = Br or Ph) were found to have the bect activity/HDAC6 selectivity.  The high potency and selectivity of the oxazoles was rationalized by mol. modeling and docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH3cCvoW67w7Vg90H21EOLACvtfcHk0lj5CVi60agP-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO&md5=19436b79e523ac3ad5a2a3fcec7c5493</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01493%26sid%3Dliteratum%253Aachs%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DMelesina%26aufirst%3DJ.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%2520oxazole%2520hydroxamates%2520as%2520highly%2520selective%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1545%26epage%3D1555%26doi%3D10.1021%2Facs.jmedchem.5b01493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.-p.</span></span> <span> </span><span class="NLM_article-title">The recent progress of isoxazole in medicinal chemistry</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3065</span>– <span class="NLM_lpage">3075</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bmc.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29853341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3065-3075&author=J.+Zhuauthor=J.+Moauthor=H.-z.+Linauthor=Y.+Chenauthor=H.-p.+Sun&title=The+recent+progress+of+isoxazole+in+medicinal+chemistry&doi=10.1016%2Fj.bmc.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The recent progress of isoxazole in medicinal chemistry</span></div><div class="casAuthors">Zhu, Jie; Mo, Jun; Lin, Hong-zhi; Chen, Yao; Sun, Hao-peng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3065-3075</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Isoxazole compds. exhibit a wide spectrum of targets and broad biol. activities.  Developing compds. with heterocycle rings has been one of the trends.  The integration of isoxazole ring can offer improved phys.-chem. properties.  Because of the unique profiles, isoxazole ring becomes a popular moiety in compds. design.  In this review article, the major focus has been paid to the applications of isoxazole compds. in treating multiple diseases, including anticancer, antimicrobial, anti-inflammatory, etc.  Strategies for compds. design for preclin., clin., and FDA approved drugs were discussed.  Also, the emphasis has been addressed to the future perspectives and trend for the application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Igl9jCgG1rVg90H21EOLACvtfcHk0lignsR457UGLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL&md5=f2cf06eed32e8655baa76d35b41ef6a1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DH.-z.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.-p.%26atitle%3DThe%2520recent%2520progress%2520of%2520isoxazole%2520in%2520medicinal%2520chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3065%26epage%3D3075%26doi%3D10.1016%2Fj.bmc.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sysak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obmińska-Mrukowicz, B.</span></span> <span> </span><span class="NLM_article-title">Isoxazole ring as a useful scaffold in a search for new therapeutic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28605676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2017&pages=292-309&author=A.+Sysakauthor=B.+Obmi%C5%84ska-Mrukowicz&title=Isoxazole+ring+as+a+useful+scaffold+in+a+search+for+new+therapeutic+agents&doi=10.1016%2Fj.ejmech.2017.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Isoxazole ring as a useful scaffold in a search for new therapeutic agents</span></div><div class="casAuthors">Sysak, Angelika; Obminska-Mrukowicz, Bozena</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">292-309</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Due to its relatively easy synthesis, isoxazole ring has been as an object of interest for chemists and pharmacologists from research groups all over the world.  Its chem. modifications include both connection of isoxazole with other arom., heteroarom. or non arom. rings and substitution with different alkyl groups.  Thanks to their usually low cytotoxicity, isoxazole derivs. are still popular scaffolds for the development of new agents with variable biol. activities, such as antimicrobial, antiviral, anticancer, anti-inflammatory, immunomodulatory, anticonvulsant or anti-diabetic properties.  This review discusses the chem. structure of recently developed isoxazole derivs. with regards to their activity and potential therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvOCSKKoVCn7Vg90H21EOLACvtfcHk0lignsR457UGLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73N&md5=14fcce13ee431e5fb6da1c91f39df47f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DSysak%26aufirst%3DA.%26aulast%3DObmi%25C5%2584ska-Mrukowicz%26aufirst%3DB.%26atitle%3DIsoxazole%2520ring%2520as%2520a%2520useful%2520scaffold%2520in%2520a%2520search%2520for%2520new%2520therapeutic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D137%26spage%3D292%26epage%3D309%26doi%3D10.1016%2Fj.ejmech.2017.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaisina, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tueckmantel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugolkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Identification of HDAC6-selective inhibitors of low cancer cell cytotoxicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fcmdc.201500456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26592932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-92&author=I.+N.+Gaisinaauthor=W.+Tueckmantelauthor=A.+Ugolkovauthor=S.+Shenauthor=J.+Hoffenauthor=O.+Dubrovskyiauthor=A.+Mazarauthor=R.+A.+Schoonauthor=D.+Billadeauauthor=A.+P.+Kozikowski&title=Identification+of+HDAC6-selective+inhibitors+of+low+cancer+cell+cytotoxicity&doi=10.1002%2Fcmdc.201500456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity</span></div><div class="casAuthors">Gaisina, Irina N.; Tueckmantel, Werner; Ugolkov, Andrey; Shen, Sida; Hoffen, Jessica; Dubrovskyi, Oleksii; Mazar, Andrew; Schoon, Renee A.; Billadeau, Daniel; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-92</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large no. of proteins involved in cancer initiation and progression.  The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compds. would avoid some of the undesirable side effects found with the first-generation inhibitors.  A series of HDACIs previously reported by the authors were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells.  In the present work, the authors show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth.  Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells.  The authors conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required.  Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8NrQruF5oObVg90H21EOLACvtfcHk0lignsR457UGLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI&md5=2c241c869dfcdd2863cee7aec9c2e898</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500456%26sid%3Dliteratum%253Aachs%26aulast%3DGaisina%26aufirst%3DI.%2BN.%26aulast%3DTueckmantel%26aufirst%3DW.%26aulast%3DUgolkov%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHoffen%26aufirst%3DJ.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DMazar%26aufirst%3DA.%26aulast%3DSchoon%26aufirst%3DR.%2BA.%26aulast%3DBilladeau%26aufirst%3DD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIdentification%2520of%2520HDAC6-selective%2520inhibitors%2520of%2520low%2520cancer%2520cell%2520cytotoxicity%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D92%26doi%3D10.1002%2Fcmdc.201500456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapadar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchini, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span> <span> </span><span class="NLM_article-title">Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4373</span>, <span class="refDoi"> DOI: 10.1021/jm8002894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4370-4373&author=A.+P.+Kozikowskiauthor=S.+Tapadarauthor=D.+N.+Luchiniauthor=K.+H.+Kimauthor=D.+D.+Billadeau&title=Use+of+the+nitrile+oxide+cycloaddition+%28NOC%29+reaction+for+molecular+probe+generation%3A+a+new+class+of+enzyme+selective+histone+deacetylase+inhibitors+%28HDACIs%29+showing+picomolar+activity+at+HDAC6&doi=10.1021%2Fjm8002894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span></div><div class="casAuthors">Kozikowski, Alan P.; Tapadar, Subhasish; Luchini, Doris N.; Kim, Ki Hwan; Billadeau, Daniel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4370-4373</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of hydroxamate based HDAC inhibitors contg. a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddn. chem.  An HDAC6 selective inhibitor having a potency of ∼2 picomolar was identified.  Some of the compds. were examd. for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA (suberoylanilidehydroxamic acid).  This research provides valuable, new mol. probes for use in exploring HDAC biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7Ca9tXdBvbVg90H21EOLACvtfcHk0lifjJYiQVOvjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D&md5=006c71fe6f2bb09c2c65196e134a695e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm8002894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002894%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DUse%2520of%2520the%2520nitrile%2520oxide%2520cycloaddition%2520%2528NOC%2529%2520reaction%2520for%2520molecular%2520probe%2520generation%253A%2520a%2520new%2520class%2520of%2520enzyme%2520selective%2520histone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%2520showing%2520picomolar%2520activity%2520at%2520HDAC6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4370%26epage%3D4373%26doi%3D10.1021%2Fjm8002894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tapadar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchini, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3023</span>– <span class="NLM_lpage">3026</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bmcl.2009.04.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=19419863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVersrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3023-3026&author=S.+Tapadarauthor=R.+Heauthor=D.+N.+Luchiniauthor=D.+D.+Billadeauauthor=A.+P.+Kozikowski&title=Isoxazole+moiety+in+the+linker+region+of+HDAC+inhibitors+adjacent+to+the+Zn-chelating+group%3A+effects+on+HDAC+biology+and+antiproliferative+activity&doi=10.1016%2Fj.bmcl.2009.04.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: Effects on HDAC biology and antiproliferative activity</span></div><div class="casAuthors">Tapadar, Subhasish; He, Rong; Luchini, Doris N.; Billadeau, Daniel D.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3023-3026</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hydroxamic acid based histone deacetylase inhibitors 6-15, contg. an isoxazole moiety adjacent to the Zn-chelating hydroxamic acid, is reported herein.  Some of these compds. showed nanomolar activity in the HDAC isoform inhibitory assay and exhibited micromolar inhibitory activity against five pancreatic cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrta5zk6I47pLVg90H21EOLACvtfcHk0lifjJYiQVOvjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVersrs%253D&md5=affc37e7890fc939db595fa48397390c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.058%26sid%3Dliteratum%253Aachs%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIsoxazole%2520moiety%2520in%2520the%2520linker%2520region%2520of%2520HDAC%2520inhibitors%2520adjacent%2520to%2520the%2520Zn-chelating%2520group%253A%2520effects%2520on%2520HDAC%2520biology%2520and%2520antiproliferative%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3023%26epage%3D3026%26doi%3D10.1016%2Fj.bmcl.2009.04.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+a+free+web+tool+to+evaluate+pharmacokinetics%2C+drug-likeness+and+medicinal+chemistry+friendliness+of+small+molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2eYDvNOhM6QdWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520a%2520free%2520web%2520tool%2520to%2520evaluate%2520pharmacokinetics%252C%2520drug-likeness%2520and%2520medicinal%2520chemistry%2520friendliness%2520of%2520small%2520molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fcmdc.201500486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26603496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=15-21&author=S.+Shenauthor=A.+P.+Kozikowski&title=Why+Hydroxamates+May+Not+Be+the+Best+Histone+Deacetylase+Inhibitors-What+Some+May+Have+Forgotten+or+Would+Rather+Forget%3F&doi=10.1002%2Fcmdc.201500486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Hydroxamate-based histone deacetylase inhibitors (HDACIs) have been approved as therapeutic agents by the US Food and Drug Administration for use in oncol. applications.  While the potential utility of such HDACIs in other areas of medicinal chem. is tremendous, there are significant concerns that "pan-HDAC inhibitors" may be too broadly acting and/or toxic for clin. use beyond oncol.  In addn. to the isoenzyme selectivity challenge, the potential mutagenicity of hydroxamate-contg. HDAC inhibitors represents a major hindrance in their application to other therapeutic areas.  Herein the authors report on the mutagenicity of known hydroxamates, discuss the mechanisms responsible for their genotoxicity, and review some of the current alternatives to hydroxamates.  The authors conclude that the hydroxamate group, while providing high-potency HDACIs, is not necessarily the best zinc-binding group for HDACI drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplftHMFVoN6rVg90H21EOLACvtfcHk0ljsSWzh6a3ZIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL&md5=5183d2c0a4c86fe67bea480a66bc5dc6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500486%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWhy%2520Hydroxamates%2520May%2520Not%2520Be%2520the%2520Best%2520Histone%2520Deacetylase%2520Inhibitors-What%2520Some%2520May%2520Have%2520Forgotten%2520or%2520Would%2520Rather%2520Forget%253F%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D15%26epage%3D21%26doi%3D10.1002%2Fcmdc.201500486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invidiata, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondanin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaudo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannizzo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbusca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessandro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolomeo, M.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Relationship Studies of Novel Heteroretinoids: Induction of Apoptosis in the HL-60 Cell Line by a Novel Isoxazole-Containing Heteroretinoid</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4969</span>, <span class="refDoi"> DOI: 10.1021/jm991059n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991059n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADyaK1MXntVaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4961-4969&author=D.+Simoniauthor=F.+P.+Invidiataauthor=R.+Rondaninauthor=S.+Grimaudoauthor=G.+Cannizzoauthor=E.+Barbuscaauthor=F.+Porrettoauthor=N.+D%E2%80%99Alessandroauthor=M.+Tolomeo&title=Structure%E2%80%93Activity+Relationship+Studies+of+Novel+Heteroretinoids%3A+Induction+of+Apoptosis+in+the+HL-60+Cell+Line+by+a+Novel+Isoxazole-Containing+Heteroretinoid&doi=10.1021%2Fjm991059n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Novel Heteroretinoids: Induction of Apoptosis in the HL-60 Cell Line by a Novel Isoxazole-Containing Heteroretinoid</span></div><div class="casAuthors">Simoni, Daniele; Invidiata, Francesco Paolo; Rondanin, Riccardo; Grimaudo, Stefania; Cannizzo, Giuliana; Barbusca, Eleonora; Porretto, Ferdinando; D'Alessandro, Nicola; Tolomeo, Manlio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4961-4969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a search for retinoic acid receptor (RAR and RXR)-selective ligands, a series of isoxazole retinoids was synthesized and evaluated in vitro in transcriptional activation and competition binding assays for RARs and RXRs.  In addn., these compds. were evaluated for their differentiating, cytotoxic, and apoptotic activities.  In general, these derivs. showed scarcely any binding affinity and were not active in the transcriptional assay.  However, among these isoxazole derivs., one cis-compds. was identified as a potent inducer of apoptosis, and its activity was found to be 6.5 and 4 times superior than that of 13-cis- and 9-cis-retinoic acids, resp.  On the other hand, a compd. which have the trans stereochem. at the double bond, was found not to be active in the apoptotic assay, but it was endowed with appreciable differentiating activity.  Therefore, it seems that the different stereochem. of the double bond may be assocd. with a different biol. activity: potent apoptotic activity for the cis-isomer but differentiating activity for the trans structure.  This biol. behavior was found, at least in part, for the 9-cis- and 13-cis-retinoic acids with respect to the all-trans-retinoic acid.  Thus, isoxazole retinoids could offer an interesting model for the design of new compds. endowed with apoptotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ni1MSQmk1LVg90H21EOLACvtfcHk0ljsSWzh6a3ZIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVaks7g%253D&md5=4fec1bfd4b89eed7c6e491eaffd2b06a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm991059n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991059n%26sid%3Dliteratum%253Aachs%26aulast%3DSimoni%26aufirst%3DD.%26aulast%3DInvidiata%26aufirst%3DF.%2BP.%26aulast%3DRondanin%26aufirst%3DR.%26aulast%3DGrimaudo%26aufirst%3DS.%26aulast%3DCannizzo%26aufirst%3DG.%26aulast%3DBarbusca%26aufirst%3DE.%26aulast%3DPorretto%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Alessandro%26aufirst%3DN.%26aulast%3DTolomeo%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationship%2520Studies%2520of%2520Novel%2520Heteroretinoids%253A%2520Induction%2520of%2520Apoptosis%2520in%2520the%2520HL-60%2520Cell%2520Line%2520by%2520a%2520Novel%2520Isoxazole-Containing%2520Heteroretinoid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4961%26epage%3D4969%26doi%3D10.1021%2Fjm991059n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segretti, M. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallerini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Thiol-based potent and selective HDAC6 inhibitors promote tubulin acetylation and T-regulatory cell suppressive function</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1156-1161&author=M.+C.+F.+Segrettiauthor=G.+P.+Valleriniauthor=C.+Brochierauthor=B.+Langleyauthor=L.+Wangauthor=W.+W.+Hancockauthor=A.+P.+Kozikowski&title=Thiol-based+potent+and+selective+HDAC6+inhibitors+promote+tubulin+acetylation+and+T-regulatory+cell+suppressive+function&doi=10.1021%2Facsmedchemlett.5b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function</span></div><div class="casAuthors">Segretti, Mariana C. F.; Vallerini, Gian Paolo; Brochier, Camille; Langley, Brett; Wang, Liqing; Hancock, Wayne W.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1156-1161</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several new mercaptoacetamides were synthesized and studied as HDAC6 inhibitors.  One compd., I, bearing an aminoquinoline cap group, was found to show 1.3 nM potency at HDAC6, with >3000-fold selectivity over HDAC1.  I also showed excellent efficacy at increasing tubulin acetylation in rat primary cortical cultures, inducing a 10-fold increase in acetylated tubulin at 1 μM.  To assess possible therapeutic effects, compds. were assayed for their ability to increase T-regulatory (Treg) suppressive function.  Some but not all of the compds. increased Treg function, and thereby decreased conventional T cell activation and proliferation in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFoMNCfBF-MbVg90H21EOLACvtfcHk0ljsSWzh6a3ZIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsbnF&md5=10f24c7712c46f4b69fe2e4d17231a35</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00303%26sid%3Dliteratum%253Aachs%26aulast%3DSegretti%26aufirst%3DM.%2BC.%2BF.%26aulast%3DVallerini%26aufirst%3DG.%2BP.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DThiol-based%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%2520promote%2520tubulin%2520acetylation%2520and%2520T-regulatory%2520cell%2520suppressive%2520function%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1156%26epage%3D1161%26doi%3D10.1021%2Facsmedchemlett.5b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of mercaptoacetamides as potent, selective, and brain permeable histone deacetylase 6 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=510-515&author=W.+Lvauthor=G.+Zhangauthor=C.+Barinkaauthor=J.+H.+Eubanksauthor=A.+P.+Kozikowski&title=Design+and+synthesis+of+mercaptoacetamides+as+potent%2C+selective%2C+and+brain+permeable+histone+deacetylase+6+inhibitors&doi=10.1021%2Facsmedchemlett.7b00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Lv, Wei; Zhang, Guangming; Barinka, Cyril; Eubanks, James H.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of non-hydroxamate HDAC6 inhibitors were prepd. in our effort to develop potent and selective compds. for possible use in Central Nervous System (CNS) disorders, thus obviating the genotoxicity often assocd. with the hydroxamates.  Halogens are incorporated in the cap groups of the designed mercaptoacetamides in order to increase brain accessibility.  The indole analog and quinoline analog displayed potent HDAC6 inhibitory activity (IC50 11 nM and 2.8 nM) and excellent selectivity against HDAC1.  Both compds., together with their ester prodrug and disulfide prodrugs were found to be effective in promoting tubulin acetylation in HEK cells.  The disulfide prodrugs also released a stable concn. of the indole and quinoline analogs upon microsomal incubation.  Administration of disulfide prodrugs in vivo was found to trigger an increase of tubulin acetylation in mouse cortex.  These results suggest that further exploration of these com-pounds for the treatment of CNS disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4LBQBS-jHCrVg90H21EOLACvtfcHk0lgoy4NAEC1Tmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D&md5=f7709c8f4c339737da3201149afe0f82</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00012%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520mercaptoacetamides%2520as%2520potent%252C%2520selective%252C%2520and%2520brain%2520permeable%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D510%26epage%3D515%26doi%3D10.1021%2Facsmedchemlett.7b00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmenon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caignard, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennuyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audinot-Bouchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutin, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ktorza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viaud-Massuard, M.-C.</span></span> <span> </span><span class="NLM_article-title">4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1617</span>– <span class="NLM_lpage">1622</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bmcl.2008.01.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=18255290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1Ckt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1617-1622&author=C.+Parmenonauthor=J.+Guillardauthor=D.-H.+Caignardauthor=N.+Hennuyerauthor=B.+Staelsauthor=V.+Audinot-Bouchezauthor=J.-A.+Boutinauthor=C.+Dacquetauthor=A.+Ktorzaauthor=M.-C.+Viaud-Massuard&title=4%2C4-Dimethyl-1%2C2%2C3%2C4-tetrahydroquinoline-based+PPAR%CE%B1%2F%CE%B3+agonists.+Part+I%3A+Synthesis+and+pharmacological+evaluation&doi=10.1016%2Fj.bmcl.2008.01.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation</span></div><div class="casAuthors">Parmenon, Cecile; Guillard, Jerome; Caignard, Daniel-Henri; Hennuyer, Nathalie; Staels, Bart; Audinot-Bouchez, Valerie; Boutin, Jean-Albert; Dacquet, Catherine; Ktorza, Alain; Viaud-Massuard, Marie-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1617-1622</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of 4,4-dimethyl-1,2,3,4-tetrahydroquinolines, e.g. I (R = H, Me), was synthesized and studied as human PPARγ selective agonists and dual PPARα/γ agonists for potential treatment of type-2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp08HKGqPuCVLVg90H21EOLACvtfcHk0lgoy4NAEC1Tmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1Ckt70%253D&md5=93ad385b32df02483e5cd41d979000de</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.067%26sid%3Dliteratum%253Aachs%26aulast%3DParmenon%26aufirst%3DC.%26aulast%3DGuillard%26aufirst%3DJ.%26aulast%3DCaignard%26aufirst%3DD.-H.%26aulast%3DHennuyer%26aufirst%3DN.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DAudinot-Bouchez%26aufirst%3DV.%26aulast%3DBoutin%26aufirst%3DJ.-A.%26aulast%3DDacquet%26aufirst%3DC.%26aulast%3DKtorza%26aufirst%3DA.%26aulast%3DViaud-Massuard%26aufirst%3DM.-C.%26atitle%3D4%252C4-Dimethyl-1%252C2%252C3%252C4-tetrahydroquinoline-based%2520PPAR%25CE%25B1%252F%25CE%25B3%2520agonists.%2520Part%2520I%253A%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1617%26epage%3D1622%26doi%3D10.1016%2Fj.bmcl.2008.01.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowkett, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span> <span> </span><span class="NLM_article-title">Haloarene derivatives of carbamazepine with reduced bioactivation liabilities: 2-monohalo and 2,8-dihalo derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9773</span>– <span class="NLM_lpage">9784</span>, <span class="refDoi"> DOI: 10.1021/jm301013n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301013n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCrur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9773-9784&author=E.-C.+Elliottauthor=S.+L.+Reganauthor=J.+L.+Maggsauthor=E.+R.+Bowkettauthor=L.+J.+Parryauthor=D.+P.+Williamsauthor=B.+K.+Parkauthor=A.+V.+Stachulski&title=Haloarene+derivatives+of+carbamazepine+with+reduced+bioactivation+liabilities%3A+2-monohalo+and+2%2C8-dihalo+derivatives&doi=10.1021%2Fjm301013n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Haloarene Derivatives of Carbamazepine with Reduced Bioactivation Liabilities: 2-Monohalo and 2,8-Dihalo Derivatives</span></div><div class="casAuthors">Elliott, Emma-Claire; Regan, Sophie L.; Maggs, James L.; Bowkett, Elizabeth R.; Parry, Laura J.; Williams, Dominic P.; Park, B. Kevin; Stachulski, Andrew V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9773-9784</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anticonvulsant carbamazepine (I) is assocd. with adverse drug reactions (ADRs), including hepatotoxicity; oxidative metab. of I has been implicated in the pathogenesis of the ADRs.  The authors report the synthesis and evaluation of 2-monohalo and 2,8-dihalo analogs of I that were intended to minimize reactive metabolite formation via arene oxidn. and 10,11-epoxidn.  Halo analogs were obtained either by rearrangement of halogenated N-arylindoles or from specifically halogenated iminodibenzyl derivs.  In rat hepatocytes, none of the analogs underwent oxidative dehalogenation or glutathione adduction.  Some formation of the 10,11-epoxide still occurred, but arom. hydroxylation was not seen with the exception of 2-fluoro, which allowed minor monohydroxylation.  Complete inhibition of arom. hydroxylation required at least monochlorination or difluorination of I.  In human liver microsomes, difluoro analog II underwent 10,11-epoxidn. but gave no arene oxidn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDc7RDg0laObVg90H21EOLACvtfcHk0lgoy4NAEC1Tmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCrur7J&md5=d158092424146266ca119a4d5656ba30</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm301013n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301013n%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DE.-C.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DBowkett%26aufirst%3DE.%2BR.%26aulast%3DParry%26aufirst%3DL.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26atitle%3DHaloarene%2520derivatives%2520of%2520carbamazepine%2520with%2520reduced%2520bioactivation%2520liabilities%253A%25202-monohalo%2520and%25202%252C8-dihalo%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9773%26epage%3D9784%26doi%3D10.1021%2Fjm301013n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Asencio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramón, D. J.</span></span> <span> </span><span class="NLM_article-title">Copper(II) acetate-catalyzed one-pot conversion of aldehydes into primary amides through a Beckmann-type rearrangement</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3948</span>– <span class="NLM_lpage">3951</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2012.03.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.tet.2012.03.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=3948-3951&author=A.+Mart%C3%ADnez-Asencioauthor=M.+Yusauthor=D.+J.+Ram%C3%B3n&title=Copper%28II%29+acetate-catalyzed+one-pot+conversion+of+aldehydes+into+primary+amides+through+a+Beckmann-type+rearrangement&doi=10.1016%2Fj.tet.2012.03.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Copper(II) acetate-catalyzed one-pot conversion of aldehydes into primary amides through a Beckmann-type rearrangement</span></div><div class="casAuthors">Martinez-Asencio, Ana; Yus, Miguel; Ramon, Diego J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3948-3951</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Copper(II) acetate is a versatile catalyst for the direct transformation of any type of aldehydes into primary amides by stoichiometric reaction with hydroxylamine in water.  The catalyst could be recovered 10 times without losing its activity, just by a simple org. layer extn. of the product.  The catalyst and the protocol avoid the use of any type of expensive and difficult to handle org. ligand, as well as bases, showing excellent yields, under mild reaction conditions.  The great purity of the crude product permits its purifn. by a simple recrystn. process.  The whole protocol fulfills the principle of green chem. and sustainability, minimizing the use of org. solvents and any type of wastes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJCgpumte1XrVg90H21EOLACvtfcHk0lgGdInhHg6sRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWhsro%253D&md5=4c901c0ef8daf5570fb36062f842e245</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.03.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.03.085%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Asencio%26aufirst%3DA.%26aulast%3DYus%26aufirst%3DM.%26aulast%3DRam%25C3%25B3n%26aufirst%3DD.%2BJ.%26atitle%3DCopper%2528II%2529%2520acetate-catalyzed%2520one-pot%2520conversion%2520of%2520aldehydes%2520into%2520primary%2520amides%2520through%2520a%2520Beckmann-type%2520rearrangement%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D3948%26epage%3D3951%26doi%3D10.1016%2Fj.tet.2012.03.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholte, A. A.</span></span> <span> </span><span class="NLM_article-title">Reductive N-alkylation of amides, carbamates and ureas</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2295</span>– <span class="NLM_lpage">2298</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(99)00211-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fs0040-4039%2899%2900211-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVensr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=2295-2298&author=D.+Dub%C3%A9author=A.+A.+Scholte&title=Reductive+N-alkylation+of+amides%2C+carbamates+and+ureas&doi=10.1016%2Fs0040-4039%2899%2900211-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Reductive N-alkylation of amides, carbamates and ureas</span></div><div class="casAuthors">Dube, Daniel; Scholte, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2295-2298</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A one-pot selective mono-N-alkylation of primary amides, thioamides, carbamates and ureas has been developed using arom. and aliph. aldehydes as alkylating agents and trifluoroacetic acid/triethylsilane as reagents.  Application to an efficient synthesis of a primary amine from the corresponding aldehyde via the carbamate intermediate is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor_3EkWvE--bVg90H21EOLACvtfcHk0lgGdInhHg6sRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVensr4%253D&md5=8972157ea7e865a307eaa053c30452d7</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4039%2899%2900211-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4039%252899%252900211-7%26sid%3Dliteratum%253Aachs%26aulast%3DDub%25C3%25A9%26aufirst%3DD.%26aulast%3DScholte%26aufirst%3DA.%2BA.%26atitle%3DReductive%2520N-alkylation%2520of%2520amides%252C%2520carbamates%2520and%2520ureas%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26spage%3D2295%26epage%3D2298%26doi%3D10.1016%2Fs0040-4039%2899%2900211-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/s1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2Fs1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eb1Ee1e0yKMmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2Fs1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lgGdInhHg6sRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">13459</span>– <span class="NLM_lpage">13464</span>, <span class="refDoi"> DOI: 10.1073/pnas.1718823114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1073%2Fpnas.1718823114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29203661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13459-13464&author=N.+J.+Porterauthor=A.+Mahendranauthor=R.+Breslowauthor=D.+W.+Christianson&title=Unusual+zinc-binding+mode+of+HDAC6-selective+hydroxamate+inhibitors&doi=10.1073%2Fpnas.1718823114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span></div><div class="casAuthors">Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13459-13464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins.  The Zn2+-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis.  Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders.  Here, we present high-resoln. structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compds. that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-((N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide (HPB), ACY-1215 (Ricolinostat), and ACY-1083.  These structures reveal that an unusual monodentate Zn2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors.  We addnl. report the ultrahigh-resoln. structure of the HDAC6-trichostatin A complex, which reveals two Zn2+-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol.  The minor conformer is not visible in lower resoln. structure detns.  Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isoenzyme selectivity obsd. in biochem. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oUH1X_04p7Vg90H21EOLACvtfcHk0ljywm2hgNwTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI&md5=07180756239eac4891642cf59a2e6992</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1718823114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1718823114%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DUnusual%2520zinc-binding%2520mode%2520of%2520HDAC6-selective%2520hydroxamate%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2017%26volume%3D114%26spage%3D13459%26epage%3D13464%26doi%3D10.1073%2Fpnas.1718823114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3916</span>– <span class="NLM_lpage">3924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00367</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00367" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3916-3924&author=N.+J.+Porterauthor=F.+F.+Wagnerauthor=D.+W.+Christianson&title=Entropy+as+a+driver+of+selectivity+for+inhibitor+binding+to+histone+deacetylase+6&doi=10.1021%2Facs.biochem.8b00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6</span></div><div class="casAuthors">Porter, Nicholas J.; Wagner, Florence F.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3916-3924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among the metal-dependent histone deacetylases, the class IIb isoenzyme HDAC6 is remarkable due to its role in the regulation of microtubule dynamics in the cytosol.  Selective inhibition of HDAC6 results in microtubule hyperacetylation, leading to cell cycle arrest and apoptosis, which is a validated strategy for cancer chemotherapy and the treatment of other disorders.  HDAC6 inhibitors generally consist of a Zn2+-binding group such as a hydroxamate, a linker, and a capping group; the capping group is a crit. determinant of isoenzyme selectivity.  Surprisingly, however, even "capless" inhibitors exhibit appreciable HDAC6 selectivity.  To probe the chem. basis for this selectivity, we now report high-resoln. crystal structures of HDAC6 complexed with capless cycloalkylhydroxamate inhibitors 1-4.  Each inhibitor hydroxamate group coordinates to the catalytic Zn2+ ion with canonical bidentate geometry.  Addnl., the olefin moieties of compds. 2 and 4 bind in an arom. crevice between the side chains of F583 and F643.  Reasoning that similar binding could be achieved in the representative class I isoenzyme HDAC8, we employed isothermal titrn. calorimetry to study the thermodn. of inhibitor binding.  These measurements indicate that the entropy of inhibitor binding is generally pos. for binding to HDAC6 and neg. for binding to HDAC8, resulting in up to 313-fold selectivity for binding to HDAC6 relative to HDAC8.  Thus, favorable binding entropy contributes to HDAC6 selectivity.  Notably, cyclohexenylhydroxamate 2 represents a promising lead for derivatization with capping groups that may further enhance its impressive 313-fold thermodn. selectivity for HDAC6 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MmbdoXXUqrVg90H21EOLACvtfcHk0ljywm2hgNwTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D&md5=0da8abf0ee7f012db41c620101551442</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00367%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DEntropy%2520as%2520a%2520driver%2520of%2520selectivity%2520for%2520inhibitor%2520binding%2520to%2520histone%2520deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3916%26epage%3D3924%26doi%3D10.1021%2Facs.biochem.8b00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8054</span>– <span class="NLM_lpage">8060</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8054-8060&author=N.+J.+Porterauthor=J.+D.+Oskoauthor=D.+Diedrichauthor=T.+Kurzauthor=J.+M.+Hookerauthor=F.+K.+Hansenauthor=D.+W.+Christianson&title=Histone+deacetylase+6-selective+inhibitors+and+the+influence+of+capping+groups+on+hydroxamate-zinc+denticity&doi=10.1021%2Facs.jmedchem.8b01013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity</span></div><div class="casAuthors">Porter, Nicholas J.; Osko, Jeremy D.; Diedrich, Daniela; Kurz, Thomas; Hooker, Jacob M.; Hansen, Finn K.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8054-8060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Four crystal structures are presented of histone deacetylase 6 (HDAC6) complexes with para-substituted phenylhydromaxamate inhibitors, including bulky peptoids.  These structures provide insight regarding the design of capping groups that confer selectivity for binding to HDAC6, specifically with regard to interactions in a pocket formed by the L1 loop.  Capping group interactions may also influence hydroxamate-Zn2+ coordination with monodentate or bidentate geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq54PM6p6wpnrVg90H21EOLACvtfcHk0ljywm2hgNwTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE&md5=f1d227d7668d09e121e5967b2d65f1a5</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01013%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DDiedrich%26aufirst%3DD.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206-selective%2520inhibitors%2520and%2520the%2520influence%2520of%2520capping%2520groups%2520on%2520hydroxamate-zinc%2520denticity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8054%26epage%3D8060%26doi%3D10.1021%2Facs.jmedchem.8b01013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+deacetylase+6+structure+and+molecular+basis+of+catalysis+and+inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0lhW2oWKUJTFZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520structure%2520and%2520molecular%2520basis%2520of%2520catalysis%2520and%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodroofe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupcho, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niles, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">Target engagement and drug residence time can be observed in living cells with BRET</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">10091</span>, <span class="refDoi"> DOI: 10.1038/ncomms10091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fncomms10091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26631872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10091&author=M.+B.+Robersauthor=M.+L.+Dartauthor=C.+C.+Woodroofeauthor=C.+A.+Zimprichauthor=T.+A.+Kirklandauthor=T.+Machleidtauthor=K.+R.+Kupchoauthor=S.+Levinauthor=J.+R.+Hartnettauthor=K.+Zimmermanauthor=A.+L.+Nilesauthor=R.+F.+Ohanaauthor=D.+L.+Danielsauthor=M.+Slaterauthor=M.+G.+Woodauthor=M.+Congauthor=Y.-Q.+Chengauthor=K.+V.+Wood&title=Target+engagement+and+drug+residence+time+can+be+observed+in+living+cells+with+BRET&doi=10.1038%2Fncomms10091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement and drug residence time can be observed in living cells with BRET</span></div><div class="casAuthors">Robers, Matthew B.; Dart, Melanie L.; Woodroofe, Carolyn C.; Zimprich, Chad A.; Kirkland, Thomas A.; Machleidt, Thomas; Kupcho, Kevin R.; Levin, Sergiy; Hartnett, James R.; Zimmerman, Kristopher; Niles, Andrew L.; Ohana, Rachel Friedman; Daniels, Danette L.; Slater, Michael; Wood, Monika G.; Cong, Mei; Cheng, Yi-Qiang; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10091</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic action of drugs is predicated on their phys. engagement with cellular targets.  Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells.  Cell-permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement with the target proteins fused to Nanoluc luciferase.  The approach enabled us to profile isoenzyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors.  Our anal. was directed particularly to the clin. approved prodrug FK228 (Istodax/Romidepsin) because of its unique and largely unexplained mechanism of sustained intracellular action.  Anal. of the binding kinetics by BRET revealed remarkably long intracellular residence times for FK228 at HDAC1, explaining the protracted intracellular behavior of this prodrug.  Our results demonstrate a novel application of BRET for assessing target engagement within the complex milieu of the intracellular environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRFFk0LNiL_LVg90H21EOLACvtfcHk0lhW2oWKUJTFZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO&md5=723cc5dd7d229b1115da4c2c9d75c913</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fncomms10091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10091%26sid%3Dliteratum%253Aachs%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DDart%26aufirst%3DM.%2BL.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKupcho%26aufirst%3DK.%2BR.%26aulast%3DLevin%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DNiles%26aufirst%3DA.%2BL.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.-Q.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DTarget%2520engagement%2520and%2520drug%2520residence%2520time%2520can%2520be%2520observed%2520in%2520living%2520cells%2520with%2520BRET%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10091%26doi%3D10.1038%2Fncomms10091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R. A.</span></span> <span> </span><span class="NLM_article-title">A Breakthrough: macrophage-directed cancer immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-15-1737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F0008-5472.can-15-1737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26772756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=513-516&author=C.+D.+Millsauthor=L.+L.+Lenzauthor=R.+A.+Harris&title=A+Breakthrough%3A+macrophage-directed+cancer+immunotherapy&doi=10.1158%2F0008-5472.can-15-1737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A Breakthrough: Macrophage-Directed Cancer Immunotherapy</span></div><div class="casAuthors">Mills, Charles D.; Lenz, Laurel L.; Harris, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">513-516</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors.  Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting mols. that actively stimulate tumor growth in much the same way they help wounds heal.  However, modulating M2/repair-type macrophages to M1/kill-type can slow or stop cancer growth.  The effects involve direct activity of M1 kill-type as well as the ability of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells.  Macrophage responses can also predict cancer susceptibility; individuals with a high M1/kill to M2/repair ratio are less prone.  That macrophages/innate immunity can be modulated to play a central role in directly or indirectly combating cancer is a breakthrough that seems likely to finally make successful immunotherapy of cancer a reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFHZeNJZP2VLVg90H21EOLACvtfcHk0lgWtVPh5Yie0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSgsbs%253D&md5=85a2a0f1140d55bd8f16649c56501dcf</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-15-1737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-15-1737%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DC.%2BD.%26aulast%3DLenz%26aufirst%3DL.%2BL.%26aulast%3DHarris%26aufirst%3DR.%2BA.%26atitle%3DA%2520Breakthrough%253A%2520macrophage-directed%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D513%26epage%3D516%26doi%3D10.1158%2F0008-5472.can-15-1737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages: from basic research to clinical application</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">58</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0430-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs13045-017-0430-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28241846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksl2nsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=58&author=L.+Yangauthor=Y.+Zhang&title=Tumor-associated+macrophages%3A+from+basic+research+to+clinical+application&doi=10.1186%2Fs13045-017-0430-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-associated macrophages: from basic research to clinical application</span></div><div class="casAuthors">Yang, Li; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58/1-58/12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The fact that various immune cells, including macrophages, can be found in tumor tissues has long been known.  With the introduction of concept that macrophages differentiate into a classically or alternatively activated phenotype, the role of tumor-assocd. macrophages (TAMs) is now beginning to be elucidated.  TAMs act as "protumoral macrophages," contributing to disease progression.  TAMs can promote initiation and metastasis of tumor cells, inhibit antitumor immune responses mediated by T cells, and stimulate tumor angiogenesis and subsequently tumor progression.  As the relationship between TAMs and malignant tumors becomes clearer, TAMs are beginning to be seen as potential biomarkers for diagnosis and prognosis of cancers, as well as therapeutic targets in these cases.  In this review, we will discuss the origin, polarization, and role of TAMs in human malignant tumors, as well as how TAMs can be used as diagnostic and prognostic biomarkers and therapeutic targets of cancer in clinics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE2DAqgN25RrVg90H21EOLACvtfcHk0lgWtVPh5Yie0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksl2nsLo%253D&md5=2663c88c41e470910799eaba7a47eba0</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0430-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0430-2%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DTumor-associated%2520macrophages%253A%2520from%2520basic%2520research%2520to%2520clinical%2520application%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26spage%3D58%26doi%3D10.1186%2Fs13045-017-0430-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skultetyova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havlinova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansky, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11547</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11739-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fs41598-017-11739-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28912522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC1cboslOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=11547&author=L.+Skultetyovaauthor=K.+Ustinovaauthor=Z.+Kutilauthor=Z.+Novakovaauthor=J.+Pavlicekauthor=J.+Mikesovaauthor=D.+Traplauthor=P.+Baranovaauthor=B.+Havlinovaauthor=M.+Hubalekauthor=Z.+Lanskyauthor=C.+Barinka&title=Human+histone+deacetylase+6+shows+strong+preference+for+tubulin+dimers+over+assembled+microtubules&doi=10.1038%2Fs41598-017-11739-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules</span></div><div class="casAuthors">Skultetyova Lubica; Ustinova Kseniya; Kutil Zsofia; Novakova Zora; Pavlicek Jiri; Mikesova Jana; Trapl Dalibor; Baranova Petra; Havlinova Barbora; Lansky Zdenek; Barinka Cyril; Skultetyova Lubica; Hubalek Martin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11547</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human histone deacetylase 6 (HDAC6) is the major deacetylase responsible for removing the acetyl group from Lys40 of α-tubulin (αK40), which is located lumenally in polymerized microtubules.  Here, we provide a detailed kinetic analysis of tubulin deacetylation and HDAC6/microtubule interactions using individual purified components.  Our data unequivocally show that free tubulin dimers represent the preferred HDAC6 substrate, with a K M value of 0.23 μM and a deacetylation rate over 1,500-fold higher than that of assembled microtubules.  We attribute the lower deacetylation rate of microtubules to both longitudinal and lateral lattice interactions within tubulin polymers.  Using TIRF microscopy, we directly visualized stochastic binding of HDAC6 to assembled microtubules without any detectable preferential binding to microtubule tips.  Likewise, indirect immunofluorescence microscopy revealed that microtubule deacetylation by HDAC6 is carried out stochastically along the whole microtubule length, rather than from the open extremities.  Our data thus complement prior studies on tubulin acetylation and further strengthen the rationale for the correlation between tubulin acetylation and microtubule age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2XuDrQ2dPtsKL0FlyGHDofW6udTcc2eZFPEG-zes1J7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cboslOjsw%253D%253D&md5=c1b7f71ae3bd1008ad4b8c925ea30599</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11739-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11739-3%26sid%3Dliteratum%253Aachs%26aulast%3DSkultetyova%26aufirst%3DL.%26aulast%3DUstinova%26aufirst%3DK.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DTrapl%26aufirst%3DD.%26aulast%3DBaranova%26aufirst%3DP.%26aulast%3DHavlinova%26aufirst%3DB.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DLansky%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DHuman%2520histone%2520deacetylase%25206%2520shows%2520strong%2520preference%2520for%2520tubulin%2520dimers%2520over%2520assembled%2520microtubules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D11547%26doi%3D10.1038%2Fs41598-017-11739-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 11 is a fatty-acid deacylase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=685-693&author=Z.+Kutilauthor=Z.+Novakovaauthor=M.+Meleshinauthor=J.+Mikesovaauthor=M.+Schutkowskiauthor=C.+Barinka&title=Histone+deacetylase+11+is+a+fatty-acid+deacylase&doi=10.1021%2Facschembio.7b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 11 Is a Fatty-Acid Deacylase</span></div><div class="casAuthors">Kutil, Zsofia; Novakova, Zora; Meleshin, Marat; Mikesova, Jana; Schutkowski, Mike; Barinka, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-693</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 11 (HDAC11) is a sole member of the class IV HDAC subfamily with negligible intrinsic deacetylation activity.  Here, we report in vitro profiling of HDAC11 deacylase activities, and our data unequivocally show that the enzyme efficiently removes acyl moieties spanning 8-18 carbons from the side chain nitrogen of the lysine residue of a peptidic substrate.  Addnl., N-linked lipoic acid and biotin are removed by the enzyme, although with lower efficacy.  Catalytic efficiencies toward dodecanoylated and myristoylated peptides were 77 700 and 149 000 M-1 s-1, resp., making HDAC11 the most proficient fatty-acid deacylase of the HDAC family.  Interestingly, HDAC11 is strongly inhibited by free myristic, palmitic, and stearic acids with inhibition consts. of 6.5, 0.9, and 1.6 μM, resp.  At the same time, its deacylase activity is stimulated more than 2.5-fold by both palmitoyl-CoA and myristoyl-CoA, pointing toward metabolic control of the enzymic activity by fatty-acid metabolites.  Our data reveal novel enzymic activity of HDAC11 that can, in turn, facilitate the uncovering of addnl. biol. functions of the enzyme as well as the design of isoform-specific HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNsptw7rk7bVg90H21EOLACvtfcHk0liVCu_3hKwGTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D&md5=07233a3bfed4f158c6d5752fc18a8c1f</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00942%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DHistone%2520deacetylase%252011%2520is%2520a%2520fatty-acid%2520deacylase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D685%26epage%3D693%26doi%3D10.1021%2Facschembio.7b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of multi-functional histone deacetylase 6 degraders with potent anti-myeloma activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7042</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7042-7057&author=H.+Wuauthor=K.+Yangauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=Z.+Liauthor=H.+Xieauthor=J.+Liuauthor=K.+A.+Smithauthor=Z.+Novakovaauthor=C.+Barinkaauthor=W.+Tang&title=Development+of+multi-functional+histone+deacetylase+6+degraders+with+potent+anti-myeloma+activity&doi=10.1021%2Facs.jmedchem.9b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span></div><div class="casAuthors">Wu, Hao; Yang, Ka; Zhang, Zhongrui; Leisten, Eric D.; Li, Ziyuan; Xie, Haibo; Liu, Jin; Smith, Kerry A.; Novakova, Zora; Barinka, Cyril; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7042-7057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90.  HDAC6 is involved in multiple disease-relevant pathways.  Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand.  We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degrdn. for the antiproliferation of multiple myeloma (MM).  This new class of degraders exhibited improved potency and selectivity for the degrdn. of HDAC6.  After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb58zf04V2GLVg90H21EOLACvtfcHk0ljtBjydtgHwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO&md5=7aab402404a5fce732b4b68fd76395d4</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00516%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520multi-functional%2520histone%2520deacetylase%25206%2520degraders%2520with%2520potent%2520anti-myeloma%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7042%26epage%3D7057%26doi%3D10.1021%2Facs.jmedchem.9b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparta, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span> <span> </span><span class="NLM_article-title">Xdsapp2.0</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1107/s1600576716004416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2Fs1600576716004416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xosl2rtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=1085-1092&author=K.+M.+Spartaauthor=M.+Krugauthor=U.+Heinemannauthor=U.+Muellerauthor=M.+S.+Weiss&title=Xdsapp2.0&doi=10.1107%2Fs1600576716004416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">XDSAPP2.0</span></div><div class="casAuthors">Sparta, Karine M.; Krug, Michael; Heinemann, Udo; Mueller, Uwe; Weiss, Manfred S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">1600-5767</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">XDSAPP is an expert system and graphical user interface (GUI) for the automated processing of diffraction images using the XDS program suite and other programs.  The latest major update and the extension of the program are presented here.  The update includes new features, as well as improvements in the GUI and the underlying decision-making system.  XDSAPP is freely available for academic users.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ-TX0JPxrKrVg90H21EOLACvtfcHk0ljtBjydtgHwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xosl2rtLw%253D&md5=6f8dd41413be2d19cfee0e556da3cb0b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1107%2Fs1600576716004416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs1600576716004416%26sid%3Dliteratum%253Aachs%26aulast%3DSparta%26aufirst%3DK.%2BM.%26aulast%3DKrug%26aufirst%3DM.%26aulast%3DHeinemann%26aufirst%3DU.%26aulast%3DMueller%26aufirst%3DU.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26atitle%3DXdsapp2.0%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2016%26volume%3D49%26spage%3D1085%26epage%3D1092%26doi%3D10.1107%2Fs1600576716004416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2195</span>, <span class="refDoi"> DOI: 10.1107/s0907444904023510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS0907444904023510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15572771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2184-2195&author=A.+A.+Vaginauthor=R.+A.+Steinerauthor=A.+A.+Lebedevauthor=L.+Pottertonauthor=S.+McNicholasauthor=F.+Longauthor=G.+N.+Murshudov&title=REFMAC5+dictionary%3A+organization+of+prior+chemical+knowledge+and+guidelines+for+its+use&doi=10.1107%2Fs0907444904023510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span></div><div class="casAuthors">Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.; Potterton, Liz; McNicholas, Stuart; Long, Fei; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2184-2195</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">One of the most important aspects of macromol. structure refinement is the use of prior chem. knowledge.  Bond lengths, bond angles and other chem. properties are used in restrained refinement as subsidiary conditions.  This contribution describes the organization and some aspects of the use of the flexible and human/machine-readable dictionary of prior chem. knowledge used by the max.-likelihood macromol.-refinement program REFMAC5.  The dictionary stores information about monomers which represent the constitutive building blocks of biol. macromols. (amino acids, nucleic acids and saccharides) and about numerous org./inorg. compds. commonly found in macromol. crystallog.  It also describes the modifications the building blocks undergo as a result of chem. reactions and the links required for polymer formation.  More than 2000 monomer entries, 100 modification entries and 200 link entries are currently available.  Algorithms and tools for updating and adding new entries to the dictionary have also been developed and are presented here.  In many cases, the REFMAC5 dictionary allows entirely automatic generation of restraints within REFMAC5 refinement runs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjDd-k3YHGrVg90H21EOLACvtfcHk0ljtBjydtgHwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F&md5=005910422c5fb72fe2434c39b5321bf4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1107%2FS0907444904023510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904023510%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPotterton%26aufirst%3DL.%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DREFMAC5%2520dictionary%253A%2520organization%2520of%2520prior%2520chemical%2520knowledge%2520and%2520guidelines%2520for%2520its%2520use%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2184%26epage%3D2195%26doi%3D10.1107%2Fs0907444904023510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development ofCoot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/s0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+ofCoot&doi=10.1107%2Fs0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lh3fumEVCpPWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520ofCoot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2Fs0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gražulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkys, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaitkus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">AceDRG: a stereochemical description generator for ligands</span>. <i>Acta Crystallogr., Sect. D: Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/s2059798317000067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS2059798317000067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlGgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=112-122&author=F.+Longauthor=R.+A.+Nichollsauthor=P.+Emsleyauthor=S.+Gra%C5%BEulisauthor=A.+Merkysauthor=A.+Vaitkusauthor=G.+N.+Murshudov&title=AceDRG%3A+a+stereochemical+description+generator+for+ligands&doi=10.1107%2Fs2059798317000067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">AceDRG: a stereochemical description generator for ligands</span></div><div class="casAuthors">Long, Fei; Nicholls, Robert A.; Emsley, Paul; Grazulis, Saulius; Merkys, Andrius; Vaitkus, Antanas; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Structural Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACSDAD</span>;
        ISSN:<span class="NLM_cas:issn">2059-7983</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The program AceDRG is designed for the derivation of stereochem. information about small mols.  It uses local chem. and topol. environment-based atom typing to derive and organize bond lengths and angles from a small-mol. database: the Crystallog. Open Database (COD).  Information about the hybridization states of atoms, whether they belong to small rings (up to seven-membered rings), ring aromaticity and nearest-neighbor information is encoded in the atom types.  All atoms from the COD have been classified according to the generated atom types.  All bonds and angles have also been classified according to the atom types and, in a certain sense, bond types.  Derived data are tabulated in a machine-readable form that is freely available from CCP4.  AceDRG can also generate stereochem. information, provided that the basic bonding pattern of a ligand is known.  The basic bonding pattern is perceived from one of the computational chem. file formats, including SMILES, mmCIF, SDF MOL and SYBYL MOL2 files.  Using the bonding chem., atom types, and bond and angle tables generated from the COD, AceDRG derives the 'ideal' bond lengths, angles, plane groups, arom. rings and chirality information, and writes them to an mmCIF file that can be used by the refinement program REFMAC5 and the model-building program Coot.  Other refinement and model-building programs such as PHENIX and BUSTER can also use these files.  AceDRG also generates one or more coordinate sets corresponding to the most favorable conformation(s) of a given ligand.  AceDRG employs RDKit for chem. perception and for initial conformation generation, as well as for the interpretation of SMILES strings, SDF MOL and SYBYL MOL2 files.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow0LaF0rLfdLVg90H21EOLACvtfcHk0lh3fumEVCpPWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlGgu78%253D&md5=0a581d62dd3b00004e37be490ee71fe8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1107%2FS2059798317000067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2059798317000067%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DF.%26aulast%3DNicholls%26aufirst%3DR.%2BA.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DGra%25C5%25BEulis%26aufirst%3DS.%26aulast%3DMerkys%26aufirst%3DA.%26aulast%3DVaitkus%26aufirst%3DA.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DAceDRG%253A%2520a%2520stereochemical%2520description%2520generator%2520for%2520ligands%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Struct.%2520Biol.%26date%3D2017%26volume%3D73%26spage%3D112%26epage%3D122%26doi%3D10.1107%2Fs2059798317000067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/s0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2Fs0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0lhVQ0QYQj2qLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2Fs0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacketor, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin-Anduix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3928</span>– <span class="NLM_lpage">3937</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-11-2837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F0008-5472.can-11-2837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22693252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2rtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3928-3937&author=R.+C.+Koyaauthor=S.+Mokauthor=N.+Otteauthor=K.+J.+Blacketorauthor=B.+Comin-Anduixauthor=P.+C.+Tumehauthor=A.+Minasyanauthor=N.+A.+Grahamauthor=T.+G.+Graeberauthor=T.+Chodonauthor=A.+Ribas&title=BRAF+inhibitor+vemurafenib+improves+the+antitumor+activity+of+adoptive+cell+immunotherapy&doi=10.1158%2F0008-5472.can-11-2837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy</span></div><div class="casAuthors">Koya, Richard C.; Mok, Stephen; Otte, Nicholas; Blacketor, Kevin J.; Comin-Anduix, Begonya; Tumeh, Paul C.; Minasyan, Aspram; Graham, Nicholas A.; Graeber, Thomas G.; Chodon, Thinle; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3928-3937</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted therapeutics that produce robust clin. responses are likely benefiting from inherent adjuvant effects that degrade immune escape, a feature that could be leveraged most effectively by combinatorial uses in settings such as that described here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg6bb5bmox1bVg90H21EOLACvtfcHk0lhVQ0QYQj2qLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2rtr3J&md5=d8ec5438042feca327a3227c6d2a2381</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-11-2837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-11-2837%26sid%3Dliteratum%253Aachs%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DOtte%26aufirst%3DN.%26aulast%3DBlacketor%26aufirst%3DK.%2BJ.%26aulast%3DComin-Anduix%26aufirst%3DB.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DMinasyan%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DBRAF%2520inhibitor%2520vemurafenib%2520improves%2520the%2520antitumor%2520activity%2520of%2520adoptive%2520cell%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3928%26epage%3D3937%26doi%3D10.1158%2F0008-5472.can-11-2837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaffl, M. W.</span></span> <span> </span><span class="NLM_article-title">A new mathematical model for relative quantification in real-time RT-PCR</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">e45</span> <span class="refDoi"> DOI: 10.1093/nar/29.9.e45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1093%2Fnar%2F29.9.e45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=11328886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD38nis12jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&author=M.+W.+Pfaffl&title=A+new+mathematical+model+for+relative+quantification+in+real-time+RT-PCR&doi=10.1093%2Fnar%2F29.9.e45"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A new mathematical model for relative quantification in real-time RT-PCR</span></div><div class="casAuthors">Pfaffl M W</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Use of the real-time polymerase chain reaction (PCR) to amplify cDNA products reverse transcribed from mRNA is on the way to becoming a routine tool in molecular biology to study low abundance gene expression.  Real-time PCR is easy to perform, provides the necessary accuracy and produces reliable as well as rapid quantification results.  But accurate quantification of nucleic acids requires a reproducible methodology and an adequate mathematical model for data analysis.  This study enters into the particular topics of the relative quantification in real-time RT-PCR of a target gene transcript in comparison to a reference gene transcript.  Therefore, a new mathematical model is presented.  The relative expression ratio is calculated only from the real-time PCR efficiencies and the crossing point deviation of an unknown sample versus a control.  This model needs no calibration curve.  Control levels were included in the model to standardise each reaction run with respect to RNA integrity, sample loading and inter-PCR variations.  High accuracy and reproducibility (<2.5% variation) were reached in LightCycler PCR using the established mathematical model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-M-IJ-nr2KCSm0e6ZOaemfW6udTcc2eZ7kw3cJySh7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nis12jtw%253D%253D&md5=a0507843d416d259ae526f8c378a7e72</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F29.9.e45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F29.9.e45%26sid%3Dliteratum%253Aachs%26aulast%3DPfaffl%26aufirst%3DM.%2BW.%26atitle%3DA%2520new%2520mathematical%2520model%2520for%2520relative%2520quantification%2520in%2520real-time%2520RT-PCR%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2001%26volume%3D29%26doi%3D10.1093%2Fnar%2F29.9.e45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 26 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sida Shen, Cristina Picci, Kseniya Ustinova, Veronick Benoy, Zsófia Kutil, Guiping Zhang, Maurício T. Tavares, Jiří Pavlíček, Chad A. Zimprich, Matthew B. Robers, Ludo Van Den Bosch, Cyril Bařinka, Brett Langley, <span class="NLM_string-name hlFld-ContribAuthor">Alan P. Kozikowski</span>. </span><span class="cited-content_cbyCitation_article-title">Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot–Marie–Tooth Type 2A Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4810-4840. <a href="https://doi.org/10.1021/acs.jmedchem.0c02210" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02210%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTetrahydroquinoline-Capped%252BHistone%252BDeacetylase%252B6%252BInhibitor%252BSW-101%252BAmeliorates%252BPathological%252BPhenotypes%252Bin%252Ba%252BCharcot%2525E2%252580%252593Marie%2525E2%252580%252593Tooth%252BType%252B2A%252BMouse%252BModel%26aulast%3DShen%26aufirst%3DSida%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D21122020%26date%3D08042021%26volume%3D64%26issue%3D8%26spage%3D4810%26epage%3D4840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, Mussa Yussuf Khamis, Yi-Han Li, Li-Ying Ma, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Min Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1362-1391. <a href="https://doi.org/10.1021/acs.jmedchem.0c01782" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01782%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BReview%252Bof%252BProgress%252Bin%252BHistone%252BDeacetylase%252B6%252BInhibitors%252BResearch%25253A%252BStructural%252BSpecificity%252Band%252BFunctional%252BDiversity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D01022021%26volume%3D64%26issue%3D3%26spage%3D1362%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mi-Na Zhao, Gui-Wan Ning, De-Suo Yang, Ming-Jin Fan, Sheng Zhang, Peng Gao, <span class="NLM_string-name hlFld-ContribAuthor">Li-Fang Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Iron-Catalyzed Cycloaddition of Amides and 2,3-Diaryl-2H-azirines To Access Oxazoles via C–N Bond Cleavage. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (3)
                                     , 2957-2964. <a href="https://doi.org/10.1021/acs.joc.0c02843" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02843%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DIron-Catalyzed%252BCycloaddition%252Bof%252BAmides%252Band%252B2%25252C3-Diaryl-2H-azirines%252BTo%252BAccess%252BOxazoles%252Bvia%252BC%2525E2%252580%252593N%252BBond%252BCleavage%26aulast%3DZhao%26aufirst%3DMi-Na%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30112020%26date%3D14012021%26volume%3D86%26issue%3D3%26spage%3D2957%26epage%3D2964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca De Angelis, Alexandra M. Crawford, Yong-Liang Su, Daniel Wherritt, Hadi Arman, <span class="NLM_string-name hlFld-ContribAuthor">Michael P. Doyle</span>. </span><span class="cited-content_cbyCitation_article-title">Catalyst-Free Formation of Nitrile Oxides and Their Further Transformations to Diverse Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     , 925-929. <a href="https://doi.org/10.1021/acs.orglett.0c04130" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c04130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c04130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c04130%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCatalyst-Free%252BFormation%252Bof%252BNitrile%252BOxides%252Band%252BTheir%252BFurther%252BTransformations%252Bto%252BDiverse%252BHeterocycles%26aulast%3DDe%2BAngelis%26aufirst%3DLuca%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D14122020%26date%3D08012021%26volume%3D23%26issue%3D3%26spage%3D925%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Satish Noonepalle, Sida Shen, Jakub Ptáček, Maurício T. Tavares, Guiping Zhang, Jan Stránský, Jiří Pavlíček, Glaucio M. Ferreira, Melissa Hadley, Guido Pelaez, Cyril Bařinka, Alan P. Kozikowski, <span class="NLM_string-name hlFld-ContribAuthor">Alejandro Villagra</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10246-10262. <a href="https://doi.org/10.1021/acs.jmedchem.0c00567" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00567%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDesign%252Bof%252BSuprastat%25253A%252BA%252BNovel%252BSelective%252BHistone%252BDeacetylase%252B6%252BInhibitor%252Bwith%252Bthe%252BAbility%252Bto%252BPotentiate%252BImmunotherapy%252Bin%252BMelanoma%252BModels%26aulast%3DNoonepalle%26aufirst%3DSatish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06042020%26date%3D02092020%26date%3D20082020%26volume%3D63%26issue%3D18%26spage%3D10246%26epage%3D10262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Barbara Vergani, Giovanni Sandrone, Mattia Marchini, Chiara Ripamonti, Edoardo Cellupica, Elisabetta Galbiati, Gianluca Caprini, Gianfranco Pavich, Giulia Porro, Ilaria Rocchio, Maria Lattanzio, Marcello Pezzuto, Malgorzata Skorupska, Paola Cordella, Paolo Pagani, Pietro Pozzi, Roberta Pomarico, Daniela Modena, Flavio Leoni, Raffaella Perego, Gianluca Fossati, Christian Steinkühler, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Stevenazzi</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10711-10739. <a href="https://doi.org/10.1021/acs.jmedchem.9b01194" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01194%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BBenzohydroxamate-Based%252BPotent%252Band%252BSelective%252BHistone%252BDeacetylase%252B6%252B%252528HDAC6%252529%252BInhibitors%252BBearing%252Ba%252BPentaheterocyclic%252BScaffold%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DVergani%26aufirst%3DBarbara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24072019%26date%3D25112019%26date%3D11112019%26volume%3D62%26issue%3D23%26spage%3D10711%26epage%3D10739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanchun  Li</span>, <span class="hlFld-ContribAuthor ">Jishun  Quan</span>, <span class="hlFld-ContribAuthor ">Haoxuan  Song</span>, <span class="hlFld-ContribAuthor ">Dongzhu  Li</span>, <span class="hlFld-ContribAuthor ">Enlong  Ma</span>, <span class="hlFld-ContribAuthor ">Yanjuan  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105081. <a href="https://doi.org/10.1016/j.bioorg.2021.105081" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105081%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252Bpyrrolo%25255B2%25252C1-c%25255D%25255B1%25252C4%25255Dbenzodiazepine-3%25252C11-dione%252B%252528PBD%252529%252Bderivatives%252Bas%252Bselective%252BHDAC6%252Binhibitors%252Bto%252Bsuppress%252Btumor%252Bmetastasis%252Band%252Binvasion%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DLi%26aufirst%3DYanchun%26date%3D2021%26volume%3D114%26spage%3D105081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Xie</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Xiong</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">He  Huang</span>, <span class="hlFld-ContribAuthor ">Feng-Bo  Wu</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Shen</span>, <span class="hlFld-ContribAuthor ">Cheng  Peng</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>, <span class="hlFld-ContribAuthor ">Bo  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Design and organocatalytic synthesis of spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (8)
                                     , 1836-1843. <a href="https://doi.org/10.1039/D0QO01626H" title="DOI URL">https://doi.org/10.1039/D0QO01626H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01626H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01626H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DDesign%252Band%252Borganocatalytic%252Bsynthesis%252Bof%252Bspirooxindole%2525E2%252580%252593cyclopentene%2525E2%252580%252593isoxazole%252Bhybrids%252Bas%252Bnovel%252BMDM2%2525E2%252580%252593p53%252Binhibitors%26aulast%3DXie%26aufirst%3DXin%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D8%26spage%3D1836%26epage%3D1843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maurício Temotheo  Tavares</span>, <span class="hlFld-ContribAuthor ">Larissa Costa  de Almeida</span>, <span class="hlFld-ContribAuthor ">Thales  Kronenberger</span>, <span class="hlFld-ContribAuthor ">Glaucio  Monteiro Ferreira</span>, <span class="hlFld-ContribAuthor ">Thainá  Fujii de Divitiis</span>, <span class="hlFld-ContribAuthor ">Mônica  Franco Zannini Junqueira Toledo</span>, <span class="hlFld-ContribAuthor ">Neuza  Mariko Aymoto Hassimotto</span>, <span class="hlFld-ContribAuthor ">João  Agostinho Machado-Neto</span>, <span class="hlFld-ContribAuthor ">Letícia  Veras Costa-Lotufo</span>, <span class="hlFld-ContribAuthor ">Roberto  Parise-Filho</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>35 </em>, 116085. <a href="https://doi.org/10.1016/j.bmc.2021.116085" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116085%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Band%252Bmechanistic%252Bstudies%252Bfor%252Ba%252Bseries%252Bof%252Bcinnamyl%252Bhydroxamate%252Bhistone%252Bdeacetylase%252Binhibitors%26aulast%3DTavares%26aufirst%3DMaur%25C3%25ADcio%2BTemotheo%26date%3D2021%26volume%3D35%26spage%3D116085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mussa  Yussuf Khamis</span>, <span class="hlFld-ContribAuthor ">Hui-Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qin  Ma</span>, <span class="hlFld-ContribAuthor ">Yi-Han  Li</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Xin-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104754. <a href="https://doi.org/10.1016/j.bioorg.2021.104754" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104754%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DOvercome%252Bthe%252Btumor%252Bimmunotherapy%252Bresistance%252Bby%252Bcombination%252Bof%252Bthe%252BHDAC6%252Binhibitors%252Bwith%252Bantitumor%252Bimmunomodulatory%252Bagents%26aulast%3DYussuf%2BKhamis%26aufirst%3DMussa%26date%3D2021%26volume%3D109%26spage%3D104754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yonghai  Hui</span>, <span class="hlFld-ContribAuthor ">Yongfei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongyue  Luo</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Li</span>, <span class="hlFld-ContribAuthor ">Yun  Wang</span>, <span class="hlFld-ContribAuthor ">Tianming  Gao</span>, <span class="hlFld-ContribAuthor ">Jialiang  Xia</span>, <span class="hlFld-ContribAuthor ">Sheng  Wang</span>, <span class="hlFld-ContribAuthor ">Shiqi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of spiro thiazolidinone via cyclic ketones, amines and thioglycolic acid by MCM-41-Schiff base-CuSO4·5H2O. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2021,</strong> <em>47 </em>
                                    (2)
                                     , 521-532. <a href="https://doi.org/10.1007/s11164-020-04283-9" title="DOI URL">https://doi.org/10.1007/s11164-020-04283-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-020-04283-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-020-04283-9%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DFacile%252Bsynthesis%252Bof%252Bspiro%252Bthiazolidinone%252Bvia%252Bcyclic%252Bketones%25252C%252Bamines%252Band%252Bthioglycolic%252Bacid%252Bby%252BMCM-41-Schiff%252Bbase-CuSO4%2525C2%2525B75H2O%26aulast%3DHui%26aufirst%3DYonghai%26date%3D2021%26date%3D2020%26volume%3D47%26issue%3D2%26spage%3D521%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franca M.  Cordero</span>, <span class="hlFld-ContribAuthor ">Luisa  Lascialfari</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Machetti</span>. </span><span class="cited-content_cbyCitation_article-title">Five-membered ring systems with O and N atoms. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 365-395. <a href="https://doi.org/10.1016/B978-0-323-89812-6.00011-0" title="DOI URL">https://doi.org/10.1016/B978-0-323-89812-6.00011-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-323-89812-6.00011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-323-89812-6.00011-0%26sid%3Dliteratum%253Aachs%26atitle%3DFive-membered%252Bring%252Bsystems%252Bwith%252BO%252Band%252BN%252Batoms%26aulast%3DCordero%26aufirst%3DFranca%2BM.%26date%3D2021%26spage%3D365%26epage%3D395%26pub%3DElsevier%26date%3D2021%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maurício T.  Tavares</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>, <span class="hlFld-ContribAuthor ">Sida  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112887. <a href="https://doi.org/10.1016/j.ejmech.2020.112887" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112887</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112887%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMercaptoacetamide%25253A%252BA%252Bpromising%252Bzinc-binding%252Bgroup%252Bfor%252Bthe%252Bdiscovery%252Bof%252Bselective%252Bhistone%252Bdeacetylase%252B6%252Binhibitors%26aulast%3DTavares%26aufirst%3DMaur%25C3%25ADcio%2BT.%26date%3D2021%26volume%3D209%26spage%3D112887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">立园  张</span>. </span><span class="cited-content_cbyCitation_article-title">Progress in the Research of Selective Histone deacetylase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Advances in Material Chemistry</span><span> <strong>2021,</strong> <em>09 </em>
                                    (01)
                                     , 9-23. <a href="https://doi.org/10.12677/AMC.2021.91002" title="DOI URL">https://doi.org/10.12677/AMC.2021.91002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/AMC.2021.91002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FAMC.2021.91002%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvances%2520in%2520Material%2520Chemistry%26atitle%3DProgress%252Bin%252Bthe%252BResearch%252Bof%252BSelective%252BHistone%252Bdeacetylase%252BInhibitors%26aulast%3D%25E5%25BC%25A0%26aufirst%3D%25E7%25AB%258B%25E5%259B%25AD%26date%3D2021%26volume%3D09%26issue%3D01%26spage%3D9%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Pulya</span>, <span class="hlFld-ContribAuthor ">Sk. Abdul  Amin</span>, <span class="hlFld-ContribAuthor ">Nilanjan  Adhikari</span>, <span class="hlFld-ContribAuthor ">Swati  Biswas</span>, <span class="hlFld-ContribAuthor ">Tarun  Jha</span>, <span class="hlFld-ContribAuthor ">Balaram  Ghosh</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC6 as privileged target in drug discovery: A perspective. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>163 </em>, 105274. <a href="https://doi.org/10.1016/j.phrs.2020.105274" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.105274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.105274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.105274%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DHDAC6%252Bas%252Bprivileged%252Btarget%252Bin%252Bdrug%252Bdiscovery%25253A%252BA%252Bperspective%26aulast%3DPulya%26aufirst%3DSravani%26date%3D2021%26volume%3D163%26spage%3D105274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colleen E.  Quaas</span>, <span class="hlFld-ContribAuthor ">David T.  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting (de)acetylation: A Diversity of Mechanism and Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00076-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00076-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00076-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00076-1%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252B%252528de%252529acetylation%25253A%252BA%252BDiversity%252Bof%252BMechanism%252Band%252BDisease%26aulast%3DQuaas%26aufirst%3DColleen%2BE.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro de S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2177-2211. <a href="https://doi.org/10.1002/med.21701" title="DOI URL">https://doi.org/10.1002/med.21701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21701%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistone%252Bdeacetylases%252Bas%252Btargets%252Bfor%252Bthe%252Btreatment%252Bof%252Bneurodegenerative%252Bdisorders%25253A%252BChallenges%252Band%252Bfuture%252Bopportunities%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2177%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yufeng  Xiao</span>, <span class="hlFld-ContribAuthor ">Xuan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in small molecular modulators targeting histone deacetylase 6. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (4)
                                     , FDD53. <a href="https://doi.org/10.4155/fdd-2020-0023" title="DOI URL">https://doi.org/10.4155/fdd-2020-0023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0023%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DRecent%252Badvances%252Bin%252Bsmall%252Bmolecular%252Bmodulators%252Btargeting%252Bhistone%252Bdeacetylase%252B6%26aulast%3DXiao%26aufirst%3DYufeng%26date%3D2020%26volume%3D2%26issue%3D4%26spage%3DFDD53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debarati  Banik</span>, <span class="hlFld-ContribAuthor ">Satish  Noonepalle</span>, <span class="hlFld-ContribAuthor ">Melissa  Hadley</span>, <span class="hlFld-ContribAuthor ">Erica  Palmer</span>, <span class="hlFld-ContribAuthor ">Maria  Gracia-Hernandez</span>, <span class="hlFld-ContribAuthor ">Christian  Zevallos-Delgado</span>, <span class="hlFld-ContribAuthor ">Namratta  Manhas</span>, <span class="hlFld-ContribAuthor ">Hayk  Simonyan</span>, <span class="hlFld-ContribAuthor ">Colin N.  Young</span>, <span class="hlFld-ContribAuthor ">Anastas  Popratiloff</span>, <span class="hlFld-ContribAuthor ">Katherine B.  Chiappinelli</span>, <span class="hlFld-ContribAuthor ">Rohan  Fernandes</span>, <span class="hlFld-ContribAuthor ">Eduardo M.  Sotomayor</span>, <span class="hlFld-ContribAuthor ">Alejandro  Villagra</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (17)
                                     , 3649-3662. <a href="https://doi.org/10.1158/0008-5472.CAN-19-3738" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-19-3738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-19-3738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-19-3738%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DHDAC6%252BPlays%252Ba%252BNoncanonical%252BRole%252Bin%252Bthe%252BRegulation%252Bof%252BAntitumor%252BImmune%252BResponses%25252C%252BDissemination%25252C%252Band%252BInvasiveness%252Bof%252BBreast%252BCancer%26aulast%3DBanik%26aufirst%3DDebarati%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D17%26spage%3D3649%26epage%3D3662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ehab  Ghazy</span>, <span class="hlFld-ContribAuthor ">Patrik  Zeyen</span>, <span class="hlFld-ContribAuthor ">Daniel  Herp</span>, <span class="hlFld-ContribAuthor ">Martin  Hügle</span>, <span class="hlFld-ContribAuthor ">Karin  Schmidtkunz</span>, <span class="hlFld-ContribAuthor ">Frank  Erdmann</span>, <span class="hlFld-ContribAuthor ">Dina  Robaa</span>, <span class="hlFld-ContribAuthor ">Matthias  Schmidt</span>, <span class="hlFld-ContribAuthor ">Elizabeth R.  Morales</span>, <span class="hlFld-ContribAuthor ">Christophe  Romier</span>, <span class="hlFld-ContribAuthor ">Stefan  Günther</span>, <span class="hlFld-ContribAuthor ">Manfred  Jung</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Sippl</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112338. <a href="https://doi.org/10.1016/j.ejmech.2020.112338" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112338%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bdual%252Btargeting%252Binhibitors%252Bof%252Bhistone%252Bdeacetylase%252B6%25252F8%252Band%252Bbromodomain%252BBRPF1%26aulast%3DGhazy%26aufirst%3DEhab%26date%3D2020%26volume%3D200%26spage%3D112338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xingrui  He</span>, <span class="hlFld-ContribAuthor ">Zhen  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Tao  Zhuo</span>, <span class="hlFld-ContribAuthor ">Zi  Hui</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). </span><span class="cited-content_cbyCitation_journal-name">Recent Patents on Anti-Cancer Drug Discovery</span><span> <strong>2020,</strong> <em>15 </em>
                                    (1)
                                     , 32-48. <a href="https://doi.org/10.2174/1574892815666200217125419" title="DOI URL">https://doi.org/10.2174/1574892815666200217125419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1574892815666200217125419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1574892815666200217125419%26sid%3Dliteratum%253Aachs%26jtitle%3DRecent%2520Patents%2520on%2520Anti-Cancer%2520Drug%2520Discovery%26atitle%3DNovel%252BSelective%252BHistone%252BDeacetylase%252B6%252B%252528HDAC6%252529%252BInhibitors%25253A%252BA%252BPatent%252BReview%252B%2525282016-2019%252529%26aulast%3DHe%26aufirst%3DXingrui%26date%3D2020%26volume%3D15%26issue%3D1%26spage%3D32%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeremy D.  Osko</span>, <span class="hlFld-ContribAuthor ">David W.  Christianson</span>. </span><span class="cited-content_cbyCitation_article-title">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (8)
                                     , 127023. <a href="https://doi.org/10.1016/j.bmcl.2020.127023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructural%252Bdeterminants%252Bof%252Baffinity%252Band%252Bselectivity%252Bin%252Bthe%252Bbinding%252Bof%252Binhibitors%252Bto%252Bhistone%252Bdeacetylase%252B6%26aulast%3DOsko%26aufirst%3DJeremy%2BD.%26date%3D2020%26volume%3D30%26issue%3D8%26spage%3D127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Tingting  Fu</span>, <span class="hlFld-ContribAuthor ">Yuxiang  Ren</span>, <span class="hlFld-ContribAuthor ">Fengcheng  Li</span>, <span class="hlFld-ContribAuthor ">Guoxun  Zheng</span>, <span class="hlFld-ContribAuthor ">Jiajun  Hong</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>, <span class="hlFld-ContribAuthor ">Weiwei  Xue</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00041" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00041%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DSelective%252BInhibition%252Bof%252BHDAC1%252Bby%252BMacrocyclic%252BPolypeptide%252Bfor%252Bthe%252BTreatment%252Bof%252BGlioblastoma%25253A%252BA%252BBinding%252BMechanistic%252BAnalysis%252BBased%252Bon%252BMolecular%252BDynamics%26aulast%3DZhang%26aufirst%3DYang%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaorui  Xie</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunfei  Wei</span>, <span class="hlFld-ContribAuthor ">Heliang  Du</span>, <span class="hlFld-ContribAuthor ">Yuanbo  Xu</span>, <span class="hlFld-ContribAuthor ">Qihao  Xu</span>, <span class="hlFld-ContribAuthor ">Yongkui  Jing</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 111991. <a href="https://doi.org/10.1016/j.ejmech.2019.111991" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111991%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252B18%2525CE%2525B2-glycyrrhetinic%252Bacid%252Bconjugate%252Bwith%252BVorinostat%252Bdegrades%252BHDAC3%252Band%252BHDAC6%252Bwith%252Bimproved%252Bantitumor%252Beffects%26aulast%3DHuang%26aufirst%3DMin%26date%3D2020%26volume%3D188%26spage%3D111991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sida  Shen</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (2)
                                     , 121-136. <a href="https://doi.org/10.1080/13543776.2019.1708901" title="DOI URL">https://doi.org/10.1080/13543776.2019.1708901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252Bhistone%252Bdeacetylase%252B6%252Binhibitors%252Bin%252Bneurodegenerative%252Bdiseases%252B%2525282014-2019%252529%26aulast%3DShen%26aufirst%3DSida%26date%3D2020%26date%3D2019%26volume%3D30%26issue%3D2%26spage%3D121%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hélène  Losson</span>, <span class="hlFld-ContribAuthor ">Michael  Schnekenburger</span>, <span class="hlFld-ContribAuthor ">Mario  Dicato</span>, <span class="hlFld-ContribAuthor ">Marc  Diederich</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (2)
                                     , 318. <a href="https://doi.org/10.3390/cancers12020318" title="DOI URL">https://doi.org/10.3390/cancers12020318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12020318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12020318%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DHDAC6%2525E2%252580%252594An%252BEmerging%252BTarget%252BAgainst%252BChronic%252BMyeloid%252BLeukemia%25253F%26aulast%3DLosson%26aufirst%3DH%25C3%25A9l%25C3%25A8ne%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D2%26spage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of recent published HDAC6 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of isoxazole-3-hydroxamate HDAC inhibitors <b>1a–d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route to Compounds <b>7a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Phthalimide, Ph<sub>3</sub>P, DEAD, tetrahydrofuran (THF), 0 °C to rt, yield: 93%; (b) hydrazine monohydrate, MeOH, rt; (c) ArCOCl, TEA, dichloromethane (DCM), 0 °C, yields: 52–90% over two steps; (d) ethyl 2-chloro-2-(hydroxyimino)acetate, NaHCO<sub>3</sub>, EtOAc, 100 °C (MW), yields: 49–78%; (e) NH<sub>2</sub>OH (aq, 50%), NaOH, THF/MeOH (1:1), 0 °C to rt, yields: 10–43%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes to Compounds <b>11a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Ethyl 2-chloro-2-(hydroxyimino)acetate, NaHCO<sub>3</sub>, EtOAc, 100 °C (MW), yields: 67–87%; (b) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, rt, yield: 89%; (c) 5,6-dichloro-1<i>H</i>-indole, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 80%; (d) NH<sub>2</sub>OH (aq, 50%), NaOH, THF/MeOH (1:1), 0 °C to rt, yields: 34–94%; (e) PCC, DCM, rt, yield: 88%; (f) 3-chloropropanoyl chloride, acetone, reflux, yield: 54%; (g) (i) AlCl<sub>3</sub>, 140 °C (neat), (ii) LiAlH<sub>4</sub>, THF, 0 °C to reflux, yield: 70% over two steps; (h) <b>9b</b>, NaBH(OAc)<sub>3</sub>, AcOH/EtOH, rt, yields: 42–58%; (i) 3,3-dimethylacryloyl chloride, CHCl<sub>3</sub>, reflux, yield: 48%; (j) (i) AlCl<sub>3</sub>, toluene, 80 °C, (ii) LiAlH<sub>4</sub>, THF, 0 °C to reflux, yield: 55% over two steps; (k) NCS, silica gel, CHCl<sub>3</sub>, rt, yield: 74%; (l) 1,4-dibromobutane, NaH, DMF, rt, yield: 43%; (m) sodium acetylide, xylene/DMF, 40 °C, yield: 25%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes to Compounds <b>20a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) ethyl 2-chloro-2-(hydroxyimino)acetate, NaHCO<sub>3</sub>, EtOAc, 100 °C (MW), yields: 58–96%; (b) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, rt, yield: 83%; (c) 3,4-dichlorophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, yield: 80%; (d) NH<sub>2</sub>OH (aq, 50%), NaOH, THF/MeOH (1:1), 0 °C to rt, yields: 30–40%; for <b>20c</b>, yield: 22% over three steps; (e) (i) LiAlH<sub>4</sub>, THF, 0 °C to reflux, (ii) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, 0 °C to rt, yield: 11% over two steps; (f) NaCN, dimethyl sulfoxide (DMSO), 100 °C, yield: 72%; (g) (i) aq NaOH, EtOH, reflux, (ii) BH<sub>3</sub>-THF, THF, 0 °C to rt, yield: 88% over two steps; (h) (i) CBr<sub>4</sub>, Ph<sub>3</sub>P, DCM, rt, (ii) sodium acetylide, DMF, 40 °C, yield: 39% over two steps; (i) NH<sub>2</sub>OH·HCl, K<sub>2</sub>CO<sub>3</sub>, Cu(OAc)<sub>2</sub>, H<sub>2</sub>O, reflux; (j) TFA, Et<sub>3</sub>SiH, methyl 4-formylbenzoate, toluene, reflux.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structure of the drHDAC6-CD2/SS-208 complex. (A) Detailed view of the substrate tunnel of HDAC6 in the complex with SS-208. <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> maps (green mesh) for SS-208 are contoured at 4.0 σ and the inhibitor and selected HDAC6 residues are shown in stick representation with atoms colored grey (carbon), red (oxygen), blue (nitrogen), and green (chlorine). The active-site zinc ion and water molecules are shown as orange and red spheres, respectively. H-bonds and salt bridges are shown as dashed lines. (B) Interactions between the capping dichlorophenyl moiety and the “L1-loop pocket” formed by side chains of H463, P464, F583, and L712 (colored blue). The surface of HDAC6 is shown in a semitransparent surface representation. (C) Superposition of SS-208 and DDK-115 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DVL">6DVL</a>) in the substrate tunnel of HDAC6. Carbon atoms are colored green and pink for SS-208 and DDK-115, respectively. The active-site zinc ion is coordinated in a bidentate fashion by SS-208, while the monodentate coordination is observed for DDK-115, resulting in a 0.5 Å shift of the SS-208 ring closer toward the zinc ion.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SS-208 selectively inhibits HDAC6-CD2 in cells. The HDAC1 and HDAC6 (catalytic domain 2) NanoBRET target engagement assay for compound SS-208 in HEK293. IC<sub>50</sub> values are the mean of four technical replicates ± SD obtained from curve-fitting of a 12-point engagement assay starting from a concentration of 20 μM with 3-fold serial dilution. SAHA was used as a positive control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. SS-208 activity is similar to other selective HDAC6is in cancer cells in vitro. (A) SS-208 treatment of SM1 murine melanoma cells resulted in increased Ac-α-Tubulin similar to other HDAC6is NextA and TubA. (B) Activity of HDAC6 inhibition with SS-208 was dose-dependent as indicated by the Western-blot analysis of Ac-α-Tubulin in WM164 human melanoma cells. (C) SM1 melanoma cells were treated with SS-208, NextA, or LBH589 for 24 h. The levels of Ac-H3 were evaluated by the Western-blot analysis. (D) SS-208, NextA, and TubA exhibited a similar inhibition of deacetylase activity when tested in a panel of cell lines of various tissue origins. (E) Similarly, HDAC6is did not induce cell death across the range of concentrations tested. (F) Multiplexed assay indicated that pan-HDACi, LBH589 exhibited apoptosis and cytotoxicity at concentrations as low as 100 nM, while the HDAC6is tested did not affect cell viability up to 10 μM. HDAC6is also did not induce apoptosis and cytotoxicity compared to LBH589.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Immunomodulatory role of SS-208 by decreasing the expression of PD-L1 in melanoma cells. (A) SM1 murine melanoma cells were pre-treated with 5 μM of SS-208 followed by IL-6 treatment overnight and effectively reduced the expression of immunosuppressive molecule PD-L1 at the protein level. (B) SS-208 decreased IL-6 mediated STAT3 activation measured as Y705 phosphorylation and subsequently PD-L1 gene expression measured by qRT-PCR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/medium/jm9b00946_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo antitumor activity of SS-208 is mediated through the modulation of TME. (A) SS-208 treatment (25 mg/kg, ip) significantly decreased the tumor growth compared to the control group in the SM1 murine melanoma syngeneic model. (B) Tumor growth curves of individual animals in control and SS-208 treatment groups. Animals receiving SS-208 treatment consistently showed a lower tumor volume during the course of the study compared to control groups. The decrease in tumor volume in the SS-208 treatment group was associated with the infiltration of intratumoral CD8+ T-cells (C), CD4+ T-cells (D), and a significant increase in NKT-cells (E). SS-208 treatment was associated with a significant increase in antitumor M1 macrophages (F), M2 macrophages (G), and the ratio of M1/M2 (H) which is an indication of effective antitumor immunity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00946/20190920/images/large/jm9b00946_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00946&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 101 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfinos, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oratz, R.</span></span> <span> </span><span class="NLM_article-title">A comparison of survival rates for treatment of melanoma metastatic to the brain</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1081/cnv-200026387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1081%2Fcnv-200026387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15565805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD2crpt1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=492-497&author=A.+Stoneauthor=J.+Cooperauthor=K.+L.+Koenigauthor=J.+G.+Golfinosauthor=R.+Oratz&title=A+comparison+of+survival+rates+for+treatment+of+melanoma+metastatic+to+the+brain&doi=10.1081%2Fcnv-200026387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of survival rates for treatment of melanoma metastatic to the brain</span></div><div class="casAuthors">Stone Anne; Cooper Jay; Koenig Karen L; Golfinos John G; Oratz Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Cancer investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">492-7</span>
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    </div><div class="casAbstract">INTRODUCTION:  A retrospective review of 91 patients with brain metastases from malignant melanoma treated at New York University Medical Center between 1989-1999.  Overall survival was the outcome evaluated.  METHODS:  Charts of 91 patients having malignant melanoma with brain metastases were reviewed.  Cases were stratified according to therapy: surgical excision, surgical excision plus whole brain radiation therapy, gamma knife stereotactic radiosurgery, gamma knife stereotactic radiosurgery plus whole brain radiation therapy, and whole brain radiation therapy alone.  Patients treated with gamma knife stereotactic radiosurgery plus radiation therapy were combined with patients treated with surgical excision plus radiation therapy and compared to those treated with radiation therapy alone.  Prognostic characteristics of the two groups were compared and survival curves were generated using the Kaplan-Meier method.  The Cox proportional hazards model was used to control for prognostic factors that differed between the groups.  RESULTS:  Patients treated with gamma knife stereotactic radiosurgery or surgical excision plus radiation therapy were younger, less likely to present with symptoms, and presented with fewer metastases to the brain than patients treated with radiation therapy alone.  A survival benefit of 7.3 months (p = 0.05) was found to be associated with gamma knife radiosurgery or surgical excision plus radiation therapy over radiation therapy alone after controlling for differences in age, number of brain lesions, and presence of symptoms.  DISCUSSION:  This retrospective study of 91 patients treated for melanoma metastases to the brain attempts to examine the effectiveness of different treatments in prolonging survival.  Our results suggest that surgical excision or stereotactic radiosurgery with gamma knife in addition to radiation therapy may be more effective than radiation alone at prolonging survival for patients with a limited number of brain lesions.  CONCLUSION:  Survival of patients with melanoma metastases to the brain may be prolonged by treatment with gamma knife stereotactic radiosurgery or surgical excision plus whole brain radiation therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxg-QgcqARse_Q9URG6Dx8fW6udTcc2eY76MQu2GIUDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpt1Cgsg%253D%253D&md5=139a7351d4c7ca2ce4308c23d424e7d4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1081%2Fcnv-200026387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252Fcnv-200026387%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DJ.%26aulast%3DKoenig%26aufirst%3DK.%2BL.%26aulast%3DGolfinos%26aufirst%3DJ.%2BG.%26aulast%3DOratz%26aufirst%3DR.%26atitle%3DA%2520comparison%2520of%2520survival%2520rates%2520for%2520treatment%2520of%2520melanoma%2520metastatic%2520to%2520the%2520brain%26jtitle%3DCancer%2520Invest.%26date%3D2004%26volume%3D22%26spage%3D492%26epage%3D497%26doi%3D10.1081%2Fcnv-200026387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, E. P.</span></span> <span> </span><span class="NLM_article-title">Management of cutaneous melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">2770</span>– <span class="NLM_lpage">2771</span>, <span class="refDoi"> DOI: 10.1056/nejm200412233512620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejm200412233512620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15619744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD2cnktFemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=2770-2771&author=E.+P.+Miranda&title=Management+of+cutaneous+melanoma&doi=10.1056%2Fnejm200412233512620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Management of cutaneous melanoma</span></div><div class="casAuthors">Miranda Edward P</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2770-1; author reply 2770-1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCLjbo6IonL_6xYuD7tu2XfW6udTcc2eaBJd-vZVawQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cnktFemsA%253D%253D&md5=d9bf7b30515be1642c0916cbfb167394</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2Fnejm200412233512620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejm200412233512620%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DE.%2BP.%26atitle%3DManagement%2520of%2520cutaneous%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D2770%26epage%3D2771%26doi%3D10.1056%2Fnejm200412233512620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Targeted agents and immunotherapies: optimizing outcomes in melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnrclinonc.2017.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28374786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFSisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=463-482&author=J.+J.+Lukeauthor=K.+T.+Flahertyauthor=A.+Ribasauthor=G.+V.+Long&title=Targeted+agents+and+immunotherapies%3A+optimizing+outcomes+in+melanoma&doi=10.1038%2Fnrclinonc.2017.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted agents and immunotherapies: optimizing outcomes in melanoma</span></div><div class="casAuthors">Luke, Jason J.; Flaherty, Keith T.; Ribas, Antoni; Long, Georgina V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">463-482</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Treatment options for patients with metastatic melanoma, and esp. BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents.  During this period, the treatment paradigm for BRAF-mutant disease has evolved rapidly: the std.-of-care BRAF-targeted approach has shifted from single-agent BRAF inhibition to combination therapy with a BRAF and a MEK inhibitor.  Concurrently, immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic T-lymphocyte-assocd. antigen-4 (CTLA-4) and, now, the programmed cell-death protein 1 (PD-1) immune checkpoints.  These changes in the treatment landscape have dramatically improved patient outcomes, with the median overall survival of patients with advanced-stage melanoma increasing from approx. 9 mo before 2011 to at least 2 years - and probably longer for those with BRAF-V600-mutant disease.  Herein, we review the clin. trial data that established the std.-of-care treatment approaches for advanced-stage melanoma.  Mechanisms of resistance and biomarkers of response to BRAF-targeted treatments and immunotherapies are discussed, and the contrasting clin. benefits and limitations of these therapies are explored.  We summarize the state of the field and outline a rational approach to frontline-treatment selection for each individual patient with BRAF-mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CKP8dyLWfbVg90H21EOLACvtfcHk0lj4X1JPqvoOcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFSisr8%253D&md5=a1811bd4b82d81e7210c2f7f29086c84</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.43%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DTargeted%2520agents%2520and%2520immunotherapies%253A%2520optimizing%2520outcomes%2520in%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D463%26epage%3D482%26doi%3D10.1038%2Fnrclinonc.2017.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livingstone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaubel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management</span>. <i>Chin. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2304-3865.2014.03.03</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.3978%2Fj.issn.2304-3865.2014.03.03" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25841455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjht1Sqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=29&author=E.+Livingstoneauthor=L.+Zimmerauthor=J.+Vaubelauthor=D.+Schadendorf&title=BRAF%2C+MEK+and+KIT+inhibitors+for+melanoma%3A+adverse+events+and+their+management&doi=10.3978%2Fj.issn.2304-3865.2014.03.03"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management</span></div><div class="casAuthors">Livingstone Elisabeth; Zimmer Lisa; Vaubel Julia; Schadendorf Dirk</div><div class="citationInfo"><span class="NLM_cas:title">Chinese clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The introduction of tyrosine kinase inhibitors for the treatment of malignant melanoma has led to unprecedented response rates with superior overall survival rates in patients with targetable kinase mutations.  Even though targeted, the effects of these new therapies are not limited to the cancer cells and induce a wide array of different adverse events (AEs).  Most toxicities are mild to moderate in severity and often only affect the skin, but quality of life of patients is still affected.  To prevent dose reduction and/or interruption, a sound knowledge of potential AEs and their management is required.  BRAF inhibitors should not be used in patients with known RAS-mutant tumour in the medical history.  We review common AEs of BRAF, MEK and KIT inhibitors used for the treatment of malignant melanoma and their management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjs4F7oPLiz0kUaC_kzhvyfW6udTcc2eaBJd-vZVawQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjht1Sqtg%253D%253D&md5=148b30da11eedc55a9e251835ce2afc3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2304-3865.2014.03.03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2304-3865.2014.03.03%26sid%3Dliteratum%253Aachs%26aulast%3DLivingstone%26aufirst%3DE.%26aulast%3DZimmer%26aufirst%3DL.%26aulast%3DVaubel%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DBRAF%252C%2520MEK%2520and%2520KIT%2520inhibitors%2520for%2520melanoma%253A%2520adverse%2520events%2520and%2520their%2520management%26jtitle%3DChin.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D3%26spage%3D29%26doi%3D10.3978%2Fj.issn.2304-3865.2014.03.03" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waterhouse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahinian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griesser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1126/science.270.5238.985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1126%2Fscience.270.5238.985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=7481803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADyaK2MXptlOlurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=985-988&author=P.+Waterhouseauthor=J.+M.+Penningerauthor=E.+Timmsauthor=A.+Wakehamauthor=A.+Shahinianauthor=K.+P.+Leeauthor=C.+B.+Thompsonauthor=H.+Griesserauthor=T.+W.+Mak&title=Lymphoproliferative+disorders+with+early+lethality+in+mice+deficient+in+Ctla-4&doi=10.1126%2Fscience.270.5238.985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4</span></div><div class="casAuthors">Waterhouse, Paul; Penninger, Josef M.; Timms, Emma; Wakeham, Andrew; Shahinian, Arda; Lee, Kelvin P.; Thompson, Craig B.; Griesser, Henrik; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5238</span>),
    <span class="NLM_cas:pages">985-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The role of the cell-surface mol. CTLA-4 in the regulation of T cell activation has been controversial.  Here, lymph nodes and spleens of CTLA-4-deficient mice accumulated T cell blasts with up-regulated activation markers.  These blast cells also infiltrated liver, heart, lung, and pancreas tissue, and amts. of serum Ig were elevated.  The mice invariably became moribund by 3 to 4 wk of age.  Although CTLA-4-deficient T cells proliferated spontaneously and strongly when stimulated through the T cell receptor, they were sensitive to cell death induced by crosslinking of the Fas receptor and by gamma irradn.  Thus, CTLA-4 acts as a neg. regulator of T cell activation and is vital for the control of lymphocyte homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrORE4YgijCTrVg90H21EOLACvtfcHk0lj4X1JPqvoOcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptlOlurk%253D&md5=f2837d566cedd0c1cd071e423f16cf0e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5238.985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5238.985%26sid%3Dliteratum%253Aachs%26aulast%3DWaterhouse%26aufirst%3DP.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DTimms%26aufirst%3DE.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DShahinian%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BP.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26aulast%3DGriesser%26aufirst%3DH.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DLymphoproliferative%2520disorders%2520with%2520early%2520lethality%2520in%2520mice%2520deficient%2520in%2520Ctla-4%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D985%26epage%3D988%26doi%3D10.1126%2Fscience.270.5238.985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polkowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekk-Cierniakowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czepielewska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozłowska-Wojciechowska, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1007/s00228-018-2590-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1007%2Fs00228-018-2590-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=30386910" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2018&pages=329-334&author=M.+Polkowskaauthor=P.+Ekk-Cierniakowskiauthor=E.+Czepielewskaauthor=M.+Koz%C5%82owska-Wojciechowska&title=Efficacy+and+safety+of+BRAF+inhibitors+and+anti-CTLA4+antibody+in+melanoma+patients-real-world+data&doi=10.1007%2Fs00228-018-2590-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs00228-018-2590-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-018-2590-6%26sid%3Dliteratum%253Aachs%26aulast%3DPolkowska%26aufirst%3DM.%26aulast%3DEkk-Cierniakowski%26aufirst%3DP.%26aulast%3DCzepielewska%26aufirst%3DE.%26aulast%3DKoz%25C5%2582owska-Wojciechowska%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520BRAF%2520inhibitors%2520and%2520anti-CTLA4%2520antibody%2520in%2520melanoma%2520patients-real-world%2520data%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D75%26spage%3D329%26epage%3D334%26doi%3D10.1007%2Fs00228-018-2590-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus Ipilimumab in Advanced Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2521</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1503093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejmoa1503093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25891173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2521-2532&author=C.+Robertauthor=J.+Schachterauthor=G.+V.+Longauthor=A.+Aranceauthor=J.+J.+Grobauthor=L.+Mortierauthor=A.+Daudauthor=M.+S.+Carlinoauthor=C.+McNeilauthor=M.+Lotemauthor=J.+Larkinauthor=P.+Loriganauthor=B.+Neynsauthor=C.+U.+Blankauthor=O.+Hamidauthor=C.+Mateusauthor=R.+Shapira-Frommerauthor=M.+Koshauthor=H.+Zhouauthor=N.+Ibrahimauthor=S.+Ebbinghausauthor=A.+Ribas&title=Pembrolizumab+versus+Ipilimumab+in+Advanced+Melanoma&doi=10.1056%2Fnejmoa1503093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus ipilimumab in advanced melanoma</span></div><div class="casAuthors">Robert, Caroline; Schachter, Jacob; Long, Georgina V.; Arance, Ana; Grob, Jean Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S.; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian U.; Hamid, Omid; Mateus, Christine; Shapira-Frommer, Ronnie; Kosh, Michele; Zhou, Honghong; Ibrahim, Nageatte; Ebbinghaus, Scot; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2521-2532</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The immune checkpoint inhibitor ipilimumab is the std.-of-care treatment for patients with advanced melanoma.  Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.  Methods In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kg of body wt.) every 2 wk or every 3 wk or four doses of ipilimumab (at 3 mg per kg) every 3 wk.  Primary end points were progression-free and overall survival. results The estd. 6-mo progression-free-survival rates were 47.3% for pembrolizumab every 2 wk, 46.4% for pembrolizumab every 3 wk, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens vs. ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, resp.).  Estd. 12-mo survival rates were 74.1%, 68.4%, and 58.2%, resp. (hazard ratio for death for pembrolizumab every 2 wk, 0.63; 95% CI, 0.47 to 0.83; P = 0.0005; hazard ratio for pembrolizumab every 3 wk, 0.69; 95% CI, 0.52 to 0.90; P = 0.0036).  The response rate was improved with pembrolizumab administered every 2 wk (33.7%) and every 3 wk (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons).  Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, resp., after a median follow-up of 7.9 mo.  Efficacy was similar in the two pembrolizumab groups.  Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%).  Conclusions The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKg2FC7SX5rVg90H21EOLACvtfcHk0ligFsVxeIBAVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF&md5=b37f62f7aefe7d8948ff06babb9b711e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1503093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1503093%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DMcNeil%26aufirst%3DC.%26aulast%3DLotem%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DNeyns%26aufirst%3DB.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DKosh%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DEbbinghaus%26aufirst%3DS.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPembrolizumab%2520versus%2520Ipilimumab%2520in%2520Advanced%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2521%26epage%3D2532%26doi%3D10.1056%2Fnejmoa1503093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Vecchio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Rodas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queirolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pril, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabater, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qureshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span> <span> </span><span class="NLM_article-title">Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1824</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1709030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejmoa1709030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28891423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWku7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1824-1835&author=J.+Weberauthor=M.+Mandalaauthor=M.+Del+Vecchioauthor=H.+J.+Gogasauthor=A.+M.+Aranceauthor=C.+L.+Coweyauthor=S.+Dalleauthor=M.+Schenkerauthor=V.+Chiarion-Sileniauthor=I.+Marquez-Rodasauthor=J.-J.+Grobauthor=M.+O.+Butlerauthor=M.+R.+Middletonauthor=M.+Maioauthor=V.+Atkinsonauthor=P.+Queiroloauthor=R.+Gonzalezauthor=R.+R.+Kudchadkarauthor=M.+Smylieauthor=N.+Meyerauthor=L.+Mortierauthor=M.+B.+Atkinsauthor=G.+V.+Longauthor=S.+Bhatiaauthor=C.+Lebb%C3%A9author=P.+Rutkowskiauthor=K.+Yokotaauthor=N.+Yamazakiauthor=T.+M.+Kimauthor=V.+de+Prilauthor=J.+Sabaterauthor=A.+Qureshiauthor=J.+Larkinauthor=P.+A.+Ascierto&title=Adjuvant+Nivolumab+versus+Ipilimumab+in+Resected+Stage+III+or+IV+Melanoma&doi=10.1056%2Fnejmoa1709030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma</span></div><div class="casAuthors">Weber, J.; Mandala, M.; Del Vecchio, M.; Gogas, H. J.; Arance, A. M.; Cowey, C. L.; Dalle, S.; Schenker, M.; Chiarion-Sileni, V.; Marquez-Rodas, I.; Grob, J.-J.; Butler, M. O.; Middleton, M. R.; Maio, M.; Atkinson, V.; Queirolo, P.; Gonzalez, R.; Kudchadkar, R. R.; Smylie, M.; Meyer, N.; Mortier, L.; Atkins, M. B.; Long, G. V.; Bhatia, S.; Lebbe, C.; Rutkowski, P.; Yokota, K.; Yamazaki, N.; Kim, T. M.; de Pril, V.; Sabater, J.; Qureshi, A.; Larkin, J.; Ascierto, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1824-1835</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma.  In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial.  We wanted to det. the efficacy of nivolumab vs. ipilimumab for adjuvant therapy in patients with resected advanced melanoma. methods In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an i.v. infusion of either nivolumab at a dose of 3 mg per kg of body wt. every 2 wk (453 patients) or ipilimumab at a dose of 10 mg per kg every 3 wk for four doses and then every 12 wk (453 patients).  The patients were treated for a period of up to 1 yr or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent.  The primary end point was recurrence-free survival in the intention-to-treat population. results At a min. follow-up of 18 mo, the 12-mo rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001).  Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, resp.  Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. conclusions Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN1wxJv5dbtrVg90H21EOLACvtfcHk0ligFsVxeIBAVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWku7jJ&md5=bd303be4878e58315a006ee879920840</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1709030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1709030%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDel%2BVecchio%26aufirst%3DM.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26aulast%3DArance%26aufirst%3DA.%2BM.%26aulast%3DCowey%26aufirst%3DC.%2BL.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DSchenker%26aufirst%3DM.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMarquez-Rodas%26aufirst%3DI.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DButler%26aufirst%3DM.%2BO.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DQueirolo%26aufirst%3DP.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DLebb%25C3%25A9%26aufirst%3DC.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DYokota%26aufirst%3DK.%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3Dde%2BPril%26aufirst%3DV.%26aulast%3DSabater%26aufirst%3DJ.%26aulast%3DQureshi%26aufirst%3DA.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26atitle%3DAdjuvant%2520Nivolumab%2520versus%2520Ipilimumab%2520in%2520Resected%2520Stage%2520III%2520or%2520IV%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1824%26epage%3D1835%26doi%3D10.1056%2Fnejmoa1709030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrucci, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechter, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Rodas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidoboni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1709684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1056%2Fnejmoa1709684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28889792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1345-1356&author=J.+D.+Wolchokauthor=V.+Chiarion-Sileniauthor=R.+Gonzalezauthor=P.+Rutkowskiauthor=J.-J.+Grobauthor=C.+L.+Coweyauthor=C.+D.+Laoauthor=J.+Wagstaffauthor=D.+Schadendorfauthor=P.+F.+Ferrucciauthor=M.+Smylieauthor=R.+Dummerauthor=A.+Hillauthor=D.+Hoggauthor=J.+Haanenauthor=M.+S.+Carlinoauthor=O.+Bechterauthor=M.+Maioauthor=I.+Marquez-Rodasauthor=M.+Guidoboniauthor=G.+McArthurauthor=C.+Lebb%C3%A9author=P.+A.+Asciertoauthor=G.+V.+Longauthor=J.+Cebonauthor=J.+Sosmanauthor=M.+A.+Postowauthor=M.+K.+Callahanauthor=D.+Walkerauthor=L.+Rollinauthor=R.+Bhoreauthor=F.+S.+Hodiauthor=J.+Larkin&title=Overall+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma&doi=10.1056%2Fnejmoa1709684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span></div><div class="casAuthors">Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.-J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; Dummer, R.; Hill, A.; Hogg, D.; Haanen, J.; Carlino, M. S.; Bechter, O.; Maio, M.; Marquez-Rodas, I.; Guidoboni, M.; McArthur, G.; Lebbe, C.; Ascierto, P. A.; Long, G. V.; Cebon, J.; Sosman, J.; Postow, M. A.; Callahan, M. K.; Walker, D.; Rollin, L.; Bhore, R.; Hodi, F. S.; Larkin, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.  We now report 3-yr overall survival outcomes in this trial. methods We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kg of body wt. plus ipilimumab at a dose of 3 mg per kg every 3 wk for four doses, followed by nivolumab at a dose of 3 mg per kg every 2 wk; nivolumab at a dose of 3 mg per kg every 2 wk plus placebo; or ipilimumab at a dose of 3 mg per kg every 3 wk for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent.  Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.  The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group vs. the ipilimumab group. results At a min. follow-up of 36 mo, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 mo in the nivolumab group, as compared with 19.9 mo in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]).  The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group.  The safety profile was unchanged from the initial report.  Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. conclusions Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY91ga-k7LxbVg90H21EOLACvtfcHk0lhOBGJFYJ4WFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I&md5=bf5e5c47178631cd4485cf79dca12dd8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2Fnejmoa1709684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmoa1709684%26sid%3Dliteratum%253Aachs%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGrob%26aufirst%3DJ.-J.%26aulast%3DCowey%26aufirst%3DC.%2BL.%26aulast%3DLao%26aufirst%3DC.%2BD.%26aulast%3DWagstaff%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DFerrucci%26aufirst%3DP.%2BF.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DA.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DBechter%26aufirst%3DO.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMarquez-Rodas%26aufirst%3DI.%26aulast%3DGuidoboni%26aufirst%3DM.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DLebb%25C3%25A9%26aufirst%3DC.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DRollin%26aufirst%3DL.%26aulast%3DBhore%26aufirst%3DR.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DOverall%2520survival%2520with%2520combined%2520nivolumab%2520and%2520ipilimumab%2520in%2520advanced%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2Fnejmoa1709684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan
Coyne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulley, J. L.</span></span> <span> </span><span class="NLM_article-title">Nivolumab: promising survival signal coupled with limited toxicity raises expectations</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.54.5996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1200%2Fjco.2013.54.5996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=24590655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpvFOktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=986-988&author=G.+O%E2%80%99Sullivan%0ACoyneauthor=R.+A.+Madanauthor=J.+L.+Gulley&title=Nivolumab%3A+promising+survival+signal+coupled+with+limited+toxicity+raises+expectations&doi=10.1200%2Fjco.2013.54.5996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab: promising survival signal coupled with limited toxicity raises expectations</span></div><div class="casAuthors">O'Sullivan Coyne Geraldine; Madan Ravi A; Gulley James L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">986-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQw-fcUUfl7lhBrI9DTGjC0fW6udTcc2eY5ctPkx2yLTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpvFOktA%253D%253D&md5=17c646c9a4176eb344ecc549a2a6687f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2Fjco.2013.54.5996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2013.54.5996%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%2BCoyne%26aufirst%3DG.%26aulast%3DMadan%26aufirst%3DR.%2BA.%26aulast%3DGulley%26aufirst%3DJ.%2BL.%26atitle%3DNivolumab%253A%2520promising%2520survival%2520signal%2520coupled%2520with%2520limited%2520toxicity%2520raises%2520expectations%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D986%26epage%3D988%26doi%3D10.1200%2Fjco.2013.54.5996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?</span>. <i>Genome Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13073-016-0365-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs13073-016-0365-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27782862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=111&author=J.+S.+O%E2%80%99Donnellauthor=M.+J.+Smythauthor=M.+W.+Teng&title=Acquired+resistance+to+anti-PD1+therapy%3A+checkmate+to+checkpoint+blockade%3F&doi=10.1186%2Fs13073-016-0365-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?</span></div><div class="casAuthors">O'Donnell, Jake S.; Smyth, Mark J.; Teng, Michele W. L.</div><div class="citationInfo"><span class="NLM_cas:title">Genome Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/3</span>CODEN:
                <span class="NLM_cas:coden">GMEECG</span>;
        ISSN:<span class="NLM_cas:issn">1756-994X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large no. of patients present with or develop resistance to them.  Unfortunately, very little is known regarding the mechanisms of resistance to such therapies.  A recent study sought to identify mutations assocd. with resistance to anti-PD1 therapy.  Results from this study demonstrated that mutations which affected the sensitivity of tumor cells to T-cell-derived interferons, and mutations limiting tumor-cell antigen presentation, could cause acquired resistance.  These findings have significant implications for understanding the mechanisms by which anti-PD1 therapies exert their efficacy, comprehending why and how some patients acquire resistance over time, and ultimately guiding the development of combination therapies designed to overcome, or potentially prevent, the development of acquired immunotherapeutic resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsMmJtpOsIe7Vg90H21EOLACvtfcHk0ljh-UIGMz4LEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOkt7Y%253D&md5=c099718cdb766f6143f0e0fb0061ce11</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs13073-016-0365-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13073-016-0365-1%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BS.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26atitle%3DAcquired%2520resistance%2520to%2520anti-PD1%2520therapy%253A%2520checkmate%2520to%2520checkpoint%2520blockade%253F%26jtitle%3DGenome%2520Med.%26date%3D2016%26volume%3D8%26spage%3D111%26doi%3D10.1186%2Fs13073-016-0365-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gide, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilmott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolyer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-17-2267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F1078-0432.ccr-17-2267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29127120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1ymu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=1260-1270&author=T.+N.+Gideauthor=J.+S.+Wilmottauthor=R.+A.+Scolyerauthor=G.+V.+Long&title=Primary+and+acquired+resistance+to+immune+checkpoint+inhibitors+in+metastatic+melanoma&doi=10.1158%2F1078-0432.ccr-17-2267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma</span></div><div class="casAuthors">Gide, Tuba N.; Wilmott, James S.; Scolyer, Richard A.; Long, Georgina V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1260-1270</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-stage metastatic melanoma, as well as patients with many other solid cancers, yielding long-lasting responses and improved survival.  However, a subset of patients who initially respond to immunotherapy, later relapse and develop therapy resistance (termed "acquired resistance"), whereas others do not respond at all (termed "primary resistance").  Primary and acquired resistance are key clin. barriers to further improving outcomes of patients with metastatic melanoma, and the known mechanisms underlying each involves various components of the cancer immune cycle, and interactions between multiple signaling mols. and pathways.  Due to this complexity, current knowledge on resistance mechanisms is still incomplete.  Overcoming therapy resistance requires a thorough understanding of the mechanisms underlying immune evasion by tumors.  In this review, we explore the mechanisms of primary and acquired resistance to immunotherapy in melanoma and detail potential therapeutic strategies to prevent and overcome them.  Clin Cancer Res; 24(6); 1260-70. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0AuajvHeorVg90H21EOLACvtfcHk0ljh-UIGMz4LEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1ymu7k%253D&md5=52f94231395bc6d0beff0c5b9200ad54</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-17-2267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-17-2267%26sid%3Dliteratum%253Aachs%26aulast%3DGide%26aufirst%3DT.%2BN.%26aulast%3DWilmott%26aufirst%3DJ.%2BS.%26aulast%3DScolyer%26aufirst%3DR.%2BA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DPrimary%2520and%2520acquired%2520resistance%2520to%2520immune%2520checkpoint%2520inhibitors%2520in%2520metastatic%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D1260%26epage%3D1270%26doi%3D10.1158%2F1078-0432.ccr-17-2267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coussens, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span> <span> </span><span class="NLM_article-title">Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies</span>. <i>Am. Soc. Clin. Oncol. Educ. Book</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1200/edbk_237987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1200%2Fedbk_237987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=31099649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BB3M7mvVCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=165-174&author=M.+Dattaauthor=L.+M.+Coussensauthor=H.+Nishikawaauthor=F.+S.+Hodiauthor=R.+K.+Jain&title=Reprogramming+the+tumor+microenvironment+to+improve+immunotherapy%3A+emerging+strategies+and+combination+therapies&doi=10.1200%2Fedbk_237987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies</span></div><div class="casAuthors">Datta Meenal; Jain Rakesh K; Coussens Lisa M; Nishikawa Hiroyoshi; Hodi F Stephen</div><div class="citationInfo"><span class="NLM_cas:title">American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165-174</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Emerging immunotherapeutic approaches have revolutionized the treatment of multiple malignancies.  Immune checkpoint blockers (ICBs) have enabled never-before-seen success rates in durable tumor control and enhanced survival benefit in patients with advanced cancers.  However, this effect is not universal, resulting in responder and nonresponder populations not only between, but also within solid tumor types.  Although ICBs are thought to be most effective against tumors with more genetic mutations and higher antigen loads, this is not always the case for all cancers or for all patients within a cancer subtype.  Furthermore, debilitating and sometimes deadly immune-related adverse events (irAEs) have resulted from aberrant activation of T-cell responses following immunotherapy.  Thus, we must identify new ways to overcome resistance to ICB-based immunotherapies and limit irAEs.  In fact, preclinical and clinical data have identified abnormalities in the tumor microenvironment (TME) that can thwart the efficacy of immunotherapies such as ICBs.  Here, we will discuss how reprogramming various facets of the TME (blood vessels, myeloid cells, and regulatory T cells [Tregs]) may overcome TME-instigated resistance mechanisms to immunotherapy.  We will discuss clinical applications of this strategic approach, including the recent successful phase III trial combining bevacizumab with atezolizumab and chemotherapy for metastatic nonsquamous non-small cell lung cancer that led to rapid approval by the U.S.  Food and Drug Administration of this regimen for first-line treatment.  Given the accelerated testing and approval of ICBs combined with various targeted therapies in larger numbers of patients with cancer, we will discuss how these concepts and approaches can be incorporated into clinical practice to improve immunotherapy outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZnD5FVjfpNRKDYG3bNImrfW6udTcc2ebTYcJQvYwyF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7mvVCmtw%253D%253D&md5=ca372b1e6f25a8416345564772f0abe3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2Fedbk_237987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fedbk_237987%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DM.%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26aulast%3DNishikawa%26aufirst%3DH.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DReprogramming%2520the%2520tumor%2520microenvironment%2520to%2520improve%2520immunotherapy%253A%2520emerging%2520strategies%2520and%2520combination%2520therapies%26jtitle%3DAm.%2520Soc.%2520Clin.%2520Oncol.%2520Educ.%2520Book%26date%3D2019%26volume%3D39%26spage%3D165%26epage%3D174%26doi%3D10.1200%2Fedbk_237987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">Re-education of macrophages as a therapeutic strategy in cancer</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.2217/imt-2018-0156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.2217%2Fimt-2018-0156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=31088236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGnu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=677-689&author=J.+Kowalauthor=M.+Korneteauthor=J.+A.+Joyce&title=Re-education+of+macrophages+as+a+therapeutic+strategy+in+cancer&doi=10.2217%2Fimt-2018-0156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Re-education of macrophages as a therapeutic strategy in cancer</span></div><div class="casAuthors">Kowal, Joanna; Kornete, Mara; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Immunotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">677-689</span>CODEN:
                <span class="NLM_cas:coden">IMMUCO</span>;
        ISSN:<span class="NLM_cas:issn">1750-7448</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Tumor-assocd. macrophages (TAMs) can be educated within the tumor microenvironment to promote cancer development and progression.  While TAM-targeted agents have largely focused on macrophage depletion as an anticancer strategy, it is becoming increasingly evident that TAM re-education may represent a more effective approach.  In this perspective, we discuss different means to achieve TAM re-education, and review the beneficial effects of these strategies, particularly when combined with immune checkpoint inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8b0qb76nqB7Vg90H21EOLACvtfcHk0ljh-UIGMz4LEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGnu77E&md5=6048835e73f46a8adada57e09d9131e9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2217%2Fimt-2018-0156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2018-0156%26sid%3Dliteratum%253Aachs%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DKornete%26aufirst%3DM.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DRe-education%2520of%2520macrophages%2520as%2520a%2520therapeutic%2520strategy%2520in%2520cancer%26jtitle%3DImmunotherapy%26date%3D2019%26volume%3D11%26spage%3D677%26epage%3D689%26doi%3D10.2217%2Fimt-2018-0156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voorwerk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slagter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlings, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vijver, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Maaker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nederlof, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluin, R. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiersma, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, N. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketelaars, S. L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C. A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Werkhoven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Tinteren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandjes, I. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onderwater, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalabi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilgenhof, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Visser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonke, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, M.</span></span> <span> </span><span class="NLM_article-title">Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1038/s41591-019-0432-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fs41591-019-0432-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=31086347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=920-928&author=L.+Voorwerkauthor=M.+Slagterauthor=H.+M.+Horlingsauthor=K.+Sikorskaauthor=K.+K.+van+de+Vijverauthor=M.+de+Maakerauthor=I.+Nederlofauthor=R.+J.+C.+Kluinauthor=S.+Warrenauthor=S.+Ongauthor=T.+G.+Wiersmaauthor=N.+S.+Russellauthor=F.+Lalezariauthor=P.+C.+Schoutenauthor=N.+A.+M.+Bakkerauthor=S.+L.+C.+Ketelaarsauthor=D.+Petersauthor=C.+A.+H.+Langeauthor=E.+van+Werkhovenauthor=H.+van+Tinterenauthor=I.+A.+M.+Mandjesauthor=I.+Kemperauthor=S.+Onderwaterauthor=M.+Chalabiauthor=S.+Wilgenhofauthor=J.+B.+A.+G.+Haanenauthor=R.+Salgadoauthor=K.+E.+de+Visserauthor=G.+S.+Sonkeauthor=L.+F.+A.+Wesselsauthor=S.+C.+Linnauthor=T.+N.+Schumacherauthor=C.+U.+Blankauthor=M.+Kok&title=Immune+induction+strategies+in+metastatic+triple-negative+breast+cancer+to+enhance+the+sensitivity+to+PD-1+blockade%3A+the+TONIC+trial&doi=10.1038%2Fs41591-019-0432-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial</span></div><div class="casAuthors">Voorwerk, Leonie; Slagter, Maarten; Horlings, Hugo M.; Sikorska, Karolina; van de Vijver, Koen K.; de Maaker, Michiel; Nederlof, Iris; Kluin, Roelof J. C.; Warren, Sarah; Ong, SuFey; Wiersma, Terry G.; Russell, Nicola S.; Lalezari, Ferry; Schouten, Philip C.; Bakker, Noor A. M.; Ketelaars, Steven L. C.; Peters, Dennis; Lange, Charlotte A. H.; van Werkhoven, Erik; van Tinteren, Harm; Mandjes, Ingrid A. M.; Kemper, Inge; Onderwater, Suzanne; Chalabi, Myriam; Wilgenhof, Sofie; Haanen, John B. A. G.; Salgado, Roberto; de Visser, Karin E.; Sonke, Gabe S.; Wessels, Lodewyk F. A.; Linn, Sabine C.; Schumacher, Ton N.; Blank, Christian U.; Kok, Marleen</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">920-928</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-neg. breast cancer (TNBC) is low1-5, highlighting a need for strategies that render the tumor microenvironment more sensitive to PD-1 blockade.  Preclin. research has suggested immunomodulatory properties for chemotherapy and irradn.6-13.  In the first stage of this adaptive, non-comparative phase 2 trial, 67 patients with metastatic TNBC were randomized to nivolumab (1) without induction or with 2-wk low-dose induction, or with (2) irradn. (3 x 8 Gy), (3) cyclophosphamide, (4) cisplatin or (5) doxorubicin, all followed by nivolumab.  In the overall cohort, the objective response rate (ORR; iRECIST14) was 20%.  The majority of responses were obsd. in the cisplatin (ORR 23%) and doxorubicin (ORR 35%) cohorts.  After doxorubicin and cisplatin induction, we detected an upregulation of immune-related genes involved in PD-1-PD-L1 (programmed death ligand 1) and T cell cytotoxicity pathways.  This was further supported by enrichment among upregulated genes related to inflammation, JAK-STAT and TNF-α signaling after doxorubicin.  Together, the clin. and translational data of this study indicate that short-term doxorubicin and cisplatin may induce a more favorable tumor microenvironment and increase the likelihood of response to PD-1 blockade in TNBC.  These data warrant confirmation in TNBC and exploration of induction treatments prior to PD-1 blockade in other cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAB3hgaMeCUbVg90H21EOLACvtfcHk0li-U6htzT_lPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbrN&md5=43aa338a68b8efb399c983aab185e3f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41591-019-0432-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-019-0432-4%26sid%3Dliteratum%253Aachs%26aulast%3DVoorwerk%26aufirst%3DL.%26aulast%3DSlagter%26aufirst%3DM.%26aulast%3DHorlings%26aufirst%3DH.%2BM.%26aulast%3DSikorska%26aufirst%3DK.%26aulast%3Dvan%2Bde%2BVijver%26aufirst%3DK.%2BK.%26aulast%3Dde%2BMaaker%26aufirst%3DM.%26aulast%3DNederlof%26aufirst%3DI.%26aulast%3DKluin%26aufirst%3DR.%2BJ.%2BC.%26aulast%3DWarren%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DS.%26aulast%3DWiersma%26aufirst%3DT.%2BG.%26aulast%3DRussell%26aufirst%3DN.%2BS.%26aulast%3DLalezari%26aufirst%3DF.%26aulast%3DSchouten%26aufirst%3DP.%2BC.%26aulast%3DBakker%26aufirst%3DN.%2BA.%2BM.%26aulast%3DKetelaars%26aufirst%3DS.%2BL.%2BC.%26aulast%3DPeters%26aufirst%3DD.%26aulast%3DLange%26aufirst%3DC.%2BA.%2BH.%26aulast%3Dvan%2BWerkhoven%26aufirst%3DE.%26aulast%3Dvan%2BTinteren%26aufirst%3DH.%26aulast%3DMandjes%26aufirst%3DI.%2BA.%2BM.%26aulast%3DKemper%26aufirst%3DI.%26aulast%3DOnderwater%26aufirst%3DS.%26aulast%3DChalabi%26aufirst%3DM.%26aulast%3DWilgenhof%26aufirst%3DS.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%2BA.%2BG.%26aulast%3DSalgado%26aufirst%3DR.%26aulast%3Dde%2BVisser%26aufirst%3DK.%2BE.%26aulast%3DSonke%26aufirst%3DG.%2BS.%26aulast%3DWessels%26aufirst%3DL.%2BF.%2BA.%26aulast%3DLinn%26aufirst%3DS.%2BC.%26aulast%3DSchumacher%26aufirst%3DT.%2BN.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DKok%26aufirst%3DM.%26atitle%3DImmune%2520induction%2520strategies%2520in%2520metastatic%2520triple-negative%2520breast%2520cancer%2520to%2520enhance%2520the%2520sensitivity%2520to%2520PD-1%2520blockade%253A%2520the%2520TONIC%2520trial%26jtitle%3DNat.%2520Med.%26date%3D2019%26volume%3D25%26spage%3D920%26epage%3D928%26doi%3D10.1038%2Fs41591-019-0432-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyamfi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. S.</span></span> <span> </span><span class="NLM_article-title">The role of tumor-associated macrophage in breast cancer biology</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.14670/HH-11-916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.14670%2FHH-11-916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28681373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=133-145&author=J.+Choiauthor=J.+Gyamfiauthor=H.+Jangauthor=J.+S.+Koo&title=The+role+of+tumor-associated+macrophage+in+breast+cancer+biology&doi=10.14670%2FHH-11-916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The role of tumor-associated macrophage in breast cancer biology</span></div><div class="casAuthors">Choi, Junjeong; Gyamfi, Jones; Jang, Haerin; Koo, Ja Seung</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1,2,3</span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">University of Murcia</span>)
        </div><div class="casAbstract">A review.  Breast cancer is the most commonly diagnosed malignant tumor in women worldwide and contributes significantly as the primary cause of female cancer related mortality.  Hence, research is focused on discovering new and effective treatment targets.  The breast tumor microenvironment (TME) comprising of recruited host stromal cells and tumor cells, has recently emerged as an important player in tumor progression, with the potential for future treatment.  The TME comprises immune system elements (such as macrophages and lymphocytes), cells composing blood vessel, fibroblast, myofibroblast, mesenchymal stem cells, adipocytes and extracellular matrix (ECM).  Among these cells, tumor-assocd. macrophages (TAM) are the prominent components of TME in breast cancers.  Macrophages exhibit a high plasticity in response to various external signals and participate in innate and adoptive immune responses to control numerous factors of TME.  Depending on the microenvironmental signal present, macrophages are polarized into two distinct phenotypes, the classically activated (M1) or the alternative activated (M2) macrophages.  Tumor-assocd. macrophages (TAMs) closely resemble the M2-polarized.  Clinicopathol. studies have suggested that TAM accumulation in tumors correlates with a poor clin. outcome.  In human breast carcinomas, high TAM d. correlates with poor prognosis.  Over the years, studies into the role of TAMs in breast cancer progression have identified TAMs to be capable of inducing angiogenesis, remodelling the tumor extracellular matrix to aid invasion, modeling breast cancer cells to evade host immune system and recruiting immunosuppressive leukocytes to the tumor microenvironment.  Along with these functions, the potential role for TAMs in activation of breast cancer stem cells (CSC) has also emerged.  Thus, TAMs in breast cancer can enhance cancer cell invasion by degrading the ECM, stimulate tumor vascularization and angiogenesis and suppress the antitumor functions of cytotoxic T cells resulting in poor prognosis for patients.  These observations make TAMs an attractive target for therapeutic intervention by targeting various aspects of their function.  This review discusses the mechanisms responsible for TAM recruitment and highlights the roles of TAMs in regulating tumor angiogenesis, invasion, metastasis, immunosuppression, and chemotherapeutic resistance.  Finally, the potential for TAM-targeted therapy as a promising novel strategy is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIKh8NLowpfLVg90H21EOLACvtfcHk0li-U6htzT_lPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGmsLs%253D&md5=f935c2ca750285a65c3fd1d1a1e3cee1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.14670%2FHH-11-916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-11-916%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DGyamfi%26aufirst%3DJ.%26aulast%3DJang%26aufirst%3DH.%26aulast%3DKoo%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520role%2520of%2520tumor-associated%2520macrophage%2520in%2520breast%2520cancer%2520biology%26jtitle%3DHistol.%2520Histopathol.%26date%3D2018%26volume%3D33%26spage%3D133%26epage%3D145%26doi%3D10.14670%2FHH-11-916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=21416059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=166-179&author=H.+J.+Kimauthor=S.+C.+Bae&title=Histone+deacetylase+inhibitors%3A+molecular+mechanisms+of+action+and+clinical+trials+as+anti-cancer+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs</span></div><div class="casAuthors">Kim, Hyun-Jung; Bae, Suk-Chul</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">166-179</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells.  Recently, their use has been clin. validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA.  Also, clin. trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing.  However, the mol. mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood.  In this review, we summarize our understanding of the mol. and biol. events that underpin the anti-cancer effects of HDAC inhibitors and the outcomes of recent clin. trials involving these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6o4vH0OXL7bVg90H21EOLACvtfcHk0lg2tu4posS-4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtVSqur0%253D&md5=2f4388dec15ec9b517836f4f3b225641</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DBae%26aufirst%3DS.%2BC.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520molecular%2520mechanisms%2520of%2520action%2520and%2520clinical%2520trials%2520as%2520anti-cancer%2520drugs%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2011%26volume%3D3%26spage%3D166%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 in cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+deacetylase+6+in+cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0lg2tu4posS-4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%25206%2520in%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganai, S. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors modulating non-epigenetic players: the novel mechanism for small molecule based therapeutic intervention</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160527143257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.2174%2F1389450117666160527143257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27231104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFGisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=593-601&author=S.+A.+Ganai&title=Histone+deacetylase+inhibitors+modulating+non-epigenetic+players%3A+the+novel+mechanism+for+small+molecule+based+therapeutic+intervention&doi=10.2174%2F1389450117666160527143257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Modulating Nonepigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention</span></div><div class="casAuthors">Ganai, Shabir Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-601</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in regulating the expression and activity of myriad of proteins involved in tumor onset and progression.  HDAC activity results in a nonpermissive chromatin conformation by erasing acetyl moiety from histone substrates culminating in transcriptional repression of those genes having significant role in tumorigenesis.  Apart from histones, HDACs deacetylate a variety of nonhistone proteins including transcription factors involved in controlling cell growth, differentiation and apoptosis.  Histone deacetylase inhibitors (HDACi) are smallmols. restraining HDACs and hence modulating their biol. activity.  Emerging evidences suggest that acetylation of nonhistone proteins plays a crit. role in various cellular processes including mRNA stability, protein localization and degrdn.  Abnormal turnover or expression of nonhistone proteins like nuclear factor kappaB (NF&#954;B), heat shock protein 90 (HSP90) and frataxin fuels various diseases including cancer.  The present article explores the therapeutic role of HDACi with special emphasis on modulation of clin. relevant nonhistone mol. targets.  Extensive details regarding the nonhistone proteins and their deregulation in disease states have also been provided.  Moreover, the underlying mol. mechanism triggered by HDACi to overcome disease states by modulating the predefined targets has also been illuminated.  The article strongly suggests the promising use of HDACi in therapeutic intervention against complications arising due to nonhistone protein deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRxadLdK3QT7Vg90H21EOLACvtfcHk0lg2tu4posS-4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFGisLc%253D&md5=b54f842bb35184b014eac0bf42fc843c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160527143257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160527143257%26sid%3Dliteratum%253Aachs%26aulast%3DGanai%26aufirst%3DS.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520modulating%2520non-epigenetic%2520players%253A%2520the%2520novel%2520mechanism%2520for%2520small%2520molecule%2520based%2520therapeutic%2520intervention%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2018%26volume%3D19%26spage%3D593%26epage%3D601%26doi%3D10.2174%2F1389450117666160527143257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Acetylation and deacetylation of non-histone proteins</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2005.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.gene.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=16289629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2005&pages=15-23&author=M.+A.+Glozakauthor=N.+Senguptaauthor=X.+Zhangauthor=E.+Seto&title=Acetylation+and+deacetylation+of+non-histone+proteins&doi=10.1016%2Fj.gene.2005.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation and deacetylation of non-histone proteins</span></div><div class="casAuthors">Glozak, Michele A.; Sengupta, Nilanjan; Zhang, Xiaohong; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs.  Of these, transcription factors comprise the largest class of new targets.  The substrates for HATs extend to cytoskeletal proteins, mol. chaperones and nuclear import factors.  Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function.  This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghezJOUSImbVg90H21EOLACvtfcHk0lg2tu4posS-4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN&md5=c6befd12e4556a9154628d9fe9ebe53a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSengupta%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DAcetylation%2520and%2520deacetylation%2520of%2520non-histone%2520proteins%26jtitle%3DGene%26date%3D2005%26volume%3D363%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.gene.2005.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDACs and HDAC inhibitors in cancer development and therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a026831</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a026831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1101%2Fcshperspect.a026831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27599530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=a026831&author=Y.+Liauthor=E.+Seto&title=HDACs+and+HDAC+inhibitors+in+cancer+development+and+therapy&doi=10.1101%2Fcshperspect.a026831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HDACs and HDAC inhibitors in cancer development and therapy</span></div><div class="casAuthors">Li, Yixuan; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">a026831/1-a026831/35</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer.  Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.  Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs).  By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.  In addn.,HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biol. processes including cancer initiation and progression.  This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRL0Y7L3_s7Vg90H21EOLACvtfcHk0lijdPRjF1vRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D&md5=1c647aa38027de1c4c92f74340d9041a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDACs%2520and%2520HDAC%2520inhibitors%2520in%2520cancer%2520development%2520and%2520therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26spage%3Da026831%26doi%3D10.1101%2Fcshperspect.a026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as anticancer drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">E1414</span> <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+deacetylase+inhibitors+as+anticancer+drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0lijdPRjF1vRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Landreville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agapova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matatall, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneass, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onken, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowcock, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbour, J. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-11-0946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F1078-0432.ccr-11-0946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22038994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=408-416&author=S.+Landrevilleauthor=O.+A.+Agapovaauthor=K.+A.+Matatallauthor=Z.+T.+Kneassauthor=M.+D.+Onkenauthor=R.+S.+Leeauthor=A.+M.+Bowcockauthor=J.+W.+Harbour&title=Histone+deacetylase+inhibitors+induce+growth+arrest+and+differentiation+in+uveal+melanoma&doi=10.1158%2F1078-0432.ccr-11-0946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma</span></div><div class="casAuthors">Landreville, Solange; Agapova, Olga A.; Matatall, Katie A.; Kneass, Zachary T.; Onken, Michael D.; Lee, Ryan S.; Bowcock, Anne M.; Harbour, J. William</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">408-416</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Metastasis is responsible for the death of most cancer patients, yet few therapeutic agents are available which specifically target the mol. events that lead to metastasis.  We recently showed that inactivating mutations in the tumor suppressor gene BAP1 are closely assocd. with loss of melanocytic differentiation in uveal melanoma (UM) and metastasis.  The purpose of this study was to identify therapeutic agents that reverse the phenotypic effects of BAP1 loss in UM.  Exptl. Design: In silico screens were done to identify therapeutic compds. predicted to differentiate UM cells using Gene Set Enrichment Anal. and Connectivity Map databases.  Valproic acid (VPA), trichostatin A, LBH-589, and suberoylanilide hydroxamic acid were evaluated for their effects on UM cells using morphol. evaluation, MTS viability assays, bromodeoxyuridine incorporation, flow cytometry, clonogenic assays, gene expression profiling, histone acetylation and ubiquitination assays, and a murine xenograft tumorigenicity model.  RESULTS: Histone deacetylase (HDAC) inhibitors induced morphol. differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells.  VPA inhibited the growth of UM tumors in vivo.  CONCLUSIONS: These findings suggest that HDAC inhibitors may have therapeutic potential for inducing differentiation and prolonged dormancy of micrometastatic disease in UM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4_gyFoEhAN7Vg90H21EOLACvtfcHk0lijdPRjF1vRpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqsr4%253D&md5=a020fc9b897bc9eb8907fcb5d94330b8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-0946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-0946%26sid%3Dliteratum%253Aachs%26aulast%3DLandreville%26aufirst%3DS.%26aulast%3DAgapova%26aufirst%3DO.%2BA.%26aulast%3DMatatall%26aufirst%3DK.%2BA.%26aulast%3DKneass%26aufirst%3DZ.%2BT.%26aulast%3DOnken%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DR.%2BS.%26aulast%3DBowcock%26aufirst%3DA.%2BM.%26aulast%3DHarbour%26aufirst%3DJ.%2BW.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520induce%2520growth%2520arrest%2520and%2520differentiation%2520in%2520uveal%2520melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D408%26epage%3D416%26doi%3D10.1158%2F1078-0432.ccr-11-0946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, G. A.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as cancer therapeutics</span>. <i>Ann. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">287</span>, <span class="refDoi"> DOI: 10.21037/atm.2016.07.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.21037%2Fatm.2016.07.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27568481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFKqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=287&author=G.+A.+Clawson&title=Histone+deacetylase+inhibitors+as+cancer+therapeutics&doi=10.21037%2Fatm.2016.07.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as cancer therapeutics</span></div><div class="casAuthors">Clawson, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">287/1-287/5</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Cancer cells contain significant alterations in their epigenomic landscape, which several enzyme families reversibly contribute to.  One class of epigenetic modifying enzymes is that of histone deacetylases (HDAC), which are receiving considerable scrutiny clin. as a therapeutic target in many cancers.  The underlying rationale is that inhibiting HDACs will reverse dysregulated target gene expression by modulating functional histone (or other) acetylation marks.  This perspective will discuss a recent paper by Markozashvili and co-workers which appeared in Gene, which indicates that the mechanisms by which HDAC inhibitors (HDACis) alter the epigenetic landscape include widespread alternative effects beyond simply controlling regional epigenetic marks.  HDACs are involved in many processes/diseases, and it is not surprising that HDACis have considerable off-target effects, and thus a major effort is being directed toward identification of inhibitors which are selective for HDAC isoforms often uniquely implicated in various cancers.  This Perspective will also discuss some representative work with inhibitors targeting individual HDAC classes or isoforms.  At present, it is not really clear that isoform-specific HDACis will avoid non-selective effects on other unrecognized activities of HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraa-xek0cV4LVg90H21EOLACvtfcHk0lhvGjGIEAtCzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFKqsro%253D&md5=59c7b371e6d1a22ff874ba700500375f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.21037%2Fatm.2016.07.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2016.07.22%26sid%3Dliteratum%253Aachs%26aulast%3DClawson%26aufirst%3DG.%2BA.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520cancer%2520therapeutics%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D287%26doi%3D10.21037%2Fatm.2016.07.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orillion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pili, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors as immunomodulators in cancer therapeutics</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.2217/epi.15.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.2217%2Fepi.15.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26950532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=415-428&author=L.+Shenauthor=A.+Orillionauthor=R.+Pili&title=Histone+deacetylase+inhibitors+as+immunomodulators+in+cancer+therapeutics&doi=10.2217%2Fepi.15.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as immunomodulators in cancer therapeutics</span></div><div class="casAuthors">Shen, Li; Orillion, Ashley; Pili, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-428</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">HDAC inhibitors (HDACIs) are anticancer agents being developed in preclin. and clin. settings due to their capacity to modulate gene expression involved in cell growth, differentiation and apoptosis, through modification of both chromatin histone and nonhistone proteins.  Most HDACIs in clin. development have cytotoxic or cytostatic properties and their direct inhibitory effects on tumor cells are well documented.  Numerous studies have revealed that HDACIs have potent immunomodulatory activity in tumor-bearing animals and cancer patients, providing guidance to apply these agents in cancer immunotherapies.  Here, we summarize recent reports addressing the effects of HDACIs on tumor cell immunogenicity, and on different components of the host immune system.  In addn., we discuss the complexity of the immunomodulatory activity of these agents, which depends on the class specificity of the HDACIs, different exptl. settings and the target immune cell populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWrKeBY7Wqw7Vg90H21EOLACvtfcHk0lhvGjGIEAtCzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOju7k%253D&md5=22641a485661b749cc6710441760b619</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2217%2Fepi.15.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.15.118%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DOrillion%26aufirst%3DA.%26aulast%3DPili%26aufirst%3DR.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520as%2520immunomodulators%2520in%2520cancer%2520therapeutics%26jtitle%3DEpigenomics%26date%3D2016%26volume%3D8%26spage%3D415%26epage%3D428%26doi%3D10.2217%2Fepi.15.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heppt, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berking, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside</span>. <i>Exog. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1111/exd.13089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1111%2Fexd.13089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=831-838&author=E.+Hornigauthor=M.+V.+Hepptauthor=S.+A.+Grafauthor=T.+Ruzickaauthor=C.+Berking&title=Inhibition+of+histone+deacetylases+in+melanoma-a+perspective+from+bench+to+bedside&doi=10.1111%2Fexd.13089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fexd.13089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13089%26sid%3Dliteratum%253Aachs%26aulast%3DHornig%26aufirst%3DE.%26aulast%3DHeppt%26aufirst%3DM.%2BV.%26aulast%3DGraf%26aufirst%3DS.%2BA.%26aulast%3DRuzicka%26aufirst%3DT.%26aulast%3DBerking%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520histone%2520deacetylases%2520in%2520melanoma-a%2520perspective%2520from%2520bench%2520to%2520bedside%26jtitle%3DExog.%2520Dermatol.%26date%3D2016%26volume%3D25%26spage%3D831%26epage%3D838%26doi%3D10.1111%2Fexd.13089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodre, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.cir-15-0077-t</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F2326-6066.cir-15-0077-t" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26297712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=1375-1385&author=D.+M.+Woodsauthor=A.+L.+Sodreauthor=A.+Villagraauthor=A.+Sarnaikauthor=E.+M.+Sotomayorauthor=J.+Weber&title=HDAC+inhibition+upregulates+PD-1+ligands+in+melanoma+and+augments+immunotherapy+with+PD-1+blockade&doi=10.1158%2F2326-6066.cir-15-0077-t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade</span></div><div class="casAuthors">Woods, David M.; Sodre, Andressa L.; Villagra, Alejandro; Sarnaik, Amod; Sotomayor, Eduardo M.; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1375-1385</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Expression of PD-1 ligands by tumors and interaction with PD-1-expressing T cells in the tumor microenvironment can result in tolerance.  Therapies targeting this coinhibitory axis have proven clin. successful in the treatment of metastatic melanoma, non-small cell lung cancer, and other malignancies.  Therapeutic agents targeting the epigenetic regulatory family of histone deacetylases (HDAC) have shown clin. success in the treatment of some hematol. malignancies.  Beyond direct tumor cell cytotoxicity, HDAC inhibitors have also been shown to alter the immunogenicity and enhance antitumor immune responses.  Here, we show that class I HDAC inhibitors upregulated the expression of PD-L1 and, to a lesser degree, PD-L2 in melanomas.  Evaluation of human and murine cell lines and patient tumors treated with a variety of HDAC inhibitors in vitro displayed upregulation of these ligands.  This upregulation was robust and durable, with enhanced expression lasting past 96 h.  These results were validated in vivo in a B16F10 syngeneic murine model.  Mechanistically, HDAC inhibitor treatment resulted in rapid upregulation of histone acetylation of the PD-L1 gene leading to enhanced and durable gene expression.  The efficacy of combining HDAC inhibition with PD-1 blockade for treatment of melanoma was also explored in a murine B16F10 model.  Mice receiving combination therapy had a slower tumor progression and increased survival compared with control and single-agent treatments.  These results highlight the ability of epigenetic modifiers to augment immunotherapies, providing a rationale for combining HDAC inhibitors with PD-1 blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEnfkgZl-yp7Vg90H21EOLACvtfcHk0lhvGjGIEAtCzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lu7zO&md5=c543bcb49c533bfadbdf9ab73c6c8a2e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.cir-15-0077-t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.cir-15-0077-t%26sid%3Dliteratum%253Aachs%26aulast%3DWoods%26aufirst%3DD.%2BM.%26aulast%3DSodre%26aufirst%3DA.%2BL.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DHDAC%2520inhibition%2520upregulates%2520PD-1%2520ligands%2520in%2520melanoma%2520and%2520augments%2520immunotherapy%2520with%2520PD-1%2520blockade%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2015%26volume%3D3%26spage%3D1375%26epage%3D1385%26doi%3D10.1158%2F2326-6066.cir-15-0077-t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienlaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villaroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marante, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1447</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2015.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.molonc.2015.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25957812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1447-1457&author=K.+V.+Woanauthor=M.+Lienlafauthor=P.+Perez-Villaroelauthor=C.+Leeauthor=F.+Chengauthor=T.+Knoxauthor=D.+M.+Woodsauthor=K.+Barriosauthor=J.+Powersauthor=E.+Sahakianauthor=H.+W.+Wangauthor=J.+Canalesauthor=D.+Maranteauthor=K.+S.+M.+Smalleyauthor=J.+Bergmanauthor=E.+Setoauthor=A.+Kozikowskiauthor=J.+Pinilla-Ibarzauthor=A.+Sarnaikauthor=E.+Celisauthor=J.+Weberauthor=E.+M.+Sotomayorauthor=A.+Villagra&title=Targeting+histone+deacetylase+6+mediates+a+dual+anti-melanoma+effect%3A+enhanced+antitumor+immunity+and+impaired+cell+proliferation&doi=10.1016%2Fj.molonc.2015.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation</span></div><div class="casAuthors">Woan, K. V.; Lienlaf, M.; Perez-Villaroel, P.; Lee, C.; Cheng, F.; Knox, T.; Woods, D. M.; Barrios, K.; Powers, J.; Sahakian, E.; Wang, H. W.; Canales, J.; Marante, D.; Smalley, K. S. M.; Bergman, J.; Seto, E.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Celis, E.; Weber, J.; Sotomayor, E. M.; Villagra, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1457</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The median survival for metastatic melanoma is in the realm of 8-16 mo and there are few therapies that offer significant improvement in overall survival.  One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells.  Our group and others have previously demonstrated that pan-HDAC inhibitors induce apoptosis, cell cycle arrest and changes in the immunogenicity of melanoma cells.  Here we interrogated specific HDACs which may be responsible for this effect.  We found that both genetic abrogation and pharmacol. inhibition of HDAC6 decreases in vitro proliferation and induces G1 arrest of melanoma cell lines without inducing apoptosis.  Moreover, targeting this mol. led to an important upregulation in the expression of tumor assocd. antigens and MHC class I, suggesting a potential improvement in the immunogenicity of these cells.  Of note, this anti-melanoma activity was operative regardless of mutational status of the cells.  These effects translated into a pronounced delay of in vivo melanoma tumor growth which was, at least in part, dependent on intact immunity as evidenced by the restoration of tumor growth after CD4+ and CD8+ depletion.  Given our findings, we provide the initial rationale for the further development of selective HDAC6 inhibitors as potential therapeutic anti-melanoma agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDIQ5LKbZF8bVg90H21EOLACvtfcHk0ljhQc2TyRbwfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D&md5=7534df9db01f52a71f97f0e112db37cc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DWoan%26aufirst%3DK.%2BV.%26aulast%3DLienlaf%26aufirst%3DM.%26aulast%3DPerez-Villaroel%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DWoods%26aufirst%3DD.%2BM.%26aulast%3DBarrios%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%2BW.%26aulast%3DCanales%26aufirst%3DJ.%26aulast%3DMarante%26aufirst%3DD.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DTargeting%2520histone%2520deacetylase%25206%2520mediates%2520a%2520dual%2520anti-melanoma%2520effect%253A%2520enhanced%2520antitumor%2520immunity%2520and%2520impaired%2520cell%2520proliferation%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D1447%26epage%3D1457%26doi%3D10.1016%2Fj.molonc.2015.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">Inside HDACs with more selective HDAC inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2016.05.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27318122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=451-483&author=J.+Rocheauthor=P.+Bertrand&title=Inside+HDACs+with+more+selective+HDAC+inhibitors&doi=10.1016%2Fj.ejmech.2016.05.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inside HDACs with more selective HDAC inhibitors</span></div><div class="casAuthors">Roche, Joelle; Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451-483</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compds. approved by the Food and Drug Administration.  During the last five years, several groups have made continuous efforts to improve this class of compds., designing more selective compds. or compds. with multiple capacities.  After a survey of the HDAC biol. and structures, this review summarizes the results of the chemists working in this field, and highlights when possible the behavior of the mols. inside their targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHO5YBuaN7c7Vg90H21EOLACvtfcHk0ljhQc2TyRbwfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI&md5=3bbd062c1fb8a402c039e20bacd4af14</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.047%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DJ.%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DInside%2520HDACs%2520with%2520more%2520selective%2520HDAC%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D451%26epage%3D483%26doi%3D10.1016%2Fj.ejmech.2016.05.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponichtera, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourzia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span> <span> </span><span class="NLM_article-title">Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1038/nature21409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnature21409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28273064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=428-432&author=J.+L.+Guerrieroauthor=A.+Sotayoauthor=H.+E.+Ponichteraauthor=J.+A.+Castrillonauthor=A.+L.+Pourziaauthor=S.+Schadauthor=S.+F.+Johnsonauthor=R.+D.+Carrascoauthor=S.+Lazoauthor=R.+T.+Bronsonauthor=S.+P.+Davisauthor=M.+Loberaauthor=M.+A.+Nolanauthor=A.+Letai&title=Class+IIa+HDAC+inhibition+reduces+breast+tumours+and+metastases+through+anti-tumour+macrophages&doi=10.1038%2Fnature21409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Class IIa HDAC inhibition reduces breast tumors and metastases through anti-tumor macrophages</span></div><div class="casAuthors">Guerriero, Jennifer L.; Sotayo, Alaba; Ponichtera, Holly E.; Castrillon, Jessica A.; Pourzia, Alexandra L.; Schad, Sara; Johnson, Shawn F.; Carrasco, Ruben D.; Lazo, Suzan; Bronson, Roderick T.; Davis, Scott P.; Lobera, Mercedes; Nolan, Michael A.; Letai, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7645</span>),
    <span class="NLM_cas:pages">428-432</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the main focus of immuno-oncol. has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumor redn. and elimination.  Tumor-assocd. macrophages often have net pro-tumor effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumors.  Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumor-assocd. macrophages have had some success.  We hypothesized that pharmacol. modulation of macrophage phenotype could produce an anti-tumor effect.  We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.  Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumor microenvironment and reduces tumor burden and pulmonary metastases by modulating macrophage phenotypes.  TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors.  Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumor redn.  These data introduce class IIa HDAC inhibition as a means to harness the anti-tumor potential of macrophages to enhance cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEzcFKak-anrVg90H21EOLACvtfcHk0ljhQc2TyRbwfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D&md5=0356d851bbeb834038527f5190d0e4b8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnature21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21409%26sid%3Dliteratum%253Aachs%26aulast%3DGuerriero%26aufirst%3DJ.%2BL.%26aulast%3DSotayo%26aufirst%3DA.%26aulast%3DPonichtera%26aufirst%3DH.%2BE.%26aulast%3DCastrillon%26aufirst%3DJ.%2BA.%26aulast%3DPourzia%26aufirst%3DA.%2BL.%26aulast%3DSchad%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DS.%2BF.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DLazo%26aufirst%3DS.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DDavis%26aufirst%3DS.%2BP.%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26aulast%3DLetai%26aufirst%3DA.%26atitle%3DClass%2520IIa%2520HDAC%2520inhibition%2520reduces%2520breast%2520tumours%2520and%2520metastases%2520through%2520anti-tumour%2520macrophages%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D428%26epage%3D432%26doi%3D10.1038%2Fnature21409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Creation of a histone deacetylase 6 inhibitor and its biological effects</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">12005</span>– <span class="NLM_lpage">12010</span>, <span class="refDoi"> DOI: 10.1073/pnas.1515882112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1073%2Fpnas.1515882112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26371309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=12005-12010&author=J.-H.+Leeauthor=Y.+Yaoauthor=A.+Mahendranauthor=L.+Ngoauthor=G.+Venta-Perezauthor=M.+L.+Choyauthor=R.+Breslowauthor=P.+A.+Marks&title=Creation+of+a+histone+deacetylase+6+inhibitor+and+its+biological+effects&doi=10.1073%2Fpnas.1515882112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a histone deacetylase 6 inhibitor and its biological effects</span></div><div class="casAuthors">Lee, Ju-Hee; Yao, Yuanshan; Mahendran, Adaickapillai; Ngo, Lang; Venta-Perez, Gisela; Choy, Megan L.; Breslow, Ronald; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12005-12010</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor, HPB (N-hydroxy-4-[(N-(((2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide)]).  This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells.  The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonHNFE0-PzyLVg90H21EOLACvtfcHk0lgy_6Fhnd7GNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK&md5=d6dc50c8c83e0b03c5ecebc3da3a96c7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1515882112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1515882112%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DCreation%2520of%2520a%2520histone%2520deacetylase%25206%2520inhibitor%2520and%2520its%2520biological%2520effects%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D12005%26epage%3D12010%26doi%3D10.1073%2Fpnas.1515882112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detroja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsin, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Targeting breast cancer stem cells by novel HDAC3-selective inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.08.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28923385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=42-51&author=H.-Y.+Hsiehauthor=H.-C.+Chuangauthor=F.-H.+Shenauthor=K.+Detrojaauthor=L.-W.+Hsinauthor=C.-S.+Chen&title=Targeting+breast+cancer+stem+cells+by+novel+HDAC3-selective+inhibitors&doi=10.1016%2Fj.ejmech.2017.08.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting breast cancer stem cells by novel HDAC3-selective inhibitors</span></div><div class="casAuthors">Hsieh, Hao-Yu; Chuang, Hsiao-Ching; Shen, Fang-Hsiu; Detroja, Kinjal; Hsin, Ling-Wei; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42-51</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Although histone deacetylase (HDAC) inhibitors have been known to suppress the cancer stem cell (CSC) population in multiple types of cancer cells, it remains unclear which HDAC isoforms and corresponding mechanisms contribute to this anti-CSC activity.  Pursuant to our previous finding that HDAC8 regulates CSCs in triple-neg. breast cancer (TNBC) cells by targeting Notch1 stability, we investigated related pathways and found HDAC3 to be mechanistically linked to CSC homeostasis by increasing β-catenin expression through the Akt/GSK3β pathway.  Accordingly, we used a pan-HDAC inhibitor, AR-42 (1), as a scaffold to develop HDAC3-selective inhibitors, obtaining the proof-of-concept with 18 and 28.  These two derivs. exhibited high potency and isoform selectivity in HDAC3 inhibition.  Equally important, they showed in vitro and/or in vivo efficacy in suppressing the CSC subpopulation of TNBC cells via the down regulation of β-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooFIxRkkBCsrVg90H21EOLACvtfcHk0lgy_6Fhnd7GNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWnsbnL&md5=a0ad5d8e018d7471975602be2ba238eb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.069%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DH.-Y.%26aulast%3DChuang%26aufirst%3DH.-C.%26aulast%3DShen%26aufirst%3DF.-H.%26aulast%3DDetroja%26aufirst%3DK.%26aulast%3DHsin%26aufirst%3DL.-W.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DTargeting%2520breast%2520cancer%2520stem%2520cells%2520by%2520novel%2520HDAC3-selective%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D42%26epage%3D51%26doi%3D10.1016%2Fj.ejmech.2017.08.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">80109</span>– <span class="NLM_lpage">80123</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.18632%2Foncotarget.19019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29113288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=80109-80123&author=T.+Hideshimaauthor=R.+Mazitschekauthor=J.+Qiauthor=N.+Mimuraauthor=J.-C.+Tsengauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=K.+C.+Anderson&title=HDAC6+inhibitor+WT161+downregulates+growth+factor+receptors+in+breast+cancer&doi=10.18632%2Foncotarget.19019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span></div><div class="casAuthors">Hideshima Teru; Qi Jun; Mimura Naoya; Bradner James E; Anderson Kenneth C; Mazitschek Ralph; Mimura Naoya; Tseng Jen-Chieh; Kung Andrew L; Tseng Jen-Chieh; Kung Andrew L; Kung Andrew L; Bradner James E</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">80109-80123</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models.  However, its activity in other type of cancers has not yet been shown.  In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines.  WT161 triggers apoptotic cell death in MCF7, T47D, BT474, and MDA-MB231 cells, associated with decreased expression of EGFR, HER2, and ERα and downstream signaling.  However, HDAC6 knockdown shows that cytotoxicity and destabilization of these receptors triggered by WT161 are not dependent on HDAC6 inhibition.  Moreover WT161 analog MAZ1793, which lacks HDAC inhibitory effect, similarly triggers cell line growth inhibition and downregulation of these receptors.  We also confirm that WT161 significantly inhibits in vivo MCF7 cell growth, associated with downregulation of ERα, in a murine xenograft model.  Finally, WT161 synergistically enhances bortezomib-induced cytotoxicity, even in bortezomib-resistant breast cancer cells.  Our results therefore provide the rationale to develop a novel class of therapeutic agents targeting growth pathways central to the pathogenesis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWi2bvABUN7K2q3xNe7a7QfW6udTcc2earug9RKeE6Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D&md5=50fcf37b8db1e8acb520e650f6702bf5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19019%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DHDAC6%2520inhibitor%2520WT161%2520downregulates%2520growth%2520factor%2520receptors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D80109%26epage%3D80123%26doi%3D10.18632%2Foncotarget.19019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">(N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=905-917&author=H.-Y.+Leeauthor=K.+Nepaliauthor=F.-I.+Huangauthor=C.-Y.+Changauthor=M.-J.+Laiauthor=Y.-H.+Liauthor=H.-L.+Huangauthor=C.-R.+Yangauthor=J.-P.+Liou&title=%28N-Hydroxycarbonylbenylamino%29quinolines+as+selective+histone+deacetylase+6+inhibitors+suppress+growth+of+multiple+myeloma+in+vitro+and+in+vivo&doi=10.1021%2Facs.jmedchem.7b01404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">(N-Hydroxycarbonylbenzylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span></div><div class="casAuthors">Lee, Hsueh-Yun; Nepali, Kunal; Huang, Fang-I.; Chang, Chih-Yi; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7-31) have been examd. as novel histone deacetylase 6 (HDAC6) inhibitors.  One compd. (13, N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide) exhibits remarkable inhibitory activity of HDAC6 with an IC50 value of 0.29 nM, which is 4000-43,000 times more selective over other HDAC isoforms.  Compd. 13 was shown to have antiproliferative activity against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells with no effect on normal bone marrow cells.  Compd. 13, as a single drug, suppresses the growth of tumors by a %TGI factor of 60.4% in human multiple myeloma RPMI 8226 xenograft models and, in combination with bortezomib, shows significant in vivo antitumor activity (%TGI = 86.2%).  Compd. 13 also demonstrates good human hepatocytic stability and high permeability, without any effect on mutagenicity and cytotoxicity.  Thus, compd. 13 is a potent HDAC6 inhibitor that could be developed for the treatment of multiple myeloma in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRGAacR3ID_LVg90H21EOLACvtfcHk0lje9_xlC2nySQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D&md5=4e76a60f13c7414ba7cf871aa0193b14</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01404%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DF.-I.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26aulast%3DHuang%26aufirst%3DH.-L.%26aulast%3DYang%26aufirst%3DC.-R.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3D%2528N-Hydroxycarbonylbenylamino%2529quinolines%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%2520suppress%2520growth%2520of%2520multiple%2520myeloma%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D905%26epage%3D917%26doi%3D10.1021%2Facs.jmedchem.7b01404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of selective histone deacetylase 6 inhibitors in melanoma models</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1031-1036&author=M.+T.+Tavaresauthor=S.+Shenauthor=T.+Knoxauthor=M.+Hadleyauthor=Z.+Kutilauthor=C.+Ba%C5%99inkaauthor=A.+Villagraauthor=A.+P.+Kozikowski&title=Synthesis+and+pharmacological+evaluation+of+selective+histone+deacetylase+6+inhibitors+in+melanoma+models&doi=10.1021%2Facsmedchemlett.7b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models</span></div><div class="casAuthors">Tavares, Mauricio T.; Shen, Sida; Knox, Tessa; Hadley, Melissa; Kutil, Zsofia; Barinka, Cyril; Villagra, Alejandro; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1031-1036</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Only a handful of therapies offer significant improvement in the overall survival in cases of melanoma, a cancer whose incidence has continued to rise in the past 30 years.  In our effort to identify potent and isoform-selective histone deacetylase (HDAC) inhibitors as a therapeutic approach to melanoma, a series of new HDAC6 inhibitors based on the nexturastat A scaffold were prepd.  The new analogs bearing added hydrophilic substituents, so as to establish addnl. hydrogen bonding on the rim of the HDAC6 catalytic pocket, exhibit improved potency against HDAC6 and retain selectivity over HDAC1.  Compd. I exhibits antiproliferative effects on several types of melanoma and lymphoma cells.  Further studies indicates that I selectively increases acetylated tubulin levels in vitro and elicits an immune response through down-regulating cytokine IL-10.  A preliminary in vivo efficacy study indicates that I possesses improved capability to inhibit melanoma tumor growth and that this effect is based on the regulation of inflammatory and immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cF7frE1ffLVg90H21EOLACvtfcHk0lje9_xlC2nySQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL&md5=305123b6d7ecc3e4273d5fa02565367f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00223%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%2520in%2520melanoma%2520models%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1031%26epage%3D1036%26doi%3D10.1021%2Facsmedchemlett.7b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruijter, A. J. M. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gennip, A. H. v.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuilenburg, A. B. P. v.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases (HDACs): characterization of the classical HDAC family</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/bj20021321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1042%2Fbj20021321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=12429021" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2003&pages=737-749&author=A.+J.+M.+d.+Ruijterauthor=A.+H.+v.+Gennipauthor=H.+N.+Caronauthor=S.+Kempauthor=A.+B.+P.+v.+Kuilenburg&title=Histone+deacetylases+%28HDACs%29%3A+characterization+of+the+classical+HDAC+family&doi=10.1042%2Fbj20021321"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1042%2Fbj20021321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj20021321%26sid%3Dliteratum%253Aachs%26aulast%3DRuijter%26aufirst%3DA.%2BJ.%2BM.%2Bd.%26aulast%3DGennip%26aufirst%3DA.%2BH.%2Bv.%26aulast%3DCaron%26aufirst%3DH.%2BN.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3DKuilenburg%26aufirst%3DA.%2BB.%2BP.%2Bv.%26atitle%3DHistone%2520deacetylases%2520%2528HDACs%2529%253A%2520characterization%2520of%2520the%2520classical%2520HDAC%2520family%26jtitle%3DBiochem.%2520J.%26date%3D2003%26volume%3D370%26spage%3D737%26epage%3D749%26doi%3D10.1042%2Fbj20021321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haberland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1038/nrg2485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnrg2485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=19065135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=32-42&author=M.+Haberlandauthor=R.+L.+Montgomeryauthor=E.+N.+Olson&title=The+many+roles+of+histone+deacetylases+in+development+and+physiology%3A+implications+for+disease+and+therapy&doi=10.1038%2Fnrg2485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of histone deacetylases in development and physiology: implications for disease and therapy</span></div><div class="casAuthors">Haberland, Michael; Montgomery, Rusty L.; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The expression of many histone deacetylase (HDAC) isoforms in eukaryotic cells raises questions regarding their specificity and the programs of gene expression that they control.  HDAC knockout mice are a powerful tool for addressing these questions and have revealed that individual HDACs have specific functions in development and disease.  Histone deacetylases (HDACs) are part of a vast family of enzymes that have crucial roles in numerous biol. processes, largely through their repressive influence on transcription.  The expression of many HDAC isoforms in eukaryotic cells raises questions about their possible specificity or redundancy, and whether they control global or specific programs of gene expression.  Recent analyses of HDAC knockout mice have revealed highly specific functions of individual HDACs in development and disease.  Mutant mice lacking individual HDACs are a powerful tool for defining the functions of HDACs in vivo and the mol. targets of HDAC inhibitors in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWcIo3mrsM7Vg90H21EOLACvtfcHk0lje9_xlC2nySQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWis7bI&md5=0678d8655e86994cd4f0174c1e9d0eb1</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrg2485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2485%26sid%3Dliteratum%253Aachs%26aulast%3DHaberland%26aufirst%3DM.%26aulast%3DMontgomery%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DThe%2520many%2520roles%2520of%2520histone%2520deacetylases%2520in%2520development%2520and%2520physiology%253A%2520implications%2520for%2520disease%2520and%2520therapy%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2009%26volume%3D10%26spage%3D32%26epage%3D42%26doi%3D10.1038%2Fnrg2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khochbin, S.</span></span> <span> </span><span class="NLM_article-title">HDAC6 a new cellular stress surveillance factor</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.4161/cc.7.1.5186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.4161%2Fcc.7.1.5186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=18196966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVKntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=7-10&author=P.+Matthiasauthor=M.+Yoshidaauthor=S.+Khochbin&title=HDAC6+a+new+cellular+stress+surveillance+factor&doi=10.4161%2Fcc.7.1.5186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 a new cellular stress surveillance factor</span></div><div class="casAuthors">Matthias, Patrick; Yoshida, Minoru; Khochbin, Saadi</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-10</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Less than a decade has passed since histone deacetylase harboring (HDAC6) was first identified and regarded as an unusual histone deacetylase harboring 2 catalytic domains.  Early demonstration of its cytoplasmic localization, its ubiquitin-binding, and its tubulin-deacetylase activities took HDAC6 far away from everything known to involve other histone-deacetylases.  Recent discoveries confirmed the very unique functions of HDAC6 among deacetylases and pointed to this protein as a master regulator of cell response to cytotoxic assaults.  HDAC6 appears both as a sensor of stressful stimuli and as an effector, which, thanks to its wide range of activities, mediates and coordinates appropriate cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Tzz-Xi44N7Vg90H21EOLACvtfcHk0liJuyEGBiRoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVKntLY%253D&md5=6b0784dad7b4fac9a31e803548bc7a84</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4161%2Fcc.7.1.5186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.7.1.5186%26sid%3Dliteratum%253Aachs%26aulast%3DMatthias%26aufirst%3DP.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKhochbin%26aufirst%3DS.%26atitle%3DHDAC6%2520a%2520new%2520cellular%2520stress%2520surveillance%2520factor%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D7%26epage%3D10%26doi%3D10.4161%2Fcc.7.1.5186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span> <span> </span><span class="NLM_article-title">Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1549</span>, <span class="refDoi"> DOI: 10.1111/cas.13062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1111%2Fcas.13062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27554046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=1543-1549&author=Y.+Imaiauthor=Y.+Maruauthor=J.+Tanaka&title=Action+mechanisms+of+histone+deacetylase+inhibitors+in+the+treatment+of+hematological+malignancies&doi=10.1111%2Fcas.13062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies</span></div><div class="casAuthors">Imai, Yoichi; Maru, Yoshiro; Tanaka, Junji</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1543-1549</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Histone deacetylases (HDACs) critically regulate gene expression by detg. the acetylation status of histones.  In addn., studies have increasingly focused on the activities of HDACs, esp. involving non-histone proteins, and their various biol. effects.  Aberrant HDAC expression obsd. in several kinds of human tumors makes HDACs potential targets for cancer treatment.  Several preclin. studies have suggested that HDAC inhibitors exhibit some efficacy in the treatment of acute myelogenous leukemia (AML) with AML1-ETO, which mediates transcriptional repression through its interaction with a complex including HDAC1.  Recurrent mutations in epigenetic regulators are found in T-cell lymphomas (TCLs), and HDAC inhibitors and hypomethylating agents were shown to act cooperatively in the treatment of TCLs.  Preclin. modeling has suggested that persistent activation of the signal transducer and activator of transcription (STAT) signaling pathway could serve as a useful biomarker of resistance to HDAC inhibitor in patients with cutaneous TCL.  Panobinostat, a pan-HDAC inhibitor, in combination with bortezomib and dexamethasone, has achieved longer progression-free survival in patients with relapsed/refractory multiple myeloma (MM) than the placebo in combination with bortezomib and dexamethasone.  Panobinostat inhibited MM cell growth by degrading protein phosphatase 3 catalytic subunit α (PPP3CA), a catalytic subunit of calcineurin.  This degrdn. was suggested to be mediated by the blockade of the chaperone function of heat shock protein 90 (HSP90) due to HDAC6 inhibition.  Aberrant PPP3CA expression in advanced MM indicated a possible correlation between high PPP3CA expression and the pathogenesis of MM.  Furthermore, PPP3CA was suggested as a common target of panobinostat and bortezomib.  This article is protected by copyright.  All rights reserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8mVwuDgQ9LVg90H21EOLACvtfcHk0liJuyEGBiRoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlykur3O&md5=d97540b4f33bb4ce6c044717785f9954</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fcas.13062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13062%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DY.%26aulast%3DMaru%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DJ.%26atitle%3DAction%2520mechanisms%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520hematological%2520malignancies%26jtitle%3DCancer%2520Sci.%26date%3D2016%26volume%3D107%26spage%3D1543%26epage%3D1549%26doi%3D10.1111%2Fcas.13062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keusch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span> <span> </span><span class="NLM_article-title">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnchembio.2140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27454931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=748-754&author=Y.+Miyakeauthor=J.+J.+Keuschauthor=L.+Wangauthor=M.+Saitoauthor=D.+Hessauthor=X.+Wangauthor=B.+J.+Melanconauthor=P.+Helquistauthor=H.+Gutauthor=P.+Matthias&title=Structural+insights+into+HDAC6+tubulin+deacetylation+and+its+selective+inhibition&doi=10.1038%2Fnchembio.2140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span></div><div class="casAuthors">Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong; Saito, Makoto; Hess, Daniel; Wang, Xiaoning; Melancon, Bruce J.; Helquist, Paul; Gut, Heinz; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor, nexturastat A.  The tandem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry.  The authors identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective inhibitors.  HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA had moderate selectivity for HDAC6.  The authors identified a uniquely positioned α-helix and a flexible Trp residue in the loop joining α-helixes H20 to H21 as crit. for deacetylation of the physiol. substrate, tubulin.  Using single-mol. measurements and biochem. assays, the authors demonstrated that HDAC6 catalytic domain 2 deacetylated α-tubulin Lys-40 in the lumen of microtubules, but that its preferred substrate was unpolymd. tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpERJRurS1cC7Vg90H21EOLACvtfcHk0liJuyEGBiRoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM&md5=4abe529ab89615df33f54350a1a8c69a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2140%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DKeusch%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DMatthias%26aufirst%3DP.%26atitle%3DStructural%2520insights%2520into%2520HDAC6%2520tubulin%2520deacetylation%2520and%2520its%2520selective%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fnchembio.2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faria
Freitas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuendet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">HDAC inhibitors: a 2013-2017 patent survey</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1459568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1080%2F13543776.2018.1459568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVSns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=365-381&author=M.+Faria%0AFreitasauthor=M.+Cuendetauthor=P.+Bertrand&title=HDAC+inhibitors%3A+a+2013-2017+patent+survey&doi=10.1080%2F13543776.2018.1459568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors: a 2013-2017 patent survey</span></div><div class="casAuthors">Faria Freitas, Micaela; Cuendet, Muriel; Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-381</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A Review.  Zinc-dependent histone deacetylases (HDAC) inhibitors represent an important class of biol. active compds. with four of them approved by the FDA.  A wide range of mols. has been reported for applications in several human diseases.: This review covers recent efforts in the synthesis and applications of HDAC inhibitors from 2013-2017.: HDAC inhibitors represent an important class of biol. active compds. for single or combination therapies.  The current synthetic methodologies are oriented towards selective HDAC isoforms to achieve better therapeutic effects.  Among the recent patents available, most of them focus on HDAC6 selective inhibitors.  Beside this search for isoform selectivity, the quest for zinc binding groups with better pharmacokinetic properties and high potency against HDACs only motivates medicinal chemists, as well as the design of inhibitors targeting HDACs and at the same time another biol. target.  If the major applications are for anticancer activity, one can note the emerging applications in neurol. or metabolic disorders or for the stimulation of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgdOR23sC-crVg90H21EOLACvtfcHk0lheXf502iqYuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVSns7w%253D&md5=0bed63ff4bcd3599758686197372f35b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1459568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1459568%26sid%3Dliteratum%253Aachs%26aulast%3DFaria%2BFreitas%26aufirst%3DM.%26aulast%3DCuendet%26aufirst%3DM.%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DHDAC%2520inhibitors%253A%2520a%25202013-2017%2520patent%2520survey%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D365%26epage%3D381%26doi%3D10.1080%2F13543776.2018.1459568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span> </span><span class="NLM_article-title">Clinical trials for ACY-1215</span>. <a href="https://clinicaltrials.gov/ct2/results?term=ACY-1215&amp;Search=Search" class="extLink">https://clinicaltrials.gov/ct2/results?term=ACY-1215&Search=Search</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+trials+for+ACY-1215.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DACY-1215%26Search%3DSearch+%28accessed+Mar+15%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DClinical%2520trials%2520for%2520ACY-1215%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span> </span><span class="NLM_article-title">Clinical
trials for ACY-241</span>. <a href="https://clinicaltrials.gov/ct2/results?term=ACY-241&amp;Search=Search" class="extLink">https://clinicaltrials.gov/ct2/results?term=ACY-241&Search=Search</a> (accessed Mar 15, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical%0Atrials+for+ACY-241.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DACY-241%26Search%3DSearch+%28accessed+Mar+15%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DClinical%250Atrials%2520for%2520ACY-241%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Loss of deacetylation activity of Hdac6 affects emotional behavior in mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e30924</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0030924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1371%2Fjournal.pone.0030924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22328923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFyrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=M.+Fukadaauthor=A.+Hanaiauthor=A.+Nakayamaauthor=T.+Suzukiauthor=N.+Miyataauthor=R.+M.+Rodriguizauthor=W.+C.+Wetselauthor=T.-P.+Yaoauthor=Y.+Kawaguchi&title=Loss+of+deacetylation+activity+of+Hdac6+affects+emotional+behavior+in+mice&doi=10.1371%2Fjournal.pone.0030924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of deacetylation activity of Hdac6 affects emotional behavior in mice</span></div><div class="casAuthors">Fukada, Masahide; Hanai, Atsuko; Nakayama, Atsuo; Suzuki, Takayoshi; Miyata, Naoki; Rodriguiz, Ramona M.; Wetsel, William C.; Yao, Tso-Pang; Kawaguchi, Yoshiharu</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e30924</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Acetylation is mediated by acetyltransferases and deacetylases, and occurs not only on histones but also on diverse proteins.  Although histone acetylation in chromatin structure and transcription has been well studied, the biol. roles of non-histone acetylation remain elusive.  Histone deacetylase 6 (Hdac6), a member of the histone deacetylase (HDAC) family, is a unique deacetylase that localizes to cytoplasm and functions in many cellular events by deacetylating non-histone proteins including α-tubulin, Hsp90, and cortactin.  Since robust expression of Hdac6 is obsd. in brain, it would be expected that Hdac6-mediated reversible acetylation plays essential roles in CNS.  Here we demonstrate the crucial roles of Hdac6 deacetylase activity in the expression of emotional behavior in mice.  We found that Hdac6-deficient mice exhibit hyperactivity, less anxiety, and antidepressant-like behavior in behavioral tests.  Moreover, administration of Hdac6-specific inhibitor replicated antidepressant-like behavior in mice.  In good agreement with behavioral phenotypes of Hdac6-deficient mice, Hdac6 dominantly localizes to the dorsal and median raphe nuclei, which are involved in emotional behaviors.  These findings suggest that HDAC6-mediated reversible acetylation might contribute to maintain proper neuronal activity in serotonergic neurons, and also provide a new therapeutic target for depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YHadk45NKLVg90H21EOLACvtfcHk0lheXf502iqYuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFyrt7k%253D&md5=5e7626d464e872485369149e9e18d270</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0030924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0030924%26sid%3Dliteratum%253Aachs%26aulast%3DFukada%26aufirst%3DM.%26aulast%3DHanai%26aufirst%3DA.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMiyata%26aufirst%3DN.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DYao%26aufirst%3DT.-P.%26aulast%3DKawaguchi%26aufirst%3DY.%26atitle%3DLoss%2520of%2520deacetylation%2520activity%2520of%2520Hdac6%2520affects%2520emotional%2520behavior%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0030924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jochems, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blendy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berton, O.</span></span> <span> </span><span class="NLM_article-title">Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnpp.2013.207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=23954848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=389-400&author=J.+Jochemsauthor=J.+Bouldenauthor=B.+G.+Leeauthor=J.+A.+Blendyauthor=M.+Jarpeauthor=R.+Mazitschekauthor=J.+H.+Van+Duzerauthor=S.+Jonesauthor=O.+Berton&title=Antidepressant-like+properties+of+novel+HDAC6-selective+inhibitors+with+improved+brain+bioavailability&doi=10.1038%2Fnpp.2013.207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability</span></div><div class="casAuthors">Jochems, Jeanine; Boulden, Janette; Lee, Bridgin G.; Blendy, Julie A.; Jarpe, Matthew; Mazitschek, Ralph; Van Duzer, John H.; Jones, Simon; Berton, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-400</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">HDAC inhibitors have been reported to produce antidepressant and pro-cognitive effects in animal models, however, poor brain bioavailability or lack of isoform selectivity of current probes has limited our understanding of their mode of action.  We report the characterization of novel pyrimidine hydroxyl amide small mol. inhibitors of HDAC6, brain bioavailable upon systemic administration.  We show that two compds. in this family, ACY-738 and ACY-775, inhibit HDAC6 with low nanomolar potency and a selectivity of 60- to 1500-fold over class I HDACs.  In contrast to tubastatin A, a ref. HDAC6 inhibitor with similar potency and peripheral activity, but more limited brain bioavailability, ACY-738 and ACY-775 induce dramatic increases in α-tubulin acetylation in brain and stimulate mouse exploratory behaviors in novel, but not familiar environments.  Interestingly, despite a lack of detectable effect on histone acetylation, we show that ACY-738 and ACY-775 share the antidepressant-like properties of other HDAC inhibitors, such as SAHA and MS-275, in the tail suspension test and social defeat paradigm.  These effects of ACY-738 and ACY-775 are directly attributable to the inhibition of HDAC6 expressed centrally, as they are fully abrogated in mice with a neural-specific loss of function of HDAC6.  Furthermore, administered in combination, a behaviorally inactive dose of ACY-738 markedly potentiates the anti-immobility activity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.  Our results validate new isoform-selective probes for in vivo pharmacol. studies of HDAC6 in the CNS and reinforce the viability of this HDAC isoform as a potential target for antidepressant development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yEjJGIv3jbVg90H21EOLACvtfcHk0lheXf502iqYuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbjN&md5=9e0f4d3856c84e629602b589161eb4ab</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.207%26sid%3Dliteratum%253Aachs%26aulast%3DJochems%26aufirst%3DJ.%26aulast%3DBoulden%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DB.%2BG.%26aulast%3DBlendy%26aufirst%3DJ.%2BA.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DVan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DJones%26aufirst%3DS.%26aulast%3DBerton%26aufirst%3DO.%26atitle%3DAntidepressant-like%2520properties%2520of%2520novel%2520HDAC6-selective%2520inhibitors%2520with%2520improved%2520brain%2520bioavailability%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D389%26epage%3D400%26doi%3D10.1038%2Fnpp.2013.207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">d’Ydewalle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiheb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irobi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghe, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robberecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">968</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1038/nm.2396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnm.2396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=21785432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlamu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=968-974&author=C.+d%E2%80%99Ydewalleauthor=J.+Krishnanauthor=D.+M.+Chihebauthor=P.+Van+Dammeauthor=J.+Irobiauthor=A.+P.+Kozikowskiauthor=P.+V.+Bergheauthor=V.+Timmermanauthor=W.+Robberechtauthor=L.+Van+Den+Bosch&title=HDAC6+inhibitors+reverse+axonal+loss+in+a+mouse+model+of+mutant+HSPB1-induced+Charcot-Marie-Tooth+disease&doi=10.1038%2Fnm.2396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease</span></div><div class="casAuthors">d'Ydewalle, Constantin; Krishnan, Jyothsna; Chiheb, Driss M.; Van Damme, Philip; Irobi, Joy; Kozikowski, Alan P.; Vanden Berghe, Pieter; Timmerman, Vincent; Robberecht, Wim; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">968-974</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Charcot-Marie-Tooth disease (CMT) is the most common inherited disorder of the peripheral nervous system.  Mutations in the 27-kDa small heat-shock protein gene (HSPB1) cause axonal CMT or distal hereditary motor neuropathy (distal HMN).  We developed and characterized transgenic mice expressing two different HSPB1 mutations (S135F and P182L) in neurons only.  These mice showed all features of CMT or distal HMN dependent on the mutation.  Expression of mutant HSPB1 decreased acetylated α-tubulin abundance and induced severe axonal transport deficits.  An increase of α-tubulin acetylation induced by pharmacol. inhibition of histone deacetylase 6 (HDAC6) cor. the axonal transport defects caused by HSPB1 mutations and rescued the CMT phenotype of symptomatic mutant HSPB1 mice.  Our findings demonstrate the pathogenic role of α-tubulin deacetylation in mutant HSPB1-induced neuropathies and offer perspectives for using HDAC6 inhibitors as a therapeutic strategy for hereditary axonopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcNnO5Y6PAjLVg90H21EOLACvtfcHk0lh5k5jA9Qa-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlamu7o%253D&md5=3571d817e9a3d61d8df5f1dd6fc8358c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnm.2396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2396%26sid%3Dliteratum%253Aachs%26aulast%3Dd%25E2%2580%2599Ydewalle%26aufirst%3DC.%26aulast%3DKrishnan%26aufirst%3DJ.%26aulast%3DChiheb%26aufirst%3DD.%2BM.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DIrobi%26aufirst%3DJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DBerghe%26aufirst%3DP.%2BV.%26aulast%3DTimmerman%26aufirst%3DV.%26aulast%3DRobberecht%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DHDAC6%2520inhibitors%2520reverse%2520axonal%2520loss%2520in%2520a%2520mouse%2520model%2520of%2520mutant%2520HSPB1-induced%2520Charcot-Marie-Tooth%2520disease%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D968%26epage%3D974%26doi%3D10.1038%2Fnm.2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span> <span> </span><span class="NLM_article-title">Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/s12967-015-0753-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs12967-015-0753-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26747087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktlWhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=7&author=J.+Liuauthor=J.+Guauthor=Z.+Fengauthor=Y.+Yangauthor=N.+Zhuauthor=W.+Luauthor=F.+Qi&title=Both+HDAC5+and+HDAC6+are+required+for+the+proliferation+and+metastasis+of+melanoma+cells&doi=10.1186%2Fs12967-015-0753-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells</span></div><div class="casAuthors">Liu, Jiaqi; Gu, Jianying; Feng, Zihao; Yang, Yanhong; Zhu, Ningwen; Lu, Weiyue; Qi, Fazhi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7/1-7/13</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Histone deacetylase (HDAC) inhibitors are widely used in clin. investigation as novel drug targets.  For example, panobinostat and vorinostat have been used to treat patients with melanoma.  However, HDAC inhibitors are small-mol. compds. without a specific target, and their mechanism of action is unclear.  Therefore, it is necessary to investigate which HDACs are required for the proliferation and metastasis of melanoma cells.  Methods: We used overexpression and knocking down lentivirus to clarify the influence of HDAC5 and HDAC6 in melanoma development.  Also, we introduced stable HDAC5 or HDAC6 knockdown cells into null mice and found that the knockdown cells were unable to form solid tumors.  Finally, we tested HDAC5 and HDAC6 expression and sublocation in clin. melanoma tissues and tumor adjacent tissues.  Results: In this study, and found that HDAC5 and HDAC6 were highly expressed in melanoma cells but exhibited low expression levels in normal skin cells.  Furthermore, we knocked down HDAC5 or HDAC6 in A375 cells and demonstrated that both HDAC5 and HDAC6 contributed to the proliferation and metastasis of melanoma cells.  Conclusions: This study demonstrated both HDAC5 and HDAC6 were required for melanoma cell proliferation and metastasis through different signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQCR7qOohx8bVg90H21EOLACvtfcHk0lh5k5jA9Qa-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktlWhsQ%253D%253D&md5=4c881a7dcd7a4a4e3ba9cc578b3a9daf</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1186%2Fs12967-015-0753-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-015-0753-0%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DF.%26atitle%3DBoth%2520HDAC5%2520and%2520HDAC6%2520are%2520required%2520for%2520the%2520proliferation%2520and%2520metastasis%2520of%2520melanoma%2520cells%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2016%26volume%3D14%26spage%3D7%26doi%3D10.1186%2Fs12967-015-0753-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span> <span> </span><span class="NLM_article-title">HDAC6 interacts with PTPN1 to enhance melanoma cells progression</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>495</i></span>,  <span class="NLM_fpage">2630</span>– <span class="NLM_lpage">2636</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.12.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bbrc.2017.12.145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29278704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=495&publication_year=2018&pages=2630-2636&author=J.+Liuauthor=W.+Luanauthor=Y.+Zhangauthor=J.+Guauthor=Y.+Shiauthor=Y.+Yangauthor=Z.+Fengauthor=F.+Qi&title=HDAC6+interacts+with+PTPN1+to+enhance+melanoma+cells+progression&doi=10.1016%2Fj.bbrc.2017.12.145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 interacts with PTPN1 to enhance melanoma cells progression</span></div><div class="casAuthors">Liu, Jiaqi; Luan, Wenjie; Zhang, Yong; Gu, Jianying; Shi, Yuedong; Yang, Yanwen; Feng, Zihao; Qi, Fazhi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">495</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2630-2636</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) plays an important role in oncogenic transformation and cancer metastasis.  Our previous study has demonstrated that HDAC6 was highly expressed in melanoma cells, and contributed to the proliferation and metastasis of melanoma cells.  However, the underlying mechanism of HDAC6 in melanoma metastasis and progression remains largely unclear.  In this study, we reported that HDAC6 directly interacted with Tyrosine-protein phosphatase non-receptor type 1 (PTPN1) by performing co-immunopptn. (Co-IP) combined with liq. chromatog. tandem mass spectrometry (LC-MS/MS).  HDAC6 increased the protein level of PTPN1 independent of histone modifying activity.  In addn., PTPN1 promoted proliferation, colony formation and migration while decreased apoptosis of melanoma cells through activating extracellular signal-regulated kinase 1/2 (ERK1/2).  Furthermore, we found that matrix metallopeptidase 9 (MMP9) was increased by HDAC6/PTPN1/ERK1/2 axis, which might serve as a mechanism for melanoma invasion and metastasis.  In conclusion, HDAC6 might enhance aggressive melanoma cells progression via interacting with PTPN1, which was independent of its histone modifying activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC7-FDLlSLm7Vg90H21EOLACvtfcHk0lh5k5jA9Qa-eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGmtg%253D%253D&md5=fbc504a7e5bcccea92a737f0e1decdc0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.12.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.12.145%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DF.%26atitle%3DHDAC6%2520interacts%2520with%2520PTPN1%2520to%2520enhance%2520melanoma%2520cells%2520progression%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D495%26spage%3D2630%26epage%3D2636%26doi%3D10.1016%2Fj.bbrc.2017.12.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.3892/or.2016.5340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.3892%2For.2016.5340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28035401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1270-1276&author=U.+Pengauthor=Z.+Wangauthor=S.+Peiauthor=Y.+Ouauthor=P.+Huauthor=W.+Liuauthor=J.+Song&title=ACY-1215+accelerates+vemurafenib+induced+cell+death+of+BRAF-mutant+melanoma+cells+via+induction+of+ER+stress+and+inhibition+of+ERK+activation&doi=10.3892%2For.2016.5340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation</span></div><div class="casAuthors">Peng, Ueihuei; Wang, Zhihao; Pei, Sa; Ou, Yunchao; Hu, Pengchao; Liu, Wanhong; Song, Jiquan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1270-1276</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">BRAFV600E mutation is found in ∼50% of melanoma patients and BRAFV600E kinase activity inhibitor, vemurafenib, has achieved a remarkable clin. response rate.  However, most patients treated with vemurafenib eventually develop resistance.  Overcoming primary and secondary resistance to selective BRAF inhibitors remains one of the most critically compelling challenges for these patients.  HDAC6 has been shown to confer resistance to chemotherapy in several types of cancer.  Few studies focused on the role of HDAC6 in vemurafenib resistance.  Here we showed that overexpression of HDAC6 confers resistance to vemurafenib in BRAF-mutant A375 cells.  ACY-1215, a selective HDAC6 inhibitor, inhibits the proliferation and induces the apoptosis of A375 cells.  Moreover, ACY-1215 sensitizes A375 cells to vemurafenib induced cell proliferation inhibition and apoptosis induction, which occur partly through induction of endoplasmic reticulum (ER) stress and inactivation of extracellular signal-regulated kinase (ERK).  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of melanoma and overcoming resistance to vemurafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoILeMJkH572bVg90H21EOLACvtfcHk0ljw3BYot_1a3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyis7o%253D&md5=e023bf4ac17f556be9fd3dd6673bc626</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3892%2For.2016.5340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.5340%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DU.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPei%26aufirst%3DS.%26aulast%3DOu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DACY-1215%2520accelerates%2520vemurafenib%2520induced%2520cell%2520death%2520of%2520BRAF-mutant%2520melanoma%2520cells%2520via%2520induction%2520of%2520ER%2520stress%2520and%2520inhibition%2520of%2520ERK%2520activation%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D1270%26epage%3D1276%26doi%3D10.3892%2For.2016.5340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lienlaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villarroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montecino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Essential role of HDAC6 in the regulation of PD-L1 in melanoma</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2015.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.molonc.2015.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26775640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=735-750&author=M.+Lienlafauthor=P.+Perez-Villarroelauthor=T.+Knoxauthor=M.+Pabonauthor=E.+Sahakianauthor=J.+Powersauthor=K.+V.+Woanauthor=C.+Leeauthor=F.+Chengauthor=S.+Dengauthor=K.+S.+M.+Smalleyauthor=M.+Montecinoauthor=A.+Kozikowskiauthor=J.+Pinilla-Ibarzauthor=A.+Sarnaikauthor=E.+Setoauthor=J.+Weberauthor=E.+M.+Sotomayorauthor=A.+Villagra&title=Essential+role+of+HDAC6+in+the+regulation+of+PD-L1+in+melanoma&doi=10.1016%2Fj.molonc.2015.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of HDAC6 in the regulation of PD-L1 in melanoma</span></div><div class="casAuthors">Lienlaf, M.; Perez-Villarroel, P.; Knox, T.; Pabon, M.; Sahakian, E.; Powers, J.; Woan, K. V.; Lee, C.; Cheng, F.; Deng, S.; Smalley, K. S. M.; Montecino, M.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Seto, E.; Weber, J.; Sotomayor, E. M.; Villagra, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">735-750</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment.  In this context, our present work demonstrates that the pharmacol. or genetic abrogation of HDAC6 in primary melanoma samples and cell lines, down-regulates the expression of PD-L1, an important co-stimulatory mol. expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T-cells.  Our data suggests that this novel mechanism of PD-L1 regulation is mainly mediated by the influence of HDAC6 over the recruitment and activation of STAT3.  Addnl., we obsd. that selective HDAC6 inhibitors impairs tumor growth and reduce the in vivo expression of several inhibitory check-point mols. and other regulatory pathways involved in immunosurveillance.  Most importantly, these results provide a key pre-clin. rationale and justification to further study isotype selective HDAC6 inhibitors as potential immuno-modulatory agents in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnUp3ctcdjRLVg90H21EOLACvtfcHk0ljw3BYot_1a3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFWkuw%253D%253D&md5=6ead389dab6bd5f4fc621c452cd4e303</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DLienlaf%26aufirst%3DM.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DPabon%26aufirst%3DM.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DWoan%26aufirst%3DK.%2BV.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DMontecino%26aufirst%3DM.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DEssential%2520role%2520of%2520HDAC6%2520in%2520the%2520regulation%2520of%2520PD-L1%2520in%2520melanoma%26jtitle%3DMol.%2520Oncol.%26date%3D2016%26volume%3D10%26spage%3D735%26epage%3D750%26doi%3D10.1016%2Fj.molonc.2015.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia-Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6136</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-42237-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fs41598-019-42237-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=30992475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=6136&author=T.+Knoxauthor=E.+Sahakianauthor=D.+Banikauthor=M.+Hadleyauthor=E.+Palmerauthor=S.+Noonepalleauthor=J.+Kimauthor=J.+Powersauthor=M.+Gracia-Hernandezauthor=V.+Oliveiraauthor=F.+Chengauthor=J.+Chenauthor=C.+Barinkaauthor=J.+Pinilla-Ibarzauthor=N.+H.+Leeauthor=A.+Kozikowskiauthor=A.+Villagra&title=Selective+HDAC6+inhibitors+improve+anti-PD-1+immune+checkpoint+blockade+therapy+by+decreasing+the+anti-inflammatory+phenotype+of+macrophages+and+down-regulation+of+immunosuppressive+proteins+in+tumor+cells&doi=10.1038%2Fs41598-019-42237-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span></div><div class="casAuthors">Knox Tessa; Banik Debarati; Hadley Melissa; Palmer Erica; Noonepalle Satish; Kim Jennifer; Gracia-Hernandez Maria; Cheng Fengdong; Chen Jie; Lee Norman H; Villagra Alejandro; Sahakian Eva; Powers John; Pinilla-Ibarz Javier; Oliveira Vasco; Barinka Cyril; Kozikowski Alan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment.  Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific immune cells.  In particular, the selective inhibition of HDAC6 has been reported to decrease tumor growth in several malignancies.  However, there is still no clarity about the cellular components mediating this effect.  In this study, we evaluated the HDAC6i Nexturastat A as a priming agent to facilitate the transition of the tumor microenvironment from "cold" to "hot", and potentially augment immune check-point blockade therapies.  This combination modality demonstrated to significantly reduce tumor growth in syngeneic melanoma tumor models.  Additionally, we observed a complete neutralization of the up-regulation of PD-L1 and other immunosuppressive pathways induced by the treatment with anti-PD-1 blockade.  This combination also showed profound changes in the tumor microenvironment such as enhanced infiltration of immune cells, increased central and effector T cell memory, and a significant reduction of pro-tumorigenic M2 macrophages.  The evaluation of individual components of the tumor microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells.  Overall, our results indicate that selective HDAC6i could be used as immunological priming agents to sensitize immunologically "cold" tumors and subsequently improve ongoing immune check-point blockade therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl6RaBRQ4Kdw8IxFYvehhofW6udTcc2eYKoES5m1cdt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D&md5=137a9261e021e60b002d9312608eba76</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-42237-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-42237-3%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DBanik%26aufirst%3DD.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DE.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DGracia-Hernandez%26aufirst%3DM.%26aulast%3DOliveira%26aufirst%3DV.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DN.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DSelective%2520HDAC6%2520inhibitors%2520improve%2520anti-PD-1%2520immune%2520checkpoint%2520blockade%2520therapy%2520by%2520decreasing%2520the%2520anti-inflammatory%2520phenotype%2520of%2520macrophages%2520and%2520down-regulation%2520of%2520immunosuppressive%2520proteins%2520in%2520tumor%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D6136%26doi%3D10.1038%2Fs41598-019-42237-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2694</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.18632%2Foncotarget.13738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27926524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2694-2707&author=P.+Huangauthor=I.+Almeciga-Pintoauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Selective+HDAC+inhibition+by+ACY-241+enhances+the+activity+of+paclitaxel+in+solid+tumor+models&doi=10.18632%2Foncotarget.13738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span></div><div class="casAuthors">Huang Pengyu; Almeciga-Pinto Ingrid; Jarpe Matthew; van Duzer John H; Yang Min; Jones Simon S; Quayle Steven N; Mazitschek Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2694-2707</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242).  Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness.  We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth.  In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone.  Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells.  At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and γ-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification.  The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFIBfKb6ELK8t0fW6udTcc2eYKoES5m1cdt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D&md5=b8a516375b03fc65536598ab9c0e4a21</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13738%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DSelective%2520HDAC%2520inhibition%2520by%2520ACY-241%2520enhances%2520the%2520activity%2520of%2520paclitaxel%2520in%2520solid%2520tumor%2520models%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2694%26epage%3D2707%26doi%3D10.18632%2Foncotarget.13738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+activity%2C+pharmacodynamic%2C+and+pharmacokinetic+properties+of+a+selective+HDAC6+inhibitor%2C+ACY-1215%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0liT6rh0XFTfeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520activity%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520selective%2520HDAC6%2520inhibitor%252C%2520ACY-1215%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span> <span> </span><span class="NLM_article-title">How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin A enantiomers based on molecular dynamics</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2467</span>– <span class="NLM_lpage">2480</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00729</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00729" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1eksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2467-2480&author=Y.+Zhangauthor=J.+B.+Yingauthor=J.+J.+Hongauthor=F.+C.+Liauthor=T.+T.+Fuauthor=F.+Y.+Yangauthor=G.+X.+Zhengauthor=X.+J.+Yaoauthor=Y.+Louauthor=Y.+Qiuauthor=W.+W.+Xueauthor=F.+Zhu&title=How+does+chirality+determine+the+selective+inhibition+of+histone+deacetylase+6%3F+A+lesson+from+trichostatin+A+enantiomers+based+on+molecular+dynamics&doi=10.1021%2Facschemneuro.8b00729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics</span></div><div class="casAuthors">Zhang, Yang; Ying, Jun Biao; Hong, Jia Jun; Li, Feng Cheng; Fu, Ting Ting; Yang, Feng Yuan; Zheng, Guo Xun; Yao, Xiao Jun; Lou, Yan; Qiu, Yunqing; Xue, Wei Wei; Zhu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2467-2480</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) plays a key role in a variety of neurol. disorders, which makes it attractive drug target for the treatment of Alzheimer's disease, Parkinson's disease, and memory/learning impairment.  The selectivity of HDAC6 inhibitors (sHDAC6Is) are widely considered to be susceptible to the sizes of their Cap group and the physicochem. properties of their linker or zinc-binding group, which makes the discovery of new sHDAC6Is extremely difficult.  With the discovery of the distinct selectivity between Trichostatin A (TSA) enantiomers, the chirality residing in the connective units between TSA's Cap and linker shows a great impact on its selectivity.  However, the mechanism underlining (S)-TSA's selectivity is still elusive, and the way chirality switches the selective (S)-TSA to nonselective (R)-TSA is unknown.  In this study, multiple computational approaches were collectively applied to explore, validate, and differentiate the binding modes of two TSA enantiomers in HDACs (esp. the HDAC6) at at. level.  First, two nonconservative residues (G200/M205 and Y197/F202 in HDAC1/6) in loop3 and four conservative residues deep inside the hydrophobic binding pocket were discovered as the decisive residues of (S)-TSA's selectivity toward HDAC6.  Then, a novel mechanism underlying the selectivity of (S)-TSA toward HDAC6 was proposed, which was composed of the trigger by two nonconservative residues F202 and M205 in HDAC6 and a subsequently improved fit of (S)-TSA deep inside HDAC6's hydrophobic binding pocket.  TSA enantiomers were used as a mol. probe to explore the mechanism underlying sHDAC6Is' selectivity in this study.  Because of their decisive roles in (S)-TSA's selectivity to HDAC6, both F202 and M205 in HDAC6 should be esp. considered in the discovery of novel sHDAC6Is.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovlpI1_r-zqbVg90H21EOLACvtfcHk0lgIqGkueFB3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1eksLY%253D&md5=cc905b1cad5fd1ad2b9fc677c3425dbc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00729%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYing%26aufirst%3DJ.%2BB.%26aulast%3DHong%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DF.%2BC.%26aulast%3DFu%26aufirst%3DT.%2BT.%26aulast%3DYang%26aufirst%3DF.%2BY.%26aulast%3DZheng%26aufirst%3DG.%2BX.%26aulast%3DYao%26aufirst%3DX.%2BJ.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DW.%2BW.%26aulast%3DZhu%26aufirst%3DF.%26atitle%3DHow%2520does%2520chirality%2520determine%2520the%2520selective%2520inhibition%2520of%2520histone%2520deacetylase%25206%253F%2520A%2520lesson%2520from%2520trichostatin%2520A%2520enantiomers%2520based%2520on%2520molecular%2520dynamics%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D2467%26epage%3D2480%26doi%3D10.1021%2Facschemneuro.8b00729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+design+and+simple+chemistry+yield+a+superior%2C+neuroprotective+HDAC6+inhibitor%2C+tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lgIqGkueFB3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520design%2520and%2520simple%2520chemistry%2520yield%2520a%2520superior%252C%2520neuroprotective%2520HDAC6%2520inhibitor%252C%2520tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villarroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9891</span>– <span class="NLM_lpage">9899</span>, <span class="refDoi"> DOI: 10.1021/jm301098e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301098e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9891-9899&author=J.+A.+Bergmanauthor=K.+Woanauthor=P.+Perez-Villarroelauthor=A.+Villagraauthor=E.+M.+Sotomayorauthor=A.+P.+Kozikowski&title=Selective+histone+deacetylase+6+inhibitors+bearing+substituted+urea+linkers+inhibit+melanoma+cell+growth&doi=10.1021%2Fjm301098e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth</span></div><div class="casAuthors">Bergman, Joel A.; Woan, Karrune; Perez-Villarroel, Patricio; Villagra, Alejandro; Sotomayor, Eduardo M.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9891-9899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies.  In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor.  Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compds. bearing a branched linker group results in increased potency and selectivity for HDAC6.  Compd. 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ∼600-fold relative to the inhibition of HDAC1.  These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth.  To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkTtPLqvwsrVg90H21EOLACvtfcHk0lgIqGkueFB3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ&md5=d6be4c0efb3922fc35d814ba00ae9ed1</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm301098e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301098e%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DWoan%26aufirst%3DK.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%2520histone%2520deacetylase%25206%2520inhibitors%2520bearing%2520substituted%2520urea%2520linkers%2520inhibit%2520melanoma%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9891%26epage%3D9899%26doi%3D10.1021%2Fjm301098e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebl, M.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chindavong, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1006-1014&author=M.%0AG.+Streblauthor=A.+J.+Campbellauthor=W.-N.+Zhaoauthor=F.+A.+Schroederauthor=M.+M.+Rileyauthor=P.+S.+Chindavongauthor=T.+M.+Morinauthor=S.+J.+Haggartyauthor=F.+F.+Wagnerauthor=T.+Ritterauthor=J.+M.+Hooker&title=HDAC6+Brain+Mapping+with+%5B18F%5DBavarostat+Enabled+by+a+Ru-Mediated+Deoxyfluorination&doi=10.1021%2Facscentsci.7b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination</span></div><div class="casAuthors">Strebl, Martin G.; Campbell, Arthur J.; Zhao, Wen-Ning; Schroeder, Frederick A.; Riley, Misha M.; Chindavong, Peter S.; Morin, Thomas M.; Haggarty, Stephen J.; Wagner, Florence F.; Ritter, Tobias; Hooker, Jacob M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1006-1014</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) function and dysregulation have been implicated in the etiol. of certain cancers and more recently in central nervous system (CNS) disorders including Rett syndrome, Alzheimer's and Parkinson's diseases, and major depressive disorder.  HDAC6-selective inhibitors have therapeutic potential, but in the CNS drug space the development of highly brain penetrant HDAC inhibitors has been a persistent challenge.  Moreover, no tool exists to directly characterize HDAC6 and its related biol. in the living human brain.  Here, we report a highly brain penetrant HDAC6 inhibitor, Bavarostat, that exhibits excellent HDAC6 selectivity (>80-fold over all other Zn-contg. HDAC paralogues), modulates tubulin acetylation selectively over histone acetylation, and has excellent brain penetrance.  We further demonstrate that Bavarostat can be radiolabeled with 18F by deoxyfluorination through in situ formation of a ruthenium π-complex of the corresponding phenol precursor: the only method currently suitable for synthesis of [18F]Bavarostat.  Finally, by using [18F]Bavarostat in a series of rodent and nonhuman primate imaging expts., we demonstrate its utility for mapping HDAC6 in the living brain, which sets the stage for first-in-human neurochem. imaging of this important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmXyZxgRQnAbVg90H21EOLACvtfcHk0lieyKpvTYGLMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaqsLjK&md5=269c6b99919bd156272afc8ad3502146</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00274%26sid%3Dliteratum%253Aachs%26aulast%3DStrebl%26aufirst%3DM.%2BG.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DSchroeder%26aufirst%3DF.%2BA.%26aulast%3DRiley%26aufirst%3DM.%2BM.%26aulast%3DChindavong%26aufirst%3DP.%2BS.%26aulast%3DMorin%26aufirst%3DT.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DRitter%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26atitle%3DHDAC6%2520Brain%2520Mapping%2520with%2520%255B18F%255DBavarostat%2520Enabled%2520by%2520a%2520Ru-Mediated%2520Deoxyfluorination%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26spage%3D1006%26epage%3D1014%26doi%3D10.1021%2Facscentsci.7b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Steen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaeghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougarne, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bosscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">9868</span>– <span class="NLM_lpage">9871</span>, <span class="refDoi"> DOI: 10.1039/c5cc03295d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1039%2Fc5cc03295d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=25994553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1eksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=9868-9871&author=R.+De%0AVreeseauthor=N.+Van+Steenauthor=T.+Verhaegheauthor=T.+Desmetauthor=N.+Bougarneauthor=K.+De+Bosscherauthor=V.+Benoyauthor=W.+Haeckauthor=L.+Van+Den+Boschauthor=M.+D%E2%80%99Hooghe&title=Synthesis+of+benzothiophene-based+hydroxamic+acids+as+potent+and+selective+HDAC6+inhibitors&doi=10.1039%2Fc5cc03295d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">De Vreese, Rob; Van Steen, Nicholas; Verhaeghe, Tom; Desmet, Tom; Bougarne, Nadia; De Bosscher, Karolien; Benoy, Veronick; Haeck, Wanda; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9868-9871</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A small library of 3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophenes, e.g., I, was prepd. and assessed as a novel class of HDAC6 inhibitors, leading to the identification of three representatives as potent and selective HDAC6 inhibitors.  Further tests with regard to inflammatory responses indicated that HDAC6 inhibition can be uncoupled from transcriptional inhibition at the level of activated NF-κB, AP-1, and GR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pF0JIopbXLVg90H21EOLACvtfcHk0lieyKpvTYGLMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1eksb0%253D&md5=ec0347e42b49e724615f45f5c4a12038</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1039%2Fc5cc03295d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc5cc03295d%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DVan%2BSteen%26aufirst%3DN.%26aulast%3DVerhaeghe%26aufirst%3DT.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DBougarne%26aufirst%3DN.%26aulast%3DDe%2BBosscher%26aufirst%3DK.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DHaeck%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520benzothiophene-based%2520hydroxamic%2520acids%2520as%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D9868%26epage%3D9871%26doi%3D10.1039%2Fc5cc03295d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frojuello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Bicyclic-capped histone deacetylase 6 inhibitors with improved activity in a model of axonal Charcot-Marie-Tooth disease</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyktLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=240-258&author=S.+Shenauthor=V.+Benoyauthor=J.+A.+Bergmanauthor=J.+H.+Kalinauthor=M.+Frojuelloauthor=G.+Vistoliauthor=W.+Haeckauthor=L.+Van+Den+Boschauthor=A.+P.+Kozikowski&title=Bicyclic-capped+histone+deacetylase+6+inhibitors+with+improved+activity+in+a+model+of+axonal+Charcot-Marie-Tooth+disease&doi=10.1021%2Facschemneuro.5b00286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease</span></div><div class="casAuthors">Shen, Sida; Benoy, Veronick; Bergman, Joel A.; Kalin, Jay H.; Frojuello, Mariana; Vistoli, Giulio; Haeck, Wanda; Van Den Bosch, Ludo; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-258</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Charcot-Marie-Tooth (CMT) disease is a disorder of the peripheral nervous system where progressive degeneration of motor and sensory nerves leads to motor problems and sensory loss and for which no pharmacol. treatment is available.  Recently, it has been shown in a model for the axonal form of CMT that histone deacetylase 6 (HDAC6) can serve as a target for the development of a pharmacol. therapy.  Therefore, the authors aimed at developing new selective and activity-specific HDAC6 inhibitors with improved biochem. properties.  By utilizing a bicyclic cap as the structural scaffold from which to build upon, the authors developed several analogs that showed improved potency compared to tubastatin A while maintaining excellent selectivity compared to HDAC1.  Further screening in N2a cells examg. both the acetylation of α-tubulin and histones narrowed down the library of compds. to three potent and selective HDAC6 inhibitors.  In mutant HSPB1-expressing DRG neurons, serving as an in vitro model for CMT2, these inhibitors were able to restore the mitochondrial axonal transport deficits.  Combining structure-based development of HDAC6 inhibitors, screening in N2a cells and in a neuronal model for CMT2F, and preliminary ADMET and pharmacokinetic profiles, resulted in the selection of compd. I that possesses improved biochem., functional, and druglike properties compared to tubastatin A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEQ8GZug94Z7Vg90H21EOLACvtfcHk0lieyKpvTYGLMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyktLvF&md5=79b7f824103b5a0f799f1d69fafed7de</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00286%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DFrojuello%26aufirst%3DM.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DHaeck%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DBicyclic-capped%2520histone%2520deacetylase%25206%2520inhibitors%2520with%2520improved%2520activity%2520in%2520a%2520model%2520of%2520axonal%2520Charcot-Marie-Tooth%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D240%26epage%3D258%26doi%3D10.1021%2Facschemneuro.5b00286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer’s disease phenotypes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7087</span>– <span class="NLM_lpage">7102</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00151</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00151" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKmsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7087-7102&author=H.-Y.+Leeauthor=S.-J.+Fanauthor=F.-I.+Huangauthor=H.-Y.+Chaoauthor=K.-C.+Hsuauthor=T.+E.+Linauthor=T.-K.+Yehauthor=M.-J.+Laiauthor=Y.-H.+Liauthor=H.-L.+Huangauthor=C.-R.+Yangauthor=J.-P.+Liou&title=5-Aroylindoles+act+as+selective+histone+deacetylase+6+inhibitors+ameliorating+Alzheimer%E2%80%99s+disease+phenotypes&doi=10.1021%2Facs.jmedchem.8b00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes</span></div><div class="casAuthors">Lee, Hsueh-Yun; Fan, Sheng-Jun; Huang, Fang-I.; Chao, Hsin-Yi; Hsu, Kai-Cheng; Lin, Tony Eight; Yeh, Teng-Kuang; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7087-7102</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids.  N-Hydroxy-4-((5-(4-methoxybenzoyl)-1H-indol-1-yl)methyl)benzamide (6) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC50 value of 3.92 nM.  It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins.  Compd. 6 also shows neuroprotective activity by triggering ubiquitination.  In animal models, compd. 6 is able to ameliorate the impaired learning and memory, and it crosses the blood-brain barrier after oral administration.  Compd. 6 can be developed as a potential treatment for Alzheimer's disease in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrJdt1D5uVurVg90H21EOLACvtfcHk0ljZobfL5a83Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKmsL3L&md5=6065438bfabec38e1f8fa4b5ea47e3ce</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00151%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DFan%26aufirst%3DS.-J.%26aulast%3DHuang%26aufirst%3DF.-I.%26aulast%3DChao%26aufirst%3DH.-Y.%26aulast%3DHsu%26aufirst%3DK.-C.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26aulast%3DHuang%26aufirst%3DH.-L.%26aulast%3DYang%26aufirst%3DC.-R.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3D5-Aroylindoles%2520act%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%2520ameliorating%2520Alzheimer%25E2%2580%2599s%2520disease%2520phenotypes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7087%26epage%3D7102%26doi%3D10.1021%2Facs.jmedchem.8b00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of potent and selective HDAC6 inhibitors bearing a cyclohexane- or cycloheptane-annulated 1,5-benzothiazepine scaffold</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1002/chem.201604167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fchem.201604167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27717044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=128-136&author=R.+De%0AVreeseauthor=L.+Galleauthor=Y.+Depetterauthor=J.+Franceusauthor=T.+Desmetauthor=K.+Van+Heckeauthor=V.+Benoyauthor=L.+Van+Den%0ABoschauthor=M.+D%E2%80%99hooghe&title=Synthesis+of+potent+and+selective+HDAC6+inhibitors+bearing+a+cyclohexane-+or+cycloheptane-annulated+1%2C5-benzothiazepine+scaffold&doi=10.1002%2Fchem.201604167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold</span></div><div class="casAuthors">De Vreese, Rob; Galle, Lisa; Depetter, Yves; Franceus, Jorick; Desmet, Tom; Van Hecke, Kristof; Benoy, Veronick; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-136</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and isolation of (dihydrobenzo[b][1,4]thiazepinyl)methyl-N-hydroxybenzamides I [R = H, Cl, CF3; X = S, SO, SO2; n = 1, 2], a new class of HDAC6 inhibitors, is reported.  Evaluations of their HDAC-inhibiting activity resulted in the identification of I (X = SO2; n = 1; R = H, CF3) as highly potent and selective HDAC6 inhibitors with activity in the low nanomolar range, which also showed excellent selectivity on the enzymic and cellular levels.  Furthermore, four promising inhibitors were subjected to an Ames fluctuation assay, which revealed no mutagenic effects assocd. with these structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQAN_gYUuzi7Vg90H21EOLACvtfcHk0ljZobfL5a83Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFKjtrzF&md5=589c80b2c951fd8e59b931875b9087f0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604167%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DGalle%26aufirst%3DL.%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DFranceus%26aufirst%3DJ.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%2520bearing%2520a%2520cyclohexane-%2520or%2520cycloheptane-annulated%25201%252C5-benzothiazepine%2520scaffold%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D128%26epage%3D136%26doi%3D10.1002%2Fchem.201604167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depetter, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaeghe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2537</span>– <span class="NLM_lpage">2549</span>, <span class="refDoi"> DOI: 10.1039/c5ob02625c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1039%2Fc5ob02625c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26822143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslegtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=2537-2549&author=R.+De%0AVreeseauthor=Y.+Depetterauthor=T.+Verhaegheauthor=T.+Desmetauthor=V.+Benoyauthor=W.+Haeckauthor=L.+Van+Den%0ABoschauthor=M.+D%E2%80%99hooghe&title=Synthesis+and+SAR+assessment+of+novel+Tubathian+analogs+in+the+pursuit+of+potent+and+selective+HDAC6+inhibitors&doi=10.1039%2Fc5ob02625c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">De Vreese, Rob; Depetter, Yves; Verhaeghe, Tom; Desmet, Tom; Benoy, Veronick; Haeck, Wanda; Van Den Bosch, Ludo; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2537-2549</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of novel isoform-selective HDAC inhibitors is considered to be an important, emerging field in medicinal chem.  In this paper, the prepn. and assessment of thirteen selective HDAC6 inhibitors is disclosed, elaborating on a previously developed thiaheterocyclic Tubathian series.  All compds. were evaluated in vitro for their ability to inhibit HDAC6, and a selection of five potent compds. was further screened toward all HDAC isoforms (HDAC1-11).  The capability of these Tubathian analogs to inhibit α-tubulin deacetylation was assessed as well, and ADME/Tox data were collected.  This thorough SAR evaluation revealed that the oxidized, para-substituted hydroxamic acids can be recognized as valuable lead structures in the pursuit of novel potent and selective HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOc-PcpWwhT7Vg90H21EOLACvtfcHk0ljZobfL5a83Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslegtA%253D%253D&md5=d0a6f067b9c15cac567954b6fbf4ceab</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1039%2Fc5ob02625c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc5ob02625c%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DDepetter%26aufirst%3DY.%26aulast%3DVerhaeghe%26aufirst%3DT.%26aulast%3DDesmet%26aufirst%3DT.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DHaeck%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520SAR%2520assessment%2520of%2520novel%2520Tubathian%2520analogs%2520in%2520the%2520pursuit%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D2537%26epage%3D2549%26doi%3D10.1039%2Fc5ob02625c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarics, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Brain penetrable histone deacetylase 6 inhibitor SW-100 ameliorates memory and learning impairments in a mouse model of Fragile X Syndrome</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1679</span>– <span class="NLM_lpage">1695</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1679-1695&author=A.+P.+Kozikowskiauthor=S.+Shenauthor=M.+Pardoauthor=M.+T.+Tavaresauthor=D.+Szaricsauthor=V.+Benoyauthor=C.+A.+Zimprichauthor=Z.+Kutilauthor=G.+Zhangauthor=C.+Ba%C5%99inkaauthor=M.+B.+Robersauthor=L.+Van+Den+Boschauthor=J.+H.+Eubanksauthor=R.+S.+Jope&title=Brain+penetrable+histone+deacetylase+6+inhibitor+SW-100+ameliorates+memory+and+learning+impairments+in+a+mouse+model+of+Fragile+X+Syndrome&doi=10.1021%2Facschemneuro.8b00600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00600%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DSzarics%26aufirst%3DD.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DBrain%2520penetrable%2520histone%2520deacetylase%25206%2520inhibitor%2520SW-100%2520ameliorates%2520memory%2520and%2520learning%2520impairments%2520in%2520a%2520mouse%2520model%2520of%2520Fragile%2520X%2520Syndrome%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D10%26spage%3D1679%26epage%3D1695%26doi%3D10.1021%2Facschemneuro.8b00600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vögerl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01090</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01090" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1138-1166&author=K.+V%C3%B6gerlauthor=N.+Ongauthor=J.+Sengerauthor=D.+Herpauthor=K.+Schmidtkunzauthor=M.+Marekauthor=M.+M%C3%BCllerauthor=K.+Bartelauthor=T.+B.+Shaikauthor=N.+J.+Porterauthor=D.+Robaaauthor=D.+W.+Christiansonauthor=C.+Romierauthor=W.+Sipplauthor=M.+Jungauthor=F.+Bracher&title=Synthesis+and+biological+investigation+of+phenothiazine-based+benzhydroxamic+acids+as+selective+histone+deacetylase+6+inhibitors&doi=10.1021%2Facs.jmedchem.8b01090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Vogerl Katharina; Ong Nghia; Muller Martin; Bartel Karin; Bracher Franz; Senger Johanna; Herp Daniel; Schmidtkunz Karin; Jung Manfred; Marek Martin; Shaik Tajith B; Romier Christophe; Porter Nicholas J; Christianson David W; Robaa Dina; Sippl Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1138-1166</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phenothiazine system was identified as a favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors.  Here, we report the preparation and systematic variation of phenothiazines and their analogues containing a benzhydroxamic acid moiety as the zinc-binding group.  We evaluated their ability to selectively inhibit HDAC6 by a recombinant HDAC enzyme assay, by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines.  Structure-activity relationship studies revealed that incorporation of a nitrogen atom into the phenothiazine framework results in increased potency and selectivity for HDAC6 (more than 500-fold selectivity relative to the inhibition of HDAC1, HDAC4, and HDAC8), as rationalized by molecular modeling and docking studies.  The binding mode was confirmed by co-crystallization of the potent azaphenothiazine inhibitor with catalytic domain 2 from Danio rerio HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkSJzGKNxKWK69lAbTj9rGfW6udTcc2eZh1OS395_EErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D&md5=9d72da7b8f4bb63cd05ccc5f907d2dca</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01090%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25B6gerl%26aufirst%3DK.%26aulast%3DOng%26aufirst%3DN.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DBartel%26aufirst%3DK.%26aulast%3DShaik%26aufirst%3DT.%2BB.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%2520phenothiazine-based%2520benzhydroxamic%2520acids%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1138%26epage%3D1166%26doi%3D10.1021%2Facs.jmedchem.8b01090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, R.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1406</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29133060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1406-1418&author=X.-X.+Wangauthor=R.-Z.+Wanauthor=Z.-P.+Liu&title=Recent+advances+in+the+discovery+of+potent+and+selective+HDAC6+inhibitors&doi=10.1016%2Fj.ejmech.2017.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">Wang, Xiu-Xiu; Wan, Ren-Zhong; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1406-1418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among HDAC enzymes in having two active catalytic domains, and has unique physiol. function.  In addn. to the modification of histone, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degrdn., cell shape and migration.  Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, cancer, and immunol.  Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors.  Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur contg. ZBG based derivs. and other ZBG-derived compds., and their enzymic inhibitory activity, selectivity and other biol. activities are introduced and summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdsNBEWGhpCrVg90H21EOLACvtfcHk0lhau_edmUfG7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM&md5=f24fea971dbed247e1bb2568f85d1703</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-X.%26aulast%3DWan%26aufirst%3DR.-Z.%26aulast%3DLiu%26aufirst%3DZ.-P.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1406%26epage%3D1418%26doi%3D10.1016%2Fj.ejmech.2017.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Vreese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Hooghe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28453994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslOhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=174-195&author=R.+De%0AVreeseauthor=M.+D%E2%80%99Hooghe&title=Synthesis+and+applications+of+benzohydroxamic+acid-based+histone+deacetylase+inhibitors&doi=10.1016%2Fj.ejmech.2017.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors</span></div><div class="casAuthors">De Vreese, Rob; D'hooghe, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">174-195</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This paper provides an overview of the synthesis and biol. activity of the most representative benzohydroxamic acid-based histone deacetylase inhibitors published to date.  Benzohydroxamic acids comprise an important class of HDAC inhibitors, and recently several of these structures have been evaluated in clin. trials for the treatment of a variety of cancers.  In this overview, benzohydroxamic acids were divided in four different classes based on their reported selectivity towards zinc-dependent HDACs: a first and major class consists of HDAC6 selective inhibitors, a second class deals with pan-HDAC inhibitors, a third class comprises HDAC8 selective inhibitors and a fourth, minor class includes dual HDAC6/8 selective inhibitors.  Through this approach, structure-activity relationships were identified for each class, which could help future researchers in the design and development of novel benzohydroxamic acid-based HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyKAa1s9hoSbVg90H21EOLACvtfcHk0lhau_edmUfG7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslOhur0%253D&md5=769c343bdbb3fe610eff001afa79e0bb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVreese%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Hooghe%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520applications%2520of%2520benzohydroxamic%2520acid-based%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D135%26spage%3D174%26epage%3D195%26doi%3D10.1016%2Fj.ejmech.2017.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlimme, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carafa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolfa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellamare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span> <span> </span><span class="NLM_article-title">Carbamate prodrug concept for hydroxamate HDAC inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fcmdc.201100007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=21416613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1193-1198&author=S.+Schlimmeauthor=A.-T.+Hauserauthor=V.+Carafaauthor=R.+Heinkeauthor=S.+Kannanauthor=D.+A.+Stolfaauthor=S.+Cellamareauthor=A.+Carottiauthor=L.+Altucciauthor=M.+Jungauthor=W.+Sippl&title=Carbamate+prodrug+concept+for+hydroxamate+HDAC+inhibitors&doi=10.1002%2Fcmdc.201100007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors</span></div><div class="casAuthors">Schlimme, Sonja; Hauser, Alexander-Thomas; Carafa, Vincenzo; Heinke, Ralf; Kannan, Srinivasaraghavan; Stolfa, Diana A.; Cellamare, Saverio; Carotti, Angelo; Altucci, Lucia; Jung, Manfred; Sippl, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1193-1198</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Virtual screening against a HDAC6 homol. model has led to the indentification of a new HDAC6-selective inhibitor I and a carbamate deriv. that acts as a prodrug in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5mxc5jtnXe7Vg90H21EOLACvtfcHk0lhau_edmUfG7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVCnsbs%253D&md5=21fdb2c7de1ca402e9cf370cd3607eeb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100007%26sid%3Dliteratum%253Aachs%26aulast%3DSchlimme%26aufirst%3DS.%26aulast%3DHauser%26aufirst%3DA.-T.%26aulast%3DCarafa%26aufirst%3DV.%26aulast%3DHeinke%26aufirst%3DR.%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DStolfa%26aufirst%3DD.%2BA.%26aulast%3DCellamare%26aufirst%3DS.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSippl%26aufirst%3DW.%26atitle%3DCarbamate%2520prodrug%2520concept%2520for%2520hydroxamate%2520HDAC%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D1193%26epage%3D1198%26doi%3D10.1002%2Fcmdc.201100007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melesina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01493</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01493" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1545-1555&author=J.+Sengerauthor=J.+Melesinaauthor=M.+Marekauthor=C.+Romierauthor=I.+Oehmeauthor=O.+Wittauthor=W.+Sipplauthor=M.+Jung&title=Synthesis+and+biological+investigation+of+oxazole+hydroxamates+as+highly+selective+histone+deacetylase+6+%28HDAC6%29+inhibitors&doi=10.1021%2Facs.jmedchem.5b01493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors</span></div><div class="casAuthors">Senger, Johanna; Melesina, Jelena; Marek, Martin; Romier, Christophe; Oehme, Ina; Witt, Olaf; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1545-1555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins.  Herein, the prepn. of thiazole-, oxazole-, and oxadiazole-contg. biarylhydroxamic acids by a short synthetic procedure is reported.  They were identified as selective HDAC6 inhibitors by investigating the inhibition of recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation).  The most active compds. exhibited nanomolar potency and high selectivity for HDAC6.  For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8.  This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent.  Compds. I (R = Br or Ph) were found to have the bect activity/HDAC6 selectivity.  The high potency and selectivity of the oxazoles was rationalized by mol. modeling and docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH3cCvoW67w7Vg90H21EOLACvtfcHk0lhf3tD15srB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO&md5=19436b79e523ac3ad5a2a3fcec7c5493</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01493%26sid%3Dliteratum%253Aachs%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DMelesina%26aufirst%3DJ.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%2520oxazole%2520hydroxamates%2520as%2520highly%2520selective%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1545%26epage%3D1555%26doi%3D10.1021%2Facs.jmedchem.5b01493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.-p.</span></span> <span> </span><span class="NLM_article-title">The recent progress of isoxazole in medicinal chemistry</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3065</span>– <span class="NLM_lpage">3075</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bmc.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29853341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3065-3075&author=J.+Zhuauthor=J.+Moauthor=H.-z.+Linauthor=Y.+Chenauthor=H.-p.+Sun&title=The+recent+progress+of+isoxazole+in+medicinal+chemistry&doi=10.1016%2Fj.bmc.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The recent progress of isoxazole in medicinal chemistry</span></div><div class="casAuthors">Zhu, Jie; Mo, Jun; Lin, Hong-zhi; Chen, Yao; Sun, Hao-peng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3065-3075</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Isoxazole compds. exhibit a wide spectrum of targets and broad biol. activities.  Developing compds. with heterocycle rings has been one of the trends.  The integration of isoxazole ring can offer improved phys.-chem. properties.  Because of the unique profiles, isoxazole ring becomes a popular moiety in compds. design.  In this review article, the major focus has been paid to the applications of isoxazole compds. in treating multiple diseases, including anticancer, antimicrobial, anti-inflammatory, etc.  Strategies for compds. design for preclin., clin., and FDA approved drugs were discussed.  Also, the emphasis has been addressed to the future perspectives and trend for the application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Igl9jCgG1rVg90H21EOLACvtfcHk0lhf3tD15srB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL&md5=f2cf06eed32e8655baa76d35b41ef6a1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DH.-z.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.-p.%26atitle%3DThe%2520recent%2520progress%2520of%2520isoxazole%2520in%2520medicinal%2520chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3065%26epage%3D3075%26doi%3D10.1016%2Fj.bmc.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sysak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obmińska-Mrukowicz, B.</span></span> <span> </span><span class="NLM_article-title">Isoxazole ring as a useful scaffold in a search for new therapeutic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.ejmech.2017.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28605676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2017&pages=292-309&author=A.+Sysakauthor=B.+Obmi%C5%84ska-Mrukowicz&title=Isoxazole+ring+as+a+useful+scaffold+in+a+search+for+new+therapeutic+agents&doi=10.1016%2Fj.ejmech.2017.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Isoxazole ring as a useful scaffold in a search for new therapeutic agents</span></div><div class="casAuthors">Sysak, Angelika; Obminska-Mrukowicz, Bozena</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">292-309</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Due to its relatively easy synthesis, isoxazole ring has been as an object of interest for chemists and pharmacologists from research groups all over the world.  Its chem. modifications include both connection of isoxazole with other arom., heteroarom. or non arom. rings and substitution with different alkyl groups.  Thanks to their usually low cytotoxicity, isoxazole derivs. are still popular scaffolds for the development of new agents with variable biol. activities, such as antimicrobial, antiviral, anticancer, anti-inflammatory, immunomodulatory, anticonvulsant or anti-diabetic properties.  This review discusses the chem. structure of recently developed isoxazole derivs. with regards to their activity and potential therapeutic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvOCSKKoVCn7Vg90H21EOLACvtfcHk0lhf3tD15srB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73N&md5=14fcce13ee431e5fb6da1c91f39df47f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DSysak%26aufirst%3DA.%26aulast%3DObmi%25C5%2584ska-Mrukowicz%26aufirst%3DB.%26atitle%3DIsoxazole%2520ring%2520as%2520a%2520useful%2520scaffold%2520in%2520a%2520search%2520for%2520new%2520therapeutic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D137%26spage%3D292%26epage%3D309%26doi%3D10.1016%2Fj.ejmech.2017.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaisina, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tueckmantel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugolkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Identification of HDAC6-selective inhibitors of low cancer cell cytotoxicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fcmdc.201500456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26592932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-92&author=I.+N.+Gaisinaauthor=W.+Tueckmantelauthor=A.+Ugolkovauthor=S.+Shenauthor=J.+Hoffenauthor=O.+Dubrovskyiauthor=A.+Mazarauthor=R.+A.+Schoonauthor=D.+Billadeauauthor=A.+P.+Kozikowski&title=Identification+of+HDAC6-selective+inhibitors+of+low+cancer+cell+cytotoxicity&doi=10.1002%2Fcmdc.201500456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity</span></div><div class="casAuthors">Gaisina, Irina N.; Tueckmantel, Werner; Ugolkov, Andrey; Shen, Sida; Hoffen, Jessica; Dubrovskyi, Oleksii; Mazar, Andrew; Schoon, Renee A.; Billadeau, Daniel; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-92</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large no. of proteins involved in cancer initiation and progression.  The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compds. would avoid some of the undesirable side effects found with the first-generation inhibitors.  A series of HDACIs previously reported by the authors were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells.  In the present work, the authors show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth.  Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells.  The authors conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required.  Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8NrQruF5oObVg90H21EOLACvtfcHk0lhf3tD15srB4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI&md5=2c241c869dfcdd2863cee7aec9c2e898</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500456%26sid%3Dliteratum%253Aachs%26aulast%3DGaisina%26aufirst%3DI.%2BN.%26aulast%3DTueckmantel%26aufirst%3DW.%26aulast%3DUgolkov%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHoffen%26aufirst%3DJ.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DMazar%26aufirst%3DA.%26aulast%3DSchoon%26aufirst%3DR.%2BA.%26aulast%3DBilladeau%26aufirst%3DD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIdentification%2520of%2520HDAC6-selective%2520inhibitors%2520of%2520low%2520cancer%2520cell%2520cytotoxicity%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D92%26doi%3D10.1002%2Fcmdc.201500456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapadar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchini, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span> <span> </span><span class="NLM_article-title">Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4373</span>, <span class="refDoi"> DOI: 10.1021/jm8002894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4370-4373&author=A.+P.+Kozikowskiauthor=S.+Tapadarauthor=D.+N.+Luchiniauthor=K.+H.+Kimauthor=D.+D.+Billadeau&title=Use+of+the+nitrile+oxide+cycloaddition+%28NOC%29+reaction+for+molecular+probe+generation%3A+a+new+class+of+enzyme+selective+histone+deacetylase+inhibitors+%28HDACIs%29+showing+picomolar+activity+at+HDAC6&doi=10.1021%2Fjm8002894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span></div><div class="casAuthors">Kozikowski, Alan P.; Tapadar, Subhasish; Luchini, Doris N.; Kim, Ki Hwan; Billadeau, Daniel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4370-4373</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of hydroxamate based HDAC inhibitors contg. a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddn. chem.  An HDAC6 selective inhibitor having a potency of ∼2 picomolar was identified.  Some of the compds. were examd. for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA (suberoylanilidehydroxamic acid).  This research provides valuable, new mol. probes for use in exploring HDAC biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7Ca9tXdBvbVg90H21EOLACvtfcHk0lgrYVMC7W_4xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D&md5=006c71fe6f2bb09c2c65196e134a695e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm8002894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002894%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DUse%2520of%2520the%2520nitrile%2520oxide%2520cycloaddition%2520%2528NOC%2529%2520reaction%2520for%2520molecular%2520probe%2520generation%253A%2520a%2520new%2520class%2520of%2520enzyme%2520selective%2520histone%2520deacetylase%2520inhibitors%2520%2528HDACIs%2529%2520showing%2520picomolar%2520activity%2520at%2520HDAC6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4370%26epage%3D4373%26doi%3D10.1021%2Fjm8002894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tapadar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchini, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3023</span>– <span class="NLM_lpage">3026</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.04.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bmcl.2009.04.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=19419863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVersrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3023-3026&author=S.+Tapadarauthor=R.+Heauthor=D.+N.+Luchiniauthor=D.+D.+Billadeauauthor=A.+P.+Kozikowski&title=Isoxazole+moiety+in+the+linker+region+of+HDAC+inhibitors+adjacent+to+the+Zn-chelating+group%3A+effects+on+HDAC+biology+and+antiproliferative+activity&doi=10.1016%2Fj.bmcl.2009.04.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: Effects on HDAC biology and antiproliferative activity</span></div><div class="casAuthors">Tapadar, Subhasish; He, Rong; Luchini, Doris N.; Billadeau, Daniel D.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3023-3026</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hydroxamic acid based histone deacetylase inhibitors 6-15, contg. an isoxazole moiety adjacent to the Zn-chelating hydroxamic acid, is reported herein.  Some of these compds. showed nanomolar activity in the HDAC isoform inhibitory assay and exhibited micromolar inhibitory activity against five pancreatic cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrta5zk6I47pLVg90H21EOLACvtfcHk0lgrYVMC7W_4xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVersrs%253D&md5=affc37e7890fc939db595fa48397390c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.04.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.04.058%26sid%3Dliteratum%253Aachs%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DR.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIsoxazole%2520moiety%2520in%2520the%2520linker%2520region%2520of%2520HDAC%2520inhibitors%2520adjacent%2520to%2520the%2520Zn-chelating%2520group%253A%2520effects%2520on%2520HDAC%2520biology%2520and%2520antiproliferative%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3023%26epage%3D3026%26doi%3D10.1016%2Fj.bmcl.2009.04.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">42717</span>, <span class="refDoi"> DOI: 10.1038/srep42717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fsrep42717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28256516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=42717&author=A.+Dainaauthor=O.+Michielinauthor=V.+Zoete&title=SwissADME%3A+a+free+web+tool+to+evaluate+pharmacokinetics%2C+drug-likeness+and+medicinal+chemistry+friendliness+of+small+molecules&doi=10.1038%2Fsrep42717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span></div><div class="casAuthors">Daina Antoine; Michielin Olivier; Zoete Vincent; Michielin Olivier; Michielin Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42717</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur.  Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited.  In that context, computer models constitute valid alternatives to experiments.  Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar.  Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website http://www.swissadme.ch.  Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl_Uk5dOMKs6qcneEtCi92fW6udTcc2eZK47egBzQEbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czisFSrtg%253D%253D&md5=9715b8cb8a34b17c4c73ff69a5a8cc50</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fsrep42717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep42717%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DMichielin%26aufirst%3DO.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DSwissADME%253A%2520a%2520free%2520web%2520tool%2520to%2520evaluate%2520pharmacokinetics%252C%2520drug-likeness%2520and%2520medicinal%2520chemistry%2520friendliness%2520of%2520small%2520molecules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D42717%26doi%3D10.1038%2Fsrep42717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1002%2Fcmdc.201500486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26603496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=15-21&author=S.+Shenauthor=A.+P.+Kozikowski&title=Why+Hydroxamates+May+Not+Be+the+Best+Histone+Deacetylase+Inhibitors-What+Some+May+Have+Forgotten+or+Would+Rather+Forget%3F&doi=10.1002%2Fcmdc.201500486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Hydroxamate-based histone deacetylase inhibitors (HDACIs) have been approved as therapeutic agents by the US Food and Drug Administration for use in oncol. applications.  While the potential utility of such HDACIs in other areas of medicinal chem. is tremendous, there are significant concerns that "pan-HDAC inhibitors" may be too broadly acting and/or toxic for clin. use beyond oncol.  In addn. to the isoenzyme selectivity challenge, the potential mutagenicity of hydroxamate-contg. HDAC inhibitors represents a major hindrance in their application to other therapeutic areas.  Herein the authors report on the mutagenicity of known hydroxamates, discuss the mechanisms responsible for their genotoxicity, and review some of the current alternatives to hydroxamates.  The authors conclude that the hydroxamate group, while providing high-potency HDACIs, is not necessarily the best zinc-binding group for HDACI drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplftHMFVoN6rVg90H21EOLACvtfcHk0lh8tpnMc74nug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL&md5=5183d2c0a4c86fe67bea480a66bc5dc6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500486%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWhy%2520Hydroxamates%2520May%2520Not%2520Be%2520the%2520Best%2520Histone%2520Deacetylase%2520Inhibitors-What%2520Some%2520May%2520Have%2520Forgotten%2520or%2520Would%2520Rather%2520Forget%253F%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D15%26epage%3D21%26doi%3D10.1002%2Fcmdc.201500486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Invidiata, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondanin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaudo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannizzo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbusca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porretto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessandro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolomeo, M.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Relationship Studies of Novel Heteroretinoids: Induction of Apoptosis in the HL-60 Cell Line by a Novel Isoxazole-Containing Heteroretinoid</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4969</span>, <span class="refDoi"> DOI: 10.1021/jm991059n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm991059n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADyaK1MXntVaks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=4961-4969&author=D.+Simoniauthor=F.+P.+Invidiataauthor=R.+Rondaninauthor=S.+Grimaudoauthor=G.+Cannizzoauthor=E.+Barbuscaauthor=F.+Porrettoauthor=N.+D%E2%80%99Alessandroauthor=M.+Tolomeo&title=Structure%E2%80%93Activity+Relationship+Studies+of+Novel+Heteroretinoids%3A+Induction+of+Apoptosis+in+the+HL-60+Cell+Line+by+a+Novel+Isoxazole-Containing+Heteroretinoid&doi=10.1021%2Fjm991059n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Studies of Novel Heteroretinoids: Induction of Apoptosis in the HL-60 Cell Line by a Novel Isoxazole-Containing Heteroretinoid</span></div><div class="casAuthors">Simoni, Daniele; Invidiata, Francesco Paolo; Rondanin, Riccardo; Grimaudo, Stefania; Cannizzo, Giuliana; Barbusca, Eleonora; Porretto, Ferdinando; D'Alessandro, Nicola; Tolomeo, Manlio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4961-4969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In a search for retinoic acid receptor (RAR and RXR)-selective ligands, a series of isoxazole retinoids was synthesized and evaluated in vitro in transcriptional activation and competition binding assays for RARs and RXRs.  In addn., these compds. were evaluated for their differentiating, cytotoxic, and apoptotic activities.  In general, these derivs. showed scarcely any binding affinity and were not active in the transcriptional assay.  However, among these isoxazole derivs., one cis-compds. was identified as a potent inducer of apoptosis, and its activity was found to be 6.5 and 4 times superior than that of 13-cis- and 9-cis-retinoic acids, resp.  On the other hand, a compd. which have the trans stereochem. at the double bond, was found not to be active in the apoptotic assay, but it was endowed with appreciable differentiating activity.  Therefore, it seems that the different stereochem. of the double bond may be assocd. with a different biol. activity: potent apoptotic activity for the cis-isomer but differentiating activity for the trans structure.  This biol. behavior was found, at least in part, for the 9-cis- and 13-cis-retinoic acids with respect to the all-trans-retinoic acid.  Thus, isoxazole retinoids could offer an interesting model for the design of new compds. endowed with apoptotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ni1MSQmk1LVg90H21EOLACvtfcHk0lh8tpnMc74nug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVaks7g%253D&md5=4fec1bfd4b89eed7c6e491eaffd2b06a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm991059n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm991059n%26sid%3Dliteratum%253Aachs%26aulast%3DSimoni%26aufirst%3DD.%26aulast%3DInvidiata%26aufirst%3DF.%2BP.%26aulast%3DRondanin%26aufirst%3DR.%26aulast%3DGrimaudo%26aufirst%3DS.%26aulast%3DCannizzo%26aufirst%3DG.%26aulast%3DBarbusca%26aufirst%3DE.%26aulast%3DPorretto%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Alessandro%26aufirst%3DN.%26aulast%3DTolomeo%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationship%2520Studies%2520of%2520Novel%2520Heteroretinoids%253A%2520Induction%2520of%2520Apoptosis%2520in%2520the%2520HL-60%2520Cell%2520Line%2520by%2520a%2520Novel%2520Isoxazole-Containing%2520Heteroretinoid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D4961%26epage%3D4969%26doi%3D10.1021%2Fjm991059n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Segretti, M. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallerini, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Thiol-based potent and selective HDAC6 inhibitors promote tubulin acetylation and T-regulatory cell suppressive function</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1156-1161&author=M.+C.+F.+Segrettiauthor=G.+P.+Valleriniauthor=C.+Brochierauthor=B.+Langleyauthor=L.+Wangauthor=W.+W.+Hancockauthor=A.+P.+Kozikowski&title=Thiol-based+potent+and+selective+HDAC6+inhibitors+promote+tubulin+acetylation+and+T-regulatory+cell+suppressive+function&doi=10.1021%2Facsmedchemlett.5b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function</span></div><div class="casAuthors">Segretti, Mariana C. F.; Vallerini, Gian Paolo; Brochier, Camille; Langley, Brett; Wang, Liqing; Hancock, Wayne W.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1156-1161</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several new mercaptoacetamides were synthesized and studied as HDAC6 inhibitors.  One compd., I, bearing an aminoquinoline cap group, was found to show 1.3 nM potency at HDAC6, with >3000-fold selectivity over HDAC1.  I also showed excellent efficacy at increasing tubulin acetylation in rat primary cortical cultures, inducing a 10-fold increase in acetylated tubulin at 1 μM.  To assess possible therapeutic effects, compds. were assayed for their ability to increase T-regulatory (Treg) suppressive function.  Some but not all of the compds. increased Treg function, and thereby decreased conventional T cell activation and proliferation in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFoMNCfBF-MbVg90H21EOLACvtfcHk0lh8tpnMc74nug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SlsbnF&md5=10f24c7712c46f4b69fe2e4d17231a35</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00303%26sid%3Dliteratum%253Aachs%26aulast%3DSegretti%26aufirst%3DM.%2BC.%2BF.%26aulast%3DVallerini%26aufirst%3DG.%2BP.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DThiol-based%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%2520promote%2520tubulin%2520acetylation%2520and%2520T-regulatory%2520cell%2520suppressive%2520function%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D1156%26epage%3D1161%26doi%3D10.1021%2Facsmedchemlett.5b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of mercaptoacetamides as potent, selective, and brain permeable histone deacetylase 6 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=510-515&author=W.+Lvauthor=G.+Zhangauthor=C.+Barinkaauthor=J.+H.+Eubanksauthor=A.+P.+Kozikowski&title=Design+and+synthesis+of+mercaptoacetamides+as+potent%2C+selective%2C+and+brain+permeable+histone+deacetylase+6+inhibitors&doi=10.1021%2Facsmedchemlett.7b00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Lv, Wei; Zhang, Guangming; Barinka, Cyril; Eubanks, James H.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of non-hydroxamate HDAC6 inhibitors were prepd. in our effort to develop potent and selective compds. for possible use in Central Nervous System (CNS) disorders, thus obviating the genotoxicity often assocd. with the hydroxamates.  Halogens are incorporated in the cap groups of the designed mercaptoacetamides in order to increase brain accessibility.  The indole analog and quinoline analog displayed potent HDAC6 inhibitory activity (IC50 11 nM and 2.8 nM) and excellent selectivity against HDAC1.  Both compds., together with their ester prodrug and disulfide prodrugs were found to be effective in promoting tubulin acetylation in HEK cells.  The disulfide prodrugs also released a stable concn. of the indole and quinoline analogs upon microsomal incubation.  Administration of disulfide prodrugs in vivo was found to trigger an increase of tubulin acetylation in mouse cortex.  These results suggest that further exploration of these com-pounds for the treatment of CNS disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4LBQBS-jHCrVg90H21EOLACvtfcHk0liN3d2hvle7tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D&md5=f7709c8f4c339737da3201149afe0f82</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00012%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520mercaptoacetamides%2520as%2520potent%252C%2520selective%252C%2520and%2520brain%2520permeable%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D510%26epage%3D515%26doi%3D10.1021%2Facsmedchemlett.7b00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmenon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caignard, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennuyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staels, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audinot-Bouchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutin, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dacquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ktorza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viaud-Massuard, M.-C.</span></span> <span> </span><span class="NLM_article-title">4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1617</span>– <span class="NLM_lpage">1622</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.bmcl.2008.01.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=18255290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjt1Ckt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1617-1622&author=C.+Parmenonauthor=J.+Guillardauthor=D.-H.+Caignardauthor=N.+Hennuyerauthor=B.+Staelsauthor=V.+Audinot-Bouchezauthor=J.-A.+Boutinauthor=C.+Dacquetauthor=A.+Ktorzaauthor=M.-C.+Viaud-Massuard&title=4%2C4-Dimethyl-1%2C2%2C3%2C4-tetrahydroquinoline-based+PPAR%CE%B1%2F%CE%B3+agonists.+Part+I%3A+Synthesis+and+pharmacological+evaluation&doi=10.1016%2Fj.bmcl.2008.01.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation</span></div><div class="casAuthors">Parmenon, Cecile; Guillard, Jerome; Caignard, Daniel-Henri; Hennuyer, Nathalie; Staels, Bart; Audinot-Bouchez, Valerie; Boutin, Jean-Albert; Dacquet, Catherine; Ktorza, Alain; Viaud-Massuard, Marie-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1617-1622</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of 4,4-dimethyl-1,2,3,4-tetrahydroquinolines, e.g. I (R = H, Me), was synthesized and studied as human PPARγ selective agonists and dual PPARα/γ agonists for potential treatment of type-2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp08HKGqPuCVLVg90H21EOLACvtfcHk0liN3d2hvle7tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjt1Ckt70%253D&md5=93ad385b32df02483e5cd41d979000de</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.067%26sid%3Dliteratum%253Aachs%26aulast%3DParmenon%26aufirst%3DC.%26aulast%3DGuillard%26aufirst%3DJ.%26aulast%3DCaignard%26aufirst%3DD.-H.%26aulast%3DHennuyer%26aufirst%3DN.%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DAudinot-Bouchez%26aufirst%3DV.%26aulast%3DBoutin%26aufirst%3DJ.-A.%26aulast%3DDacquet%26aufirst%3DC.%26aulast%3DKtorza%26aufirst%3DA.%26aulast%3DViaud-Massuard%26aufirst%3DM.-C.%26atitle%3D4%252C4-Dimethyl-1%252C2%252C3%252C4-tetrahydroquinoline-based%2520PPAR%25CE%25B1%252F%25CE%25B3%2520agonists.%2520Part%2520I%253A%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1617%26epage%3D1622%26doi%3D10.1016%2Fj.bmcl.2008.01.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowkett, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stachulski, A. V.</span></span> <span> </span><span class="NLM_article-title">Haloarene derivatives of carbamazepine with reduced bioactivation liabilities: 2-monohalo and 2,8-dihalo derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9773</span>– <span class="NLM_lpage">9784</span>, <span class="refDoi"> DOI: 10.1021/jm301013n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301013n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCrur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9773-9784&author=E.-C.+Elliottauthor=S.+L.+Reganauthor=J.+L.+Maggsauthor=E.+R.+Bowkettauthor=L.+J.+Parryauthor=D.+P.+Williamsauthor=B.+K.+Parkauthor=A.+V.+Stachulski&title=Haloarene+derivatives+of+carbamazepine+with+reduced+bioactivation+liabilities%3A+2-monohalo+and+2%2C8-dihalo+derivatives&doi=10.1021%2Fjm301013n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Haloarene Derivatives of Carbamazepine with Reduced Bioactivation Liabilities: 2-Monohalo and 2,8-Dihalo Derivatives</span></div><div class="casAuthors">Elliott, Emma-Claire; Regan, Sophie L.; Maggs, James L.; Bowkett, Elizabeth R.; Parry, Laura J.; Williams, Dominic P.; Park, B. Kevin; Stachulski, Andrew V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9773-9784</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anticonvulsant carbamazepine (I) is assocd. with adverse drug reactions (ADRs), including hepatotoxicity; oxidative metab. of I has been implicated in the pathogenesis of the ADRs.  The authors report the synthesis and evaluation of 2-monohalo and 2,8-dihalo analogs of I that were intended to minimize reactive metabolite formation via arene oxidn. and 10,11-epoxidn.  Halo analogs were obtained either by rearrangement of halogenated N-arylindoles or from specifically halogenated iminodibenzyl derivs.  In rat hepatocytes, none of the analogs underwent oxidative dehalogenation or glutathione adduction.  Some formation of the 10,11-epoxide still occurred, but arom. hydroxylation was not seen with the exception of 2-fluoro, which allowed minor monohydroxylation.  Complete inhibition of arom. hydroxylation required at least monochlorination or difluorination of I.  In human liver microsomes, difluoro analog II underwent 10,11-epoxidn. but gave no arene oxidn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDc7RDg0laObVg90H21EOLACvtfcHk0liN3d2hvle7tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCrur7J&md5=d158092424146266ca119a4d5656ba30</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm301013n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301013n%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DE.-C.%26aulast%3DRegan%26aufirst%3DS.%2BL.%26aulast%3DMaggs%26aufirst%3DJ.%2BL.%26aulast%3DBowkett%26aufirst%3DE.%2BR.%26aulast%3DParry%26aufirst%3DL.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DStachulski%26aufirst%3DA.%2BV.%26atitle%3DHaloarene%2520derivatives%2520of%2520carbamazepine%2520with%2520reduced%2520bioactivation%2520liabilities%253A%25202-monohalo%2520and%25202%252C8-dihalo%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9773%26epage%3D9784%26doi%3D10.1021%2Fjm301013n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Asencio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramón, D. J.</span></span> <span> </span><span class="NLM_article-title">Copper(II) acetate-catalyzed one-pot conversion of aldehydes into primary amides through a Beckmann-type rearrangement</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3948</span>– <span class="NLM_lpage">3951</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2012.03.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fj.tet.2012.03.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=3948-3951&author=A.+Mart%C3%ADnez-Asencioauthor=M.+Yusauthor=D.+J.+Ram%C3%B3n&title=Copper%28II%29+acetate-catalyzed+one-pot+conversion+of+aldehydes+into+primary+amides+through+a+Beckmann-type+rearrangement&doi=10.1016%2Fj.tet.2012.03.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Copper(II) acetate-catalyzed one-pot conversion of aldehydes into primary amides through a Beckmann-type rearrangement</span></div><div class="casAuthors">Martinez-Asencio, Ana; Yus, Miguel; Ramon, Diego J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3948-3951</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Copper(II) acetate is a versatile catalyst for the direct transformation of any type of aldehydes into primary amides by stoichiometric reaction with hydroxylamine in water.  The catalyst could be recovered 10 times without losing its activity, just by a simple org. layer extn. of the product.  The catalyst and the protocol avoid the use of any type of expensive and difficult to handle org. ligand, as well as bases, showing excellent yields, under mild reaction conditions.  The great purity of the crude product permits its purifn. by a simple recrystn. process.  The whole protocol fulfills the principle of green chem. and sustainability, minimizing the use of org. solvents and any type of wastes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJCgpumte1XrVg90H21EOLACvtfcHk0lgijdndGKA2DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWhsro%253D&md5=4c901c0ef8daf5570fb36062f842e245</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2012.03.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2012.03.085%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADnez-Asencio%26aufirst%3DA.%26aulast%3DYus%26aufirst%3DM.%26aulast%3DRam%25C3%25B3n%26aufirst%3DD.%2BJ.%26atitle%3DCopper%2528II%2529%2520acetate-catalyzed%2520one-pot%2520conversion%2520of%2520aldehydes%2520into%2520primary%2520amides%2520through%2520a%2520Beckmann-type%2520rearrangement%26jtitle%3DTetrahedron%26date%3D2012%26volume%3D68%26spage%3D3948%26epage%3D3951%26doi%3D10.1016%2Fj.tet.2012.03.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholte, A. A.</span></span> <span> </span><span class="NLM_article-title">Reductive N-alkylation of amides, carbamates and ureas</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2295</span>– <span class="NLM_lpage">2298</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(99)00211-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2Fs0040-4039%2899%2900211-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADyaK1MXhvVensr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=2295-2298&author=D.+Dub%C3%A9author=A.+A.+Scholte&title=Reductive+N-alkylation+of+amides%2C+carbamates+and+ureas&doi=10.1016%2Fs0040-4039%2899%2900211-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Reductive N-alkylation of amides, carbamates and ureas</span></div><div class="casAuthors">Dube, Daniel; Scholte, Andrew A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2295-2298</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A one-pot selective mono-N-alkylation of primary amides, thioamides, carbamates and ureas has been developed using arom. and aliph. aldehydes as alkylating agents and trifluoroacetic acid/triethylsilane as reagents.  Application to an efficient synthesis of a primary amine from the corresponding aldehyde via the carbamate intermediate is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor_3EkWvE--bVg90H21EOLACvtfcHk0lgijdndGKA2DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvVensr4%253D&md5=8972157ea7e865a307eaa053c30452d7</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4039%2899%2900211-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4039%252899%252900211-7%26sid%3Dliteratum%253Aachs%26aulast%3DDub%25C3%25A9%26aufirst%3DD.%26aulast%3DScholte%26aufirst%3DA.%2BA.%26atitle%3DReductive%2520N-alkylation%2520of%2520amides%252C%2520carbamates%2520and%2520ureas%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26spage%3D2295%26epage%3D2298%26doi%3D10.1016%2Fs0040-4039%2899%2900211-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groom, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alex, A.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency: a useful metric for lead selection</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/s1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+a+useful+metric+for+lead+selection&doi=10.1016%2Fs1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2ebelQ4FrRYZ9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520a%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2Fs1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallego, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Lipophilic efficiency as an important metric in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6401</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00077</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00077" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6401-6420&author=T.+W.+Johnsonauthor=R.+A.+Gallegoauthor=M.+P.+Edwards&title=Lipophilic+efficiency+as+an+important+metric+in+drug+design&doi=10.1021%2Facs.jmedchem.8b00077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Lipophilic Efficiency as an Important Metric in Drug Design</span></div><div class="casAuthors">Johnson, Ted W.; Gallego, Rebecca A.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6401-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chem. lead optimization programs.  In this perspective, using literature drug discovery examples, we discuss the concept of rigorously applying LipE to guide medicinal chem. lead optimization toward drug candidates with potential for superior in vivo efficacy and safety, esp. when guided by physiochem. property-based optimization (PPBO).  Also highlighted are examples of small structural modifications such as addn. of single atoms, small functional groups, and cyclizations that produce large increases in LipE.  Understanding the factors that may contribute to LipE changes through anal. of ligand-protein crystal structures and using structure-based drug design (SBDD) to increase LipE by design is also discussed.  Herein we advocate for use of LipE anal. coupled with PPBO and SBDD as an efficient mechanism for drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXQ8DOcOj6GrVg90H21EOLACvtfcHk0lgkJsrh7P-mwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsVahsbg%253D&md5=29f38880914fa75c33be3a640ace4309</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DGallego%26aufirst%3DR.%2BA.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DLipophilic%2520efficiency%2520as%2520an%2520important%2520metric%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6401%26epage%3D6420%26doi%3D10.1021%2Facs.jmedchem.8b00077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">13459</span>– <span class="NLM_lpage">13464</span>, <span class="refDoi"> DOI: 10.1073/pnas.1718823114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1073%2Fpnas.1718823114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=29203661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13459-13464&author=N.+J.+Porterauthor=A.+Mahendranauthor=R.+Breslowauthor=D.+W.+Christianson&title=Unusual+zinc-binding+mode+of+HDAC6-selective+hydroxamate+inhibitors&doi=10.1073%2Fpnas.1718823114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span></div><div class="casAuthors">Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13459-13464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins.  The Zn2+-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis.  Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders.  Here, we present high-resoln. structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compds. that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-((N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide (HPB), ACY-1215 (Ricolinostat), and ACY-1083.  These structures reveal that an unusual monodentate Zn2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors.  We addnl. report the ultrahigh-resoln. structure of the HDAC6-trichostatin A complex, which reveals two Zn2+-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol.  The minor conformer is not visible in lower resoln. structure detns.  Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isoenzyme selectivity obsd. in biochem. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oUH1X_04p7Vg90H21EOLACvtfcHk0lgkJsrh7P-mwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI&md5=07180756239eac4891642cf59a2e6992</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1718823114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1718823114%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DUnusual%2520zinc-binding%2520mode%2520of%2520HDAC6-selective%2520hydroxamate%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2017%26volume%3D114%26spage%3D13459%26epage%3D13464%26doi%3D10.1073%2Fpnas.1718823114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3916</span>– <span class="NLM_lpage">3924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00367</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00367" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3916-3924&author=N.+J.+Porterauthor=F.+F.+Wagnerauthor=D.+W.+Christianson&title=Entropy+as+a+driver+of+selectivity+for+inhibitor+binding+to+histone+deacetylase+6&doi=10.1021%2Facs.biochem.8b00367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6</span></div><div class="casAuthors">Porter, Nicholas J.; Wagner, Florence F.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3916-3924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among the metal-dependent histone deacetylases, the class IIb isoenzyme HDAC6 is remarkable due to its role in the regulation of microtubule dynamics in the cytosol.  Selective inhibition of HDAC6 results in microtubule hyperacetylation, leading to cell cycle arrest and apoptosis, which is a validated strategy for cancer chemotherapy and the treatment of other disorders.  HDAC6 inhibitors generally consist of a Zn2+-binding group such as a hydroxamate, a linker, and a capping group; the capping group is a crit. determinant of isoenzyme selectivity.  Surprisingly, however, even "capless" inhibitors exhibit appreciable HDAC6 selectivity.  To probe the chem. basis for this selectivity, we now report high-resoln. crystal structures of HDAC6 complexed with capless cycloalkylhydroxamate inhibitors 1-4.  Each inhibitor hydroxamate group coordinates to the catalytic Zn2+ ion with canonical bidentate geometry.  Addnl., the olefin moieties of compds. 2 and 4 bind in an arom. crevice between the side chains of F583 and F643.  Reasoning that similar binding could be achieved in the representative class I isoenzyme HDAC8, we employed isothermal titrn. calorimetry to study the thermodn. of inhibitor binding.  These measurements indicate that the entropy of inhibitor binding is generally pos. for binding to HDAC6 and neg. for binding to HDAC8, resulting in up to 313-fold selectivity for binding to HDAC6 relative to HDAC8.  Thus, favorable binding entropy contributes to HDAC6 selectivity.  Notably, cyclohexenylhydroxamate 2 represents a promising lead for derivatization with capping groups that may further enhance its impressive 313-fold thermodn. selectivity for HDAC6 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MmbdoXXUqrVg90H21EOLACvtfcHk0lgkJsrh7P-mwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Onsrg%253D&md5=0da8abf0ee7f012db41c620101551442</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00367%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DEntropy%2520as%2520a%2520driver%2520of%2520selectivity%2520for%2520inhibitor%2520binding%2520to%2520histone%2520deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3916%26epage%3D3924%26doi%3D10.1021%2Facs.biochem.8b00367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8054</span>– <span class="NLM_lpage">8060</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8054-8060&author=N.+J.+Porterauthor=J.+D.+Oskoauthor=D.+Diedrichauthor=T.+Kurzauthor=J.+M.+Hookerauthor=F.+K.+Hansenauthor=D.+W.+Christianson&title=Histone+deacetylase+6-selective+inhibitors+and+the+influence+of+capping+groups+on+hydroxamate-zinc+denticity&doi=10.1021%2Facs.jmedchem.8b01013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity</span></div><div class="casAuthors">Porter, Nicholas J.; Osko, Jeremy D.; Diedrich, Daniela; Kurz, Thomas; Hooker, Jacob M.; Hansen, Finn K.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8054-8060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Four crystal structures are presented of histone deacetylase 6 (HDAC6) complexes with para-substituted phenylhydromaxamate inhibitors, including bulky peptoids.  These structures provide insight regarding the design of capping groups that confer selectivity for binding to HDAC6, specifically with regard to interactions in a pocket formed by the L1 loop.  Capping group interactions may also influence hydroxamate-Zn2+ coordination with monodentate or bidentate geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq54PM6p6wpnrVg90H21EOLACvtfcHk0lgkJsrh7P-mwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFansLnE&md5=f1d227d7668d09e121e5967b2d65f1a5</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01013%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DDiedrich%26aufirst%3DD.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206-selective%2520inhibitors%2520and%2520the%2520influence%2520of%2520capping%2520groups%2520on%2520hydroxamate-zinc%2520denticity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8054%26epage%3D8060%26doi%3D10.1021%2Facs.jmedchem.8b01013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+deacetylase+6+structure+and+molecular+basis+of+catalysis+and+inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0ljK_-RZhwdFQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520structure%2520and%2520molecular%2520basis%2520of%2520catalysis%2520and%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodroofe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupcho, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niles, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">Target engagement and drug residence time can be observed in living cells with BRET</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">10091</span>, <span class="refDoi"> DOI: 10.1038/ncomms10091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fncomms10091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26631872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10091&author=M.+B.+Robersauthor=M.+L.+Dartauthor=C.+C.+Woodroofeauthor=C.+A.+Zimprichauthor=T.+A.+Kirklandauthor=T.+Machleidtauthor=K.+R.+Kupchoauthor=S.+Levinauthor=J.+R.+Hartnettauthor=K.+Zimmermanauthor=A.+L.+Nilesauthor=R.+F.+Ohanaauthor=D.+L.+Danielsauthor=M.+Slaterauthor=M.+G.+Woodauthor=M.+Congauthor=Y.-Q.+Chengauthor=K.+V.+Wood&title=Target+engagement+and+drug+residence+time+can+be+observed+in+living+cells+with+BRET&doi=10.1038%2Fncomms10091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement and drug residence time can be observed in living cells with BRET</span></div><div class="casAuthors">Robers, Matthew B.; Dart, Melanie L.; Woodroofe, Carolyn C.; Zimprich, Chad A.; Kirkland, Thomas A.; Machleidt, Thomas; Kupcho, Kevin R.; Levin, Sergiy; Hartnett, James R.; Zimmerman, Kristopher; Niles, Andrew L.; Ohana, Rachel Friedman; Daniels, Danette L.; Slater, Michael; Wood, Monika G.; Cong, Mei; Cheng, Yi-Qiang; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10091</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic action of drugs is predicated on their phys. engagement with cellular targets.  Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells.  Cell-permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement with the target proteins fused to Nanoluc luciferase.  The approach enabled us to profile isoenzyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors.  Our anal. was directed particularly to the clin. approved prodrug FK228 (Istodax/Romidepsin) because of its unique and largely unexplained mechanism of sustained intracellular action.  Anal. of the binding kinetics by BRET revealed remarkably long intracellular residence times for FK228 at HDAC1, explaining the protracted intracellular behavior of this prodrug.  Our results demonstrate a novel application of BRET for assessing target engagement within the complex milieu of the intracellular environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRFFk0LNiL_LVg90H21EOLACvtfcHk0ljK_-RZhwdFQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO&md5=723cc5dd7d229b1115da4c2c9d75c913</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fncomms10091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10091%26sid%3Dliteratum%253Aachs%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DDart%26aufirst%3DM.%2BL.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKupcho%26aufirst%3DK.%2BR.%26aulast%3DLevin%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DNiles%26aufirst%3DA.%2BL.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.-Q.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DTarget%2520engagement%2520and%2520drug%2520residence%2520time%2520can%2520be%2520observed%2520in%2520living%2520cells%2520with%2520BRET%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10091%26doi%3D10.1038%2Fncomms10091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, R. A.</span></span> <span> </span><span class="NLM_article-title">A Breakthrough: macrophage-directed cancer immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-15-1737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F0008-5472.can-15-1737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=26772756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=513-516&author=C.+D.+Millsauthor=L.+L.+Lenzauthor=R.+A.+Harris&title=A+Breakthrough%3A+macrophage-directed+cancer+immunotherapy&doi=10.1158%2F0008-5472.can-15-1737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A Breakthrough: Macrophage-Directed Cancer Immunotherapy</span></div><div class="casAuthors">Mills, Charles D.; Lenz, Laurel L.; Harris, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">513-516</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors.  Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting mols. that actively stimulate tumor growth in much the same way they help wounds heal.  However, modulating M2/repair-type macrophages to M1/kill-type can slow or stop cancer growth.  The effects involve direct activity of M1 kill-type as well as the ability of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells.  Macrophage responses can also predict cancer susceptibility; individuals with a high M1/kill to M2/repair ratio are less prone.  That macrophages/innate immunity can be modulated to play a central role in directly or indirectly combating cancer is a breakthrough that seems likely to finally make successful immunotherapy of cancer a reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFHZeNJZP2VLVg90H21EOLACvtfcHk0ljK_-RZhwdFQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSgsbs%253D&md5=85a2a0f1140d55bd8f16649c56501dcf</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-15-1737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-15-1737%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DC.%2BD.%26aulast%3DLenz%26aufirst%3DL.%2BL.%26aulast%3DHarris%26aufirst%3DR.%2BA.%26atitle%3DA%2520Breakthrough%253A%2520macrophage-directed%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D513%26epage%3D516%26doi%3D10.1158%2F0008-5472.can-15-1737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages: from basic research to clinical application</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">58</span>, <span class="refDoi"> DOI: 10.1186/s13045-017-0430-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1186%2Fs13045-017-0430-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28241846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksl2nsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=58&author=L.+Yangauthor=Y.+Zhang&title=Tumor-associated+macrophages%3A+from+basic+research+to+clinical+application&doi=10.1186%2Fs13045-017-0430-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-associated macrophages: from basic research to clinical application</span></div><div class="casAuthors">Yang, Li; Zhang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58/1-58/12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The fact that various immune cells, including macrophages, can be found in tumor tissues has long been known.  With the introduction of concept that macrophages differentiate into a classically or alternatively activated phenotype, the role of tumor-assocd. macrophages (TAMs) is now beginning to be elucidated.  TAMs act as "protumoral macrophages," contributing to disease progression.  TAMs can promote initiation and metastasis of tumor cells, inhibit antitumor immune responses mediated by T cells, and stimulate tumor angiogenesis and subsequently tumor progression.  As the relationship between TAMs and malignant tumors becomes clearer, TAMs are beginning to be seen as potential biomarkers for diagnosis and prognosis of cancers, as well as therapeutic targets in these cases.  In this review, we will discuss the origin, polarization, and role of TAMs in human malignant tumors, as well as how TAMs can be used as diagnostic and prognostic biomarkers and therapeutic targets of cancer in clinics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE2DAqgN25RrVg90H21EOLACvtfcHk0liTOt-2DWvfLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksl2nsLo%253D&md5=2663c88c41e470910799eaba7a47eba0</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fs13045-017-0430-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-017-0430-2%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DTumor-associated%2520macrophages%253A%2520from%2520basic%2520research%2520to%2520clinical%2520application%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2017%26volume%3D10%26spage%3D58%26doi%3D10.1186%2Fs13045-017-0430-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skultetyova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havlinova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansky, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11547</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11739-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1038%2Fs41598-017-11739-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=28912522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BC1cboslOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=11547&author=L.+Skultetyovaauthor=K.+Ustinovaauthor=Z.+Kutilauthor=Z.+Novakovaauthor=J.+Pavlicekauthor=J.+Mikesovaauthor=D.+Traplauthor=P.+Baranovaauthor=B.+Havlinovaauthor=M.+Hubalekauthor=Z.+Lanskyauthor=C.+Barinka&title=Human+histone+deacetylase+6+shows+strong+preference+for+tubulin+dimers+over+assembled+microtubules&doi=10.1038%2Fs41598-017-11739-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules</span></div><div class="casAuthors">Skultetyova Lubica; Ustinova Kseniya; Kutil Zsofia; Novakova Zora; Pavlicek Jiri; Mikesova Jana; Trapl Dalibor; Baranova Petra; Havlinova Barbora; Lansky Zdenek; Barinka Cyril; Skultetyova Lubica; Hubalek Martin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11547</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human histone deacetylase 6 (HDAC6) is the major deacetylase responsible for removing the acetyl group from Lys40 of α-tubulin (αK40), which is located lumenally in polymerized microtubules.  Here, we provide a detailed kinetic analysis of tubulin deacetylation and HDAC6/microtubule interactions using individual purified components.  Our data unequivocally show that free tubulin dimers represent the preferred HDAC6 substrate, with a K M value of 0.23 μM and a deacetylation rate over 1,500-fold higher than that of assembled microtubules.  We attribute the lower deacetylation rate of microtubules to both longitudinal and lateral lattice interactions within tubulin polymers.  Using TIRF microscopy, we directly visualized stochastic binding of HDAC6 to assembled microtubules without any detectable preferential binding to microtubule tips.  Likewise, indirect immunofluorescence microscopy revealed that microtubule deacetylation by HDAC6 is carried out stochastically along the whole microtubule length, rather than from the open extremities.  Our data thus complement prior studies on tubulin acetylation and further strengthen the rationale for the correlation between tubulin acetylation and microtubule age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2XuDrQ2dPtsKL0FlyGHDofW6udTcc2eYC7SKZiT-bIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cboslOjsw%253D%253D&md5=c1b7f71ae3bd1008ad4b8c925ea30599</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11739-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11739-3%26sid%3Dliteratum%253Aachs%26aulast%3DSkultetyova%26aufirst%3DL.%26aulast%3DUstinova%26aufirst%3DK.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DTrapl%26aufirst%3DD.%26aulast%3DBaranova%26aufirst%3DP.%26aulast%3DHavlinova%26aufirst%3DB.%26aulast%3DHubalek%26aufirst%3DM.%26aulast%3DLansky%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DHuman%2520histone%2520deacetylase%25206%2520shows%2520strong%2520preference%2520for%2520tubulin%2520dimers%2520over%2520assembled%2520microtubules%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D11547%26doi%3D10.1038%2Fs41598-017-11739-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 11 is a fatty-acid deacylase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=685-693&author=Z.+Kutilauthor=Z.+Novakovaauthor=M.+Meleshinauthor=J.+Mikesovaauthor=M.+Schutkowskiauthor=C.+Barinka&title=Histone+deacetylase+11+is+a+fatty-acid+deacylase&doi=10.1021%2Facschembio.7b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 11 Is a Fatty-Acid Deacylase</span></div><div class="casAuthors">Kutil, Zsofia; Novakova, Zora; Meleshin, Marat; Mikesova, Jana; Schutkowski, Mike; Barinka, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-693</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 11 (HDAC11) is a sole member of the class IV HDAC subfamily with negligible intrinsic deacetylation activity.  Here, we report in vitro profiling of HDAC11 deacylase activities, and our data unequivocally show that the enzyme efficiently removes acyl moieties spanning 8-18 carbons from the side chain nitrogen of the lysine residue of a peptidic substrate.  Addnl., N-linked lipoic acid and biotin are removed by the enzyme, although with lower efficacy.  Catalytic efficiencies toward dodecanoylated and myristoylated peptides were 77 700 and 149 000 M-1 s-1, resp., making HDAC11 the most proficient fatty-acid deacylase of the HDAC family.  Interestingly, HDAC11 is strongly inhibited by free myristic, palmitic, and stearic acids with inhibition consts. of 6.5, 0.9, and 1.6 μM, resp.  At the same time, its deacylase activity is stimulated more than 2.5-fold by both palmitoyl-CoA and myristoyl-CoA, pointing toward metabolic control of the enzymic activity by fatty-acid metabolites.  Our data reveal novel enzymic activity of HDAC11 that can, in turn, facilitate the uncovering of addnl. biol. functions of the enzyme as well as the design of isoform-specific HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNsptw7rk7bVg90H21EOLACvtfcHk0liTOt-2DWvfLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D&md5=07233a3bfed4f158c6d5752fc18a8c1f</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00942%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DHistone%2520deacetylase%252011%2520is%2520a%2520fatty-acid%2520deacylase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D685%26epage%3D693%26doi%3D10.1021%2Facschembio.7b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of multi-functional histone deacetylase 6 degraders with potent anti-myeloma activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7042</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7042-7057&author=H.+Wuauthor=K.+Yangauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=Z.+Liauthor=H.+Xieauthor=J.+Liuauthor=K.+A.+Smithauthor=Z.+Novakovaauthor=C.+Barinkaauthor=W.+Tang&title=Development+of+multi-functional+histone+deacetylase+6+degraders+with+potent+anti-myeloma+activity&doi=10.1021%2Facs.jmedchem.9b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span></div><div class="casAuthors">Wu, Hao; Yang, Ka; Zhang, Zhongrui; Leisten, Eric D.; Li, Ziyuan; Xie, Haibo; Liu, Jin; Smith, Kerry A.; Novakova, Zora; Barinka, Cyril; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7042-7057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90.  HDAC6 is involved in multiple disease-relevant pathways.  Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand.  We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degrdn. for the antiproliferation of multiple myeloma (MM).  This new class of degraders exhibited improved potency and selectivity for the degrdn. of HDAC6.  After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb58zf04V2GLVg90H21EOLACvtfcHk0lj_tSBeb4yPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO&md5=7aab402404a5fce732b4b68fd76395d4</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00516%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520multi-functional%2520histone%2520deacetylase%25206%2520degraders%2520with%2520potent%2520anti-myeloma%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7042%26epage%3D7057%26doi%3D10.1021%2Facs.jmedchem.9b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sparta, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span> <span> </span><span class="NLM_article-title">Xdsapp2.0</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1085</span>– <span class="NLM_lpage">1092</span>, <span class="refDoi"> DOI: 10.1107/s1600576716004416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2Fs1600576716004416" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC28Xosl2rtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2016&pages=1085-1092&author=K.+M.+Spartaauthor=M.+Krugauthor=U.+Heinemannauthor=U.+Muellerauthor=M.+S.+Weiss&title=Xdsapp2.0&doi=10.1107%2Fs1600576716004416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">XDSAPP2.0</span></div><div class="casAuthors">Sparta, Karine M.; Krug, Michael; Heinemann, Udo; Mueller, Uwe; Weiss, Manfred S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1085-1092</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">1600-5767</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">XDSAPP is an expert system and graphical user interface (GUI) for the automated processing of diffraction images using the XDS program suite and other programs.  The latest major update and the extension of the program are presented here.  The update includes new features, as well as improvements in the GUI and the underlying decision-making system.  XDSAPP is freely available for academic users.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ-TX0JPxrKrVg90H21EOLACvtfcHk0lj_tSBeb4yPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xosl2rtLw%253D&md5=6f8dd41413be2d19cfee0e556da3cb0b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1107%2Fs1600576716004416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs1600576716004416%26sid%3Dliteratum%253Aachs%26aulast%3DSparta%26aufirst%3DK.%2BM.%26aulast%3DKrug%26aufirst%3DM.%26aulast%3DHeinemann%26aufirst%3DU.%26aulast%3DMueller%26aufirst%3DU.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26atitle%3DXdsapp2.0%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2016%26volume%3D49%26spage%3D1085%26epage%3D1092%26doi%3D10.1107%2Fs1600576716004416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2195</span>, <span class="refDoi"> DOI: 10.1107/s0907444904023510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS0907444904023510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=15572771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2184-2195&author=A.+A.+Vaginauthor=R.+A.+Steinerauthor=A.+A.+Lebedevauthor=L.+Pottertonauthor=S.+McNicholasauthor=F.+Longauthor=G.+N.+Murshudov&title=REFMAC5+dictionary%3A+organization+of+prior+chemical+knowledge+and+guidelines+for+its+use&doi=10.1107%2Fs0907444904023510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span></div><div class="casAuthors">Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.; Potterton, Liz; McNicholas, Stuart; Long, Fei; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2184-2195</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">One of the most important aspects of macromol. structure refinement is the use of prior chem. knowledge.  Bond lengths, bond angles and other chem. properties are used in restrained refinement as subsidiary conditions.  This contribution describes the organization and some aspects of the use of the flexible and human/machine-readable dictionary of prior chem. knowledge used by the max.-likelihood macromol.-refinement program REFMAC5.  The dictionary stores information about monomers which represent the constitutive building blocks of biol. macromols. (amino acids, nucleic acids and saccharides) and about numerous org./inorg. compds. commonly found in macromol. crystallog.  It also describes the modifications the building blocks undergo as a result of chem. reactions and the links required for polymer formation.  More than 2000 monomer entries, 100 modification entries and 200 link entries are currently available.  Algorithms and tools for updating and adding new entries to the dictionary have also been developed and are presented here.  In many cases, the REFMAC5 dictionary allows entirely automatic generation of restraints within REFMAC5 refinement runs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjDd-k3YHGrVg90H21EOLACvtfcHk0lj_tSBeb4yPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F&md5=005910422c5fb72fe2434c39b5321bf4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1107%2FS0907444904023510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904023510%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPotterton%26aufirst%3DL.%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DREFMAC5%2520dictionary%253A%2520organization%2520of%2520prior%2520chemical%2520knowledge%2520and%2520guidelines%2520for%2520its%2520use%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2184%26epage%3D2195%26doi%3D10.1107%2Fs0907444904023510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development ofCoot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/s0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+ofCoot&doi=10.1107%2Fs0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lj_tSBeb4yPPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520ofCoot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2Fs0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gražulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkys, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaitkus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">AceDRG: a stereochemical description generator for ligands</span>. <i>Acta Crystallogr., Sect. D: Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/s2059798317000067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS2059798317000067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlGgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=112-122&author=F.+Longauthor=R.+A.+Nichollsauthor=P.+Emsleyauthor=S.+Gra%C5%BEulisauthor=A.+Merkysauthor=A.+Vaitkusauthor=G.+N.+Murshudov&title=AceDRG%3A+a+stereochemical+description+generator+for+ligands&doi=10.1107%2Fs2059798317000067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">AceDRG: a stereochemical description generator for ligands</span></div><div class="casAuthors">Long, Fei; Nicholls, Robert A.; Emsley, Paul; Grazulis, Saulius; Merkys, Andrius; Vaitkus, Antanas; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Structural Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACSDAD</span>;
        ISSN:<span class="NLM_cas:issn">2059-7983</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The program AceDRG is designed for the derivation of stereochem. information about small mols.  It uses local chem. and topol. environment-based atom typing to derive and organize bond lengths and angles from a small-mol. database: the Crystallog. Open Database (COD).  Information about the hybridization states of atoms, whether they belong to small rings (up to seven-membered rings), ring aromaticity and nearest-neighbor information is encoded in the atom types.  All atoms from the COD have been classified according to the generated atom types.  All bonds and angles have also been classified according to the atom types and, in a certain sense, bond types.  Derived data are tabulated in a machine-readable form that is freely available from CCP4.  AceDRG can also generate stereochem. information, provided that the basic bonding pattern of a ligand is known.  The basic bonding pattern is perceived from one of the computational chem. file formats, including SMILES, mmCIF, SDF MOL and SYBYL MOL2 files.  Using the bonding chem., atom types, and bond and angle tables generated from the COD, AceDRG derives the 'ideal' bond lengths, angles, plane groups, arom. rings and chirality information, and writes them to an mmCIF file that can be used by the refinement program REFMAC5 and the model-building program Coot.  Other refinement and model-building programs such as PHENIX and BUSTER can also use these files.  AceDRG also generates one or more coordinate sets corresponding to the most favorable conformation(s) of a given ligand.  AceDRG employs RDKit for chem. perception and for initial conformation generation, as well as for the interpretation of SMILES strings, SDF MOL and SYBYL MOL2 files.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow0LaF0rLfdLVg90H21EOLACvtfcHk0lhr5IGLFU0bYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlGgu78%253D&md5=0a581d62dd3b00004e37be490ee71fe8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1107%2FS2059798317000067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2059798317000067%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DF.%26aulast%3DNicholls%26aufirst%3DR.%2BA.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DGra%25C5%25BEulis%26aufirst%3DS.%26aulast%3DMerkys%26aufirst%3DA.%26aulast%3DVaitkus%26aufirst%3DA.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DAceDRG%253A%2520a%2520stereochemical%2520description%2520generator%2520for%2520ligands%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Struct.%2520Biol.%26date%3D2017%26volume%3D73%26spage%3D112%26epage%3D122%26doi%3D10.1107%2Fs2059798317000067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arendall, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immormino, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span> <span> </span><span class="NLM_article-title">MolProbity: all-atom structure validation for macromolecular crystallography</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1107/s0907444909042073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1107%2FS0907444909042073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=20057044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=12-21&author=V.+B.+Chenauthor=W.+B.+Arendallauthor=J.+J.+Headdauthor=D.+A.+Keedyauthor=R.+M.+Immorminoauthor=G.+J.+Kapralauthor=L.+W.+Murrayauthor=J.+S.+Richardsonauthor=D.+C.+Richardson&title=MolProbity%3A+all-atom+structure+validation+for+macromolecular+crystallography&doi=10.1107%2Fs0907444909042073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">MolProbity: all-atom structure validation for macromolecular crystallography</span></div><div class="casAuthors">Chen, Vincent B.; Arendall, W. Bryan, III; Headd, Jeffrey J.; Keedy, Daniel A.; Immormino, Robert M.; Kapral, Gary J.; Murray, Laura W.; Richardson, Jane S.; Richardson, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MolProbity is a structure-validation web service that provides broad-spectrum solidly based evaluation of model quality at both the global and local levels for both proteins and nucleic acids.  It relies heavily on the power and sensitivity provided by optimized hydrogen placement and all-atom contact anal., complemented by updated versions of covalent-geometry and torsion-angle criteria.  Some of the local corrections can be performed automatically in MolProbity and all of the diagnostics are presented in chart and graphical forms that help guide manual rebuilding.  X-ray crystallog. provides a wealth of biol. important mol. data in the form of at. three-dimensional structures of proteins, nucleic acids and increasingly large complexes in multiple forms and states.  Advances in automation, in everything from crystn. to data collection to phasing to model building to refinement, have made solving a structure using crystallog. easier than ever.  However, despite these improvements, local errors that can affect biol. interpretation are widespread at low resoln. and even high-resoln. structures nearly all contain at least a few local errors such as Ramachandran outliers, flipped branched protein side chains and incorrect sugar puckers.  It is crit. both for the crystallographer and for the end user that there are easy and reliable methods to diagnose and correct these sorts of errors in structures.  MolProbity is the authors' contribution to helping solve this problem and this article reviews its general capabilities, reports on recent enhancements and usage, and presents evidence that the resulting improvements are now beneficially affecting the global database.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIjgsh59dO-7Vg90H21EOLACvtfcHk0lhr5IGLFU0bYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktg%253D%253D&md5=b5fc7574f43f01dd6e43c3663ca4f779</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1107%2FS0907444909042073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909042073%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DArendall%26aufirst%3DW.%2BB.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DKeedy%26aufirst%3DD.%2BA.%26aulast%3DImmormino%26aufirst%3DR.%2BM.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DMurray%26aufirst%3DL.%2BW.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26atitle%3DMolProbity%253A%2520all-atom%2520structure%2520validation%2520for%2520macromolecular%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D12%26epage%3D21%26doi%3D10.1107%2Fs0907444909042073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacketor, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin-Anduix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minasyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3928</span>– <span class="NLM_lpage">3937</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-11-2837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1158%2F0008-5472.can-11-2837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=22693252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2rtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3928-3937&author=R.+C.+Koyaauthor=S.+Mokauthor=N.+Otteauthor=K.+J.+Blacketorauthor=B.+Comin-Anduixauthor=P.+C.+Tumehauthor=A.+Minasyanauthor=N.+A.+Grahamauthor=T.+G.+Graeberauthor=T.+Chodonauthor=A.+Ribas&title=BRAF+inhibitor+vemurafenib+improves+the+antitumor+activity+of+adoptive+cell+immunotherapy&doi=10.1158%2F0008-5472.can-11-2837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy</span></div><div class="casAuthors">Koya, Richard C.; Mok, Stephen; Otte, Nicholas; Blacketor, Kevin J.; Comin-Anduix, Begonya; Tumeh, Paul C.; Minasyan, Aspram; Graham, Nicholas A.; Graeber, Thomas G.; Chodon, Thinle; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3928-3937</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted therapeutics that produce robust clin. responses are likely benefiting from inherent adjuvant effects that degrade immune escape, a feature that could be leveraged most effectively by combinatorial uses in settings such as that described here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg6bb5bmox1bVg90H21EOLACvtfcHk0lhr5IGLFU0bYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2rtr3J&md5=d8ec5438042feca327a3227c6d2a2381</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-11-2837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-11-2837%26sid%3Dliteratum%253Aachs%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DOtte%26aufirst%3DN.%26aulast%3DBlacketor%26aufirst%3DK.%2BJ.%26aulast%3DComin-Anduix%26aufirst%3DB.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DMinasyan%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DBRAF%2520inhibitor%2520vemurafenib%2520improves%2520the%2520antitumor%2520activity%2520of%2520adoptive%2520cell%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3928%26epage%3D3937%26doi%3D10.1158%2F0008-5472.can-11-2837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaffl, M. W.</span></span> <span> </span><span class="NLM_article-title">A new mathematical model for relative quantification in real-time RT-PCR</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">e45</span> <span class="refDoi"> DOI: 10.1093/nar/29.9.e45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=10.1093%2Fnar%2F29.9.e45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=11328886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;key=1%3ACAS%3A280%3ADC%252BD38nis12jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2001&author=M.+W.+Pfaffl&title=A+new+mathematical+model+for+relative+quantification+in+real-time+RT-PCR&doi=10.1093%2Fnar%2F29.9.e45"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A new mathematical model for relative quantification in real-time RT-PCR</span></div><div class="casAuthors">Pfaffl M W</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic acids research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Use of the real-time polymerase chain reaction (PCR) to amplify cDNA products reverse transcribed from mRNA is on the way to becoming a routine tool in molecular biology to study low abundance gene expression.  Real-time PCR is easy to perform, provides the necessary accuracy and produces reliable as well as rapid quantification results.  But accurate quantification of nucleic acids requires a reproducible methodology and an adequate mathematical model for data analysis.  This study enters into the particular topics of the relative quantification in real-time RT-PCR of a target gene transcript in comparison to a reference gene transcript.  Therefore, a new mathematical model is presented.  The relative expression ratio is calculated only from the real-time PCR efficiencies and the crossing point deviation of an unknown sample versus a control.  This model needs no calibration curve.  Control levels were included in the model to standardise each reaction run with respect to RNA integrity, sample loading and inter-PCR variations.  High accuracy and reproducibility (<2.5% variation) were reached in LightCycler PCR using the established mathematical model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-M-IJ-nr2KCSm0e6ZOaemfW6udTcc2eZM-HBwRVA7LLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nis12jtw%253D%253D&md5=a0507843d416d259ae526f8c378a7e72</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F29.9.e45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F29.9.e45%26sid%3Dliteratum%253Aachs%26aulast%3DPfaffl%26aufirst%3DM.%2BW.%26atitle%3DA%2520new%2520mathematical%2520model%2520for%2520relative%2520quantification%2520in%2520real-time%2520RT-PCR%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2001%26volume%3D29%26doi%3D10.1093%2Fnar%2F29.9.e45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM','PDB','5EEM'); return false;">PDB: 5EEM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DVL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DVL','PDB','6DVL'); return false;">PDB: 6DVL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEK','PDB','5EEK'); return false;">PDB: 5EEK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0K','PDB','6R0K'); return false;">PDB: 6R0K</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00946">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_15243"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00946">10.1021/acs.jmedchem.9b00946</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional data on the Ames test and the hERG assay, crystallization data collection, and refinement statistics, and physicochemical properties, <sup>1</sup>H NMR spectra, and <sup>13</sup>C NMR spectra for compounds <b>7a–d</b>, <b>11a–d</b>, and <b>20a–c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings including screening data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_001.pdf">jm9b00946_si_001.pdf (3.15 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00946/suppl_file/jm9b00946_si_002.csv">jm9b00946_si_002.csv (2.66 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates and corresponding structure factors for the drHDAC6-CD2/SS-208 complex have been deposited at the Protein Data Bank as the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0K">6R0K</a> entry.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00946%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00946" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0c2873f35223c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
